EP1603885A1 - Fused tri and tetra-cyclic pyrazole kinase inhibitors - Google Patents

Fused tri and tetra-cyclic pyrazole kinase inhibitors

Info

Publication number
EP1603885A1
EP1603885A1 EP04717503A EP04717503A EP1603885A1 EP 1603885 A1 EP1603885 A1 EP 1603885A1 EP 04717503 A EP04717503 A EP 04717503A EP 04717503 A EP04717503 A EP 04717503A EP 1603885 A1 EP1603885 A1 EP 1603885A1
Authority
EP
European Patent Office
Prior art keywords
dihydroindeno
pyrazol
methoxy
hydroxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04717503A
Other languages
German (de)
French (fr)
Inventor
Yunsong Tong
Akiyo K. Claiborne
Gaoquan Li
Nan-Horng Lin
Hing Sham
Zhi-Fu Tao
Tom Sowin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/792,564 external-priority patent/US7320986B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of EP1603885A1 publication Critical patent/EP1603885A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to fused pyrazoles, to methods of making the compounds, to compositions containing the compounds, and to methods of treatment using the compounds.
  • Protein kinases are important in the progression of many disease states that are induced by the inappropriate proliferation of cells. These kinases are often found to be up-regulated in many hyperproliferative states such as cancer. These kinases may also be important in cell signaling, where their inappropriate activation induces cells to proliferate (e.g., EGFR, ERBB2, VEGFR, FGFR, PDGFR, c-Met, IGF-lR, RET, TBE2). Alternatively, kinases may be involved in signal transduction within cells (e.g., c-Src, PKC, Akt, PKA, c-Abl, PDK-1) where these signal transduction genes are recognized proto-oncogenes.
  • kinases control cell cycle progression near the Gl-S transition (e.g., Cdk2, Cdk4), at the G2-M transition (e.g., Weel, Mytl, Chkl, Cdc2) or at the spindle checkpoint (Plk, Auroral or 2, Bubl or 3).
  • kinases are intimately linked to the DNA damage response (e.g., ATM, ATR, Chkl, Chk2).
  • Deregulation of these cellular functions: cell signaling, signal transduction, cell cycle control, and DNA repair are all hallmarks of hyperproliferative diseases, particularly cancer. Therefore, pharmacological modulation of one or more kinases would be useful in slowing or stopping diseases that are induced by the inappropriate proliferation of cells such as cancer.
  • the present invention relates to compounds of formula (I)
  • R ⁇ and R 2 are independently selected from the group consisting of hydrogen, alkenyl, alkenyloxy, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkynyl, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, cycloalkenylalkoxy, cycloalkylalkoxy, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkyloxy, formyl, haloalkoxy, haloalkoxyalkynyl,
  • Ri and R 2 together with the carbon atoms to which they are attached form a 5, 6, 7, or 8- membered nonaromatic ring wherein the ring contains 0, 1, or 2 heteroatoms selected from the group consisting of O, N(Rc), and N(R D ), wherein the nonaromatic ring is substituted with 0, 1, or 2 substituents selected from the group consisting of alkyl and hydroxy;
  • R 3 is selected from the group consisting of hydrogen, alkenyl, alkenyloxy, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR E R F , (NR E Rp) lkoxy (NReR R lalkyl, (NR E RF)carbonyl, and (NR E RF)carbonylalkyl;
  • R 4 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkylcarbonylalkoxy, aryl, arylalkoxy, arylalkyl, aryloxy, carboxy, cyano, halogen, heteroaryl, heteroarylalkoxy, heteroarylalkyl, heteroaryloxy, heterocycle, heterocyclealkoxy, heterocyclealkyl, heterocycleoxy, hydroxy, -NR E R F , and (NR E R F )carbonyl;
  • R 5 is absent or selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, halogen, heteroaryl, hydroxy, nitro, -NR E R F , and (NR E Rp)carbonyl; or
  • R 4 and R 5 together with the atoms to which they are attached, form a phenyl ring optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR G RH, (NR ⁇ Ri alkoxy, (NR ⁇ R ⁇ alkyl, (NR ⁇ Ri ⁇ carbonyl, and (NR G R H )sulfonyl; or
  • R 4 and R 5 together with the atoms to which they are attached, form a heterocycle optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, oxo, -NR G RH, (NRGRH)alkoxy, (NRGR ⁇ -)alkyl, and (NR G RH)carbonyl; provided that when R 5 is hydrogen, R 4 is other than hydrogen;
  • R 6 is selected from the group consisting of hydrogen, lower alkoxy, lower alkyl, halogen, hydroxy, and -NRERF;
  • R A and R B are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkoxyalkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylcarbonyl, alkoxysulfonyl, alkoxysulfonylalkyl, alkoxysulfonylalkylcarbonyl, alkyl, alkylcarbonyl, alkynyl, aryl, carboxyalkyl, carboxyalkylcarbonyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkylcarbonyl, cycloalkylcarbonyl, cycloalkylcarbonylalkyl, cycloalkylcarbonylalkylcarbonyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, heterocyclealkylcarbonyl, heterocyclecarbonylalkylalkylalky
  • Re and R D are independently selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, and alkylcarbonyl;
  • R E and R F are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, cycloalkyl, heteroarylalkyl, and hydroxyalkyl;
  • Xi, X 3 , and X are independently selected from the group consisting of CH and N;
  • X 5 is selected from the group consisting of C and N;
  • R 7 is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxy, lower alkoxy, lower alkyl, and hydroxyalkyl;
  • R 8 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, alkylcarbonyl, and hydroxyalkyl.
  • the present invention relates to pharmaceutical compositions comprising a compound of formula (I), or a therapeutically acceptable salt thereof, in combination with a therapeutically acceptable carrier.
  • the present invention relates to a method for inhibiting protein kinases in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I), or a therapeutically acceptable salt thereof.
  • the present invention relates to a method for treating cancer in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I), or a therapeutically acceptable salt thereof.
  • Ri and R 2 are independently selected from the group consisting of hydrogen, alkenyl, alkenyloxy, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkynyl, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, cycloalkenylalkoxy, cycloalkylalkoxy, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkyloxy, formyl, haloalkoxy, haloalkoxyalkynyl, haloalkyl, halogen, heteroarylalkoxy, heteroarylalkoxyalk
  • Ri and R 2 together with the carbon atoms to which they are attached form a 5, 6, 7, or 8- membered nonaromatic ring wherein the ring contains 0, 1, or 2 heteroatoms selected from the group consisting of O, N(Rc), and N(R D ), wherein the nonaromatic ring is substituted with 0, 1, or 2 substituents selected from the group consisting of alkyl and hydroxy;
  • R 3 is selected from the group consisting of hydrogen, alkenyl, alkenyloxy, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR E RF, (NRERp)alkoxy (NRERp) lkyl, (NR E Rp)carbonyl, and (NR E RF)carbonylalkyl;
  • R is selected from the group consisting of hydrogen, alkoxycarbonyl, alkylcarbonylalkoxy, aryl, arylalkoxy, arylalkyl, aryloxy, carboxy, cyano, halogen, heteroaryl, heteroarylalkoxy, heteroarylalkyl, heteroaryloxy, heterocycle, heterocyclealkoxy, heterocyclealkyl, heterocycleoxy, hydroxy, -NR E R F , and (NRERp)carbonyl;
  • R 5 is absent or selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, halogen, heteroaryl,hydroxy, nitro, -NR E R F , an (NRERp)carbonyl; or
  • R 4 . and R 5 together with the atoms to which they are attached, form a phenyl ring optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NRQR H , (NR ⁇ Ri alkoxy, (NR G R ⁇ .)alkyl, (NR G R H )carbonyl, and (NR G R H )sulf
  • R and R 5 together with the atoms to which they are attached, form a heterocycle optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, oxo, -NR G RH, (NRoR ⁇ alkoxy, (NRoR ⁇ alkyl, and (NR G R H )carbonyl; provided that when R 5 is hydrogen, R 4 is other than hydrogen;
  • R 6 is selected from the group consisting of hydrogen, lower alkoxy, lower alkyl, halogen, hydroxy, and -NRERF',
  • R A and R B are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkoxyalkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylcarbonyl, alkoxysulfonyl, alkoxysulfonylalkyl, alkoxysulfonylalkylcarbonyl, alkyl, alkylcarbonyl, alkynyl, aryl, carboxyalkyl, carboxyalkylcarbonyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkylcarbonyl, cycloalkylcarbonyl, cycloalkylcarbonylalkyl, cycloalkylcarbonylalkylcarbonyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, heterocyclealkylcarbonyl, heterocyclecarbonylalkylalkylalky
  • Re and R D are independently selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, and alkylcarbonyl;
  • R E and R F are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, cycloalkyl, heteroarylalkyl, and hydroxyalkyl;
  • X 1( X 3 , and X 4 are independently selected from the group consisting of CH and N;
  • X 5 is selected from the group consisting of C and N;
  • R 7 is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxy, lower alkoxy, lower alkyl, and hydroxyalkyl;
  • R 8 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, alkylcarbonyl, and hydroxyalkyl.
  • the present invention relates to a compound of formula (I) wherein X l5 X 3 , and X are CH; X is CH(R 7 ); X 5 is C; Rj and R 2 are independently selected from the group consisting of hydrogen, alkenyloxy, alkoxy, alkoxyalkyl, heterocyclealkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ ) lkyl, and (NR A R ⁇ )carbonyl; R 3 is hydrogen; R 4 is selected from the group consisting of hydrogen, alkoxycarbonyl, aryl, carboxy, cyano, heteroaryl, hydroxy, -NR E R F , and (NR E Rp)carbonyl; R 5 is selected from the group consisting of hydrogen and -NR E R F ; R ⁇ is hydrogen; R 7 is hydrogen; R A is selected from the group consisting of hydrogen and alkyl; R ⁇ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, heteroarylal
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X are CH; X 2 is CH(R ); X 5 is C; Ri and R 2 are independently selected from the group consisting of hydrogen, alkenyloxy, alkoxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRAR ⁇ )alkyl, (NR A RB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R 3 is hydrogen; R is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, cyano, heteroaryl, hydroxy, -NR E R F , (NR E Rp)carbonyl, and aryl, wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy
  • RS is selected from the group consisting of hydrogen and -NR E R F ;
  • R O is hydrogen;
  • R 7 is hydrogen;
  • R A is selected from the group consisting of hydrogen and alkyl;
  • R ⁇ is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy;
  • R E is selected from the group consisting of hydrogen and alkyl; and
  • R F is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
  • the present invention relates to a compound of formula (I) wherein X ls X 3 , and X are CH; X 2 is CH(R 7 ); X 5 is C; R l5 R 3 , R 5 , and R 6 are hydrogen; R 2 is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ )alkyl, (NR A R B )c rbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, and (NRERp)carbo yl; R is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohex
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X are CH; X 2 is CH(R ); X 5 is C; Ri, R 3 , R 5 , and R 6 are hydrogen; R 2 is selected from the group consisting of hydrogen, alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ )alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R 4 is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NR G R H ", 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloal
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X 4 are CH; X 2 is CH(R ); X 5 is C; Ri, R 3 , R5, and R 6 are hydrogen; R is selected from the group consisting of hydrogen, alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ )alkyl, (NR A R B )carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is heteroaryl; R 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; and R B is selected from the group consisting of hydrogen and alkyl.
  • the present invention relates to a compound of formula (I) wherein X 1 ⁇ X 3 , and X are CH; X 2 is CH(R ); X 5 is C; R 1; R 3 , R5, and R 6 are hydrogen; R is alkenyloxy; R is heteroaryl wherein the heteroaryl is tetraazolyl; and R 7 is hydrogen.
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X are CH; X 2 is CH(R 7 ); X 5 is C; Ri, R 3 , and R 6 are hydrogen; R 2 is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ )alkyl, (NR A R ⁇ )carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is selected from the group consisting of hydrogen, carboxy, and cyano; R 5 is selected from the group consisting of alkoxycarbonyl, carboxy, hydroxy, hydroxyalkyl, -NR E R F , and (NR E R F )carbo yl; R 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X are CH; X 2 is CH(R 7 ); X 5 is C; R ls R 3 , and R 6 are hydrogen; R 2 is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ ) lkyl, (NR A R ⁇ )carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is selected from the group consisting of hydrogen, carboxy, and cyano; R 5 is -NR E R F ⁇ R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy;
  • the present invention relates to a compound of formula (I) wherein X 1; X 3 , and X are CH; X 2 is CH(R 7 ); X 5 is C; R , R 3 , R 5 , and R 6 are hydrogen; Rt is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRAR ⁇ )alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NR E R F , and (NRERF) arbonyl; R 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is
  • the present invention relates to a compound of formula (I) wherein X l5 X 3 , and X are CH; X 2 is CH(R 7 ); X 5 is C; R 2 , R 3 , R 5 , and R 6 are hydrogen; Ri is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ )alkyl, (NR A RB)carbo yl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R 4 is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NR G R H ; 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl,
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X are CH; X 2 is CH(R ); X 5 is C; R 2 , R 3 , and R 6 are hydrogen; R t is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NR A R ⁇ )alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R 4 is selected from the group consisting of hydrogen, carboxy, and cyano; R 5 is selected from the group consisting of alkoxycarbonyl, carboxy, hydroxy, hydroxyalkyl, -NR E R F , and (NRERp)carbonyl; R 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cyclo
  • the present invention relates to a compound of formula (I) wherein Xi, X3, and X are CH; X 2 is CH(R ); X 5 is C; Ri and R 2 are alkoxy; R 3 and R 6 are hydrogen; R is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, -NR E R F , and (NRERp)carbonyl; R 5 is selected from the group consisting of hydrogen and carboxy; R 7 is hydrogen; R E is selected from the group consisting of hydrogen and alkyl; and R F is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X are CH; X is CH(R 7 ); X 5 is C; Ri and R 2 are alkoxy; R 3 , R 5 , and R 6 are hydrogen; R 4 is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NR G R H ', 7 is hydrogen; R E is selected from the group consisting of hydrogen and alkyl; and R F is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X 4 are CH; X 2 is CH(R 7 ); X 5 is C; Ri and R 2 are alkoxy; R 3 , R5, and R 6 are hydrogen; R 4 is heteroaryl; and R 7 is hydrogen.
  • the present invention relates to a compound of formula (I) wherein X 1; X 3 , and X are CH; X 2 is CH(R 7 ); X5 is C; R ⁇ and R 2 are alkoxy; R 3 , R5, and R 6 are hydrogen; R 4 is heteroaryl wherein the heteraryl is tetraazolyl; and R 7 is hydrogen.
  • the present invention relates to a compound of formula (I) wherein X 1; X 3 , and X are CH; X 2 is CH(R 7 ); X 5 is C; Ri, R 2 , R 3 , R 5 , and Rg are hydrogen; R is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NR E R F , and (NRERp)carbonyl; and R 7 is selected from the group consisting of alkoxy and hydroxy.
  • the present invention relates to a compound of formula (I) wherein Xi is CH; X 2 is CH(R 7 ); X 3 is N; X 4 is CH; X 5 is C; Ri, R 3 , R 5 , and R 6 are hydrogen; R 2 is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRAR ⁇ )alkyl, (NRAR B )carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NR E RF, and (NRER F )carbonyl; R 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cyclo
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X are CH; X 2 is CH(R 7 ); X 5 is C; Ri and R 2 together with the carbon atoms to which they are attached form a 5 or 6-membered nonaromatic ring wherein the ring contains 0, 1, or 2 heteroatoms selected from the group consisting of O, N(Rc), and N(RD); R 3 , R 5 , and R 6 are hydrogen; R 4 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NR E RF, and (NRERp)carbonyl; R 7 is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; R ⁇ is selected from
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X 4 are CH; X 2 is CH(R 7 ); X 5 is C; R and R 2 together with the carbon atoms to which they are attached form a 5 or 6-membered nonaromatic ring wherein the ring contains 2 heteroatoms selected from the group consisting of O, N(Rc), and N(R D ); R 3 , R 5 , and R 6 are hydrogen; R 4 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NR E R F , and (NRERF)carbonyl; R 7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; R B is selected
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X 4 are CH; X is CH(R 7 ); X 5 is C; Ri and R 2 together with the carbon atoms to which they are attached form a 5 or 6-membered nonaromatic ring wherein the ring contains 0, 1, or 2 heteroatoms selected from the group consisting of O, N(Rc), and N(R D ); R 3 , R S , and R 6 are hydrogen; R 4 is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and - NR G R H ; R7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X 4 are CH; X 2 is CH(R 7 ); X5 is C; Ri and R 2 together with the carbon atoms to which they are attached form a 5 or 6-membered nonaromatic ring wherein the ring contains 2 heteroatoms selected from the group consisting of O, N(Rc), and N(RD); R 3 , R5, and R 6 are hydrogen; R is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NR G R H ; R7 is hydrogen; R A is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X 4 are CH; X 2 is CH(R 7 ); X 5 is C; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R 2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NR A R ⁇ )alkynyl, and (NRAR B )carbonyl; R 3 is selected from the group consisting of hydrogen, -NR E R F , and hydroxyalkyl; R is aryl wherein
  • the present invention relates to a compound of formula (I) wherein Xi and X are CH; X 2 is CH(R 7 ); X 3 is N; X 5 is C; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R 2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRAR ⁇ )alkynyl, and (NR A R ⁇ )carbonyl; R 3 is selected from the group consisting of hydrogen, -NR E R F , and hydroxyalkyl; Ri is selected from the group consisting of
  • the present invention relates to a compound of formula (I) wherein Xi and X 3 are CH; X 2 is CH(R 7 ); X4 is N; X 5 is C; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R 2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NR A R ⁇ )alkynyl, and (NR A R B )carbonyl; R 3 is selected from the group consisting of hydrogen, -NR E R F , and hydroxyalkyl; R 4 is selected from the
  • the present invention relates to a compound of formula (I) wherein Xi and X 3 are CH; X 2 is CH(R 7 ); X 4 and X5 are N; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R 2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRAR ⁇ )alkynyl, and (NRAR ⁇ )carbonyl; R 3 is selected from the group consisting of hydrogen, -NR E R F , and hydroxyalkyl; R is selected from the group consisting of cyan
  • the present invention relates to a compound of formula (I) wherein Xi and X 4 are CH; X 2 is CH(R 7 ); X 3 and X 5 are N; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R 2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NR A R ⁇ )alkynyl, and (NR A R ⁇ )carbonyl; R 3 is selected from the group consisting of hydrogen, -NR E R F , and hydroxyalkyl; R 4 is selected from the group consisting
  • the present invention relates to a compound of formula (I) wherein Xi, X 3 , and X 4 are CH; X 2 is CH(R 7 ); X 5 is C; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R 2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NR A R B )alkynyl, and (NR A R ⁇ )carbonyl; R 3 is selected from the group consisting of hydrogen, -NR E R F , and hydroxyalkyl; R and R 5 ,
  • alkenyl as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens.
  • Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl (allyl), 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2- heptenyl, 2-methyl-l-heptenyl, and 3-decenyl.
  • alkenyloxy means an alkenyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of alkenyloxy include, but are not limited to, allyloxy, 2-butenyloxy and 3-butenyloxy.
  • alkoxy as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
  • alkoxy alkoxy means an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of alkoxyalkoxy include, but are not limited to, 2-(methoxy)ethoxy, 2-(ethoxy)ethoxy, 2-(tert-butoxy)ethoxy, and 3-(methoxy)butoxy.
  • alkoxyalkoxyalkynyl as used herein, means an alkoxyalkoxy group, as defined herein, appended to the parent molecular moiety through an alkynyl group, as defined herein.
  • Representative examples of alkoxyalkoxyalkynyl include, but are not limited to, 3-(2-iso ⁇ ropoxyethoxy) ⁇ rop- 1 -ynyl, 3-(2-methoxyethoxy)prop- 1-ynyl, and 4-(2-iso ⁇ ropoxyethoxy)but- 1 -ynyl.
  • alkoxyalkyl as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of alkoxyalkyl include, but are not limited to, mefhoxymethyl, ethoxymethyl, 2-ethoxyethyl, tert-butoxymethyl, and 2-methoxyethyl.
  • alkoxyalkylcarbonyl as used herein, means an alkoxyalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkoxyalkylcarbonyl include, but are not limited to, 3- methoxypropanoyl and 5-methoxypentanoyl.
  • alkoxycarbonyl as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.
  • alkoxycarbonylalkyl as used herein, means an alkoxycarbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • alkoxycarbonylalkyl include, but are not limited to, 3- methoxycarbonylpropyl, 4-ethoxycarbonylbutyl, and 2-tert-butoxycarbonylethyl.
  • alkoxycarbonylalkylcarbonyl means an alkoxycarbonylalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkoxycarbonylalkylcarbonyl include, but are not limited to, 5-methoxy-5-oxopentanoyl, 5-ethoxy-5-oxopentanoyl, and 4-methoxy-4-oxobutanoyl.
  • alkoxysulfonyl as used herein, means an alkoxy group, as defined herein, appended appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of alkoxysulfonyl include, but are not limited to, methoxysulfonyl, ethoxysulfonyl and propoxy sulfonyl.
  • alkoxysulfonylalkyl as used herein, means an alkoxysulfonyl group, as defined herein, appended appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of alkoxysulfonylalkyl include, but are not limited to, 3-(methoxysulfonyl)propyl, 3-(ethoxysulfonyl)propyl, and 2-(methoxysulfonyl)ethyl.
  • alkoxysulfonylalkylcarbonyl means an alkoxysulfonylalkyl group, as defined herein, appended appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of alkoxysulfonylalkylcarbonyl include, but are not limited to, 3-(methoxysulfonyl)propanoyl, 3-(ethoxysulfonyl)propanoyl, and 4-(methoxysulfonyl)butanoyl .
  • alkyl as used herein, means a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms.
  • Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.
  • alkylcarbonyl as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-l-oxopropyl, 1-oxobutyl, and 1-oxopentyl.
  • alkylcarbonylalkoxy means an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of alkylcarbonylalkoxy include, but are not limited to, acetyl, 2-oxopropoxy, 2-oxobutoxy, and 3-oxobutoxy, 4-oxopentyloxy.
  • alkylcarbonyloxy means an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, and tert-butylcarbonyloxy.
  • alkylsulfinyl as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfinyl group, as defined herein.
  • Representative examples of alkylsulfinyl include, but are not limited to, methylsulfinyl and ethylsulfinyl.
  • alkylsulfonyl as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of alkylsulfonyl include, but are not limited to, methylsulfonyl and ethylsulfonyl.
  • alkylthio as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom.
  • Representative examples of alkylthio include, but are not limited, methylthio, ethylthio, tert-butylthio, and hexylthio.
  • alkylthioalkyl as used herein, means an alkylthio group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of alkylthioalkyl include, but are not limited, methylthiomethyl and 2- (ethylthio)ethyl.
  • alkynyl as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond.
  • Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2- propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
  • aryl as used herein, means a monocyclic-ring system or a bicyclic-fused ring system wherein one or more of the fused rings are aromatic.
  • Representative examples of aryl include, but are not limited to, indenyl, naphthyl, phenyl, and tetrahydronaphthyl.
  • the aryl groups of the present invention are substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR G R H , (NRcR ⁇ alkoxy, (NRcR ⁇ lkyl, (NR G R H )carbonyl, and (NRcR H )sulfonyl.
  • the aryl groups of the present invention may be optionally substituted with one heterocycle, as defined herein.
  • the heterocycle may be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR G R H , (NR G R H )alkoxy, (NR G R H )alkyl, (NR G R H )carbonyl, and (NR G R H )s
  • arylalkoxy as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of arylalkoxy include, but are not limited to, 2-phenylethoxy, 3-phenylpropoxy, and 5- phenylpentyloxy.
  • arylalkyl as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of arylalkyl include, but are not limited to, 4-carboxyphenylmefhyl, 2-(4-hydroxyphenyl)ethyl, and 3-(4-carboxyphenyl)propyl.
  • aryloxy as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of aryloxy include, but are not limited to, 4-carboxyphenoxy, 4-hydroxyphenoxy, and 3,4- dihy droxyphenoxy .
  • carboxyalkyl as used herein, means a carboxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of carboxyalkyl include, but are not limited to, carboxymethyl, 2- carboxyethyl, and 3-carboxypropyl.
  • carboxyalkylcarbonyl means a carboxyalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of carboxyalkylcarbonyl include, but are not limited to, 4- carboxybutanoyl, 3-carboxypropanoyl, and 5-carboxypentanoyl.
  • cyano means a -CN group.
  • cycloalkyl as used herein, means a saturated cyclic hydrocarbon group containing from 3 to 8 carbons. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • the cycloalkyl groups of the present invention are substituted with 0, 1, 2, 3, or 4 substituents selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, -NR G R H , (NR G R H )alkoxy, (NR G R H )alkyl, and (NR G R H )carbonyl.
  • cycloalkenyl means a non-aromatic, partially unsaturated monocyclic, bicyclic, or tricyclic ring system having four to eight carbon atoms and zero heteroatoms.
  • Representative examples of cycloalkenyl groups include, but are not limited to, cyclohexenyl and cyclopentenyl.
  • cycloalkenylalkoxy means a cycloalkenyl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • cycloalkylalkoxy means a cycloalkyl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of cycloalkylalkoxy include, but are not limited to, cyclopropylmethoxy, 2-cyclobutylethoxy, cyclopentylmethoxy, cyclohexylmethoxy, 2-cyclohexylethoxy, 3-cyclohexylpropoxy, 4-cyclohexylbutoxy, 4-(4-aminocyclohexyl)butoxy, 4-(4-dimethylaminocyclohexyl)butoxy, 4-(4-hydroxycyclohexyl)butoxy, and 4-cycloheptylbutoxy .
  • cycloalkylalkyl means a cycloalkyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of cycloalkylalkyl include, but are not limited to, cyclopropylmethyl, 2- cyclobutylethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclohexylethyl, 3-cyclohexylpropyl, 4-cyclohexylbutyl, 4-(4-aminocyclohexyl)butyl, 4-(4-dimethylaminocyclohexyl)butyl, 4-(4- hydroxycyclohexyl)butyl, and 4-cycloheptylbutyl.
  • cycloalkylalkylcarbonyl means a cycloalkylalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of cycloalkylalkylcarbonyl include, but are not limited to, 4- cyclohexylbutanoyl, 3-cyclohexylpropanoyl, and 5-cyclohexylpentanoyl.
  • cycloalkylcarbonyl as used herein, means a cycloalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of cycloalkylcarbonyl include, but are not limited to, cyclohexylcarbonyl and cyclopentylcarbonyl.
  • cycloalkyloxy means a cycloalkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of cycloalkyloxy include, but are not limited to, cyclohexyloxy and cyclopentyloxy.
  • cycloalkylcarbonylalkyl as used herein, means a cycloalkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of cycloalkylcarbonylalkyl include, but are not limited to, 4- cyclohexyl-4-oxobutyl and 3-cyclohexyl-3-oxopropyl.
  • cycloalkylcarbonylalkylcarbonyl as used herein, means a cycloalkylcarbonylalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of cycloalkylcarbonylalkylcarbonyl include, but are not limited to, 4-cyclohexyl-4-oxobutanoyl and 3 -cyclohexyl-3 -oxopropanoyl .
  • halo or halogen as used herein, means -Cl, -Br, -I or -F.
  • haloalkoxy means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Additionally, the alkyl group may optionally be substituted with at least one halogen atom.
  • Representative examples of haloalkoxy include, but are not limited to, chloromethoxy, 2- fluoroethoxy, trifluoromethoxy, pentafluoroethoxy,and 3-chloro-2-(hydroxymethyl)-2- methylpropoxy.
  • haloalkoxyalkynyl as used herein, means a haloalkoxy group, as defined herein, appended to the parent molecular moiety through an alkynyl group, as defined herein.
  • Representative examples of haloalkoxyalkynyl include, but are not limited to, 3-(2,2,2-trifluoroethoxy)prop-l-ynyl and 3-(trifluoromethoxy)prop-l-ynyl.
  • haloalkyl as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl.
  • heteroaryl refers to an aromatic five- or six-membered ring wherein 1, 2, 3, or 4 heteroatoms are independently selected from N, O, or S.
  • the five membered rings have two double bonds and the six membered rings have three double bonds.
  • the heteroaryl groups are connected to the parent molecular moiety through a carbon or nitrogen atom.
  • heteroaryl also includes bicyclic systems where a heteroaryl ring is fused to a phenyl group or an additional heteroaryl group.
  • heteroaryl include, but are not limited to, benzothienyl, benzoxadiazolyl, cinnolinyl, furopyridinyl, furyl, imidazolyl, indazolyl, indolyl, isoxazolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, quinolinyl, tetraazolyl, thiadiazolyl, thiazolyl, thienopyridinyl, thienyl, triazolyl, and triazinyl.
  • heteroaryl groups of the present invention are substituted with 0, 1, 2, 3, or 4 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NR G R H , (NRcR ⁇ alkoxy, (NRcRH)alkyl, (NR G R H )carbonyl, and (NR G RH)sulfonyl.
  • heteroarylalkoxy means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of heteroarylalkoxy include, but are not limited to, 5-hydroxy-2- pyridinylmethyl, 2-(5-hydroxy-2-pyridinyl)ethyl, and 5-hydroxy-2-pyrimidinylmethyl.
  • heteroarylalkoxyalkoxy means a heteroarylalkoxy group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • heteroarylalkyl as used herein, means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of heteroarylalkyl include, but are not limited to, 5-carboxy-2- pyridinylmethyl, 5-hydroxy-2-pyridinylmethyl, 2-(5-hydroxy-2-pyridinyl)ethyl, and 3-(5- hydroxy-2-pyridinyl)propyl.
  • heteroarylalkynyl as used herein, means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an alkynyl group, as defined herein.
  • heteroarylalkynyl include, but are not limited to, pyridin-2- ylethynyl, pyridin-3-ylethynyl, 4-pyridin-2-ylbut-l-ynyl, and 4-pyrazin-2-ylpent-l -ynyl.
  • heteroaryloxy means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of heteroaryloxy include, but are not limited to, 5-carboxy-2-pyridinyloxy, 5-hydroxy-2- pyridinyloxy, and 5-hydroxy-2-pyrimidinyloxy.
  • heteroaryloxyalkyl as used herein, means a heteroaryloxy group, as defined herein, appended to the parent molecular moiety through an alkyl group.
  • Representative examples of heteroaryloxyalkyl include, but are not limited to, pyridinyl5-carboxy-2- pyridinyloxymethyl, 5-hydroxy-2-pyridinyloxymethyl, and 5-hydroxy-2-pyrimidinyloxy.
  • heterocycle refers to a three, four, five, six, seven or eight membered ring containing one, two, or three heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
  • the three membered ring has zero double bonds.
  • the four and five membered rings have zero or one double bond.
  • the six membered ring has zero, one, or two double bonds.
  • the seven and eight membered rings have zero, one, two, or three double bonds.
  • the heterocycle groups of the present invention can be attached to the parent molecular moiety through a carbon atom or a nitrogen atom.
  • heterocycle include, but are not limited to, azetidinyl, azepanyl, aziridinyl, azocanyl, l,4-diazepan-2-yl, 1,4-dioxanyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl, and 1,1-dioxidothiomorpholinyl.
  • heterocycles of the present invention are substituted with 0, 1, 2, 3, or 4 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, oxo, -NR G R H , (NR G R H ) alkoxy, (NR G RH) lkyl, and (NRcR H )carbonyl.
  • substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloal
  • the heterocycles of the present invention may be optionally substituted with one aryl group, as defined herein.
  • the aryl group may be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NRGR H , (NR G R H )alkoxy, (NR G R H )alkyl, (NR G RH)carbonyl, and (NR G R H )
  • heterocyclealkoxy means a heterocycle, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of heterocyclealkoxy include, but are not limited to, 4-morpholinylmethoxy, 2-(4-morpholinyl)ethoxy, 4-thiomorpholinylmethoxy, 2-(4-thiomorpholinyl)ethoxy, 1 -piperidinylmethoxy, 2-(l-piperidinyl)ethoxy, 4-hydroxy-l- piperidinylmethoxy , 2-(4-hydroxy- 1 -piperidinyl)ethoxy, 3-hydroxy- 1 -pyrrolidinylmethoxy, 3-hydroxy- 1-azetidinylmethoxy, and 4-hydroxy-l-azepanylmethoxy.
  • heterocyclealkyl means a heterocycle, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of heterocyclealkyl include, but are not limited to, 4-morpholinylmethyl, 2-(4-morpholinyl)ethyl, 4-thiomorpholinylmethyl, 2-(4-thiomorpholinyl)ethyl, 1-piperidinylmethyl, 2-(l-piperidinyl)ethyl, 4-hydroxy-l- piperidinylmethyl, 2-(4-hydroxy- l-piperidinyl)ethyl, 3-hydroxy- 1-pyrrolidinylmethyl, 3-hydroxy-l-azetidinylmethyl, 3-hydroxy-l-azepanylmethyl, and 4-hydroxy-l-azepanylmethyl.
  • heterocyclealkylcarbonyl means a heterocyclealkyl, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of heterocyclealkylcarbonyl include, but are not limited to, 4-(l- piperidinyl)butanoyl, 3-(l-piperidinyl)propanoyl, 4-(4-morpholinyl)butanoyl, and 3-(4-morpholinyl)propanoyl.
  • heterocyclecarbonyl means a heterocycle, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of heterocyclecarbonyl include, but are not limited to, 4-morpholinylcarbonyl, 4-thiomorpholinylcarbonyl, 1-piperidinylcarbonyl, (4-hydroxy-l- piperidinyl)carbonyl, and 3-hydroxy-l-pyrrolidinylcarbonyl.
  • heterocyclecarbonylalkyl as used herein, means a heterocyclecarbonyl, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of heterocyclecarbonylalkyl include, but are not limited to, 2- (4-morpholinyl)-2-oxoethyl, 3-(4-morpholinyl)-3-oxopropyl, and 2-(l-piperidinyl)-2-oxoethyl.
  • heterocyclecarbonylalkylcarbonyl means a heterocyclecarbonylalkyl, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of heterocyclecarbonylalkylcarbonyl include, but are not limited to, 5-(4-morpholinyl)-5- oxopentanoyl, 4-(4-morpholinyl)-4-oxobutanoyl, and 5-(l-piperidinyl)-5-oxopentanoyl.
  • heterocycleoxy means a heterocycle group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of heterocycleoxy include, but are not limited to, 4-piperidinyloxy, 3-py ⁇ olidinyloxy, 3-azetidinyloxy, and tetrahydrofuran-3-yloxy.
  • hydroxy as used herein, means an -OH group.
  • hydroxyalkoxy means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of hydroxyalkoxy include, but are not limited to, 2-hydroxyethoxy, 3-hydroxypropoxy, 2,3-dihydroxypropoxy, 2,3-dihydroxypentoxy, and 3-hydroxy-2,2- dimethylpropoxy .
  • hydroxyalkyl as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2- hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypropyl, 2,3-dihydroxypentyl, 2-ethyl-4- hydroxyheptyl, and 3-hydroxy-2,2-dimethylpropyl.
  • hydroxyalkynyl as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkynyl group, as defined herein.
  • Representative examples of hydroxyalkynyl include, but are not limited to, 4-hydroxy-4- methylpent-1-ynyl, 4-hydroxybut-l-ynyl, and 3-hydroxyprop-l-ynyl.
  • hydroxyalkylcarbonyl means a hydroxyalkyl group, as defined herein, is appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of hydroxyalkylcarbonyl include, but are not limited to, glycoloyl, 3- hydroxypropanoyl, and 4-hydroxybutanoyl.
  • hydroxysulfonyl as used herein, means a HOS(O) 2 - group.
  • hydroxysulfonylalkyl as used herein, means a hydroxysulfonyl group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of hydroxysulfonylalkyl include, but are not limited to, 4- sulfobutyl, 3-sulfopropyl, and 2-sulfoethyl.
  • hydroxysulfonylalkylcarbonyl as used herein, means a hydroxysulfonylalkyl group, as defined herein, is appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of hydroxysulfonylalkylcarbonyl include, but are not limited to, 4-sulfobutanoyl and 3-sulfopropanoyl.
  • lower alkoxy as used herein, is a subset of alkoxy as defined herein and means a lower alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom, as defined herein.
  • Representative examples of lower alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, and 2-propoxy.
  • lower alkyl as used herein, is a subset of alkyl as defined herein and means a straight or branched chain hydrocarbon group containing from 1 to 3 carbon atoms. Examples of lower alkyl are methyl, ethyl, n-propyl, and iso-propyl.
  • mercapto as used herein, means a -SH group.
  • mercaptoalkyl as used herein, means a mercapto group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of mercaptoalkyl include, but are not limited to, hydroxymethyl, 2- mercaptoethyl, 3-mercaptopropyl, and 4-mercaptobutyl.
  • nitro as used herein, means a -N0 2 group.
  • R A and R B are each independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkoxyalkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylcarbonyl, alkoxysulfonyl, alkoxysulfonylalkyl, alkoxysulfonylalkylcarbonyl, alkyl, alkylcarbonyl, alkynyl, aryl, carboxyalkyl, carboxyalkylcarbonyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkylcarbonyl, cycloalkylcarbonylalkyl, cycloalkylcarbonylalkylcarbonyl, hetero
  • Representative examples of -NRAR B include, but are not limited to, amino, methylamino, dimethylamino, cyclohexylamino, (trans)-4-methylcyclohexylamino, (cis)-4-methylcyclohexylamino, (trans)-4-hydroxycyclohexylamino, and (cis)-4-hydroxycyclohexylamino.
  • (NRAR B )alkoxy means a -NR A R B group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of (NR A R ⁇ ) lko y include, but are not limited to aminomethoxy, 2- aminoethoxy, methylaminomethoxy, 2-(methylamino)ethoxy, dimethylaminomethoxy, 2- (dimethylamino)ethoxy, cyclohexylaminomethoxy, (trans)-4-methylcyclohexylaminomethoxy, (cis)-4-methylcyclohexylaminomethoxy, (trans)-4-hydroxycyclohexylaminomethoxy, and (cis)-4-hydroxycyclohexylaminomethoxy.
  • (NRAR B ) alkyl as used herein, means a -NR A R B group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of (NR A R ⁇ )alkyl include, but are not limited to aminomethyl, 2- aminoethyl, methylaminomethyl, 2-(methylamino)ethyl, dimethylaminomethyl, 2- (dimethylamino)ethyl, cyclohexylaminomethyl, (trans)-4-methylcyclohexyla ⁇ inomethyl, (cis)- 4-methylcyclohexylaminomethyl, (1 ⁇ ans)-4-hydroxycyclohexylaminomethyl, and (cis)-4-hydroxycyclohexylaminomethyl.
  • (NRAR B ) lkynyl as used herein, means a -NRARB group, as defined herein, appended to the parent molecular moiety through an alkynyl group, as defined herein.
  • Representative examples of (NR A R ⁇ )alkynyl include, but are not limited to 3-aminoprop-l-ynyl, 3-(dimethylamino)prop-l-ynyl, and 4-aminopent-l-ynyl.
  • (NRAR B )carbonyl as used herein, means a -NR A R B group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of (NR A R B )carbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, and (ethylmethylamino)carbonyl.
  • (NRAR ⁇ )carbonylalkyr' as used herein, means a (NR A R ⁇ )carbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • (NR A R ⁇ )carbonylalkyl include, but are not limited to, aminocarbonylmethyl, (methylamino)carbonylmethyl, (dimethylamino)carbonylmethyl, and (ethylmethylamino)carbonylmethyl.
  • -NR E R F means two groups, R E and Rp, which are appended to the parent molecular moiety through a nitrogen atom.
  • R E and R F are each independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, cycloalkyl, heteroarylalkyl, and hydroxyalkyl.
  • Representative examples of -NR E R F include, but are not limited to, amino, methylamino, dimethylamino, acetylamino, and acetylmethylamino.
  • (NR ⁇ R F koxy) means a -NR E R F group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of (NRERp)alkoxy include, but are not limited to aminomethoxy, 2- aminoethoxy, methylaminomethoxy, 2-(methylamino)ethoxy, dimethylaminomethoxy, and 2- (dimethylamino)ethoxy.
  • (NRERp)alkyl as used herein, means a -NR E R F group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of (NRERp)alkyl include, but are not limited to aminomethyl, 2- aminoethyl, 3-aminopropyl, methylaminomethyl, 2-(methylamino)ethyl, dimethylaminomethyl, and 2-(dimethylamino)ethyl.
  • (NR E Rp)alkylcarbonyl means a (NR E R ⁇ )alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of (NR E Rp)alkylcarbonyl include, but are not limited to aminoacetyl, 3-aminopropanoyl, 3-dimethylaminopropanoyl, and 4-aminobutanoyl.
  • (NRERF)carbonyl means a -NR E R F group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of (NRERp)carbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, and (ethylmethylamino)carbonyl.
  • (NRERF)carbonylalkyl means a (NRERp)carbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of (NR E R F )carbonylalkyl include, but are not limited to, 2- amino-2-oxoethyl, 3-amino-3-oxopropyl, and 4-amino-4-oxobutyl.
  • (NRERF)carbonylalkylcarbonyl means a (NRER F )carbonylalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of (NRER F )carbonylalkylcarbonyl include, but are not limited to, 3-amino-3-oxopropanoyl and 4- amino-4-oxobutanoyl .
  • (NRERF)sulfonyl means a -NR E RF group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of (NR E Rp)sulfonyl include, but are not limited to, aminosulfonyl, (methylamino)sulfonyl, (dimethylamino)sulfonyl, and (ethylmethylamino)sulfonyl.
  • (NRERF)sulfonylalkyl means a (NR E Rp)sulfonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of (NR £ R F )sulfonylalkyl include, but are not limited to, 2- (aminosulfonyl)ethyl, 2-(methylaminosulfonyl)ethyl, 3-(dimethylaminosulfonyl)propyl, and 4- (ethylmethylaminosulf onyl)butyl .
  • (NRERp)sulfonylalkylcarbonyl means a (NR E Rp)sulfonylalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of (NR E R F )sulfonylalkylcarbonyl include, but are not limited to, 3-(aminosulfonyl)propanoyl, 4-(methylaminosulfonyl)butanoyl, 4-(dimethylaminosulfonyl)butanoyl, and 4-(ethylmethylaminosulfonyl)butanoyl.
  • -NR G RH means two groups, R G and R H , which are appended to the parent molecular moiety through a nitrogen atom.
  • RQ and R H are each independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
  • Representative examples of -NR G R H include, but are not limited to, amino, methylamino, dimethylamino, acetylamino, and acetylmethylamino.
  • (NR G RH)alkoxy means at least one -NRQR H group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of (NR ⁇ R ⁇ lkoxy include, but are not limited to aminomethoxy, 2- aminoethoxy, methylaminomethoxy, 2-(methylamino)ethoxy, dimethylaminomethoxy, 2-(dimethylamino)ethoxy, and 2-(dimethylamino)-l-[(dimethylamino)methyl]ethoxy.
  • (NRGRH)alkyl means a -NR G R H group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of (NR ⁇ R ⁇ lkyl include, but are not limited to aminomethyl, 2- aminoethyl, 3-aminopropyl, methylaminomethyl, 2-(methylamino)ethyl, dimethylaminomethyl, and 2-(dimethylamino)ethyl.
  • (NRGRH)carbonyl means a -NR G R H group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of (NR G R H )carbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, and (ethylmethylamino)carbonyl.
  • (NRGRH)sulfonyl means a -NR G R H group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of (NR G R ⁇ )sulfonyl include, but are not limited to, aminosulfonyl, (methylamino)sulfonyl, (dimethylamino)sulfonyl, and (ethylmethylamino)sulfonyl.
  • This invention is intended to encompass compounds having formula (I) when prepared by synthetic processes or by metabolic processes. Preparation of the compounds of the invention by metabolic processes include those occurring in the human or animal body (in vivo) or processes occurring in vitro.
  • the compounds of the present invention can exist as therapeutically acceptable salts.
  • therapeutically acceptable salt represents salts or zwitterionic forms of the compounds of the present invention which are water or oil-soluble or dispersible, which are suitable for treatment of diseases without undue toxicity, irritation, and allergic response; which are commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use.
  • the salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group with a suitable acid.
  • Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2- hydroxyethansulfonate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate,trifluoroacetate, phosphate, glutamate, bi
  • amino groups in the compounds of the present invention can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.
  • acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.
  • Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • the cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethyla ine, diethylamine, ethylamine, tributylamine, pyridine, N,N- dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procame, dibenzyl amine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N - dibenzylethylenediamine.
  • Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
  • the present compounds can also exist as therapeutically acceptable prodrugs.
  • therapeutically acceptable prodrug refers to those prodrugs which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
  • prodrug refers to compounds which are rapidly transformed in vivo to parent compounds of formula (I) for example, by hydrolysis in blood.
  • a representative example of a prodrug of the present invention includes, but is not limited to, 4'-(6,7-dimethoxy-l,4-dihydroindeno[l,2- c]pyrazol-3-yl)- 1 , 1 '-biphenyl-4-yl 1 ,4'-bipiperidine-l '-carboxylate.
  • Asymmetric centers exist in the compounds of the present invention. These centers are designated by the symbols "R” or "S,” depending on the configuration of substituents around the chiral carbon atom. It should be understood that the invention encompasses all stereochemical isomeric forms, or mixtures thereof, which possess the ability to inhibit protein kinases.
  • Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, or direct separation of enantiomers on chiral chromatographic columns.
  • Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the ait.
  • the compounds can be administered alone or in combination with other anticancer agents.
  • the specific therapeutically effective dose level for any particular patient will depend upon factors such as the disorder being treated and the severity of the disorder; the activity of the particular compound used; the specific composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration; the route of administration; the rate of excretion of the compound employed; the duration of treatment; and drugs used in combination with or coincidently with the compound used.
  • the compounds can be administered orally, parenterally, osmotically (nasal sprays), rectally, vaginally, or topically in unit dosage formulations containing carriers, adjuvants, diluents, vehicles, or combinations thereof.
  • parenteral includes infusion as well as subcutaneous, intravenous, intramuscular, and intrasternal injection.
  • Parenterally administered aqueous or oleaginous suspensions of the compounds can be formulated with dispersing, wetting, or suspending agents.
  • the injectable preparation can also be an injectable solution or suspension in a diluent or solvent.
  • acceptable diluents or solvents employed are water, saline, Ringer's solution, buffers, monoglycerides, diglycerides, fatty acids such as oleic acid, and fixed oils such as monoglycerides or diglycerides.
  • the anticancer effect of parenterally administered compounds can be prolonged by slowing their absorption.
  • One way to slow the absorption of a particular compound is administering injectable depot forms comprising suspensions of crystalline, amorphous, or otherwise water-insoluble forms of the compound.
  • the rate of absorption of the compound is dependent on its rate of dissolution which is, in turn, dependent on its physical state.
  • Another way to slow absorption of a particular compound is administering injectable depot forms comprising the compound as an oleaginous solution or suspension.
  • injectable depot forms comprising microcapsule matrices of the compound trapped within liposomes, microemulsions, or biodegradable polymers such as polylactide-polyglycolide, polyorthoesters or poly anhydrides.
  • biodegradable polymers such as polylactide-polyglycolide, polyorthoesters or poly anhydrides.
  • the rate of drug release can be controlled.
  • Transdermal patches can also provide controlled delivery of the compounds.
  • the rate of absorption can be slowed by using rate controlling membranes or by trapping the compound within a polymer matrix or gel.
  • absorption enhancers can be used to increase absorption.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound can optionally comprise diluents such as sucrose, lactose, starch, talc, silicic acid, aluminum hydroxide, calcium silicates, polyamide powder, tableting lubricants, and tableting aids such as magnesium stearate or microcrystalline cellulose.
  • Capsules, tablets and pills can also comprise buffering agents, and tablets and pills can be prepared with enteric coatings or other release-controlling coatings.
  • Powders and sprays can also contain excipients such as talc, silicic acid, aluminum hydroxide, calcium silicate, polyamide powder, or mixtures thereof. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons or substitutes therefore.
  • Liquid dosage forms for oral administration include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs comprising inert diluents such as water. These compositions can also comprise adjuvants such as wetting, emulsifying, suspending, sweetening, flavoring, and perfuming agents.
  • Topical dosage forms include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and transdermal patches.
  • the compound is mixed under sterile conditions with a carrier and any needed preservatives or buffers.
  • These dosage forms can also include excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
  • Suppositories for rectal or vaginal administration can be prepared by mixing the compounds with a suitable non-irritating excipient such as cocoa butter or polyethylene glycol, each of which is solid at ordinary temperature but fluid in the rectum or vagina.
  • a suitable non-irritating excipient such as cocoa butter or polyethylene glycol, each of which is solid at ordinary temperature but fluid in the rectum or vagina.
  • Ophthalmic formulations comprising eye drops, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.
  • the total daily dose of the compounds administered to a host in single or divided doses can be in amounts from about 0.1 to about 200 mg/kg body weight or preferably from about 0.25 to about 100 mg/kg body weight.
  • Single dose compositions can contain these amounts or submultiples thereof to make up the daily dose.
  • the Chkl enzymatic assay was carried out using recombinant Chkl kinase domain protein covering amino acids from residue 1 to 289 and a polyhistidine tag at the C-terminal end.
  • Human cdc25c peptide substrate contained a sequence from amino acid residue 204 to 225.
  • the reaction mixture contained 25 mM of HEPES at pH 7.4, 10 mM MgCl 2 , 0.08 mM Triton X-100, 0.5 mM DTT, 5 ⁇ M ATP, 4 nM 33P ATP, 5 ⁇ M cdc25c peptide substrate, and 6.3 nM of the recombinant Chkl protein.
  • Compound vehicle DMSO was maintained at 2% in the final reaction.
  • Compounds of the present invention inhibited Chkl at IC 50 alues between about 0.1 nM and about 10,0000 nM.
  • Preferred compounds inhibited Chkl at IC 50 values between about 0.1 nM and about 250 nM.
  • Most preferred compounds inhibited Chkl at IC 50 values between about 0.1 nM and about 50 nM.
  • the compounds of the invention are useful in treating disorders which are caused or exacerbated by increased protein kinase levels.
  • the compounds of the invention possess the ability to inhibit protein kinases.
  • protein kinase inhibitors are useful in the treatment of both primary and metastatic solid tumors, including carcinomas of breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach, pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract (including kidney, bladder and urothelium), female genital tract (including cervix, uterus, and ovaries as well as choriocarcinoma and gestational trophoblastic disease), male genital tract (including prostate, seminal vesicles, testes and germ cell tumors), endocrine glands (including the thyroid, adrenal, and pituitary glands), and skin, as well as hemaiigiomas, melanomas, sarcomas (including those arising from bone and soft tissues as well
  • Such compounds may also be useful in treating solid tumors arising from hematopoietic malignancies such as leukemias (i.e., chloromas, plasmacytomas and the plaques and tumors of mycosis fungicides and cutaneous T- cell lymphoma/leukemia) as well as in the treatment of lymphomas (both Hodgkin's and non- Hodgkin's lymphomas).
  • leukemias i.e., chloromas, plasmacytomas and the plaques and tumors of mycosis fungicides and cutaneous T- cell lymphoma/leukemia
  • lymphomas both Hodgkin's and non- Hodgkin's lymphomas.
  • these compounds may be useful in the prevention of metastases from the tumors described above either when used alone or in combination with radiotherapy and/or other chemotherapeutic agents.
  • 3,6-Disubstituted-l,4-dihydroindeno[l,2-c]pyrazoles of general formula (5) and (6), wherein R A , R B , R , R 5 , and Rg are as defined in formula (I), can be prepared as described in Scheme 1.
  • l,4-Dihydroindeno[l,2-c]pyrazole-6-carbaldehyde prepared using the procedure described in US 6,297,238, herein incorporated by reference, can be treated with N- iodosuccinimide to provide 3-iodo-l,4-dihydroindeno[l,2-c]pyrazole-6-carbaldehyde.
  • 3-Iodo- l,4-dihydroindeno[l,2-c]pyrazole-6-carbaldehyde can be treated with amines of general formula (1) (or H 2 NOH) and a reducing agent, including but not limited to, sodium borohydride or sodium cyanoborohydride to provide amines of general formula (2).
  • a reducing agent including but not limited to, sodium borohydride or sodium cyanoborohydride
  • Amines of general formula (2) can be treated with boronic acids of general formula (4) (or 4,4,5,5-tetramethy-l,3,2- dioxaborolanes), a base, including but not limited to, cesium carbonate, sodium carbonate, or potassium carbonate, and a metal catalyst, including but not limited to, tetrakis(triphenylphoshine)palladium or bis(triphenylphoshine)palladium (II) chloride to provide 3,6-disubstituted-l,4-dihydroindeno[l,2-c]pyrazoles of general formula (5).
  • boronic acids of general formula (4) or 4,4,5,5-tetramethy-l,3,2- dioxaborolanes
  • a base including but not limited to, cesium carbonate, sodium carbonate, or potassium carbonate
  • a metal catalyst including but not limited to, tetrakis(triphenylphoshine)palladium or bis(tri
  • 3-Iodo-l,4-dihydroindeno[l,2-c]pyrazole-6-carbaldehyde can also be treated with nitrogen containing heterocycles, including but not limited to, azetidine, azepane, aziridine, azocane, morpholine, mono-protected piperazine, piperidine, 4-hydroxypi ⁇ eridine, pyrrolidine, thiomorpholine, or 1,1-dioxidothiomorpholine, for example, to provide compounds of general formula (3).
  • nitrogen containing heterocycles including but not limited to, azetidine, azepane, aziridine, azocane, morpholine, mono-protected piperazine, piperidine, 4-hydroxypi ⁇ eridine, pyrrolidine, thiomorpholine, or 1,1-dioxidothiomorpholine, for example, to provide compounds of general formula (3).
  • Compounds of general formula (3) can be treated with boronic acids of general formula (4), a base, including but not limited to, cesium carbonate, sodium carbonate, or potassium carbonate, and a metal catalyst, including but not limited to, tetrakis(triphenylphoshine)palladium or bis(triphenylphoshine)palladium (II) chloride to provide 3,6-disubstituted-l,4-dihydroindeno[l,2-c]pyrazoles of general formula (6).
  • a base including but not limited to, cesium carbonate, sodium carbonate, or potassium carbonate
  • a metal catalyst including but not limited to, tetrakis(triphenylphoshine)palladium or bis(triphenylphoshine)palladium (II) chloride to provide 3,6-disubstituted-l,4-dihydroindeno[l,2-c]pyrazoles of general formula (6).
  • 3,7-disubstituted-l,4-dihydroindeno[l,2-c]pyrazoles can be prepared from l,4-dihydroindeno[l,2-c]pyrazole-7-carbaldehyde using the methodology described in Scheme 1.
  • 5,6-Dimethoxy-l- indanone purchased from Aldrich Chemical Co., can be treated with sodium cyanide to provide 5-hydroxy-6-methoxy-l-indanone.
  • 5-Hydroxy-6-methoxy-l-indanone can be treated with nitric acid and sodium nitrite to provide 5-hydroxy-6-methoxy-4-nitro-l-indanone.
  • 5-Hydroxy-6- methoxy-4-nitro-l-indanone can be treated with iodomethane and then methodology described in Scheme 2 to provide compounds of general formula (12).
  • Compounds of general formula (12) can be treated with a reducing agent, including iron metal in the presence of acetic acid, to provide amines of general formula (13).
  • Compounds of general formula (13) where R 4 is chlorine, bromine or iodine can be further elaborated under Heck, Suzuki, or Stille conditions to provide compounds of general formula (13) wherein R 4 is aryl or heteroaryl as defined herein.
  • An example of suitable Suzuki conditions is described in Example ID herein or Suzuki conditions as described in N. Miyaura, A. Suzuki, Chem.
  • Compounds of general formula (13), wherein R) is chlorine, bromine, or iodine can be treated with aryl or heteroaryl stannanes (Me 3 SnR , Bu 3 SnR 4 ), purchased or prepared using known mehodology, a palladium source such as tris(dibenzylidineacetone)dipalladium or palladium diacetate, and a ligand such as tri(2-furyl)phosphine or triphenyl arsine in a solvent such as DMF at 25-150 °C (Stille conditions) to provide compounds of general formula (13) wherein R 4 is aryl or heteroaryl as defined herein.
  • aryl or heteroaryl stannanes Me 3 SnR , Bu 3 SnR 4
  • a palladium source such as tris(dibenzylidineacetone)dipalladium or palladium diacetate
  • a ligand such as tri(2-furyl)phosphin
  • Organotin reagents can be prepared from arylhalides, aryltriflates, heteroarylhalides, or heteroaryltriflates by reaction with distannanes like (Me 3 Sn) 2 (hexamethyl distannane) in the presence of a palladium source like Pd(Ph 3 P) as described in Kharia, et. al., Helvetica Chimica Acta, 1909-1920:81(11) (1998) and in Benaglia, et al., Tetrahedron Letters, 4737-4740:38 (1997) 38.
  • distannanes like (Me 3 Sn) 2 (hexamethyl distannane)
  • Pd(Ph 3 P) palladium source
  • 2,3,7,8- Tetrahydro-6H-indeno[5,6-b][l,4]dioxin-6-ones of general formula (16) can be treated under conditions as described in Scheme 2 to provide 1,4,7,8- tetrahydro[l,4]dioxino[2',3':5,6]indeno[l,2-c]pyrazoles of general formula (17), including but not limited to, 4-(l,4,7,8-tetrahydro[l,4]dioxino[2',3':5,6]indeno[l,2-c]pyrazol-3-yl)-l,l - biphenyl-4-ol.
  • Example 1A 1 ,4-Dihydro-indeno ⁇ 1 ,2-c1pyrazole-6-carbaldehyde
  • 6-bromo-l,4-dihydro-indeno[l,2-c]pyrazole (0.100 g, 0.425 mmol, see U.S. Patent 6297238 for preparation) in THF (3 mL) at -78 °C was added 1.8 M PhLi in cyclohexane/ether (0.71 mL, 1.28 mmol) followed by 1.3 M s-BuLi in cyclohexane (0.98 mL, 1.28 mmol) 30 minutes later.
  • the reaction mixture was stirred at -78 °C for 60 minutes and DMF (0.33 mL, 4.25 mmol) was added. The dry ice bath was removed after 30 minutes. After an additional 30 minutes, the reaction was quenched with water. The reaction mixture was extracted with EtOAc, washed with 50% brine, dried over MgSO , filtered, and concentrated. The concentrate was purified by flash chromatography eluted with EtOAc/hexane (7:3 to 8:2) to give 0.053 g (68%) of the desired product as brown solid..
  • Example IB 3-Iodo- 1.4-dihydro-indenof 1 ,2-clp yrazole-6-carbaldehyde
  • a suspension of Example 1A (7.90 g, 0.0429 mol) and N-iodosuccinimide (11.6 g, 0.0515 mol) in DMF (150 mL) was heated at 80 °C for 5.5 hours. The reaction was cooled and the solvent was evaporated. The concentrate was triturated with EtOAc and ether to give 7.20 g of brown solid as the desired product. The filtrate was concentrated and purified by flash cliromatography eluted with EtOAc/hexane (7:3) to give 1.30 g of the desired product (combined yield: 64%).
  • Example 1C N-
  • 4- methylcyclohexylamine hydrochloride (8.66 g, 0.0579 mol) and potassium carbonate (4.81 g, 0.0348 mol).
  • Example ID 4-(6- ⁇ T(1xans-4-methylcvclohexyl aminolmethyl ⁇ - 1.4-dihvdroindeno[ 1 ,2-clpyrazol-3-yl)benzoic acid A mixture of Example 1C (trans, 45.0 mg, 0.110 mmol), 4-carboxybenzene boronic acid (20.1 mg, 0.121 mmol), Na 2 C0 3 (1 M, 0.26 mL, 0.264 mmol), and Pd(PPh 3 ) 2 Cl 2 (7.70 mg, 0.0110 mmol) in DME/EtOH/H 2 O (7:2:3, 1.2 mL) in a capped 2 mL vial was heated at 160 °C for 450 seconds in a Smith Synthesizer (300 W).
  • the reaction was cooled using 40 psi pressurized air. Solvents were evaporated and the crude product was purified using preparative HPLC to give 25.0 mg (26%) of the desired product as pale yellow foam.
  • the purification was processed on a Waters Symmetry C8 column (25mm X 100mm, 7 ⁇ m particle size) using a gradient of 10% to 100% acetonitrile: 0.1% aqueous TFA over 8 min (lOmin run time) at a flow rate of 40 mL/min.
  • Example 2 4-(6- ⁇ r(cis-4-methylcvclohexyl)aminolmethyl I - 1 ,4-dihydroindeno
  • the desired product was prepared using the procudure in Example ID replacing the trans product from Example 1C with the cis product from Example lC.
  • Example 3 ethyl 4-(6-( F(trans-4-methylcyclohexyl)aminolmethyl i-1 ,4-dihydroindeno IT ,2-c1pyrazol-3- yPbenzoate
  • trans 45.0 mg, 0.110 mmol
  • DME/EtOH/H 2 0 7.3:2
  • 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzoic acid ethyl ester (31.8 ⁇ L, 0.121 mmol), Na 2 C0 3 (IM, 0.11 mL), and Pd(PPh 3 ) 2 Cl 2 (7.7 mg, 0.0110 mmol).
  • Example 4A frans-4-r(3-Iodo-l,4-dihydro-indenori,2-clpyrazol-6-ylmethyl)-aminol-cyclohexanol
  • the desired product was prepared by replacing 4-methylcyclohexylamine hydrochloride with trans-4-hydroxycyclohexylamine hydrochloride in Example IC.
  • Example 4B 4-(6- ⁇ r(trans-4-hydroxycvclohexyl)aminolmethyl ⁇ -l,4-dihydroindeno ⁇ ,2-clpyrazol-3- vDbenzoic acid
  • the desired product was prepared by replacing Example IC with Example 4A in Example ID.
  • Example 5 N- 1 " 3-(6- ⁇ r(trans-4-hvdroxycvclohexyl)amino1mefhyl 1-1 ,4-dihydroindeno I " 1 ,2-c1pyrazol-3- vDphenyllacetamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 4A and 3-acetamidobenzene boronic acid in Example ID.
  • Example 6 4-(6- ⁇ r(frans-4-hydroxycyclohexyl)aminolmethyli-1.4-dihvdroindenori,2-c1pyrazol-3- vPbenzamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 4A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 7A 3-Iodo-6-morpholin-4-ylmethyl- 4-dihvdro-indenori,2-clpyrazole
  • a mixture of Example IB (1.00 g, 3.22 mmol), morpholine (0.84 mL, 9.66 mmol), and TsOH.H 2 O (61.2 mg, 0.322 mmol) in toluene (50 mL) was heated to refluxing overnight. The solvent was evaporated. To the resulting residue were added EtOH (40 mL), THF (10 mL), and NaBH (0.182 g, 4.83 mmol) at room temperature. The mixture was stirred overnight and the resulting solid was filtered. The filtrate was concentrated, treated with IN HC1, and extracted with EtOAc.
  • Example 7B 4-r6-(4-morpholinylmethyl -l,4-dihydroindenori,2-clpyrazoI-3-yllbenzoic acid
  • Example 8 methyl 4- r6-(4-morpholinylmethyl)- 1 ,4-dihydroindeno [1 ,2-clpyrazol-3-yl1benzoate
  • MeOH MeOH
  • HC1 0.50 mL
  • the reaction mixture was concentrated and purified using HPLC.
  • the TFA salt of the desired product was converted into the HC1 (17.0 mg, 81%) using the procedure in Example 7B.
  • the HPLC condition is indicated as the following: Dynamx C18 (5 ⁇ m, 21.4x250 mm) column was used containing a Rainin Dynamax solvent delivery system with a Dynamax UV-D II detector.
  • the solvent system used was a 20% to 100% acetonitrile/water containing 0.1% TFA linear gradient.
  • the elution rate was 10 mL/min and the UV detection wavelength was set at 254 nm).
  • Example 9 4-F6-(4-morpholinylmethyl)-l,4-dihydroindenori,2-clpyrazol-3-yllbenzamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 7A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • the product was purified by flash chromatography eluted with EtOAc/MeOH NH 4 OH (10:1:0.1).
  • Example 10 N-(3-r6-(4-morpholinylmethyl)-l,4-dihydroindenon,2-clpyrazol-3-vnphenyljacetamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 7A and 3-acetamidobenzeneboronic acid in Example ID.
  • Example 11 A N-(5-Bromo-2-methyl-phenyl)-acetamide To a solution of 3-bromo-6-mefhylaniline (1.00 g , 5.37 mmol) in pyridine (8 mL) was added acetyl chloride (0.76 mL, 10.7 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour and concentrated. The residue was extracted with EtOAc, washed with 5% citric acid, dried over MgSO 4 , concentrated, and triturated with ether to give 0.750 g (61%) of the desired product as off-white crystal.
  • Example 11C 2-Acetylamino-4-(4,4,5,5-tetramethyl-Fl,3,21dioxaborolan-2-yl)-benzoic acid methyl ester
  • TMSCHN 2-Acetylamino-4-(4,4,5,5-tetramethyl-Fl,3,21dioxaborolan-2-yl)-benzoic acid methyl ester
  • Example IC The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 7A and Example 1 IC in Example ID.
  • the product was purified using the HPLC condition in Example 8.
  • Example 12 4- f 6- r(4-h ydroxy- 1 -piperidinypmethyll- 1 ,4-dihydroindeno [ " 1 ,2-clpyrazol-3-yl Ibenzoic acid
  • Example 12A l-(3-Iodo-l,4-dihvdro-indeno ⁇ .2-clpyrazol-6-ylmethyl)-piperidin-4-ol
  • the desired product was prepared by replacing morpholine with 4-hydroxypiperidine in Example 7A.
  • Example 12B 4- ⁇ 6- r(4-hvdroxy- 1 -piperidinvDmethyll- 1 ,4-dihydroindeno I " 1 ,2-c1pyrazol-3-yl Ibenzoic acid
  • the desired product was prepared by replacing Example IC with Example 12A in Example ID.
  • Example 13 4- ( 6-r(4-hydroxy- 1 -piperidinvDmethyll- 1 ,4-dihydroindenor 1 ,2-c1pyrazol-3-yl Ibenzamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 12A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 14 N-(3 - ⁇ 6- r (4-hydroxy- 1 -piperidmvDmethyl] - 1 ,4-dihydroindeno [ " 1 ,2-clpyr azol-3- yl 1 phenyl) acetamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 12A and 3-acetamidobenzeneboronic acid in Example ID.
  • Example 15 A (2,2-Dimethyl-propyl)-(3-iodo-l,4-dihydro-indenori,2-c1pyrazol-6-ylmethyl)-amine
  • the desired product was prepared by replacing morpholine with neopentylamine in Example 7A.
  • MS (DC17NH 3 ) m/z: 382.1 (M+H) + ; 1H NMR (300 MHz, CD 3 OD) ⁇ 0.92 (s, 9H), 2.34 (s, 2 H), 3.53 (s, 2 H), 3.82 (s, 2 H), 7.35 (d, J 7.80 Hz, 1 H), 7.52-7.61 (m, 2 H).
  • Example 15B 4-16-f (neopentylamino)methyn- 1 ,4-dihydroindeno F 1 ,2-c1pyrazol-3-yl Ibenzoic acid
  • the desired product was prepared by replacing Example IC with Example 15 A in Example ID.
  • Example IC The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 15A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 17 A 3- F(3-Iodo- 1 ,4-dihydro-indenoF 1 ,2-clp yrazol-6-ylmethyl)-amino1-2,2-dimethyl-propan- 1 -ol
  • the desired product was prepared by replacing morpholine with 3-amino-2,2-dimefhyl-l- propanol in Example 7A.
  • Example 17B 4-(6- ( F(3-hydroxy-2,2-dimethylpropyl)amino1methyl 1-1 ,4-dihydroindeno F 1 ,2-clpyrazol-3- vDbenzoic acid
  • the desired product was prepared by replacing Example IC with Example 17 A in Example ID.
  • Example 18 4-(6-( F(3-hydroxy-2,2-dimethylpropyl)aminolmethyl ⁇ -l,4-dihydroindenoFl,2-clpyrazol-3- ypbenzamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 17A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 19A (3-Iodo-l,4-dihydro-indenoFl,2-clpyrazol-6-yl)-methanol
  • a suspension of Example IB (0.500 g, 1.61 mmol) in a mixture of MeOH (9 mL) and THF (3 mL) was added NaBH (73.0 mg, 1.93 mmol) at room temperature.
  • the mixture was stirred for 2 hours and the solvent was evaporated.
  • the resulting concentrate was dissolved in hot CH 2 CI 2 with a small amount of MeOH and the desired product was recrystalized to give 0.324 g (65%) of the desired product as brown solid.
  • Example 19B 4-F6-(hvdroxymethyl)-l,4-dihvdroindenoFl,2-c1pyrazol-3-vnbenzoic acid
  • the desired product was prepared by replacing Example IC with Example 19A in Example ID.
  • Example 20 4-F6-(hvdroxymethyl)-l,4-dihydroindenoFl,2-clpyrazol-3-yllbenzamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 19A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 21 A 3-Iodo-6-methoxymethyl-l ,4-dihydro-indenoFl ,2-clpyrazole
  • a mixture of Example 19A (0.294 g, 0.942 mmol), LiBr (0.090 g, 1.04 mmol), and PBr 3 (0.14 mL, 11.49 mmol) in DMF (5 mL) was stirred at room temperature for 2 hours. Ice was added to the reaction mixture and the resulting precipitate was filtered. The solid was suspended in MeOH and treated with Et 3 N (1 mL). The mixture was concentrated and purified by flash chromatography eluted with EtOAc/CH 2 Cl 2 (2:98 to 5:95) to give 0.0422 g (12%) of the desired product.
  • Example 2 IB 4- F6-(methoxymethyl)- 1 ,4-dihydroindeno F 1 ,2-c1pyrazol-3-yllbenzoic acid
  • the desired product was prepared by replacing Example IC with Example 21 A in Example ID.
  • Example 22A 5-Allyloxy-indan- 1 -one To a solution of 5 -hydroxy- 1-indanone (4.27 g, 0.0288 mol) in THF/DMF (5 mL/10 mL) at 0°C was added NaH (60%, 1.21 g, 0.0303 mol) followed by allyl bromide (2.7 mL, 0.0317 mol). The reaction was warmed to room temperature and stirred overnight. The reaction mixture was quenched with water and extracted with EtOAc, washed with brine, dried over MgSO , filtered, and concentrated. The residue was purified by flash chromatography eluted with EtOAc/hexane (1:1) to give 4.29 g (79%) of the desired product as brown oil.
  • Example 22B methyl 4-F(5-(allyloxy)-l-oxo-l,3-dihydro-2H-inden-2-ylidene)(hvdroxy)methyllbenzoate
  • LDA 2.0M, 0.65 mL, 1.30 mmol
  • a pre-mixed suspension of CDI 0.191 g, 1.18 mmol
  • terephthalic acid monomethyl ester 0.213 g, 1.18 mmol
  • Example 22C methyl 4-F6-(allyloxy)-l,4-dihydroindenoFl,2-c
  • a mixture of Example 22B (1.70 g, 4.85 mmol), hydrazine monohydrate (0.28 mL, 5.82 mmol), and AcOH (0.33 mL, 5.82 mmol) in EtOH (120 mL) was heated at 90 °C overnight. The reaction was cooled and the precipitate was filtered. The filter cake was rinsed with ether to give 1.56 g (93%) of the desired product as a white solid.
  • Example 22D 4-F6-(allyloxy)-l,4-dihydromdenoFl,2-clpyrazol-3-vHbenzoic acid
  • Example 23 4-F6-(allyloxy)-l,4-dihvdroindenoFl,2-clpyrazol-3-vnbenzamide
  • a mixture of Example 22D (50.0 mg, 0.150 mmol), HOBt (28.5 mg, 0.211 mmol), EDC (40.4 mg, 0.211 mmol), NH 4 C1 (40.1 mg, 0.750 mmol), and Et 3 N (0.14 mL, 0.975 mmol) in DMF (3 mL) in a capped flask was stirred at room temperature for 24 hours. The reaction mixture was diluted with EtOAc and washed with NaHCO 3 and brine.
  • Example 24 methyl 4-(6-hydroxy- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-3-yl)benzoate
  • THF 16 mL
  • Pd(PPh 3 ) 4 0.0130 g, 2%
  • a suspension of NaBH in THF (2 mL) was added to the above reaction mixture in three portions at 0°C. The reaction was warmed to room temperature and stirred overnight. The reaction mixture was treated with acetone and the solvent was evaporated. The residue was treated with warm MeOH and the solid was filtered.
  • the desired product was prepared by replacing Example 22C with Example 24 in
  • Example 26A 3-Iodo- 1 ,4-dihydro-indeno F 1 ,2-clpyrazole-6-carboxylic acid
  • NaC10 2 (1.14 g, 0.0126 mol) in H 2 0 (15 mL) dropwise.
  • the reaction mixture was stirred for 15 minutes at 0 °C followed by the addition of NaHSO 3 (1.11 g, 0.0106 mol). The resulting suspension was warmed to room temperature and stirred for 1 hour. The reaction mixture was treated with Na 2 S 2 O3 solution and concentrated under reduced pressure. The residue was treated with water and stirred for 1 hour. The mixture was filtered and the filter cake was rinsed with water and dried in a vacuum oven to provide the title compound which was used in the next step without further purification.
  • Example 26B 3-Iodo-l,4-dihvdro-indenoFl,2-clpyrazole-6-carboxylic acid (4-hydroxy-cyclohexyl)-amide
  • the desired product was prepared by replacing NH 4 C1 and Example 22D with trans-4- amino-cyclohexanol and Example 26A in Example 23.
  • Example 26C 4-(6- ⁇ F(trans-4-hydroxycyclohexyl aminolcarbonyl)-l,4-dihydroindenori,2-clpyrazol-3- yDbenzoic acid
  • the desired product was prepared by replacing Example IC with Example 26B in Example ID.
  • Example 27A 3-Iodo- 1 ,4-dihy dro-indenoF 1 ,2-c]pyrazole-6-carboxylic acid (2,2-dimethyl-propyP-amide
  • the desired product was prepared by replacing NH C1 and Example 22D with neopentylamine and Example 26A in Example 23.
  • Example 27B 4-(6-F(neopentylamino)carbonyll-l,4-dihvdroindenoFl,2-clpyrazol-3-yllbenzoic acid The desired product was prepared by replacing Example IC with Example 27 A in Example ID.
  • Example 28 3-F4-(ar nocarbonyl)phenyll-N-neopentyl-l,4-dihvdroindenoFl,2-clpyrazole-6-carboxamide
  • the desired product was prepared replacing Example IC and 4-carboxybenzene boronic acid with Example 27A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 29A 4'-(4,4,5,5-Tetramethyl-Fl,3,21dioxaborolan-2-vP-bi ⁇ henyl-4-ol
  • Example 29B 4-(6- ⁇ F(cis-4-methylcyclohexyPaminolmethyl)-l,4-dihvdroindenoFl,2-clpyrazol-3-yP-l,r- biphenyl-4-ol
  • the desired product was prepared by replacing Example IC (trans) and 4-carboxybenzene boronic acid with Example IC (cis) and Example 29A in Example ID.
  • Example 30A 4 -Bromo-3 -methox y-biphenyl-4-ol
  • 2-methoxy-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol (0.250 g, 1.00 mmol)
  • 1,4-dibromo benzene 0.259 g, 1.10 mmol
  • Pd(PPh 3 ) 0.0580 g, 5%
  • CsF 0.456 g, 3.00 mmol
  • DME/MeOH 25 mL, 1:1
  • the desired product was prepared by replacing 4 -bromo-biphenyl-4-ol with Example
  • Example 30C 4-(6-f r(tians-4-hvdroxycvclohexyl)aminolmethyl)-l,4-dihydroindenori,2-clpyrazol-3-yl)-3- methox y- 1 , 1 -biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 4A and Example 30B in Example ID.
  • Example 31A 4 -Bromo-3-hvdroxymethyl-biphenyl-4-ol
  • the desired product was prepared by replacing 2-methoxy-4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenol with 2-hydroxymethyl-4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenol in Example 30A.
  • MS (DCI/NH 3 ) m/z: 278.0, 279.8 (M, M+2).
  • Example 3 IB 3-HvdroxymethvI-4 -(4,4,5,5-tetramethyl-Fl,3,21dioxaborolan-2-yl)-biphenyl-4-ol
  • the desired product was prepared by replacing 4-bromo-biphenyl-4-ol with Example 31 A in Example 29A.
  • Example 31C 4 -(6-(F(trans-4-hvdroxycvclohexyl)aminolmethyl)-l,4-dihvdroindenoFl,2-clpyrazol-3-yP-3-
  • Example 32 3-methoxy-4 - ⁇ 6-F(neopentylamino)methyll-l,4-dihydroindenoFl,2-clpyrazol-3-yll-l,l - biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 15A and Example 30B in Example ID.
  • Example 33 4-(6-f F(3-hydroxy-2,2-dimethylpropyl)aminolmethyl ⁇ -l,4-dihydroindenoFl,2-clpyrazol-3-yP-3- methoxy- 1 , 1 -biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 17A and Example 30B in Example ID.
  • Example 34A 5-(allyloxy)-2-F(4-bromophenvP(hydroxy methylenel-l-indanone
  • the desired product was prepared by replacing terephthalic acid monomethyl ester with 4- bromo-benzoic acid in Example 22B.
  • Example 34B 6-Allyloxy-3-(4-biOmo-phenyP-l,4-dihvdro-indenoFl,2-clpyrazole The desired product was prepared by replacing Example 22B with Example 34A in Example 22C.
  • Example 34C 3-(4 -hydroxy- 1 , 1 -biphenyl-4-yP- 1 ,4-dihydroindeno F 1 ,2-c1pyrazol-6-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 34B and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol in Example ID.
  • Example 35 3-(4'-hvdroxy-3 -mefhoxy- 1 , 1 '-biphenyl ⁇ -yP- 1 ,4-dihvdroindenoF 1.2-clpyrazol-6-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 34B and 2-methoxy-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol in Example ID.
  • Example 36 4 -F6-(hvdroxymethyl)-l,4-dihvdroindenoFl,2-clpyrazol-3-vn-l, -biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 19A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol in Example ID.
  • Example 37A 3 -Iodo- 1 ,4-dihydro-indeno [ 1 ,2-clpyr azole
  • the desired product was prepared by replacing Example 1 A with l,4-dihydro-indeno[l,2- cjpyrazole, prepared according to procedure described in U.S. Patent 6297238, in Example IB.
  • Example 37B 4 '-( 1 ,4-dihydroindeno fl ,2-clpyrazol-3-yP- 1 , 1 -biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 37 A and Example 29A in Example ID.
  • Example 38 4 '- l " 6-(h ydrox ymeth yl)- 1 ,4-dihydroindeno I " 1 , 2-clp yrazol-3 -yll -3 -methoxy- 1 , 1 -biphen yl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 19A and Example 30B in Example ID.
  • Example 39 3-(3 -fluoro-4-hvdroxy-l, -biphenyl-4-vP-l,4-dihvdroindenon,2-c1pyrazol-6-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 34B and 2-fluoro-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol in Example ID.
  • Example 40A 2-Amino-4-(4,4,5,5-tetramethyl-ri,3,21dioxaborolan-2-vP-phenol
  • Pd 2 (dba) 3 (0.0765 g)
  • Cy-MAP (0.165 g)
  • 1,4-dioxane 6 mL
  • 2-amino- 4-chloro-phenol (0.300 g, 2.09 mmol)
  • bis(pinacolato) diboron 0.557 g, 2.19 mmol
  • KOAc 0.308 g, 3.14 mmol
  • the reaction mixture was heated at 85 °C overnight, allowed to cool to room temperature, concentrated under reduced pressure and the residue was treated with EtOAc.
  • the ethyl acetate layer was washed with brine, dried over MgS0 4 , filtered, and the filtrate was concentrated under reduced pressure.
  • the residue was purified by flash chromatography eluting with hexanes/EtOAc (7:3 to 1:1) to give 0.273g (69%) of the desired product as brown solid.
  • Example 41 A 4-Bromo-4-hvdroxy-5-methoxy-biphenyl-2-carbaldehvde
  • 2-bromo-5-hydroxy-4-methoxy-benzaldehyde (1.00 g, 4.32 mmol)
  • 4- bromophenyl boronic acid (1.04 g, 5.18 mmol)
  • Pd(PPh 3 ) (0.250 g)
  • CsF (1.97 g, 12.6 mmol) in DME/MeOH (1:1, 65 mL) was heated at 70 °C overnight.
  • the mixture was diluted with CH 2 C1 2 and washed with water.
  • the organic layer was dried over MgSO , filtered, and the filtrate concentrated under reduced pressure.
  • Example 41B 4-Hvdroxy-5-methoxy-4'-(4,4,5,5-tetramethyl-n,3,21dioxaborolan-2-vP-biphenyl-2- carbaldehyde
  • the desired product was prepared by replacing 4'-bromo-biphenyl-4-ol with Example 41 A in Example 29A.
  • the product was carried into the next step without further purification.
  • Example 41C 4-hvdroxy-4'-r6-(hvdroxymethyl)-l,4-dihydroindenori,2-clpyrazol-3-yll-5-methoxy-l,r- biphenyl-2-carbaldehyde
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 19A and 41B in Example ID.
  • Example 42 3-(4-hvdroxy-l,r-biphenyl-4-vP-N-(trans-4-hydroxycvclohexyP-l,4-dihvdroindenori,2- clpyrazole-6-carboxamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 26B and Example 29A in Example ID.
  • the microwave assisted reaction was run for 450 to 2000 seconds at 160 to 180 °C.
  • Example 43 3-(4 '-hydroxy- 1 , 1 -biphenyl-4-vP-N-neopentyl- 1 ,4-dihydroindeno IT ,2-e1pyrazole-6-carboxamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 27A and Example 29A in Example ID.
  • Example 44A l,4-dihvdroindenon,2-c1pyrazole-7-carbaldehvde
  • the desired product was prepared by replacing 6-bromo-l,4-dihydro-indeno[l,2-c]pyrazole with 7-bromo-l,4-dihydro-indeno[l,2-c]pyrazole in Example 1 A.
  • Example 44B 3-iodo-l,4-dihydroindenoFl,2-c]pyrazole-7-carbaldehyde
  • the desired product was prepared by replacing Example IB with Example 44B in Example 19 A.
  • Example 44D 4-F7-(hvdroxyn ⁇ ethvP-l,4-dihydroindenoFl,2-cl ⁇ yrazol-3-vnbenzoic acid
  • the desired product was prepared by replacing Example IC with Example 44C in Example ID.
  • Example 45 4- F7-(hydroxymethvP- 1 ,4-dihydroindeno F 1 ,2-clpyr azol-3 -yllbenzamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 44C and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 46 4 -r7-(hydroxymethyl)-l,4-dihvdiOindenoFl,2-clpyrazol-3-yll-3-methoxy-l, -biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 44C and Example 30B in Example ID.
  • Example 47 N- ⁇ 3-F7-(hvdroxymethyP-l,4-dihvdroindenoFl,2-clpyrazol-3-yllphenyl
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 44C and 3-acetamidobenzene boronic acid in Example ID.
  • Example 48 A 3-Iodo-7-morpholin-4-ylmethyl-l,4-dihvdro-indenoFl,2-c1pyrazole The desired product was prepared by replacing Example IB with Example 44B in Example 7A.
  • Example 48B 4-F7-(4-morpholinylmethyl)-l,4-dihydroindenoFl,2-c1pyrazol-3-yllbenzoic acid
  • Example 49 4-F7-(4-morpholinylmethyl)-l,4-dihydroindenoFl,2-c1pyrazol-3-yllbenzoic acid
  • MS (DCI/NH 3 ) m/z
  • Example 50 4-f 7- ⁇ F(2-hvdroxyethyl)aminolmethyl 1-1 ,4-dihydroindeno F 1 ,2-clpyrazol-3-yl)benzoic acid
  • Example 50A 2-F(3-Iodo- 1 ,4-dihydro-indenoFl ,2-clpyrazol-7-ylmethyl)-aminol-ethanol
  • the desired product was prepared by replacing Example IB and morpholine with Example 44B and 2-amino-ethanol in Example 7A.
  • Example 50B 4-(7-(F(2-hydroxyethyl)amino1methyl
  • the desired product was prepared by replacing Example IC with Example 50A in Example ID.
  • Example 51 4 -r7-(hydroxymethyl)-l ,4-dihydroindenoFl ,2-clpyrazol-3-yl1-l , 1 -biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 44C and Example 29A in Example ID.
  • Example 52A (2,2-Dimethyl-propyP-(3-iodo-l,4-dihydro-indenoFl,2-clpyrazol-7-ylmethyP-amine
  • the desired product was prepared by replacing Example IB and morpholine with Example 44B and neopentylamine in Example 7A.
  • Example 52B 4- ⁇ 7-F(neopentylamino)methyll- 1 ,4-dihydroindenoF 1 ,2-clpyrazol-3-yl Ibenzamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 52A and 4-(4,4,5,5-teti"amethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • Example 53 4 - ⁇ 7-r(neopentylamino)methyll- 1 ,4-dihydroindeno Fl ,2-clpyrazol-3-yl ⁇ - 1 , 1 -biphenyl-4-ol
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 52A and Example 29 A in Example ID.
  • Example 54A 3-Iodo- 1 ,4-dihvdro-indeno F 1 ,2-clpyrazole-7-carboxylic acid
  • the desired product was prepared by replacing Example 2B with Example 44B in Example 26A.
  • Example 54B 3 -Iodo-1 ,4-dihvdro-indeno Fl ,2-clpyrazole-7-carboxylic acid methylamide
  • the desired product was prepared by replacing Example 22D and NH C1 with Example 54 A and methylamine in Example 23.
  • Example 54C 4-(7-Ffmethylamino)carbonyll-l,4-dihydroindenoFl,2-c1pyrazol-3-yl ⁇ benzoic acid
  • the desired product was prepared by replacing Example IC with Example 54B in Example ID.
  • the microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID.
  • Example 55 3- F4-(aminocarbonypphenyll -N-methyl- 1 ,4-dihydroindeno F 1 ,2-c1pyrazole-7-carboxamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 54B and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID.
  • the microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID.
  • Example 56 3-(4 -hydroxy- 1 , 1 -biphenyl-4-yl)-N-methyl- 1 ,4-dihvdroindeno F 1 ,2-clpyrazole-7-carboxamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 54B and Example 29A in Example ID.
  • the microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID.
  • Example 57 A 3 -Iodo- 1 ,4-dihy dro-indeno ⁇ 1 ,2-clp yrazole-7-carboxylic acid (2, 2-dimethyl-prop vP-amide
  • the desired product was prepared by replacing Example 22D and NH 4 C1 with Example 54A and neophentylamine in Example 23.
  • Example 57B 4-(7-F(neopentylamino)carbonyl1-l,4-dihydroindenoFl,2-c1pyrazol-3-yl)benzoic acid
  • the desired product was prepared by replacing Example IC with Example 57A in Example ID.
  • the microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID.
  • Example 58 3-(4 -hydroxy- 1 , 1 '-biphenyl-4-vP-N-neopentyl- 1 ,4-dihydroindeno Fl ,2-clpyrazole-7-carboxamide
  • the desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 57A and Example 29A in Example ID.
  • the microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID.
  • Example 59A 3-Iodo- 1 ,4-dihydro-indenoFl ,2-clpyrazole-7-carboxylic acid (trans-4-hydroxy-cvclohexyP- amide
  • the desired product was prepared by replacing Example 22D and NH 4 CI with Example 54A and trans-4-amino-cyclohexanol in Example 23.
  • Example 59B 4-(7- ⁇ F( frans-4-hvdroxycyclohexyDaminolcarbonyl 1-1 ,4-dihvdroindenoF 1 ,2-clpyrazol-3- y benzoic acid
  • the desired product was prepared by replacing Example IC with Example 59A in Example ID.
  • the microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID.
  • Example 60A methyl 6-FF5-(allyloxy)-l-oxo-l,3-dihvdro-2H-inden-2-ylidene1(hydroxy)methyllnicotinate
  • the desired product was prepared by replacing terephthalic acid monomethyl ester with 5- (methoxycarbonyl)-2-pyridinecarboxylic acid in Example 22B.
  • Example 60B methyl 6-r6-(allyloxy)-l,4-dihydroindenoFl,2-clpyrazol-3-yl1meotmate
  • the desired product was prepared by replacing Example 22B with Example 60A in Example
  • Example 60C 6-r6-(allyloxy -l,4-dihvdroindenoFl,2-clpyrazolC3-vnnicotinic acid
  • the desired product was prepared by replacing Example 22C with Example 60B in Example 22D.
  • the desired product was prepared by replacing Example 22C with Example 60B in Example 24.
  • Example 6 6-(6-hydroxy- 1 ,4-dihydroindeno Fl ,2-c1pyrazol-3-yl)nicotinic acid
  • the desired product was prepared by replacing Example 22C with Example 61 A in Example 22D.
  • Example 62A 4-FF5-(allyloxy)-l-oxo-l,3-dihydro-2H-inden-2-ylidenel(hydroxy)methyllbenzonitrile
  • the desired product was prepared by replacing terephthalic acid monomefhyl ester with 4- cyanobenzoic acid in Example 22B.
  • Example 62B 4-(6-Allyloxy-l,4-dihydro-indenoFl,2-clpyrazol-3-yl)-benzonitrile The desired product was prepared by replacing Example 22B with Example 62A in Example 22C.
  • Example 62C 6-(allyloxy)-3-r4-(lH-tetraazol-5-yl)phenvn-l,4-dihydroindenoFl,2-clpyrazole
  • a mixture of Example 62B (61.5 mg, 0.196 mmol), NaN 3 (19.1 mg, 0.294 mmol), and Et 3 N.HCl (40.5 mg, 0.294 mmol) in DMF (2 mL) was heated at 140 °C for 4 hours. To this mixture were added more NaN 3 (60.0 mg) and Et 3 N.HCl (120 mg). The reaction mixture was stirred overnight, cooled, and concentrated. The crude material was purified using the HPLC condition in Example 8 to give 20.0 mg (29%) of the desired product as brown solid.
  • Example 63 4-(6- ⁇ F(trans-4-methylcvclohexyPaminolmethyll-l,4-dihvdroindenori,2-clpyrazol-3-yl)phenol
  • the desired product was prepared by replacing 4-carboxybenzene boronic acid with 4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol in Example ID.
  • Example 64A (4-Bromophenyl)-imidazol- 1 -yl-methanone 4-Bromobenzoic acid (lOg, 50 mmol) in 50 ml of DMF was treated with carbonyl- 1,1'- dii idazole (18 g, 112.5 mmol). The mixture was stirred for 3 hours and poured into water. The mixture was filtered and the filter cake washed with water and dried to provide the title compound. MS (DCI/NH 3 ) m/z: 252.9 (M+H) + .
  • Example 64B 2-(4-Bromobenzoyl)-5 ,6-dimethoxy-indan- 1 -one 5,6-Dimethoxy-indan-l-one (2 g, 10.4 mmol) in 25 ml of THF was treated with NaH (60%, 624 mg, 15.6 mmol) at 0 °C. After the suspension was stirred at room temperature for 1 hour, the mixture was treated with Example 64A (2.61 g, 10.4 mmol) in 5 ml of THF dropwise. After stirring for 3 hours at room temperature, the mixture was poured into water and acidified with hydrochloric acid. The mixture was filtered and the filter cake was washed with water and recrystallized from ethanol to provide the title compound. MS (DCI/NH 3 ) m/z: 375.0 (M+H) + .
  • Example 64C 3-(4-Bromophenyl)-6,7-dimethoxy- 1 ,4-dihydroindeno F 1 ,2-clpyrazole
  • Example 64B (820 mg, 2.18 mmol), hydrazine monohydrate (0.127mL, 2.63 mmol), and acetic aicd (0.15 ml, 2.63 mmol) were combined in 30 ml of ethanol and heated at 90 °C for 6 hours. The mixture was allowed to cool to room temperature and filtered. The filter cake was dried to provide the title compound.
  • Example 64D 4'-(6,7-dimethoxy- 1 ,4-dihydroindenoFl ,2-c
  • Example 64C 50 mg, 0.14 mmol
  • 4-hydroxylphenyl boronic acid (23.3 mg, 0.17 mmol
  • Pd(PPh 3 ) 2 Cl 2 9.9 mg, 0.014mmol
  • Example 65 6,7-dimethoxy-3 - F4-( 1 H-tetraazol-5 -yDphenyll - 1 ,4-dihvdroindeno F 1 ,2-clpyrazole
  • Example 64C 50 mg, 0.14 mmol
  • zinc cyanide 17.4 mg, 1.48 mmol
  • Pd(PPh 3 ) 4 (15.6 mg, 0.014mmol) were combined in DMF (3 mL) in a capped 5 mL vial and heated at 180 °C for 300 seconds in a Smith Synthesizer. The mixture was cooled using 40 psi and then treated with sodium azide (105.3 mg, 1.62 mmol) and NH 4 C1 (87 mg, 1.62 mmol).
  • Example 66 4-(6,7-dimethoxy-l,4-dihydroindenoFl,2-e]pyrazol-3-yl)benzoic acid
  • Example 64C (78 mg, 0.21 mmol), PdCl 2 (dppf)-CH 2 Cl 2 (18 mg), triethyl amine (0.088 mL), were combined in THF (98 mL) and H 0 (1 mL) and stirred under a CO atmosphere (500 psi) at 120 °C for 16 hours. The mixture was allowed to cool to room temperature, concentrated under reduced pressure and the residue was purified by HPLC (for conditions, see Example ID) to provide the title compound. MS (DCI/NH 3 ) m/z: 337.0 (M+H) + .
  • Example 67A 2-(4-bromobenzoyl)-lH-indene-l,3(2H)-dione Methanol (8.5 ml) was treated with sodium (4.8 g) in benzene (90 mL). The reaction mixture was refluxed overnight, allowed to cool to room temperature, and treated with phthalic acid dimethyl ester (38.84 g) and l-(4-bromophenyl)ethanone (39.81 g) in benzene (50 mL). Distillation of the reaction mixture was performed at 80 °C overnight to remove methanol. The reaction mixture was poured into diluted HC1 and filtered. The filter cake was collected and recrystallized from ethanol to provide the title compound.
  • Example 67B 3 (4-bromophenyl)indeno F 1 ,2-clp yrazol-4( 1 H)-one
  • Example 67A (5.8 g) and hydrazine monohydrate (0.982 ml, 20.24 mmol) were combined in ethanol (300 mL) and refluxed at 90 °C overnight. The mixture was allowed to cool to room temperature and was filtered. The filter cake was dried to provide the title compound.
  • Example 67C butyl 4-(4-oxo- 1 ,4-dihydroindeno Fl ,2-clpyrazol-3-vPbenzoate Pd(OAc) 2 (3.5 mg), Ph 3 P (16 mg), DIEA (2.6 ml), and Example 67B (100 mg) were combined in butanol and treated with a stream of CO for 5 minutes. The mixture was stirred at 120 °C overnight under a CO atmosphere. The mixture was allowed to cool to room temperature, concentrated, and the residue was purified by silicon gel chromatography using a mixture of hexane and ethyl acetate as eluent to provide the title compound. MS (DCI/NH 3 ) m/z: 347.0 (M+H) + .
  • Example 67D 4-(4-hydroxy- 1 ,4-dihvdroindeno F 1 ,2-clpyrazol-3-vPbenzoic acid
  • Example 67C (51 mg) in 2 ml of THF/MeOH (1:1) was treated with NaBH 4 (5.6 mg) at 0 °C. The reaction mixture was allowed to warm to room temperature and stir for 1 hour. The mixture was concentrated and the residue was suspended in THF (1 mL), MeOH (2 mL), and aqueous NaOH (IN, 1 mL). After stirring at 60 °C for 2 hours, the mixture was concentrated and the residue was purified by HPLC to provide the title compound. MS (DCI/NH 3 ) m/z: 293.3 (M+H) + .
  • Example 68A l,4-dihvdroindenoF1.2-c1pyrazole-6-carbaldehyde To a solution of 6-bromo-l,4-dihydro-indeno[l,2-c]pyrazole (0.100 g, 0.425 mmol, see U.S. Patent 6297238 for preparation) in THF (3 mL) at -78 °C was added PhLi in cyclohexane/ether (1.8 M, 0.71 mL, 1.28 mmol) followed by s-BuLi in cyclohexane (1.3 M, 0.98 mL, 1.28 mmol) 30 minutes later.
  • the reaction mixture was stirred at -78 °C for 60 minutes and DMF (0.33 mL, 4.25 mmol) was added. The dry ice bath was removed after 30 minutes. After an additional 30 minutes, the reaction was quenched with water. The reaction mixture was extracted with EtOAc, washed with 50% brine, dried over MgS0 , filtered, and concentrated. The concentrate was purified by flash chromatography eluted with EtOAc/hexane (7:3 to 8:2) to give 0.053 g (68%) of the desired product as brown solid.
  • Example 68B 3-iodo-1.4-dihvdromdenoFl,2-elpyrazole-6-earbaldehyde
  • a suspension of Example 68A (7.90 g, 0.0429 mol) and N-iodosuccinimide (11.6 g, 0.0515 mol) in DMF (150 mL) was heated at 80 °C for 5.5 hours. The reaction was cooled and the solvent was evaporated. The concentrate was triturated with EtOAc and ether to give 7.20 g of brown solid as the desired product. The filtrate was concentrated and purified by flash chromatography eluted with EtOAc/hexane (7:3) to give 1.30 g of the desired product (combined yield: 64%).
  • Example 68C 3-iodo-6-(morpholin-4-ylmethvP- 1 ,4-dihvdroindeno Fl ,2-clpyrazole
  • a mixture of Example 68B (1.00 g, 3.22 mmol), morpholine (0.84 mL, 9.66 mmol), and TsOH.H 2 O (61.2 mg, 0.322 mmol) in toluene (50 mL) was heated to refluxing overnight. The solvent was evaporated. To the resulting residue were added EtOH (40 mL), THF (10 mL), and NaBH 4 (0.182 g, 4.83 mmol) at room temperature. The mixture was stirred overnight and the solid was filtered.
  • Example 68D 4'-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-vP-l,l -biphenyl-4-ol
  • Example 68E 4'-(6-morpholin-4-ylmethyl- 1 ,4-dihydro-indenoF 1 ,2-c1pyrazol-3-yl)-biphenyl-4-ol
  • a mixture of Example 68C (60.0 mg, 0.157 mmol), Example 68D (51.2 mg, 0.173 mmol), Na 2 CO 3 (1 M, 0.22 mL, 0.220 mmol), and Pd(PPh 3 ) 2 Cl 2 (11.0 mg, 0.0157 mmol) in DME/EtOH/H 2 O (7:2:3, 1.4 mL) in a capped 2 mL vial was heated to 160 to 170 °C for 450 to 600 seconds in a Smith Synthesizer (300W).
  • the reaction was cooled using 40 psi pressurized air. Solvents were evaporated and the crude product was purified using preparative HPLC to give 22.9 mg (22%) of the desired product as TFA salt.
  • the purification was processed on a Phenomenex® C18 column (250 mm X 21.2mm, 5 ⁇ m particle size) using a gradient of 0% to 70% acetonitrile : 0.1% aqueous TFA over 46 min at a flow rate of 25 mL/min.
  • Examples 69 to 83 represented by Figure (I) and listed in Table 1, were synthesized in a similar fashion as that described in Example 68E.
  • Example 84A 3-iodo-l,4-dihydroindenoFl,2-clpyrazole-6-carboxylic acid
  • KH 2 PO 4 5.26 g, 0.0387 mol
  • H2NSO3H 1.41 g, 0.0145 mol
  • H 2 0 15 mL
  • the reaction mixture was stirred for 15 minutes at 0 °C followed by the addition of NaHS03 (1.11 g, 0.0106 mol).
  • the resulting suspension was warmed to room temperature and stirred for 1 hour.
  • the reaction mixture was treated with N 2S 2 0 3 solution and concentrated to remove most of the solvents. Water was added to the resulting slurry and the suspension was stirred for 1 hour.
  • the solid material was filtered, rinsed with water, and dried in a vacuum oven to give 3.49 g of the desired product as yellow solid. This product was used in the following step without further purification.
  • Example 84B 3-iodo-6-(morpholin-4-ylcarbonyl)-l,4-dihydroindenoFl,2-clpyrazole
  • the desired product was prepared by substituting Example 68C with Example 84B in Example 68E.
  • the reaction temperature and time were raised to 180 °C and 1000 seconds, respectively.
  • Example 85A N-cyclohexyl-3-iodo- 1 ,4-dihydroindenoF 1 ,2-clpyrazole-6-carboxamide
  • a mixture of Example 84A (0.359 g, 1.07 mmol), HOBt (0.218 g, 1.61 mmol), EDC (0.308, 1.61 mmol), cyclohexylamine (0.18 mL, 1.61 mmol), and Et 3 N (0.22 mL1.61 mmol) in DMF (8 mL) was stirred at room temperature overnight. The reaction mixture was diluted with EtOAc and washed with NaHC0 3 and brine.
  • Example 85B N-cyclohexyl-3-(4'-hydroxy- 1 , 1 '-biphenyl-4-vD- 1 ,4-dihydroindenoF 1 ,2-clpyrazole-6- carboxamide
  • the desired product was prepared by substituting Example 68C with Example 85A in Example 68E.
  • the reaction temperature and time were raised to 180 °C and 1000 seconds, respectively.
  • Examples 86 to 97 represented by Figure (II) and listed in Table 2, were synthesized in a similar fashion as described in Example 84C or 85B.
  • Example 98A 6-bromo- 1 - ( F2-(trimethylsilvPethoxylmethyl I - 1 ,4-dihydroindeno F 1 ,2-clpyrazole and 6-bromo-2- ⁇ r2-(trimethylsilyl)ethoxylmethyll-2,4-dihydroindenoFl,2-c1pyrazole
  • 6-bromo-l,4-dihydro-indeno[l,2-c]pyrazole (4.08 g, 0.0174 mol, see U.S. Patent 6297238 for preparation) in DMF (100 mL) at 0 °C was added NaH (60%, 0.764 g, 0.0191 mol).
  • Example 98 B N-d - ( F ⁇ -ftrimethylsilvDethoxyl methyl 1-1 ,4-dihydroindeno Fl ,2-clpyrazol-6-yl)acetamide
  • Pd(OAc) 2 70.9 mg, 2 mol%)
  • Xantphos 274 mg, 3 mol%
  • Cs 2 CO 3 7.72 g, 0.0237 mol
  • acetamide 1.12 g, 0.0190 mol
  • Example 98D 2-chloro-N- 1 ,4-dihydroindeno Fl ,2-clpyrazol-6-ylacetamide
  • acetone 10 mL
  • saturated NaHCO 3 solution 5 mL
  • chloroacetyl chloride 0.13 mL, 1.61 mmol
  • the solvent was partially evaporated and water was added to the suspension.
  • the solid was filtered, washed with water, and dried to give the desired product (0.280 g, 78%) as off-white solid.
  • Example 98E 2-chloro-N-(3-iodo-l,4-dihvdroindenoFl,2-c1pyrazol-6-vPacetamide To a solution of Example 98D (0.140 g, 0.565 mmol) in DMF (3 mL) was added NIS (0.153 g, 0.678 mmol) and the mixture was heated at 80 °C for 4 hours and cooled. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed water, brine, dried, filtered, and concentrated, and purified by flash chromatography eluted with EtOAc/hexane (7:3 to 9:1) to give 47 mg of the desired product as brown solid.
  • Example 98F N-O-iodo-l -dihydroindenoF ⁇ -clpyrazol- ⁇ -yP ⁇ -morpholin ⁇ -ylacetamide
  • EtOH 2 mL
  • morpholine 31.3 ⁇ L
  • the solvent was evaporated and the residue was purified by flash chromatography eluted with EtOAc to give 39.5 mg (78%) of the desired product as yellow foam.
  • Example 98G N- F3-(4 -hydroxy- 1 , 1 -biphenyl-4-vP- 1 ,4-dihydroindeno F 1 , 2-clpyrazol-6-yll-2-morpholin-4- ylacetamide
  • the desired product was prepared by substituting Example 68C with Example 98F in Example 68E.
  • Examples 99 to 103 represented by Figure (III) and listed in Table 3, were synthesized in a similar fashion as described in Example 98G.
  • Example 104 A 2-(hvdroxymethylene -6-n ethoxyindan- 1 -one To a mixture of ethyl formate (15.75 mL, 0.195 mol) and NaH (60%, 7.80 g, 0.195 mol) in benzene (550 mL) was added a suspension of 6-methoxy-indan-l-one (15.81 g, 0.0974 mol) in benzene (150 mL) dropwise at 0 °C. The reaction mixture was stirred at room temperature overnight and treated with water. The solid was filtered, washed with water, and oven dried to give the desired product (16.86 g, 91%).
  • Example 104B 7-methoxy- 1 ,4-dihydroindeno F 1 ,2-clpyrazole
  • a mixture of Example 104A (16.86 g, 0.0886 mol), hydrazine monohydrate (5.2 mL, 0.106 mol), and AcOH (6.1 mL, 0.106 mol) in EtOH (375 mL) was heated at 90 °C for 2 hours. The solvent was evaporated and the residue was triturated with water and filtered. The filtering cake was triturated again with NaHC0 3 solution, filtered, washed with water, and oven dried to give the desired product (13.9 g, 84%).
  • Example 104C 6-bromo-7-methoxy- 1 ,4-dihydroindeno F 1 ,2-clpyr azole
  • a solution of Example 104B (8.91 g, 0.0478 mol) in AcOH (150 mL) was added Br (3.43 mL, 0.0669).
  • the reaction mixture was concentrated after 5 minutes and the residue was triturated into EtOAc and hexane, and then filtered.
  • the solid was stirred in NaHCO 3 solution and filtered, washed with water, and oven dried to give the desired product (11.99 g, 95%).
  • the material with slight impurity was used in the next step without further purification.
  • MS (DCI/NH3) m/z: 265.0 (M+H) + ; 266.9 (M+H+2) + .
  • Example 104D 7-methoxy-l,4-dihvdroindenoFl,2-c]pyrazole-6-carbaldehyde
  • PhLi 1.9 M, 21.8 mL, 0.0414 mol
  • s-BuLi 1.4 M, 29.6 mL, 0.0414 mol
  • DMF 12.8 mL, 0.166 mol
  • Example 68 A The desired product was prepared by substituting Example 68 A with Example 104D in
  • Example 104F 3-iodo-7-methoxy-l,4-dihydroindenoFl,2-clpyrazole-6-carboxylic acid
  • the desired product was prepared by substituting Example 68B with Example 104E in Example 84A.
  • the crude product was used in the next step without further purification.
  • Example 104G The desired product was prepared by substituting Example 84A and cyclohexylamine with Example 104F and 4-(aminomethyl)pyridine in Example 85 A. The slightly impure product was used in the next step without further purification. MS (DCI/NH 3 ) m/z: 447.0 (M+H) + . The formation of tertiary amides in this step towards corresponding final compounds listed in Table 4 was done following the protocol in Example 84B.
  • Example 104H 3-(4'-hydroxy- 1 , 1 -biphenyl-4-yP-7-methoxy-N-(pyridin-4-ylmethyP-l ,4-dihydroindenoF 1 ,2- clpyrazole-6-carboxamide
  • the desired product was prepared by substituting Example 68C with Example 104G in Example 68E.
  • Example 105 A 2-F(3-Iodo-7-methoxy-l,4-dihvdro-indenoFl,2-clpyrazol-6-ylmethyl)-amino1-ethanol
  • the desired product was prepared by substituting Example 68B and morpholine with Example 104D and 2-aminoethanol in Example 68C.
  • the slightly impure product was used in the next step without further purification.
  • the desired product was prepared by substituting Example 68C with Example 105 A in Example 68E.
  • Examples 106 to 116 represented by Figure (IV) and listed in Table 4, were synthesized in a similar fashion as described in Example 104H or Example 105B.
  • Example 117A (3-iodo- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-6-yl)methanol
  • a suspension of Example 68B (0.500 g, 1.61 mmol) in a mixture of MeOH (9 mL) and THF (3 mL) was added NaBH (73.0 mg, 1.93 mmol) at room temperature.
  • the mixture was stirred for 2 hours and the solvent was evaporated.
  • the desired product (0.324 g, 65%) was recrystalized from hot CH 2 C1 2 with a small amount of MeOH.
  • Example 117B 3-fluoro-4 -F6-(hvdroxymethyl)-l,4-dihvdroindenoFl,2-clpyrazol-3-yll-l, -biphenyl-4-ol
  • the desired product was prepared by substituting Example 68C and Example 68D with Example 117A and 2-fluoro-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol respectively in Example 68E.
  • Example 123 A 3-iodo-l- ⁇ F2-(trimethylsilvPethoxylmethyl)-l,4-dihydroindenoFl,2-c1pyrazole-6-carbaldehvde
  • SEMC1 0.63 mL, 3.55 mmol
  • Example 123B 3-iodo-6- F(4-methylpiperazin- 1 -v methyll - 1 - ⁇ F2-(trimethylsilyl)ethoxylmethyl j - 1 ,4- dihydroindenoFl,2-clpyrazole
  • the desired product was prepared by substituting Example 68B and morpholine with Example 123A and 1-methylpiperazine respectively in Example 68C.
  • n-BuLi 1.6M in hexane, 41.4 mL, 0.0663 mol
  • Example 123D 3-(6-fluoropyridin-3 -yP-6- F(4-methylpiper azin- 1 -yPmethyll- 1 - ⁇ F2- (trimethylsilypethoxylmethyl ⁇ - 1 ,4-dihydroindeno F 1 ,2-clpyrazole
  • the desired product was prepared by substituting Example 68C and Example 68D with Example 123B and Example 123C in Example 68E.
  • the product was purified by flash chromatography instead of reversed-phase HPLC. MS (ESI) m/z: 494.3 (M+H) + .
  • Example 123E 5- ⁇ 6-F(4-methylpi ⁇ erazin-l-yl methyn-1.4-dihydroindenoFl,2-clpyrazol-3-yl
  • Example 124 3-(6-cyanopyridin-3-yP-N-(pyridm-2-ylmethyl)-l,4-dihydroindenoFl,2-clpyrazole-6- carboxamide
  • Example 124 A 3-iodo-N-(pyridin-2-ylmethyl)-l,4-dihvdroindenoF1.2-c1pyrazole-6-carboxamide
  • the desired product was prepared by substituting cyclohexylamine with 2- (aminomethyl)pyridine in Example 85A. CH 2 CI2 was used for trituration.
  • Example 124B l-Fbis(4-methoxyphenyl)methyll-3-iodo-N-(pyridin-2-ylmethvP-l,4-dihvdroindenoFl,2- clpyrazole-6-carboxamide
  • a mixture of Example 124A (0.176 g, 0.423 mmol), bis-(4-methoxy-phenyl)-methyl chloride (0.122 g, 0.465 mmol), and Et 3 N (71 ⁇ L, 0.507 mmol) in DMF (2.0 mL) was sti ⁇ -ed at room temperature for 4 hours.
  • the reaction mixture was diluted with 50% brine and extracted with EtOAc.
  • the desired product was prepared by substituting Example 68C and Example 68D with Example 124B and Example 123C in Example 67E.
  • the product was purified by flash chromatography instead of reversed-phase HPLC. MS (ESI) m/z: 612.2 (M+H) + .
  • Example 124D 3-(6-cyanopyridin-3-vP-N-( ⁇ yridin-2-ylmethvP-1.4-dihydroindenoFl,2-clpyrazole-6- carboxamide
  • the desired product was prepared by substituting Example 123D with Example 124C in Example 123E. Acidic deprotection was done in EtOH and 1,4-dioxane at 40 °C overnight.
  • Examples 125 to 129 represented by Figure (VI) and shown in Table 6, were synthesized in the similar fashion as described in Example 123E or Example 124D.
  • the pyrazole nitrogen of the intermediates could also be protected by SEM group.
  • Example 130 A (3-iodo- 1 - ( F2-(trimethylsilyl)ethoxylmethyl 1 - 1 ,4-dihydroindeno Fl ,2-clpyrazol-6-vPmethanol
  • NaBH 4 (64.5 mg, 1.70 mmol)
  • Example 130B (3-(6-fluoropyridin-3-yl)-l-f r2-(trimethylsilyl)ethoxylmethyl
  • Example 130C 5-F6-(hydroxymethvP-l,4-dihydroindenoFl,2-c1pyrazol-3-yllpyridine-2-carbonitrile
  • the desired product was prepared by substituting Example 123D with Example 130B in Example 123E.
  • Example 131 A 5-(6-(hvdroxymethvP-l- ⁇ F2-(trimethylsilvPethoxylmethyl)-l,4-dihvdroindenoFl,2-c1pyrazol-3- yl)pyridine-2-carbonitrile
  • the desired product was prepared by substituting Example 123D with Example 130B in Example 123E except that the final removal of SEM protecting group using HCl was not performed.
  • a mixture of Example 131 A (60.0 mg, 0.143 mmol), di-t-butyl azodicarboxylate (39.6 mg, 0.172 mmol), Ph 3 P on solid support (3mmol/g, 57.3 mg, 0.172 mmol), and 3- hydroxypyridine (16.4 mg, 0.172 mmol) in THF (2 mL) was stirred at room temperature overnight. The solid was filtered and the solvent was evaporated. The crude product was treated with HCl (concentrated, 4 drops) and EtOH (4 mL).
  • Example 132 5- ⁇ 6-F(pyridin-4-yloxy)methvn-l,4-dihvdroindenoFl,2-clpyrazol-3-yllpyridine-2-carbonitrile
  • the desired product was prepared by substituting 3-hydroxypyridine with 4- hydroxypyridine in Example 13 IB.
  • Example 133 3-(6-fluoropyridin-3-yl)-7-methoxy-4,4-dimethyl-l,4-dihvdroindenoFl,2-c1pyrazol-6-ol
  • Example 133 A 6-methoxy-3 ,3-dimethyl-5- ⁇ F2-(trimethylsilyl)ethoxylmethoxy 1 indan- 1 -one
  • 5-hydroxy-6-methoxy-3,3-dimethyl-indan-l-one (40.0 g, 0.194 mol, see preparation in J. Chem. Soc. Perkin Trans.
  • Example 133B 2-(hvdroxymethylene)-6-methoxy-3 ,3-dimethyl-5- ⁇ F2-(trimethylsilvPethoxylmethoxy 1 indan- 1 - one
  • NaH 60%, 0.343 g, 8.58 mmol
  • ethyl formate 0.73 mL, 8.58 mmol
  • a mixture of Example 133B (0.886 g, 2.43 mol), hydrazine monohydrate (0.14 mL, 2.92 mol), and AcOH (38 ⁇ L, 0.729 mmol) in EtOH (20 mL) was heated at 85 °C for 1.5 hours. The solvent was evaporated and the residue was purified by flash chromatography eluted with EtOAc/hexane (1:1) to give 0.865 g of the desired product as yellow solid.
  • Example 133D 3-iodo-7-methoxy-4,4-dimethyl-6- ⁇ F2-(trimethylsilvPethoxy1methoxy)-l,4-dihvdroindenoFl,2- clpyrazole
  • a suspension of Example 133C (10.4 g, 0.0290 mol) and N-iodosuccinimide (7.82 g, 0.0348 mol) in 1,4-dioxane (300 mL) was heated at 90 °C for 7.5 hours. The reaction was cooled and the solvent was evaporated. The concentrate was purified by flash chromatography eluted with EtOAc/hexane (1:1) to give 8.79 g of the desired product.
  • Example 133E 3-(6-fluorop yridin-3-yl)-7-methoxy-4,4-dimethyl- 1 ,4-dihydroindenoF 1 ,2-c1pyrazol-6-ol
  • the desired product was prepared by substituting Example 68C and Example 68D with Example 133D and Example 123C in Example 68E.
  • the product was purified by flash chromatography instead of reversed-phase HPLC. This intermediate was treated with HCl (concentrated, 3 drops) and EtOH (2 mL). The mixture was stirred at room temperature for 2 hours. The solvent was evaporated and the residue was purified using reversed-phase HPLC to give the desired product (13.0 mg) as TFA salt.
  • Example 134 5-f6-hvdroxy-7-methoxy-4,4-dimethyl-l,4-dihydroindenoFl,2-c1pyrazol-3-yl)pyridine-2- carbonitrile
  • Example 134A 3-iodo-7-methoxy-4,4-dimethyl-6- ⁇ F2-(trimethylsilvPethoxylmethoxy I - 1 - ( F2- (trimethylsilyPethoxylmethyl I- 1 ,4-dihvdroindeno Fl ,2-clpyrazole
  • SEMCl 0.19 mL, 1.07 mmol
  • Example 134B 3-iodo-7-methoxy-4,4-dimethyl-l-f F ⁇ -CtrimethylsilyPethoxylmethyll-l -dihydroindenoFl ⁇ - clpyrazol-6-ol
  • a mixture of Example 134A (0.450 g, 0.730 mmol) and HCl (concentracted, 0.4 mL) in EtOH (10 mL) was stirred at room temperature for 3 hours. The solvent was evaporated at room temperature and the residue was purified by flash chromatography eluted with hexane/EtOAc/CH 2 Cl 2 (7:3:1 to 1:1:0) to give 0.321 g (90%) of the desired product as pale yellow gel.
  • the desired product was prepared by substituting Example 68C and Example 68D with Example 134B and Example 123C in Example 68E.
  • the product was purified by flash chromatography instead of reversed-phase HPLC. MS (ESI) m/z: 456.1 (M+H) + .
  • Example 134E 5-(6-hydroxy-7-methoxy-4,4-dimethyl-l,4-dihydroindenoFl,2-clpyrazol-3-yl)pyridine-2- carbonitrile
  • a mixture of Example 134D (23.0 mg, 0.0497 mmol) and HCl (concentrated, 2 drops) in EtOH (2 mL) was stirred at 75 °C for 1.5 hours.
  • the solvent was evaporated and the residue was purified using reversed-phase HPLC to give the desired product (4.0 mg) as TFA salt.
  • Example 135 A 3-iodo-7-methoxy-4 ,4-dimethyl-6-(pyridin-3-ylmethoxy)-l- ⁇ F2-(trimethylsilyl)ethoxylmethyl ⁇ - l,4-dihvdroindenoF1.2-clpyrazole
  • Example 135C 5-F7-methoxy-4,4-dimethyl-6-(pyridin-3-ylmethoxy)- 1 ,4-dihydroindeno Fl ,2-clpyrazol-3- yllpyridine-2-carbonitrile
  • the desired product was prepared by substituting Example 123D with Example 135B in Example 123E.
  • Examples 136 to 142 represented by Figure (VII) and shown in Table 7, were synthesized in a similar fashion as Example 135C.
  • Example 143A 6-methoxy-5-( F2-(trimethylsilyl)ett ⁇ oxylmethoxy 1 indan- 1 -one
  • 5-hydroxy-6-methoxy-indan-l-one (21.1 g, 0.118 mol, see preparation in 3. Org. Chem. 57, 1992, 589-594) and N,N-diisopropylethylamine (21.6 mL, 0.124 mol) in CH 2 C1 2 (200 mL) was added SEMCl (21.3 mL, 0.121 mol). The mixture was stirred at room temperature for 2 hours and diluted with NaHCO 3 solution.
  • Example 143B phenyl 6-chloronicotinate A mixture of 6-chloronicotinic acid (68.0 g, 0.431 mol), phenol (40.6 g, 0.431 mol), DCC (93.6 g, 0.453 mol), and DMAP (1.60 g, 0.0129 mol) in ether (1 L) was stirred at room temperature overnight. The solvent was evaporated and the residue was stirred in CH 2 C1 2 . The solid was filtered and the filtrate was purified by flash chromatography eluted with CH 2 CI 2 10 give 88.0 g (88%) of the desired product.
  • Example 143C 3-(6-chloropyridin-3-yl)-7-methoxy-6- ⁇ F2-(trimethylsilyl)ethoxylmethoxy 1-1,4- dihydroindenoF 1 ,2-clpyrazole
  • NaH 60%, 9.37 g, 0.234 mol
  • Example 143B 21.0 g, 0.0898 mol
  • Example 143D The desired product was prepared by substituting Example 68A with Example 143C in Example 123A. MS (ESI) m/z: 574.2 (M+H) + .
  • Example 143E 5-(7-methoxy-6- ⁇ F2-(trimethylsilyl)ethoxylmethoxy I - 1 - ⁇ F2-(trimethylsilyPethoxylmethyl 1-1,4- dihydroiiidenoFl,2-clpyrazol-3-yPpyridine-2-carbonitrile
  • Example 143G 5-F7-methoxy-6-(pyridin-2-ylmethoxy)-l,4-dihvdroindenoFl,2-c1pyrazol-3-yllpyridine-2- carbonitrile
  • the desired product was prepared by first substituting Example 134B and 3- pyridylcarbinol with Example 143F and 2-pyridylcarbinol in Example 135A.
  • the intermediate was treated with HCl and EtOH at about 75 °C for about 2 hours.
  • the suspension was cooled and the solid was filtered, washed with ether, and dried to give the desired product as HCl salt.
  • the intermediate after acidic treatment was purified using reversed-phase HPLC to give the desired product as TFA salt.
  • Example 144B 6-hy droxy-5 -methox yindan- 1 -one A mixture of Example 144A (28.5 g, 0.173 mol), Mel (27.0 mL, 0.433 mol), and Li 2 CO 3 (32.0 g, 0.519 mol) in DMF (800 mL) was heated at 55 °C overnight. DMF was evaporated and the residue was treated with water (IL) and HCl (concentrated, 60 mL). The solid was filtered, washed with water until the filtrate became neutral, and dried to give 21.0 g (68%) of the desired product.
  • IL water
  • HCl concentrated, 60 mL
  • Example 144C 5- ⁇ 7-F(6-chloropyridin-3-yl)methoxyl-6-methoxy-l,4-dihydroindenoFl,2-clpyrazol-3- yl lpyridme-2-carbonitrile
  • the desired product was prepared by substituting 6-hydroxy-5-methoxyindan-l-one with Example 144B in Example 143A followed by the similar procedures in Examples 143C, 143D, 143E, 143F, and 143G.
  • Examples 145 to 163 represented by Figure (VIII) and shown in Table 8 were synthesized in a similar fashion as described in Example 143G or 144C.
  • Example 164 4'-(6,7-dimethoxy-l,4-dihydromdenoFl,2-c1pyrazol-3-yl)-3-methoxy-l, -biphenyl-4-ol
  • Example 64C 50 mg, 0.14 mmol
  • 2-methoxy-4-(4,4,5,5-tetramethyl[l,3,2] dioxaborolan-2-yl)-phenol (42.3 mg, 0.17 mmol)
  • Pd(PPh 3 ) 2 Cl 2 9.9 mg, 0.014mmol
  • Example 165 A 4-Benzyloxybenzoic acid (2 g, 8.76 mmol) and Ll'-carbonyldiimidazole (2.3 g, 14 mmol) were combined in DMF. The reaction mixture was stirred overnight and poured into ice- water. The resulting precipitate was collected by filtration, washed with water, and dried. The title product (2.4 g) was obtained at 99% yield. MS (DCI/NH 3 ) m/z: 279.08 (M+H) + .
  • Example 165B 2-F4-(benzyloxy)benzovn-5 ,6-dimethoxyindan- 1-one 5,6-Dimethoxyindanone (1 g, 5.2 mmol) in 45 mL of THF was treated with NaH (60%, 312 mg, 7.8 mmol). After the addition of Example 165A (1.45 g, 5.2 mmol), the reaction mixture was stirred overnight and poured into ice water. The resulting mixture was acidified with concentrated HCl. Yellow solid was collected by filtration, washed with water and hot ethanol. The title product (1.2 g) was obtained at 57% yield. MS (DCI/NH 3 ) m/z: 403.11 (M+H) + .
  • Example 165B 500 mg, 1.24 mmol
  • hydrazine monohydrate 72 ⁇ L
  • acetic acid 85 ⁇ L
  • the precipitates were collected by filtration to give the title compound.
  • Example 165D 4-(6,7-dimethoxy-l ,4-dihydroindenoF 1 ,2-clpyrazol-3-yl)phenol
  • Example 165C (57 mg, 0.14 mmol) and Pd/C (10%, 15.2 mg) were combined in THF (20 mL) and stirred under hydrogen atmosphere for 24 hours. Pd/C was removed by filtration and the filtrate was concentrated. The residue was purified by HPLC to give the title compound. MS (DCI/NH 3 ) m z: 309.03 (M+H) + .
  • Example 166 A 3-(4-bromophenyl)-l,4-dihydroindenoFl,2-clpyrazole-6,7-diol
  • Example 64C (142 mg, 0.38 mmol) in 1,2-dichloroethane (50 mL) was treated with BBr 3 *SMe 2 (597 mg, 1.91 mmol), heated at 80°C for 30 hours and cooled. Reaction was quenched with water (20 mL), and the resulting mixture was treated with ether (100 mL). The precipitate was collected by filtration and further purified by HPLC. MS (DCI/NH3) m/z: 344.94 (M+H) + .
  • Example 166B 3-(4 -hydroxy- 1 , 1 -biphenyl-4-vP- 1 ,4-dihydroindeno F 1 ,2-clpyrazole-6,7-diol
  • Example 166A 35 mg, 0.10 mmol
  • 4-hydroxyl ⁇ henyl boronic acid 18 mg
  • Na 2 CO 3 (1 M, 0.25 mL
  • Pd(PPh 3 ) 2 Cl 2 9.9 mg, 0.014mmol
  • Example 167 4-(6,7-dimethoxy-l,4-dihvdroindenoFl,2-clpyrazol-3-yl)benzonitrile
  • Example 168A l-(6-methoxy-2-naphthovP-lH-imidazole 6-Methoxynanphthalene-2-carboxylic acid (2 g, 9.9 mmol) and i'-carbonyldiimidazole (2.4 g, 14.8 mmol) were combined in DMF ( 10 mL) and stirred overnight. The white solid was collected by filtration, washed with water and dried to give the title compound.
  • Example 168B 5-(benzyloxy)-2-(6-methoxy-2-naphthoyPindan-l-one 5-Benzyloxyindanone (1.5 g, 6.29 mmol) was treated with NaH (60%, 377 mg) in THF (50 mL), and then Example 168A (1.59 g) was added. The reaction was stirred for 6 hours at room temperature. The precipitates were collected by filtration and dissolved in water, acidified with concentrated HCl, and the resulting precipitates were collected, washed with water and dried to give the title compound.
  • Example 168C 6-(benzyloxy)-3-(6-methoxy-2-naphthvP-l,4-dihydroindenoFl,2-clpyrazole
  • Example 168D 3-(6-hydroxy-2-naphthyl)- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-6-ol
  • Example 169 6,7-dimethoxy-3-F4-(lH-pyrrol-2-yl)phenyll-l,4-dihydroindeno ⁇ ,2-clpyrazole
  • the desired product was prepared using the procedure in Example 164 replacing 2- methoxy-4-(4,4,5,5-tertramethyyl[l,3,2] dioxaborolan-2-yl)-phenol with l-tert-Bocpyrrolyl-2- boronic acid.
  • MS (DCI/NH 3 ) m/z: 358.12 (M+H) + .
  • Example 170 A l-Fchloro(4-methoxyphenyl)methyll-4-methoxybenzene Bis(4-methoxyphenyl)methanol (30 g) was treated with thionyl chloride (40 mL). The resulting mixture was refluxed for 2.5 hours and concentrated to give the desired product.
  • Example 170B 1 - rbis(4-methoxyphenyl)methyH-4-iodo- lH-pyrazole 4-Iodo-lH-pyrazole (1 g, 5.15 mmol), Example 170A (1.49 g, 5.67 mmol), and triethylamine (0.79 mL) were combined in THF (20 mL), and refluxed for 1.5 hour. The inorganic salts were removed by filtration, and the filtrate was concentrated. The residue was recrystalized from a mixture of ethyl acetate and hexane to give 1.56 g of product at 72% yield. MS (DCI/NH 3 ) m/z: 420.0 (M+H) + .
  • Example 170C 1 - rbis(4-methoxyphenvPmethvn-3-(4-bromophenyl)-6,7-dimethoxy- 1 ,4-dihvdroindeno F 1 ,2- clpyrazole
  • the desired product was prepared using the procedure in Example 170B replacing 4- iodo-lH-pyrazole with Example 64C.
  • the title product (2.0 g) was obtained at 83% yield.
  • MS (DCI/NH3) m/z: 597.12 (M+H) + .
  • Example 170D 1 -Fbis(4-methoxyphenyPmethyl1 -6,7-dimethoxy-3-F4-(4,4,5 ,5 -tetramethyl- 1 ,3,2-dioxaborolan-2- yPphenyll - 1 ,4-dihydroindeno F 1 ,2-clpyrazole
  • Example 170C (1 g, 1.67 mmol), bis(pinacolato)diborane (467 mg, 1.84 mmol), PdCl 2 (dppf CH 2 Cl 2 (41 mg, 0.05 mmol), dppf (28 mg), and K OAc were combined in 1,4- dioxane (35 mL) and purged with a stream of nitrogen.
  • Example 170E l-Fbis(4-methoxyphenyl)methyll-3-(4- ⁇ l-Fbis(4-methoxyphenyPmethyn-lH-pyrazol-4- yl ⁇ phenvP-6,7-dimethoxy-l,4-dihydroindenoFl,2-c1pyrazole
  • Example 170B (67 mg, 0.159 mmol)
  • Example 170D (84 mg, 0.13 mmol), Na 2 C ⁇ 3 (1 M, 0.3 mL), and Pd(PPh 3 )2Cl 2 (9.9 mg, 0.014 mmol) were combined in DME/EtOH/H 2 O (7:2:3, 1.5 L) in a capped 2 mL vial and heated to 160 °C for 1000 seconds in a Smith Synthesizer.
  • Example 170E (60 mg, 0.078 mmol) was treated with 4 M HCl in dioxane (5 mL). The reaction was stirred overnight and concentrated. The residue was washed with a mixture of hexane and ethyl acetate to give light yellow product. MS (DCI/NH3) m/z: 359.07 (M+H) + .
  • Example 171 4'-(6,7-dimethoxy-l,4-dihydroindenoFl,2-clpyrazol-3-yP-l, -biphenyl-4-yl l,4'-bipiperidine- - carboxylate
  • Example 171 A 4 - ⁇ l-Fbis(4-methoxyphenyPmethyll-6,7-dimethoxy- 1 ,4-dihydroindenoF l,2-clpyrazol-3-yl 1-1,1' biphenyl-4-ol
  • the desired product was prepared using the procedure in Example 166B replacing Example 166A with Example 170C. However, the product was purified by flash chromatography instead of HPLC. The title product (168 mg) was obtained at 82% yield. MS (DCI/NH3) m/z: 611.24 (M+H) + .
  • Example 171A 150 mg, 0.25 mmol
  • pyridine 4 mL
  • [l,4']bipiperidinyl-l'-carbonyl chloride 190 mg, 3 mmol
  • Example 17 IC 4'-(6.7-dimethoxy-l,4-dihydroindenoFl,2-c1pyrazol-3-vP-l, -biphenyl-4-yl l,4'-bipiperidine-r- carboxylate
  • Example 171B (90 mg, 0.11 mmol) in dichloromethane was treated with TFA (4.5 mL), and the reaction was stirred overnight and concentrated. The residue was purified by preparative HPLC. The title product (50 mg) was obtained at 56% yield. MS (DCI ⁇ NH3) m/z: 579.30 (M+H) + .
  • Example 172 A 5 -hydroxy-6-methoxyindan- 1 -one 5,6-Dimethoxy-l-indanone (1 g, 5.20 mmol) and NaCN (2.55g, 52 mmol) were combined in DMSO (10 mL). The reaction was stirred at 100°C for two days, cooled, diluted with water and extracted with dichloromethane. The aqueous solution was acidified with concentrated HCl, and extracted with dichloromethane. The organic layer was dried over MgSO and evaporated to give the title compound (500 mg). MS (DCI/NH 3 ) m/z: 178.99 (M+H) + .
  • Example 172B 6-methoxy-5-F(4-methoxybenzvPoxylindan-l-one
  • Example 172A (1.4 g, 7.86 mmol), 4-methoxybenzyl chloride (2.13 g, 15.72 mmol), Na 2 CO 3 (1.67 g, 15.72) and sodium iodide (1.18 g, 7.86) were combined in acetone (50 mL). The reaction was stirred for 3 days, and then the solvent was removed. The residue was mixed with water (300 mL) and ethyl acetate (100 mL).
  • Example 172C 2-(4-bromobenzoyl)-6-methoxy-5-F(4-methoxybenzyl)oxylindan-l-one
  • Example 172B (1.2 g, 4.0 mmol) in 40 mL of THF was treated with NaH (60%, 240 mg, 6.0 mmol). After the addition of Example 64A (1.31 g), the reaction mixture was stirred overnight and poured into ice water. The resulting mixture was acidified with concentrated HCl. The precipitate was collected by filtration and recrystallized from ethanol. The title product (1.7 g) was obtained at 88% yield. MS (DCI/NH3) m/z: 481.04 (M+H) + .
  • Example 172D 3-(4-bromophenvP-7-methoxy-6-F(4-methoxybenzvPoxy1-l,4-dihydroindenoFl,2-clpyrazole
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 172C.
  • the title compound (1.45 g) was obtained at 92% yield.
  • Example 172E 3-(4-bromophenvP-7-methoxy-l,4-dihydroindenoFl,2-c1pyrazol-6-ol
  • Example 172D (280 mg, 0.59 mmol) in HO Ac (35 mL) was heated at 90°C for 24 hours, and the solvent was evaporated. The residue was triturated with a mixture of hexane and ethyl acetate to give the title product (220 mg) at 90% yield.
  • Example 173 3-(4 -hydroxy- 1 , 1 '-biphenyl-4-yl)-7-methoxy- 1 ,4-dihydroindenoFl ,2-clpyrazol-6-ol
  • MS DCI/NH3 m/z: 371.14 (M+H) + .
  • Example 175 4 '- F7-methoxy-6-(pyridin-2-ylmethoxy)- 1 ,4-dihvdroindeno F 1 ,2-c1pyrazol-3-yll -1,1 -biphenyl-4- ol
  • Example 175A 5-(benzyloxy)-6-methoxyindan-l-one
  • Example 172A (15 g, 84.3 mmol), benzyl bromide (15 mL, 126.3 mmol), and K2CO 3 (23.25 g, 168.5 mmol) were combined in acetone (50 mL). The reaction was stirred for 2 days, and the inorganic salt was removed by filtration. The filtrate was concentrated, and the residue was recrystallized from a mixture of hexane and ethyl acetate to give the title product (17.1 g) at 76% yield. MS (DCI/NH3) m/z: 269.11 (M+H) + .
  • Example 175B 5-(benzyloxy)-2-(4-bromobenzoyl)-6-methoxyindan- 1 -one
  • the desired product was prepared using the procedure in Example 172C replacing Example 172B with Example 175A.
  • Example 175C 6-(benzyloxy -3-(4-bromophenyP-7-methoxy-l,4-dihydroindenoFl,2-clpyrazole
  • Example 175D 6-(benzyloxy)-3-(4-bromophenyP-7-methoxy-l- ⁇ F2-(trimethylsilvPethoxylmethyl
  • NaH 60%, 1.21 g, 30.25 mmol
  • DMF 150 mL
  • SEMCl 5.35 mL, 30.25 mmol
  • the reaction was stirred for 2 hours and poured into ice- water. The precipitate was collected by filtration and dried to give the title product (15.0 g) at 94% yield.
  • Example 175E 4'-(6-(benzyloxy)-7-methoxy- 1 - ⁇ F2-(trimethylsilyl)ethoxy1methyl ⁇ -l ,4-dihydroindeno Fl ,2- clpyrazol-3-yl)-l , 1 -biphenyl-4-ol
  • the desired product was prepared using the procedure in Example 166B replacing Example 166A with Example 175D.
  • MS (DC-yNH 3 ) m/z: 591.27 (M+H) + .
  • Example 175G 7-methoxy-3-(4 -(F2-(trimethylsilyl)ethoxylmethoxyl-l,l'-biphenyl-4-vP-l-(F2-
  • Example 175H 4'-r7-methoxy-6-(pyridin-2-ylmethoxy)-l,4-dihydroindenoFl,2-c1pyrazol-3-vn-l,r-biphenyl-4- ol
  • Example 175G 50 mg, 0.0792 mmol
  • Cs 2 CO 103 mg, 0.317 mmol
  • 2-chloromethylpyridine*HCl 14.3 mg, 0.087 mmol
  • Example 175G 50 mg, 0.0792 mmol
  • di-tert-butyl azodicarboxylate 44 mg, 0.19 mmol
  • polymer-supported Ph 3 P 3 mmol/g, 63 mg, 0.19 mmol
  • pyridin-3-yl-methanol 22 mg, 0.20 mmol
  • THF 3 mL
  • the reaction was stirred at room temperature for 3 days, and the insoluble material was removed by filtration and washed with THF thoroughly.
  • the filtrate was concentrated, and the residue was suspended in methanol (2 mL), treated with 4 N HCl in dioxane (2 mL) and heated at 50°C for 5 hours.
  • the precipitate was collected by filtration to give the title compound.
  • the filtrate was concentrated, and the residue was purified by HPLC to give another portion of the title compound.
  • Examples 190 to 204 represented by Figure (X) and shown in Table 10 were synthesized in a similar fashion as described in Example 189, except substituting the appropriate alcohol for pyridin-3-yl-methanol.
  • Example 205A 6-methoxy-5-(F2-(trimethylsilyl)ethoxy1methoxylindan-l-one
  • Example 172A (1 g, 5.62 mmol) and N,N-diisopropylethylamine (2.94 mL, 16.86 mmol) were combined in dichloromethane and treated with SEMCl (1.49 mL, 8.43 mmol). The reaction mixture was stirred for 1 hour, diluted with dichloromethane, washed with cold water and saturated NaHCO 3 . The organic layer was dried over MgSO and concentrated. The residue was purified by flash chromatography eluting with hexane:ethyl acetate (2:1). The title product (1.3 g) was obtained at 75% yield. MS (DCI/NH 3 ) m/z: 309.1 (M+H) + .
  • Example 205B 4-(lH-imidazol-l-ylcarbonyl)benzonitrile The desired product was prepared using the procedure in Example 165A replacing 4- benzyloxybenzoic acid with 4-cyanobenzoic acid.
  • Example 205C 4-F(6-methoxy-l-oxo-5-f F2-(trimethylsilvPethoxylmethoxyl-2,3-dihvdro-lH-inden-2- vPcarbonyllbenzonitrile
  • Example 205A (5.4 g, 17.51 mmol) in 250 mL of THF was treated with NaH (60%, 1.06 g, 26.37 mmol). After the addition of Example 205B (5.2 g, 26.37 mmol), the reaction mixture was stirred overnight and poured into ice water. The resulting mixture was acidified with concentrated HCl. Yellow solid was collected, washed with water and dried. MS (DCI/NH3) m/z: 438.17 (M+H) + .
  • Example 205D 4-(7-methoxy-6- 1 F2-(trimethylsilyl)ethoxy1methoxy i - 1 ,4-dihvdroindeno F 1 ,2-clpyrazol-3- yPbenzonitrile
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 205C.
  • the title compound (6.5 g) was obtained at 88% yield.
  • Example 205E 4-(7-methoxy-6- ⁇ F2-(trimethylsilyl)ethoxylmethoxy)-l- ⁇ F2-(trimethylsilyl)ethoxylmethyl 1-1,4- dihydroindenoFl,2-clpyrazol-3-yl)benzonitrile
  • the desired product was prepared using the procedure in Example 175D replacing Example 175C with Example 205D.
  • the title compound (6.5 g) was obtained at 83% yield.
  • MS (DCI/NH3) m/z: 564.28 (M+H) + .
  • Example 205F 4-(6-h ydroxy-7-methoxy- 1 ,4-dihydroindeno F 1 ,2-clpyr azol-3 - vDbenzonitrile
  • Example 205E (50 mg, 0.089 mmol) in ethanol (2 mL) was treated with 4 N HCl in dioxane (2 mL) and heated at 50°C for 5 hours. The precipitate was collected by filtration to give the title compound (22 mg) at 82% yield.
  • 1H NMR 400 MHz, DMSO-Dg) ⁇ ppm 3.74 (s, 2 H) 3.84 (s, 3 H) 7.01 (s, 1 H) 7.20 (s, 1 H) 7.93 (s, 4 H).
  • Example 206A 4-(6-hydroxy-7-methoxy-l- ⁇ F2-(trimethylsilyl)ethoxy1methyll-l,4-dihvdroindenoFl,2-c1pyrazol-
  • Example 206B 4-F7-methoxy-6-(pyridin-2-ylmethoxy)-l,4-dihydroindenoFl,2-c1pyrazol-3-yllbenzonitrile
  • Example 206A 50 mg, 0.115 mmol
  • di-tert-butyl azodicarboxylate 53.1 mg, 0.23 mmol
  • polymer-supported PI1 3 P 3 mmol/g, 77 mg, 0.23 mmol
  • pyridin-2-yl-methanol 25.2 mg, 0.23 mmol
  • Example 220A 6-methoxy- 1 -oxo-2,3-dihydro- lH-inden-5-yl trifluoromethanesulfonate
  • Example 172A (6 g, 33.67 mmol), 2,6-lutidine (5.88 mL, 50.52 mmol), and 4- dimethylaminopyridine (822 mg, 6.72 mmol) were combined at -35°C - -30°C and then dropwise treated with triflic anhydride (8.52 mL, 50.64 mmol). The reaction mixture was slowly warmed to room temperature with stirring and concentrated. The residue was purified by flash chromatography eluting with hexane:ethyl acetate (2:1). The title product (9.8 g) was obtained at 94% yield. MS (DCIZNH 3 ) m/z: 328.01(M+NH 4 ) + .
  • Example 220B methyl 6-methoxy-l-oxomdane-5-carboxylate
  • Example 220A (5.7 g, 18.37 mmol), PdCl 2 (dppi CH 2 Cl 2 (1.5 g) and triethylamine (7.7 mL) were combined in methanol (50 mL) and stirred for 16 hours at 110°C under carbon monoxide atmosphere (500 psi). The solvent was removed, and the residue was purified by flash chromatography eluting with hexane:ethyl acetate (2:1). The title product (3.1 g) was obtained at 77% yield. MS (DCI/NH3) m/z: 221.02(M+H) + .
  • Example 220C methyl 2-(4-cyanobenzoyl)-6-methoxy- 1 -oxoindane-5-carboxylate
  • Example 220D methyl 3-(4-cyanophenyl)-7-methoxy-l,4-dihvdroindenoFl,2-c1pyrazole-6-carboxylate
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 220C.
  • the title compound (3.7 g) was obtained at 81% yield.
  • Example 220E 3-(4-cyanophenyl)-7-methoxy- 1 ,4-dihvdroindeno F 1 ,2-c1pyrazole-6-carboxylic acid
  • Example 220D (1 g, 2.90 mmol), 2 N NaOH (10 mL), THF(20 mL) and ethanol (20 mL) were combined and stirred overnight. The reaction mixture was concentrated, diluted with water and acidified with HCl. The precipitate was collected by filtration to give the title product (905 mg) at 85% yield. MS (DCI/NH 3 ) m/z: 349.06 (M+NH 4 ) + .
  • 1H NMR 500 MHz, DMSO-D 6 ) ⁇ ppm 3.89 (s, 2 H) 3.92 (s, 3 H) 7.39 (s, 1 H) 7.85 (s, 1 H) 7.98 (s, 4 H).
  • Example 220F 3-(4-cvanophenyl)-N-(4-hvdroxycvclohexyl)-7-methoxy-l,4-dihydroindenoFl,2-c1pyrazole-6- carboxamide
  • Example 220E 50 mg, 0.15 mmol
  • 4-aminocyclohexanol 52 mg, 0.45 mmol
  • BOP Reagent 100 mg, 0.23 mmol
  • triethylamine 0.063 mL
  • Examples 221 to 227 represented by Figure (XII) and shown in Table 12 were synthesized in a similar fashion as described in Example 220F, except substituting the appropriate amine for 4-aminocyclohexanol.
  • Example 228A (trans) 4-1 F(3-iodo-7-methoxy-l,4-dihvdroindenoFl,2-clpyrazol-6- yPmethyll amino I c vclohexanol
  • Example 104E (150 mg, 0.44 mmol), trans-4-aminocyclohexanol hydrochloride (100 mg, 0.66 mmol) and K2CO 3 (91 mg, 0.66 mmol) were combined in ethanol (20 mL) and heated at 100°C for 3 hours and cooled. After addition of NaBH 4 (16.6 mg, 0.44 mmol), the reaction was stirred at room temperature overnight and concentrated.
  • Example 228 A (40 mg, 0.091 mmol), 4-cyanophenylboronic acid (16 mg, 0.11 mmol), Na 2 C0 3 (1 M, 0.25 mL), and Pd(PPh 3 ) 2 Cl 2 (6.4mg, 0.009mmol) were combined in DME/EtOH/H 2 O (7:2:3, 1.5 mL) in a capped 2 mL vial and heated to 160 °C for 600 seconds in a Smith Synthesizer. The reaction was cooled using 40 psi pressurized air, the solvents were evaporated, and the residue was purified using preparative HPLC. The title compound (20 mg) was obtained at 36% yield (based on 2TFA salt).
  • Example 229 A methyl 3 -(4-cyanophenvP-7-methoxy- 1-1 F2-(trimethylsilyl)ethoxy]methyl I - 1 ,4- dihvdroindeno F 1 ,2-clpyrazole-6-carboxylate
  • the desired product was prepared using the procedure in Example 175D replacing Example 175C with Example 220D.
  • the title compound (1.5 g) was obtained at 91% yield.
  • Example 229B 4-(6-(hydroxymethyl)-7-methoxy- 1 - ⁇ F2-(trimethylsilyPethoxy1methyl ⁇ - 1 ,4-dihvdroindeno F 1 ,2- c1pyrazol-3-yl)benzonitrile
  • Example 229A 200 mg, 0.42 mmol
  • NaBH 160 mg, 4.2 mmol
  • the residue was purified by flash chromatography eluting with a mixture of ethyl acetate and hexane.
  • Example 229C 4- r6-( lH-imidazol- 1 -ylmethyl)-7-methoxy- 1 ,4-dihydroindenoF 1 ,2-clpyrazol-3-yllbenzonitrile
  • Example 229B (20 mg, 0.045 mmol) and l,l'-carbonyldiimidazole (30 mg, 0.18 mmol) were combined in acetonitrate (3 mL), heated at 80°C for 24 hours and concentrated. The residue was treated with ethanol (2 mL) and 4 N HCl in dioxane (2 mL), and the reaction mixture was stirred overnight.
  • Example 230A 2-chloro-5-( lH-imidazol- 1 -ylcarbonvPpyridine
  • the desired product was prepared using the procedure in Example 165 A replacing 4- benzyloxybenzoic acid with 6-chloronicotinic acid.
  • Example 230B 2-F(6-chloropyridin-3-yl)earbonyll-5,6-dimethoxyindan-l-one The desired product was prepared using the procedure in Example 165B replacing Example 165A with Example 230A. MS (DCI/NH 3 ) m/z: 331.98 (M+H) + .
  • Example 230C 3-(6-chloropyridin-3-vP-6,7-dimethoxy-l,4-dihydroindenoFl,2-c1pyrazole
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 230B.
  • the title product (937 mg) was obtained at 95% yield.
  • Example 166A with Example 230C MS (DCI/NH3) m/z: 386.09 (M+H) + .
  • Example 232 4-F5-(6,7-dimethoxy-l,4-dihvdroindenoFl,2-clpyrazol-3-yl)pyridin-2-yll-2-methoxyphenol
  • the title product was prepared using the procedure in Example 164 replacing Example 64C with Example 230C at 83% yield.
  • Example 233 4-F5-(6,7-dimethoxy-l,4-dihydroindenoFl,2-clpyrazol-3-yl)pyridin-2-yll-2-fluorophenol
  • the title product was prepared using the similar procedure in Example 232 replacing 2- methoxy-4-(4,4,5,5-tetramethyl[l,3,2] dioxaborolan-2-yl)-phenol with 2-fluoro-4-(4,4,5,5- tetramethyl[l,3,2] dioxaborolan-2-yl)-phenol.
  • Example 234 5-(6,7-dimethoxy-l,4-dihydroindenoFl,2-clpyrazol-3-vPpyridine-2-carbonitrile The title product was prepared using the procedure in Example 167 replacing Example 64C with Example 230C. MS (DCI/MH 3 ) m z: 319.06 (M+H) + .
  • Example 235 6-(6,7-dimethoxy-l,4-dihvdiOindenoFl,2-clpyrazol-3-vPnicotinonitrile
  • Example 235A methyl 5-bromopyridine-2-carboxylate 2,5-Dibromopyridine (9.5 g, 40.10mmol), PdCl 2 (PPh 3 ) 2 (844 mg), triethylamine (8.36 mL), methanol (38 mL), and acetonitrile (114 mL) were combined, heated under carbon monoxide atmosphere (75 psi) at 60°C for 16 hours and concentrated.
  • Example 235B 2-F(5-bromopyridin-2-yl)carbonyn-5,6-dimethoxyindan-l-one
  • the desired product was prepared using the procedure in Example 165B replacing Example 165A with Example 235A.
  • the title compound (1.65 g) was obtained at 95% yield.
  • Example 235 C 3-(5-bromopyridin-2-yl)-6,7-dimethoxy-l,4-dihydroindenoFl,2-c1pyrazole
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 235B.
  • the title compound (1.35 g) was obtained at 85% yield.
  • Example 235D 6-(6,7-dimethoxy-l,4-dihvdroindenoFl,2-clpyrazol-3-yl)nicotinonitriIe
  • the title product was prepared using the procedure in Example 167 replacing Example 64C with Example 235C at 70% yield.
  • MS (DCI/MH3) m/z: 319.06 (M+H) + .
  • Example 236 4 '- F6-( 1 -hydroxy- 1 -methylethvP- 1 ,4-dihydroindeno Fl ,2-c1pyrazol-3-yll- 1 , 1 -biphenyl-4-ol
  • Example 236A methyl l,4-dihydroindenoFl,2-clpyrazole-6-carboxylate
  • the desired product was prepared using the procedure in Example 220B replacing Example 220A with 6-bromo- l,4-dihydro-indeno[l,2-c]pyrazole (for preparation, see U.S. Patent 6297238).
  • Example 236B methyl 3-iodo- 1 ,4-dihydroindeno F 1 ,2-c1pyrazole-6-carboxylate
  • the desired product was prepared using the procedure in Example 68B replacing Example 68A with 236A.
  • Example 236C 2-(3 -iodo- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-6-yl)propan-2-ol
  • THF 145 mL
  • 1.4 M MeMgBr 1.4 M MeMgBr in THF-toluene
  • the reaction mixture was slowly warmed to room temperature, stirred for 24 hours, quenched with aqueous NH4CI, and extracted with ethyl acetate. The organic layer was dried over MgS0 4 and concentrated.
  • Example 236D 4-F6-(l-hvdroxy-l-methylethvP-l,4-dihydroindenoFl,2-c1pyrazol-3-yll-l, -biphenyl-4-ol
  • Example 236C 45 mg, 0.13 mmol
  • Example 68D 47mg, 0.16 mmol
  • Na 2 CO 3 (1 M, 0.3 mL
  • Pd(PPh 3 ) 2 Cl 2 (9.9 mg, 0.014mmol) were combined in DME/EtOH/H 2 O (7:2:3, 1.5 mL) in a capped 2 mL vial and heated to 160 °C for 600 seconds in a Smith Synthesizer.
  • Example 237 4-F6-f 1 -hydroxy- 1 -methylethvP- 1 ,4-dihydroindenoF 1 ,2-clpyrazol-3-ynbenzonitrile
  • the desired product was prepared using the procedure in Example 236D replacing Example 68D with 4-cyanophenyl boronic acid.
  • the title compound (27.8 g) was obtained at 51% yield.
  • Example 238A methyl l-oxoindane-5-carboxylate
  • the desired product was prepared using the procedure in Example 220B replacing Example 220A with 5-bromoindanone.
  • the title product was obtained at 85% yield.
  • Example 238B methyl 2-r(6-chloropyridm-3-yl)carbonyll-l-oxoindane-5-carboxylate
  • Example 238A (2.7 g, 14.2 mmol) in 45 mL of THF was treated with NaH (60%, 1.14 g, 28.4 mmol).
  • Example 230A (7.4 g, 35.5 mmol)
  • the reaction mixture was stirred overnight and poured into ice water.
  • the resulting mixture was acidified with concentrated HCl. Yellow solid was collected by filtration, washed with water and hot ethanol.
  • the title product (4.3 g) was obtained at 92% yield.
  • Example 238C methyl 3-(6-chloropyridin-3-yl)- 1 ,4-dihvdroindenoF 1 ,2-clpyrazole-6-carboxylate
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 238B.
  • the title compound (600 mg) was obtained at 74% yield.
  • Example 238D 2-F3-(6-chloropyridin-3-yl)-l,4-dihvdroindenoFl,2-c1pyrazol-6-yllpropan-2-ol
  • the desired product was prepared using the procedure in Example 236C replacing Example 236B with Example 238C.
  • the title compound (250 mg) was obtained at 83% yield.
  • Example 239 4- ⁇ 5-F6-(l-hvdroxy-l-methylethvP-l,4-dihydroindenoFl,2-c1pyrazol-3-yllpyridin-2-yl ⁇ phenol
  • the desired product was prepared using the procedure in Example 166B replacing Example 166A with Example 238D.
  • the title compound (25.1 mg) was obtained at 28% yield.
  • Example 240A 2,3-dichloro-5-(lH-imidazol-l-ylcarbonvPpyridine
  • the desired product was prepared using the procedure in Example 165 A replacing 4- benzyloxybenzoic acid with 5, 6-chloronicotinic acid.
  • Example 240B 2-F(5,6-dichloropyridin-3-yl)carbonyll-5,6-dimethoxyindan-l-one The desired product was prepared using the procedure in Example 165B replacing Example 165 A with Example 240A.
  • Example 165B with Example 240B MS (DCI/NH 3 ) m/z: 361.98 (M+H) + .
  • Example 241 2-F3-(6-fluoropyridm-3-yl)-l,4-dihydroindenoFl,2-clpyrazol-6-yllpropan-2-ol
  • the desired product was prepared using the procedure in Example 236D replacing Example 68D with 6-fluoronicotinic boronic acid.
  • the title compound (350 g) was obtained at 96% yield.
  • Example 242A 5,6-dimethoxy-2-(pyrazin-2-ylcarbonyl)indan-l-one
  • the desired product was prepared using the procedure in Example 165B replacing Example 165A with methyl pyrazine-2-carboxylate.
  • Example 165B with Example 242A MS (DCI/NH 3 ) m/z: 295.05 (M+H) + . ! H NMR (500 MHz,
  • Example 243A 6,7-dimethoxy- 1 ,4-dihvdroindeno Fl ,2-clpyrazole
  • 5 6-dimethoxyindanone
  • formic acid ethyl ester 5.04 mL, 62 mmol
  • 95% NaH 2.35 g, 93 mmol
  • benzene 100 mL
  • the solvent was removed.
  • To the residue was added slowly ethanol (200 mL), acetic acid (20 mL) and hydrazine monohydrate (20 mL). The mixture was heated to reflux for 3 hours and cooled. The solvents were removed.
  • Example 243B 3-iodo-6,7-dimethoxy-l,4-dihydroindenoFl,2-clpyrazole
  • Example 243 A (5.80 g, 26.8 mmol), N-iodosuccinimide (7.84 g, 34.9 mmol), and anhydrous DMF (100 mL) were mixed, stirred at 80°C for 4 hours and concentrated. The residue was dissolved in dichloromethane (200 mL), washed with water (200 mLx3), dried over MgSO 4 and concentrated. The residue was purified by flash chromatography to give the title product as brown solid (5.84 g, 64%). MS (ESI) m/z 343 (M+H) + . ! H NMR (300 MHz, DMSO-Dg) ⁇ ppm 3.42 (s, 2 H) 3.79 (s, 3 H) 3.81 (s, 3 H) 7.15 (s, 1 H) 7.19 (s, 1 H)
  • Example 243C 6,7-dimethoxy-3-pyridin-3-yl-l,4-dihydroindenoFl,2-clpyrazole
  • Example 243B 100 mg, 0.29 mmol
  • pyridyl-3-boronic acid 43 mg, 0.35 mmol
  • Pd(PPh 3 ) 2 Cl 2 20 mg, 0.014mmol
  • Example 245A 6-methoxy-3-oxo-2,3-dihydro-lH-inden-5-yl trifluoromethanesulfonate
  • Example 144B (3.5 g, 19.64 mmol) and NaH (60%, 496 mg, 19.64 mmol) were combined and stirred at 40°C until no bubble came out from the reaction mixture.
  • N-phenyltrifluoromethanesulfonimide 8.41 g, 23.57 mmol
  • the reaction mixture was further stirred at 40°C for 30 min and concentrated. The residue was purified by flash chromatography eluting with 50% ethyl acetate in hexane. The title compound (5.5 g) was obtained at 90% yield.
  • Example 245B 5-methoxy-6-vinylindan- 1 -one
  • Example 245A (4.5 g, 14.5 mmol), tributylvinyltin (5.54 g, 17.4 mmol), Pd(PPh 3 ) 2 Cl 2 (1.02 g, 1.45 mmol) and lithium chloride (4.9 g, 116 mmol), were combined in DMF (60 mL) and heated at 80°C for 2 hours, cooled.
  • Example 245 C 6-ethyl-5 -methoxyindan- 1 -one
  • Example 245B (1.59 g, 8.46 mmol) and Pd-C (10%, 159 mg) were combined in THF (70 mL) and stirred under hydrogen atmosphere for 6 hours. Insoluble material was removed by filtration through Celite, the filtrate was evaporated to give the title product at quantitative yield.
  • Example 245D 2-F(6-chloropyridin-3-ypcarbonyll-6-ethyl-5-methoxymdan-l-one The desired product was prepared using the procedure in Example 238B replacing Example 238 A with Example 245C. The title compound (325 mg) was obtained at 71% yield.
  • Example 165B with Example 245D MS (DCI/NH 3 ) m/z: 326.04 (M+H) + .
  • Example 246 5-(7-ethyl-6-methoxy- 1 ,4-dihydroindenoFl ,2-c1pyrazol-3-yl)pyridine-2-carbonitrile
  • the title product was prepared using the procedure in Example 167 replacing Example 64C with Example 245E at 65% yield.
  • Example 245C (1 g, 5.31 mmol) in dichloromethane (25 mL) at -78°C was treated with BB1- 3 (2 mL, 21.24 mmol). The reaction mixture was warmed to room temperature and stirred for 24 hours. The reaction was quenched with water and extracted with ethyl acetate. Organic layer was dried over MgSO 4 and concentrated. The residue was purified by flash chromatography eluting with 50% ethyl acetate in hexane. The title compound (0.8 g) was obtained at 85% yield.
  • Example 247B 6-ethyl-5-(tetrahydro-2H-pyran-4-yloxy)indan- 1 -one
  • Example 247A 150 mg, 0.85mmol
  • polymer supported Ph 3 P 3 mmol/g, 0.57 g, 1.7 mmol
  • di-tert-butyl azodicarboxylate 392 mg, 1.70 mmol
  • tetrahydropyran-4-ol 174 mg, 1.70 mmol
  • Example 247C 2-F(6-chloropyridin-3-yl)carbonyn-6-ethyl-5-(tetrahvdro-2H-pyran-4-yloxy)indan-l-one
  • the desired product was prepared using the procedure in Example 238B replacing Example 238 A with Example 247B.
  • Example 247D 3-(6-chloropyridin-3-yl)-7-ethyl-6-(tetrahvdro-2H-pyran-4-yloxy)-1.4-dihydroindenoFl,2- clpyrazole
  • Example 248 4- ⁇ 5-F7-ethyl-6-(tetrahvdro-2H-pyran-4-yloxy)-l,4-dihydroindenoFl,2-clpyrazol-3-ynpyridin-2- yl ⁇ phenol
  • the desired product was prepared using the procedure in Example 166B replacing Example 166A with Example 247D.
  • the title compound (35.2 mg) was obtained at 43% yield.
  • Example 249A 6-ethyl-5 - ( F2-(trimethylsilyl)ethoxy1methoxy j indan- 1 -one
  • the desired product was prepared using the procedure in Example 205A replacing Example 172A with Example 247A.
  • Example 249B 2- F(6-chloropyridm-3-yl)carbonyll-6-ethyl-5- ⁇ F2-(trimethylsilyl)ethoxy1methoxy 1 indan- 1 -one
  • the desired product was prepared using the procedure in Example 238B replacing Example 238 A with Example 249A.
  • Example 249C 3-(6-chloropyridin-3-yl)-7-ethyl-6- ⁇ F2-(trimethylsilyl)ethoxylmethoxy I- 1 ,4-dihydroindeno Fl ,2- clpyrazole
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 249B.
  • the title compound (1.35 g) was obtained at 69% yield (for 3 steps).
  • Example 249D (900 mg, 1.57 mmol), Pd 2 (dba) 3 (36 mg, 0.039 mmol), dppf (43.5 mg, 0.078 mmol), zinc (204 mg, 0.39 mmol) and Zn(CN) 2 were combined in DMA (75 mL), heated at 130°C for 3 hours and concentrated.
  • Example 249F 5-( " 7-ethyl-6-hvdroxy-l- ⁇ F2-(trimethylsilyl)ethoxy1methyl
  • the desired product was prepared using the procedure in Example 206A replacing Example 205E with Example 249E.
  • the title compound (250 mg) was obtained at 81% yield.
  • Example 249G 5-F7-ethyl-6-(3-morpholin-4-ylpropoxy)-l,4-dihydroindenoFl,2-clpyrazol-3-yllpyridine-2- carbonitrile
  • Example 249F (40 mg, 0.092mmol), polymer supported PI1 3 P (3 mmol/g, 46 mg, 0.139 mmol), di-tert-butyl azodicarboxylate (32 mg, 0.139 mmol) and 3-morpholin-4-ylpropan-l-ol (27 mg, 0.184 mmol) were combined in THF (3 mL) and stirred overnight. Insoluble material was removed by filtration, and the filtrate was concentrated.
  • Examples 250 to 254 represented by Figure (XIII) and shown in Table 13 were synthesized in a similar fashion as described in Example 249G, except substituting the appropriate alcohol for 3-morpholin-4-ylpropan-l-ol.
  • Example 255A 6-ethyl-l-oxo-2,3-dihydro-lH-inden-5-yl trifluoromethanesulfonate
  • the desired product was prepared using the procedure in Example 245 A replacing Example 144B with Example 247A.
  • the title compound (8.5 g) was obtained at 72% yield.
  • Example 255B 6-ethyl-5-vinylindan-l -one
  • the desired product was prepared using the procedure in Example 245B replacing Example 245A with Example 255A.
  • the title compound (430 mg) was obtained at 52% yield.
  • Example 255 C 2-F(6-chloropyridin-3-yPcarbonyll-6-ethyl-5-vinylindan-l-one
  • the desired product was prepared using the procedure in Example 238B replacing Example 238A with Example 255B.
  • the title compound was directly used for the preparation of Example 255D.
  • Example 255D 3-(6-chloropyridin-3-vP-7-ethyl-6-vinyl-l,4-dihydroindenoFl,2-clpyrazole
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 255C.
  • the title compound (250 mg) was obtained at 46% yield (for 2 steps).
  • Example 255E l-rbis(4-methoxyphenyl)methyll-3-(6-chloropyridin-3-yP-7-ethyl-6-vinyl-l,4- dihydroindenori ,2-clpyrazole
  • the desired product was prepared using the procedure in Example 170B replacing 4- iodo-lH-pyrazole with Example 255D.
  • the title product (220 mg) was obtained at 79% yield.
  • Example 255E (130 mg) and Pt/C (5%, 13 mg) were combined in THF and stirred for 4 hours under hydrogen atmosphere. The insoluble material was removed by filtration, and the filtrate was evaporated. The title compound was obtained at quantitative yield.
  • Example 256 3-(6-chloropyridm-3-yP-6,7-bis(2-methoxyethoxy -l,4-dihydiOindenoFl,2-c1pyrazole
  • Example 256 A 5 ,6-bis(2-methoxyethoxy)indan- 1 -one
  • Example 144A 800 mg, 4.88 mmol
  • 2-bromoethyl methyl ether 8 mL, 85.1 mmol
  • CS 2 CO 3 9 g, 27.6 mmol
  • Example 256B 2-F(6-chloropyridin-3-yPcarbonyll-5,6-bis(2-methoxyethoxy)indan-l-one The desired product was prepared using the procedure in Example 238B replacing Example 238 A with Example 256 A.
  • Example 256C 3-(6-chloropyridin-3-yl)-6,7-bis(2-methoxyethoxy -l,4-dihydroindenoFl,2-clpyrazole
  • the desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 256B.
  • the title compound (617 mg) was obtained at 82% yield (for 2 steps).
  • Example 257 5-F6,7-bis(2-methoxyethoxy)- 1 ,4-dihvdroindeno Fl ,2-clpyrazol-3-yllpyridine-2-carbonitrile
  • the title product was prepared using the procedure in Example 167 replacing Example 64C with Example 256C.
  • the title product was obtained at 85% yield.
  • MS (DC17NH 3 ) m/z: 424.16 (M+NH ) + .
  • Example 258A 6-hydroxy-7-methoxy-3-(4'- 1 F2-(trimethylsilvPethoxylmethoxy 1-1,1 -biphenyl-4-vD- 1 - ⁇ F2- (trimethylsilypethoxylmethyl I indeno F 1 ,2-clp yrazol-4( 1 H)-one
  • Example 175G 310 mg, 0.49 mmol
  • CS 2 CO 3 640 mg, 1.96 mmol
  • the residue was purified by flash chromatography eluting with 33% ethyl acetate in hexane. The title product (282 mg) was obtained at 89% yield.
  • MS (DCI/NH3) m/z: 645.29 (M+NH 4 ) + .
  • Example 258B 6-hydroxy-3-(4'-hydroxy-l, -biphenyl-4-yl)-7-methoxyindenoFl,2-c1pyrazol-4(lH)-one
  • Example 258A (30 mg, 0.46 mmol) in ethanol (2 mL) was treated with 4 N HCl in dioxane (2 mL). The reaction mixture was heated at 50°C overnight and concentarted. The residue was purified by preparative HPLC. The title compound (19 mg) was obtained at 85% yield. MS (DCI/NH 3 ) m/z: 385.09 (M+NH 4 ) + .
  • Examples 260 and 261 represented by Figure (XIV) and shown in Table 14 were synthesized in a similar fashion as described in Example 259, except substituting the appropriate alcohol for 2-piperidin-l-ylethanol.
  • Example 262A 4-(7-methoxy-4-oxo-6- ⁇ r2-(trimethylsilvPethoxylmethoxy ⁇ -l- ⁇ r2- (trimethylsilypethoxylmethyl 1-1 ,4-dihydroindeno F 1 ,2-clpyr azol-3 -ypbenzonitrile
  • Example 205E (1.8 g, 3.19 mmol) and CS 2 CO3 (4.16 g, 12.76 mmol) were combined in DMF (50 mL) and heated under air at 50°C overnight. Inorganic salt was removed by filtration, and the filtrate was concentrated. The residue was purified by flash chromatography eluting with 25% ethyl acetate in hexane. The title product (1.82 g) was obtained at 99% yield. MS (DCI/NH 3 ) m/z: 578.25 (M+H) + .
  • Example 262B 4-(6-hydroxy-7-methoxy-4-oxo- 1 - ⁇ F2-(trimethylsilyl)ethoxy1methyl ⁇ - 1 ,4-dihvdroindeno F 1 ,2- c1pyrazol-3-yl)benzonitrile
  • the desired product was prepared using the procedure in Example 206A replacing Example 205E with Example 262A.
  • the title compound was obtained at quantitative yield.
  • Example 262C 4- ⁇ 6- F3 -(dimethylamino)propoxyl -7-methox v-4-oxo- 1 ,4-dihvdroindeno ⁇ 1 , 2-clpyrazol-3 - yllbenzonitrile
  • Example 262B (40 mg, 0.089 mmol), di-tert-butyl azodicarboxylate (42 mg, 0.18 mmol), polymer-supported PI13P (3 mmol/g, 60 mg, 0.18 mmol) and 3-dimethylaminopropanol (18.6 mg, 0.18 mmol) were combined in THF (3 mL).
  • Example 263 4-(6-hydroxy-7-methoxy-4-oxo-l,4-dihvdroindenoFl,2-clpyrazol-3-vPbenzonitrile The desired product was prepared using the procedure in Example 205F replacing
  • Examples 264 and 265 represented by Figure (XV) and shown in Table 15 were synthesized in a similar fashion as described in Example 262C, except substituting the appropriate alcohol for 3-dimethylaminopropanol.
  • Example 266A 3-(6-chloropyridin-3-yl)-6,7-dimethoxyindenori,2-c1pyrazol-4(lH)-one
  • Example 230C 300 mg, 0.91 mmol
  • CS 2 CO3 1.5 g, 4.6 mmol
  • the residue was suspended in water, and the orange solid were collected by filtration and dried.
  • the title product (287 mg) was obtained at 92% yield.
  • Example 266B 3-(6-chloro ⁇ yridin-3-yl)-6,7-dimethoxy-4-methyl- 1 ,4-dihydroindeno n ,2-clpyrazol-4-ol
  • THF 15 mL
  • GEbMgCl 1:1, 1.3 mL
  • the reaction was warmed to room temperature, stirred for 1 day, quenched with water and concentrated. The residue was purified by preparative HPLC. MS (DCI/NH 3 ) m/z: 358.03 (M+H) + .
  • Example 267A 1 -(4-bromobenzoyD- lH-imidazole
  • DMF 100 mL
  • l,l'-carbonyldiimidazole 39.42 g, 243.2 mmol
  • the reaction was completed and poured into ice water (1 L).
  • the precipitate was filtered, washed with water (2 L), and dried in vacuo to give the desired product (16.7 g, 68%).
  • Example 267B 6-(benzyloxy -5 -methoxyindan- 1 -one
  • Example 144B (8.65 g, 48.5 mmol), benzyl bromide (12 mL, 97.1 mmol), K 2 CO 3 (20.2 g, 146.2 mmol) and anhydrous acetone (500 mL) were mixed and refluxed overnight. Acetone was removed, and the concentrate was treated with water (300 mL). The precipitate was filtered, washed with water (300 mLx2), and dried to give the desired product (11.80 g, 91%).
  • Example 267C 6-(penzyloxy)-2-(4-bromobe ⁇ zoyl)-5-methoxyindan- 1 -one
  • a solution of Example 267B (11.50 g, 42.9 mmol) in anhydrous THF (200 mL) was added 95% NaH (3.25 g, 128.7 mmol). The mixture was stirred at room-temperature for 0.5 hour.
  • Example 267A (16.2 g, 64.35 mmol) in THF (50 mL) was added dropwise to the above mixture. The reaction was run overnight, and poured into water (1.5 L). Concentrated hydrochloric acid (30 mL) was added dropwise to neutralize the mixture.
  • Example 267D 7-(benzylo y)-3-(4-bromophenyl)-6-methoxy-l,4-dihydroindenori,2-clpyrazole
  • Example 267C 14.08 g, 31.2 mmol
  • hydrazine monohydrate (3.03 mL, 62.4 mmol)
  • absolute ethanol 300 mL
  • glacial acetic acid 3.57 mL, 62.4 mmol
  • the reaction was cooled.
  • the precipitate was filtered, washed with water (30 mLx2) and ethanol (30 mLx2), and dried in vacuo overnight to give the desired product (11.66 g, 84%).
  • MS (ESI) m/z 448 (M+H) +
  • Example 267E 7-(benzyloxy)-3-(4-bromophenyl)-6-methoxy- 1 - 1 r2-(trimethylsilyl)ethoxylmethyl I - 1 ,4- dihvdroindeno F 1 ,2-clpyrazole
  • 95% NaH 0.69 g, 27.41 mmol
  • 2-(trimethylsilyl)ethoxymethyl chloride 4.85 mL, 27.41 mmol
  • Example 267F 4'-(7-(benzyloxy)-6-methoxy- 1 - ( F2-(trimethylsilyl)ethoxylmethyl 1-1 ,4-dihydroindeno 1 ,2- clpyrazol-3-yP- 1 , 1 '-biphenyl-4-ol
  • Example 267E (518 mg, 0.896mmol), dichlorobis(triphenylphosphine)palladium(II) (63 m g, 0.090 mmol), 4-(hydroxyphenyl)boronic acid (147.3 mg, 1.07 mmol), IM Na 2 CO 3 solution (1 mL), DME/EtOH/H 2 0 (7:2:3, 3 mL) and a stirrerbar were mixed together in a capped tube.
  • DMF dimethyl methoxyl
  • To the solution of Example 267F (4.66 g, 7.9 mmol) in DMF (200 mL) was added 95 % NaH
  • Example 285 3 -(4 -hydroxy- 1 , 1 -biphenyl-4-yl)-6-methoxy- 1 ,4-dihydroindeno r 1 ,2-clpyrazol-7-ol
  • ethanol 2 mL
  • hydrochloric acid 2 mL
  • Example 267H To the solution of Example 267H (1.29 g, 2.04 mmol) in THF (10 mL) at room temperature was added 95% NaH (51.6 mg, 2.04 mmol). The mixture was stirred for half an hour, and N-phenyltrifluoromethane sulphonamide (0.88 g, 2.45 mmol) was added. The reaction mixture was stirred at 40°C overnight. The reaction mixture was purified by flash chromatography to give the desired product (1.80 g, 100%).
  • Example 286B 3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-6-methoxy-N-F2-(4-methylpiperazin- 1 -yl)ethyll- 1 ,4- dihydroindenoF 1 ,2-clpyrazole-7-carboxamide
  • Example 286A (40 mg, 0.0524 mmol), 2-(4-methylpiperazin-l-yl)ethylamine (75 mg, 0.524 mmol), triethylamine (143 ⁇ L, 1.048 mmol), PdCl 2 (dppf) (10 mg, 0.00132 mmol), and dichloromethane (5 mL) were mixed under CO (100 psi) at 100°C for 5 days.
  • Examples 287 to 299 represented by Figure (XVII) and shown in Table 17 were synthesized in a similar fashion as described in Example 286B using the appropriate amine instead of 2-(4-methylpiperazin- 1 -yl)ethylamine.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds having the formula (I) (I), are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Description

FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS
Technical Field
The present invention relates to fused pyrazoles, to methods of making the compounds, to compositions containing the compounds, and to methods of treatment using the compounds.
Background of the Invention
Protein kinases are important in the progression of many disease states that are induced by the inappropriate proliferation of cells. These kinases are often found to be up-regulated in many hyperproliferative states such as cancer. These kinases may also be important in cell signaling, where their inappropriate activation induces cells to proliferate (e.g., EGFR, ERBB2, VEGFR, FGFR, PDGFR, c-Met, IGF-lR, RET, TBE2). Alternatively, kinases may be involved in signal transduction within cells (e.g., c-Src, PKC, Akt, PKA, c-Abl, PDK-1) where these signal transduction genes are recognized proto-oncogenes. Many of these kinases control cell cycle progression near the Gl-S transition (e.g., Cdk2, Cdk4), at the G2-M transition (e.g., Weel, Mytl, Chkl, Cdc2) or at the spindle checkpoint (Plk, Auroral or 2, Bubl or 3). Furthermore, kinases are intimately linked to the DNA damage response (e.g., ATM, ATR, Chkl, Chk2). Deregulation of these cellular functions: cell signaling, signal transduction, cell cycle control, and DNA repair, are all hallmarks of hyperproliferative diseases, particularly cancer. Therefore, pharmacological modulation of one or more kinases would be useful in slowing or stopping diseases that are induced by the inappropriate proliferation of cells such as cancer. Summary of the Invention
In the principle embodiment, the present invention relates to compounds of formula (I)
(I), or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein RΪ and R2 are independently selected from the group consisting of hydrogen, alkenyl, alkenyloxy, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkynyl, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, cycloalkenylalkoxy, cycloalkylalkoxy, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkyloxy, formyl, haloalkoxy, haloalkoxyalkynyl, haloalkyl, halogen, heteroarylalkoxy, heteroarylalkoxyalkoxy, heteroarylalkyl, heteroarylalkynyl, heteroaryloxy alkyl, heterocycle, heterocyclealkoxy, heterocyclealkyl, heterocyclecarbonyl, heterocycleoxy, hydroxy, hydroxyalkoxy, hydroxyalkyl, hydroxyalkynyl, hydroxysulfonyl, hydroxysulfonylalkyl, mercapto, mercaptoalkyl, nitro, -NRARB, (NRARB) alkoxy, (NRARB)al yl, (NRARβ)alkynyl, (NRA B)carbo yl, (NRARB)carbonylalkoxy, (NRARB)carbonylalkyl, and or
Ri and R2 together with the carbon atoms to which they are attached form a 5, 6, 7, or 8- membered nonaromatic ring wherein the ring contains 0, 1, or 2 heteroatoms selected from the group consisting of O, N(Rc), and N(RD), wherein the nonaromatic ring is substituted with 0, 1, or 2 substituents selected from the group consisting of alkyl and hydroxy;
R3 is selected from the group consisting of hydrogen, alkenyl, alkenyloxy, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NRERF, (NRERp) lkoxy (NReRRlalkyl, (NRERF)carbonyl, and (NRERF)carbonylalkyl;
R4 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkylcarbonylalkoxy, aryl, arylalkoxy, arylalkyl, aryloxy, carboxy, cyano, halogen, heteroaryl, heteroarylalkoxy, heteroarylalkyl, heteroaryloxy, heterocycle, heterocyclealkoxy, heterocyclealkyl, heterocycleoxy, hydroxy, -NRERF, and (NRERF)carbonyl;
R5 is absent or selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, halogen, heteroaryl, hydroxy, nitro, -NRERF, and (NRERp)carbonyl; or
R4 and R5, together with the atoms to which they are attached, form a phenyl ring optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NRGRH, (NRϋRi alkoxy, (NRϋR^alkyl, (NRσRiύcarbonyl, and (NRGRH)sulfonyl; or
R4 and R5, together with the atoms to which they are attached, form a heterocycle optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, oxo, -NRGRH, (NRGRH)alkoxy, (NRGRι-)alkyl, and (NRGRH)carbonyl; provided that when R5 is hydrogen, R4 is other than hydrogen;
R6 is selected from the group consisting of hydrogen, lower alkoxy, lower alkyl, halogen, hydroxy, and -NRERF;
RA and RB are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkoxyalkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylcarbonyl, alkoxysulfonyl, alkoxysulfonylalkyl, alkoxysulfonylalkylcarbonyl, alkyl, alkylcarbonyl, alkynyl, aryl, carboxyalkyl, carboxyalkylcarbonyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkylcarbonyl, cycloalkylcarbonyl, cycloalkylcarbonylalkyl, cycloalkylcarbonylalkylcarbonyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, heterocyclealkylcarbonyl, heterocyclecarbonyl, heterocyclecarbonylalkyl, heterocyclecarbonylalkylcarbonyl, hydroxyalkyl, hydroxyalkylcarbonyl, hydroxysulfonyl, hydroxysulfonylalkyl, hydroxysulfonylalkylcarbonyl, (NRERp)alkyl, (NRERF)alkylcarbonyl, (NRERF)carbonyl, (NRERp)carbonylalkyl, (NRERp)carbonylalkylcarbonyl, (NRERp)sulfonyl, (NRERp)sulfonylalkyl, and (NRERF)sulfonylalkylcarbonyl;
Re and RD are independently selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, and alkylcarbonyl;
RE and RF are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, cycloalkyl, heteroarylalkyl, and hydroxyalkyl;
Xi, X3, and X are independently selected from the group consisting of CH and N;
X2 is selected from the group consisting of CH(R7), C(R7)(R8), C=O, N(RS);
X5 is selected from the group consisting of C and N; R7 is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxy, lower alkoxy, lower alkyl, and hydroxyalkyl; and
R8 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, alkylcarbonyl, and hydroxyalkyl.
In another embodiment, the present invention relates to pharmaceutical compositions comprising a compound of formula (I), or a therapeutically acceptable salt thereof, in combination with a therapeutically acceptable carrier.
In another embodiment, the present invention relates to a method for inhibiting protein kinases in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I), or a therapeutically acceptable salt thereof.
In another embodiment, the present invention relates to a method for treating cancer in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I), or a therapeutically acceptable salt thereof.
Detailed Description of the Invention
In the principle emobidment, the present invention relates to compounds of formula (I)
(I), or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein
Ri and R2 are independently selected from the group consisting of hydrogen, alkenyl, alkenyloxy, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkynyl, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, cycloalkenylalkoxy, cycloalkylalkoxy, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkyloxy, formyl, haloalkoxy, haloalkoxyalkynyl, haloalkyl, halogen, heteroarylalkoxy, heteroarylalkoxyalkoxy, heteroarylalkyl, heteroarylalkynyl, heteroaryloxyalkyl, heterocycle, heterocyclealkoxy, heterocyclealkyl, heterocyclecarbon-yl, heterocycleoxy, hydroxy, hydroxyalkoxy, hydroxyalkyl, hydroxyalkynyl, hydroxysulfonyl, hydroxysulfonylalkyl, mercapto, mercaptoalkyl, nitro, -NRARB, (NRARβ)alkoxy, (NRARβ)alkyl, (NRARB) lkynyl, (NRARB)carbonyl, (NRARB)carbonylalkoxy, (NRARB)carbonylalkyl, and (NRGRH) lko y; or
Ri and R2 together with the carbon atoms to which they are attached form a 5, 6, 7, or 8- membered nonaromatic ring wherein the ring contains 0, 1, or 2 heteroatoms selected from the group consisting of O, N(Rc), and N(RD), wherein the nonaromatic ring is substituted with 0, 1, or 2 substituents selected from the group consisting of alkyl and hydroxy;
R3 is selected from the group consisting of hydrogen, alkenyl, alkenyloxy, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NRERF, (NRERp)alkoxy (NRERp) lkyl, (NRERp)carbonyl, and (NRERF)carbonylalkyl;
R is selected from the group consisting of hydrogen, alkoxycarbonyl, alkylcarbonylalkoxy, aryl, arylalkoxy, arylalkyl, aryloxy, carboxy, cyano, halogen, heteroaryl, heteroarylalkoxy, heteroarylalkyl, heteroaryloxy, heterocycle, heterocyclealkoxy, heterocyclealkyl, heterocycleoxy, hydroxy, -NRERF, and (NRERp)carbonyl;
R5 is absent or selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, halogen, heteroaryl,hydroxy, nitro, -NRERF, an (NRERp)carbonyl; or
R4. and R5, together with the atoms to which they are attached, form a phenyl ring optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NRQRH, (NRϋRi alkoxy, (NRGRι.)alkyl, (NRGRH)carbonyl, and (NRGRH)sulfonyl; or
R and R5, together with the atoms to which they are attached, form a heterocycle optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, oxo, -NRGRH, (NRoR^alkoxy, (NRoR^alkyl, and (NRGRH)carbonyl; provided that when R5 is hydrogen, R4 is other than hydrogen;
R6 is selected from the group consisting of hydrogen, lower alkoxy, lower alkyl, halogen, hydroxy, and -NRERF',
RA and RB are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkoxyalkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylcarbonyl, alkoxysulfonyl, alkoxysulfonylalkyl, alkoxysulfonylalkylcarbonyl, alkyl, alkylcarbonyl, alkynyl, aryl, carboxyalkyl, carboxyalkylcarbonyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkylcarbonyl, cycloalkylcarbonyl, cycloalkylcarbonylalkyl, cycloalkylcarbonylalkylcarbonyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, heterocyclealkylcarbonyl, heterocyclecarbonyl, heterocyclecarbonylalkyl, heterocyclecarbonylalkylcarbonyl, hydroxyalkyl, hydroxyalkylcarbonyl, hydroxysulfonyl, hydroxysulfonylalkyl, hydroxysulfonylalkylcarbonyl, (NRERp)alkyl, (NRERF)alkylcarbonyl, (NRERp)carbonyl, (NRERF)carbonylalkyl, (NRERF)carbonylalkylcarbonyl, (NRERp)sulfonyl, (NRERp)sulfonylalkyl, and (NRERp)sulfonylalkylcarbonyl;
Re and RD are independently selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, and alkylcarbonyl;
RE and RF are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, cycloalkyl, heteroarylalkyl, and hydroxyalkyl;
X1( X3, and X4 are independently selected from the group consisting of CH and N;
X2 is selected from the group consisting of CH(R7), C(R )(R8), C=O, N(R8);
X5 is selected from the group consisting of C and N;
R7 is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxy, lower alkoxy, lower alkyl, and hydroxyalkyl; and
R8 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, alkylcarbonyl, and hydroxyalkyl.
In another embodiment, the present invention relates to a compound of formula (I) wherein Xl5 X3, and X are CH; X is CH(R7); X5 is C; Rj and R2 are independently selected from the group consisting of hydrogen, alkenyloxy, alkoxy, alkoxyalkyl, heterocyclealkyl, hydroxy, hydroxyalkyl, (NRARβ) lkyl, and (NRARβ)carbonyl; R3 is hydrogen; R4 is selected from the group consisting of hydrogen, alkoxycarbonyl, aryl, carboxy, cyano, heteroaryl, hydroxy, -NRERF, and (NRERp)carbonyl; R5 is selected from the group consisting of hydrogen and -NRERF; Rό is hydrogen; R7 is hydrogen; RA is selected from the group consisting of hydrogen and alkyl; Rβ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, heteroarylalkyl, heterocycle, and hydroxyalkyl; RE is selected from the group consisting of hydrogen and alkyl; and RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi, X3, and X are CH; X2 is CH(R ); X5 is C; Ri and R2 are independently selected from the group consisting of hydrogen, alkenyloxy, alkoxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARβ)alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R3 is hydrogen; R is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, cyano, heteroaryl, hydroxy, -NRERF, (NRERp)carbonyl, and aryl, wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NRGRH. RS is selected from the group consisting of hydrogen and -NRERF; RO is hydrogen; R7 is hydrogen; RA is selected from the group consisting of hydrogen and alkyl; Rβ is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; RE is selected from the group consisting of hydrogen and alkyl; and RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
In another embodiment, the present invention relates to a compound of formula (I) wherein Xls X3, and X are CH; X2 is CH(R7); X5 is C; Rl5 R3, R5, and R6 are hydrogen; R2 is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARβ)alkyl, (NRARB)c rbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, and (NRERp)carbo yl; R is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; and RB, RE and RF are hydrogen.
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi, X3, and X are CH; X2 is CH(R ); X5 is C; Ri, R3, R5, and R6 are hydrogen; R2 is selected from the group consisting of hydrogen, alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARβ)alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R4 is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NRGRH", 7 is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; and Rβ, RE, and RF are hydrogen.
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi, X3, and X4 are CH; X2 is CH(R ); X5 is C; Ri, R3, R5, and R6 are hydrogen; R is selected from the group consisting of hydrogen, alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARβ)alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is heteroaryl; R7 is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; and RB is selected from the group consisting of hydrogen and alkyl.
In another embodiment, the present invention relates to a compound of formula (I) wherein X1} X3, and X are CH; X2 is CH(R ); X5 is C; R1; R3, R5, and R6 are hydrogen; R is alkenyloxy; R is heteroaryl wherein the heteroaryl is tetraazolyl; and R7 is hydrogen.
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi, X3, and X are CH; X2 is CH(R7); X5 is C; Ri, R3, and R6 are hydrogen; R2 is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARβ)alkyl, (NRARβ)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is selected from the group consisting of hydrogen, carboxy, and cyano; R5 is selected from the group consisting of alkoxycarbonyl, carboxy, hydroxy, hydroxyalkyl, -NRERF, and (NRERF)carbo yl; R7 is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; Rβ is selected from the group consisting of hydrogen and alkyl; RE is selected from the group consisting of hydrogen and alkyl; and RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi, X3, and X are CH; X2 is CH(R7); X5 is C; Rls R3, and R6 are hydrogen; R2 is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARβ) lkyl, (NRARβ)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is selected from the group consisting of hydrogen, carboxy, and cyano; R5 is -NRERFΪ RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; Rβ is selected from the group consisting of hydrogen and alkyl; RE is selected from the group consisting of hydrogen and alkyl; and RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
In another embodiment, the present invention relates to a compound of formula (I) wherein X1; X3, and X are CH; X2 is CH(R7); X5 is C; R , R3, R5, and R6 are hydrogen; Rt is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARβ)alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NRERF, and (NRERF) arbonyl; R7 is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; Rβ is selected from the group consisting of hydrogen and alkyl; RE is selected from the group consisting of hydrogen and alkyl; and RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
In another embodiment, the present invention relates to a compound of formula (I) wherein Xl5 X3, and X are CH; X2 is CH(R7); X5 is C; R2, R3, R5, and R6 are hydrogen; Ri is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARβ)alkyl, (NRARB)carbo yl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R4 is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NRGRH; 7 is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; Rβ is selected from the group consisting of hydrogen and alkyl; RE is selected from the group consisting of hydrogen and alkyl; and RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi, X3, and X are CH; X2 is CH(R ); X5 is C; R2, R3, and R6 are hydrogen; Rt is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARβ)alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R4 is selected from the group consisting of hydrogen, carboxy, and cyano; R5 is selected from the group consisting of alkoxycarbonyl, carboxy, hydroxy, hydroxyalkyl, -NRERF, and (NRERp)carbonyl; R7 is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; Rβ is selected from the group consisting of hydrogen and alkyl; RE is selected from the group consisting of hydrogen and alkyl; and RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi, X3, and X are CH; X2 is CH(R ); X5 is C; Ri and R2 are alkoxy; R3 and R6 are hydrogen; R is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, -NRERF, and (NRERp)carbonyl; R5 is selected from the group consisting of hydrogen and carboxy; R7 is hydrogen; RE is selected from the group consisting of hydrogen and alkyl; and RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi, X3, and X are CH; X is CH(R7); X5 is C; Ri and R2 are alkoxy; R3, R5, and R6 are hydrogen; R4 is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NRGRH', 7 is hydrogen; RE is selected from the group consisting of hydrogen and alkyl; and RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi, X3, and X4 are CH; X2 is CH(R7); X5 is C; Ri and R2 are alkoxy; R3, R5, and R6 are hydrogen; R4 is heteroaryl; and R7 is hydrogen.
In another embodiment, the present invention relates to a compound of formula (I) wherein X1; X3, and X are CH; X2 is CH(R7); X5 is C; RΪ and R2 are alkoxy; R3, R5, and R6 are hydrogen; R4 is heteroaryl wherein the heteraryl is tetraazolyl; and R7 is hydrogen.
In another embodiment, the present invention relates to a compound of formula (I) wherein X1; X3, and X are CH; X2 is CH(R7); X5 is C; Ri, R2, R3, R5, and Rg are hydrogen; R is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NRERF, and (NRERp)carbonyl; and R7 is selected from the group consisting of alkoxy and hydroxy.
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi is CH; X2 is CH(R7); X3 is N; X4 is CH; X5 is C; Ri, R3, R5, and R6 are hydrogen; R2 is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARβ)alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; R is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NRERF, and (NRERF)carbonyl; R7 is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; Rβ is selected from the group consisting of hydrogen and alkyl; RE is selected from the group consisting of hydrogen and alkyl; and RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi, X3, and X are CH; X2 is CH(R7); X5 is C; Ri and R2 together with the carbon atoms to which they are attached form a 5 or 6-membered nonaromatic ring wherein the ring contains 0, 1, or 2 heteroatoms selected from the group consisting of O, N(Rc), and N(RD); R3, R5, and R6 are hydrogen; R4 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NRERF, and (NRERp)carbonyl; R7 is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; Rβ is selected from the group consisting of hydrogen and alkyl; RE is selected from the group consisting of hydrogen and alkyl; RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and Re and RD are as defined in formula (I).
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi, X3, and X4 are CH; X2 is CH(R7); X5 is C; R and R2 together with the carbon atoms to which they are attached form a 5 or 6-membered nonaromatic ring wherein the ring contains 2 heteroatoms selected from the group consisting of O, N(Rc), and N(RD); R3, R5, and R6 are hydrogen; R4 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NRERF, and (NRERF)carbonyl; R7 is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; RB is selected from the group consisting of hydrogen and alkyl; RE is selected from the group consisting of hydrogen and alkyl; RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and Re and RD are as defined in formula (I).
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi, X3, and X4 are CH; X is CH(R7); X5 is C; Ri and R2 together with the carbon atoms to which they are attached form a 5 or 6-membered nonaromatic ring wherein the ring contains 0, 1, or 2 heteroatoms selected from the group consisting of O, N(Rc), and N(RD); R3, RS, and R6 are hydrogen; R4 is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and - NRGRH; R7 is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; Rβ is selected from the group consisting of hydrogen and alkyl; RE is selected from the group consisting of hydrogen and alkyl; and RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and Re and RD are as defined in formula
(I).
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi, X3, and X4 are CH; X2 is CH(R7); X5 is C; Ri and R2 together with the carbon atoms to which they are attached form a 5 or 6-membered nonaromatic ring wherein the ring contains 2 heteroatoms selected from the group consisting of O, N(Rc), and N(RD); R3, R5, and R6 are hydrogen; R is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NRGRH; R7 is hydrogen; RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; Rβ is selected from the group consisting of hydrogen and alkyl; RE is selected from the group consisting of hydrogen and alkyl; and RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and Re and RD are as defined in formula (I).
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi, X3, and X4 are CH; X2 is CH(R7); X5 is C; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRARβ)alkynyl, and (NRARB)carbonyl; R3 is selected from the group consisting of hydrogen, -NRERF, and hydroxyalkyl; R is aryl wherein the aryl is phenyl substituted with 1 or 2 substituents selected from the group consisting of alkoxy, carboxy, cyano, halogen, and hydroxy; R7 is selected from the group consisting of hydrogen, lower alkoxy, lower alkyl, and hydroxy; RE and RF are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RA and RB are as defined in formula (I). In another embodiment, the present invention relates to a compound of formula (I) wherein Xj, X3, and X4 are CH; X2 is C=O; X5 is C; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRARβ)alkynyl, and (NRARB)carbonyl; R3 is selected from the group consisting of hydrogen, -NRERF, and hydroxyalkyl; R is aryl wherein the aryl is phenyl substituted with 1 or 2 substituents selected from the group consisting of alkoxy, carboxy, cyano, halogen, and hydroxy; R5 and R6 are hydrogen; RE and RF are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and R and Rβ are as defined in formula (I).
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi and X are CH; X2 is CH(R7); X3 is N; X5 is C; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRARβ)alkynyl, and (NRARβ)carbonyl; R3 is selected from the group consisting of hydrogen, -NRERF, and hydroxyalkyl; Ri is selected from the group consisting of cyano, halogen, and aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from alkoxy and hydroxy; R5 and R6 are hydrogen; R7 is selected from the group consisting of hydrogen, lower alkoxy, lower alkyl, and hydroxy; RE and RF are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RA and RB are as defined in formula (I).
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi and X4 are CH; X2 is C=0; X3 is N; X5 is C; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRARβ)alkynyl, and (NRARβ)carbonyl; R3 is selected from the group consisting of hydrogen, - NRERF, and hydroxyalkyl; R is selected from the group consisting of cyano, halogen, and aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from alkoxy and hydroxy; R5 and R6 are hydrogen; RE and RF are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RA and RB are as defined in formula (I).
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi and X3 are CH; X2 is CH(R7); X4 is N; X5 is C; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRARβ)alkynyl, and (NRARB)carbonyl; R3 is selected from the group consisting of hydrogen, -NRERF, and hydroxyalkyl; R4 is selected from the group consisting of cyano, halogen, and aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from alkoxy and hydroxy; R5 and R6 are hydrogen; R is selected from the group consisting of hydrogen, lower alkoxy, lower alkyl, and hydroxy; RE and RF are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RA and Rβ are as defined in formula (I).
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi and X3 are CH; X2 is C=0; X is N; X5 is C; Rj is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRARβ)alkynyl, and (NRARB)carbonyl; R3 is selected from the group consisting of hydrogen, -NRERF, and hydroxyalkyl; R is selected from the group consisting of cyano, halogen, and aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from alkoxy and hydroxy; R5 and R6 are hydrogen; RE and RF are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RA and RB are as defined in formula (I).
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi and X3 are CH; X2 is CH(R7); X4 and X5 are N; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRARβ)alkynyl, and (NRARβ)carbonyl; R3 is selected from the group consisting of hydrogen, -NRERF, and hydroxyalkyl; R is selected from the group consisting of cyano, halogen, and aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from alkoxy and hydroxy; R5 is absent; R6 is hydrogen; R7 is selected from the group consisting of hydrogen, lower alkoxy, lower alkyl, and hydroxy; RE and RF are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RA and Rβ are as defined in formula (I).
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi and X3 are CH; X2 is C=O; X and X5 are N; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRARB)alkynyl, and (NRARB)carbonyl; R3 is selected from the group consisting of hydrogen, -NRERF, and hydroxyalkyl; R is selected from the group consisting of cyano, halogen, and aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from alkoxy and hydroxy; R5 is absent; R6 is hydrogen; RE and RF are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RA and RB are as defined in formula (I).
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi and X4 are CH; X2 is CH(R7); X3 and X5 are N; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRARβ)alkynyl, and (NRARβ)carbonyl; R3 is selected from the group consisting of hydrogen, -NRERF, and hydroxyalkyl; R4 is selected from the group consisting of cyano, halogen, and aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from alkoxy and hydroxy; R5 is absent; R6 is hydrogen; R7 is selected from the group consisting of hydrogen, lower alkoxy, lower alkyl, and hydroxy; RE and RF are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RA and RB are as defined in formula (I).
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi and X are CH; X2 is C=O; X3 and X5 are N; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRARβ)alkynyl, and (NRARB)carbonyl; R3 is selected from the group consisting of hydrogen, -NRERF, and hydroxyalkyl; R is selected from the group consisting of cyano, halogen, and aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from alkoxy and hydroxy; R5 is absent; R6 is hydrogen; RE and RF are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RA and Rβ are as defined in formula (I).
In another embodiment, the present invention relates to a compound of formula (I) wherein Xi, X3, and X4 are CH; X2 is CH(R7); X5 is C; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRARB)alkynyl, and (NRARβ)carbonyl; R3 is selected from the group consisting of hydrogen, -NRERF, and hydroxyalkyl; R and R5, together with the atoms to which they are attached, form a phenyl ring optionally substituted with 1 or 2 substituents independently selected from alkoxy, carboxy, cyano, halogen, and hydroxy; R7 is selected from the group consisting of hydrogen, lower alkoxy, lower alkyl, and hydroxy; RE and RF are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RA and RB are as defined in formula (I).
In another embodiment, the present invention relates to a compound of formula (I) wherein Xls X3, and X4 are CH; X2 is C=0; X5 is C; Ri is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxyalkoxy, and hydroxyalkyl; R2 is selected from the group consisting of alkoxy, alkoxyalkoxyalkynyl, alkyl, haloalkoxyalkynyl, heteroarylalkoxy, heteroarylalkynyl, heteroaryloxyalkyl, heteroaryloxy, heterocyclealkoxy, heterocyclecarbonyl, heterocycleoxy, heterocycleoxyalkyl, hydroxyalkoxy, hydroxalkyl, hydroxyalkynyl, (NRARε)alkynyl, and (NRARB)carbo yl; R3 is selected from the group consisting of hydrogen, -NRERF, and hydroxyalkyl; R4 is selected from the group consisting of cyano, halogen, and aryl wherein the aryl is phenyl optionally substituted with 1 or 2 substituents independently selected from alkoxy and hydroxy; R5 is absent; R6 is hydrogen; RE and RF are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RA and RB are as defined in formula (I).
Definition of Terms
As used throughout this specification and the appended claims, the following terms have the following meanings:
The term "alkenyl" as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl (allyl), 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2- heptenyl, 2-methyl-l-heptenyl, and 3-decenyl.
The term "alkenyloxy" as used herein, means an alkenyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkenyloxy include, but are not limited to, allyloxy, 2-butenyloxy and 3-butenyloxy.
The term "alkoxy" as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
The term "alkoxy alkoxy" as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of alkoxyalkoxy include, but are not limited to, 2-(methoxy)ethoxy, 2-(ethoxy)ethoxy, 2-(tert-butoxy)ethoxy, and 3-(methoxy)butoxy.
The term "alkoxyalkoxyalkynyl" as used herein, means an alkoxyalkoxy group, as defined herein, appended to the parent molecular moiety through an alkynyl group, as defined herein. Representative examples of alkoxyalkoxyalkynyl include, but are not limited to, 3-(2-isoρropoxyethoxy)ρrop- 1 -ynyl, 3-(2-methoxyethoxy)prop- 1-ynyl, and 4-(2-isoρropoxyethoxy)but- 1 -ynyl.
The term "alkoxyalkyl" as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkoxyalkyl include, but are not limited to, mefhoxymethyl, ethoxymethyl, 2-ethoxyethyl, tert-butoxymethyl, and 2-methoxyethyl.
The term "alkoxyalkylcarbonyl" as used herein, means an alkoxyalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkoxyalkylcarbonyl include, but are not limited to, 3- methoxypropanoyl and 5-methoxypentanoyl.
The term "alkoxycarbonyl" as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.
The term "alkoxycarbonylalkyl" as used herein, means an alkoxycarbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkoxycarbonylalkyl include, but are not limited to, 3- methoxycarbonylpropyl, 4-ethoxycarbonylbutyl, and 2-tert-butoxycarbonylethyl.
The term "alkoxycarbonylalkylcarbonyl" as used herein, means an alkoxycarbonylalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkoxycarbonylalkylcarbonyl include, but are not limited to, 5-methoxy-5-oxopentanoyl, 5-ethoxy-5-oxopentanoyl, and 4-methoxy-4-oxobutanoyl.
The term "alkoxysulfonyl" as used herein, means an alkoxy group, as defined herein, appended appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of alkoxysulfonyl include, but are not limited to, methoxysulfonyl, ethoxysulfonyl and propoxy sulfonyl.
The term "alkoxysulfonylalkyl" as used herein, means an alkoxysulfonyl group, as defined herein, appended appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkoxysulfonylalkyl include, but are not limited to, 3-(methoxysulfonyl)propyl, 3-(ethoxysulfonyl)propyl, and 2-(methoxysulfonyl)ethyl.
The term "alkoxysulfonylalkylcarbonyl" as used herein, means an alkoxysulfonylalkyl group, as defined herein, appended appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkoxysulfonylalkylcarbonyl include, but are not limited to, 3-(methoxysulfonyl)propanoyl, 3-(ethoxysulfonyl)propanoyl, and 4-(methoxysulfonyl)butanoyl .
The term "alkyl" as used herein, means a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.
The term "alkylcarbonyl" as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-l-oxopropyl, 1-oxobutyl, and 1-oxopentyl.
The term "alkylcarbonylalkoxy" as used herein, means an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of alkylcarbonylalkoxy include, but are not limited to, acetyl, 2-oxopropoxy, 2-oxobutoxy, and 3-oxobutoxy, 4-oxopentyloxy.
The term "alkylcarbonyloxy" as used herein, means an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, and tert-butylcarbonyloxy.
The term "alkylsulfinyl" as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfinyl group, as defined herein. Representative examples of alkylsulfinyl include, but are not limited to, methylsulfinyl and ethylsulfinyl.
The term "alkylsulfonyl" as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of alkylsulfonyl include, but are not limited to, methylsulfonyl and ethylsulfonyl.
The term "alkylthio" as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom. Representative examples of alkylthio include, but are not limited, methylthio, ethylthio, tert-butylthio, and hexylthio.
The term "alkylthioalkyl" as used herein, means an alkylthio group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkylthioalkyl include, but are not limited, methylthiomethyl and 2- (ethylthio)ethyl.
The term "alkynyl" as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2- propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
The term "aryl" as used herein, means a monocyclic-ring system or a bicyclic-fused ring system wherein one or more of the fused rings are aromatic. Representative examples of aryl include, but are not limited to, indenyl, naphthyl, phenyl, and tetrahydronaphthyl.
The aryl groups of the present invention are substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NRGRH, (NRcR^alkoxy, (NRcR^ lkyl, (NRGRH)carbonyl, and (NRcRH)sulfonyl. The aryl groups of the present invention may be optionally substituted with one heterocycle, as defined herein. The heterocycle may be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NRGRH, (NRGRH)alkoxy, (NRGRH)alkyl, (NRGRH)carbonyl, and (NRGRH)sulfonyl
The term "arylalkoxy" as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of arylalkoxy include, but are not limited to, 2-phenylethoxy, 3-phenylpropoxy, and 5- phenylpentyloxy.
The term "arylalkyl" as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of arylalkyl include, but are not limited to, 4-carboxyphenylmefhyl, 2-(4-hydroxyphenyl)ethyl, and 3-(4-carboxyphenyl)propyl.
The term "aryloxy" as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of aryloxy include, but are not limited to, 4-carboxyphenoxy, 4-hydroxyphenoxy, and 3,4- dihy droxyphenoxy .
The term "carboxy" as used herein, means a -CO2H group.
The term "carboxyalkyl" as used herein, means a carboxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of carboxyalkyl include, but are not limited to, carboxymethyl, 2- carboxyethyl, and 3-carboxypropyl.
The term "carboxyalkylcarbonyl" as used herein, means a carboxyalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of carboxyalkylcarbonyl include, but are not limited to, 4- carboxybutanoyl, 3-carboxypropanoyl, and 5-carboxypentanoyl.
The term "cyano" as used herein, means a -CN group. The term "cycloalkyl" as used herein, means a saturated cyclic hydrocarbon group containing from 3 to 8 carbons. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
The cycloalkyl groups of the present invention are substituted with 0, 1, 2, 3, or 4 substituents selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, -NRGRH, (NRGRH)alkoxy, (NRGRH)alkyl, and (NRGRH)carbonyl.
The term "cycloalkenyl," as used herein, means a non-aromatic, partially unsaturated monocyclic, bicyclic, or tricyclic ring system having four to eight carbon atoms and zero heteroatoms. Representative examples of cycloalkenyl groups include, but are not limited to, cyclohexenyl and cyclopentenyl.
The term "cycloalkenylalkoxy" as used herein, means a cycloalkenyl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
The term "cycloalkylalkoxy" as used herein, means a cycloalkyl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of cycloalkylalkoxy include, but are not limited to, cyclopropylmethoxy, 2-cyclobutylethoxy, cyclopentylmethoxy, cyclohexylmethoxy, 2-cyclohexylethoxy, 3-cyclohexylpropoxy, 4-cyclohexylbutoxy, 4-(4-aminocyclohexyl)butoxy, 4-(4-dimethylaminocyclohexyl)butoxy, 4-(4-hydroxycyclohexyl)butoxy, and 4-cycloheptylbutoxy .
The term "cycloalkylalkyl" as used herein, means a cycloalkyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of cycloalkylalkyl include, but are not limited to, cyclopropylmethyl, 2- cyclobutylethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclohexylethyl, 3-cyclohexylpropyl, 4-cyclohexylbutyl, 4-(4-aminocyclohexyl)butyl, 4-(4-dimethylaminocyclohexyl)butyl, 4-(4- hydroxycyclohexyl)butyl, and 4-cycloheptylbutyl.
The term "cycloalkylalkylcarbonyl" as used herein, means a cycloalkylalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of cycloalkylalkylcarbonyl include, but are not limited to, 4- cyclohexylbutanoyl, 3-cyclohexylpropanoyl, and 5-cyclohexylpentanoyl. The term "cycloalkylcarbonyl" as used herein, means a cycloalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of cycloalkylcarbonyl include, but are not limited to, cyclohexylcarbonyl and cyclopentylcarbonyl.
The term "cycloalkyloxy" as used herein, means a cycloalkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of cycloalkyloxy include, but are not limited to, cyclohexyloxy and cyclopentyloxy.
The term "cycloalkylcarbonylalkyl" as used herein, means a cycloalkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of cycloalkylcarbonylalkyl include, but are not limited to, 4- cyclohexyl-4-oxobutyl and 3-cyclohexyl-3-oxopropyl.
The term "cycloalkylcarbonylalkylcarbonyl" as used herein, means a cycloalkylcarbonylalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of cycloalkylcarbonylalkylcarbonyl include, but are not limited to, 4-cyclohexyl-4-oxobutanoyl and 3 -cyclohexyl-3 -oxopropanoyl .
The term "formyl" as used herein, means a -C(O)H group.
The term "halo" or "halogen" as used herein, means -Cl, -Br, -I or -F.
The term "haloalkoxy" as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Additionally, the alkyl group may optionally be substituted with at least one halogen atom. Representative examples of haloalkoxy include, but are not limited to, chloromethoxy, 2- fluoroethoxy, trifluoromethoxy, pentafluoroethoxy,and 3-chloro-2-(hydroxymethyl)-2- methylpropoxy.
The term "haloalkoxyalkynyl" as used herein, means a haloalkoxy group, as defined herein, appended to the parent molecular moiety through an alkynyl group, as defined herein. Representative examples of haloalkoxyalkynyl include, but are not limited to, 3-(2,2,2-trifluoroethoxy)prop-l-ynyl and 3-(trifluoromethoxy)prop-l-ynyl.
The term "haloalkyl" as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl.
The term "heteroaryl," as used herein, refers to an aromatic five- or six-membered ring wherein 1, 2, 3, or 4 heteroatoms are independently selected from N, O, or S. The five membered rings have two double bonds and the six membered rings have three double bonds. The heteroaryl groups are connected to the parent molecular moiety through a carbon or nitrogen atom. The term "heteroaryl" also includes bicyclic systems where a heteroaryl ring is fused to a phenyl group or an additional heteroaryl group. Representative examples of heteroaryl include, but are not limited to, benzothienyl, benzoxadiazolyl, cinnolinyl, furopyridinyl, furyl, imidazolyl, indazolyl, indolyl, isoxazolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, quinolinyl, tetraazolyl, thiadiazolyl, thiazolyl, thienopyridinyl, thienyl, triazolyl, and triazinyl.
The heteroaryl groups of the present invention are substituted with 0, 1, 2, 3, or 4 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NRGRH, (NRcR^alkoxy, (NRcRH)alkyl, (NRGRH)carbonyl, and (NRGRH)sulfonyl.
The term "heteroarylalkoxy" as used herein, means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of heteroarylalkoxy include, but are not limited to, 5-hydroxy-2- pyridinylmethyl, 2-(5-hydroxy-2-pyridinyl)ethyl, and 5-hydroxy-2-pyrimidinylmethyl.
The term "heteroarylalkoxyalkoxy" as used herein, means a heteroarylalkoxy group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
The term "heteroarylalkyl" as used herein, means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of heteroarylalkyl include, but are not limited to, 5-carboxy-2- pyridinylmethyl, 5-hydroxy-2-pyridinylmethyl, 2-(5-hydroxy-2-pyridinyl)ethyl, and 3-(5- hydroxy-2-pyridinyl)propyl. The term "heteroarylalkynyl" as used herein, means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an alkynyl group, as defined herein. Representative examples of heteroarylalkynyl include, but are not limited to, pyridin-2- ylethynyl, pyridin-3-ylethynyl, 4-pyridin-2-ylbut-l-ynyl, and 4-pyrazin-2-ylpent-l -ynyl.
The term "heteroaryloxy" as used herein, means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of heteroaryloxy include, but are not limited to, 5-carboxy-2-pyridinyloxy, 5-hydroxy-2- pyridinyloxy, and 5-hydroxy-2-pyrimidinyloxy.
The term "heteroaryloxyalkyl" as used herein, means a heteroaryloxy group, as defined herein, appended to the parent molecular moiety through an alkyl group. Representative examples of heteroaryloxyalkyl include, but are not limited to, pyridinyl5-carboxy-2- pyridinyloxymethyl, 5-hydroxy-2-pyridinyloxymethyl, and 5-hydroxy-2-pyrimidinyloxy.
The term "heterocycle," as used herein, refers to a three, four, five, six, seven or eight membered ring containing one, two, or three heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The three membered ring has zero double bonds. The four and five membered rings have zero or one double bond. The six membered ring has zero, one, or two double bonds. The seven and eight membered rings have zero, one, two, or three double bonds. The heterocycle groups of the present invention can be attached to the parent molecular moiety through a carbon atom or a nitrogen atom. Representative examples of heterocycle include, but are not limited to, azetidinyl, azepanyl, aziridinyl, azocanyl, l,4-diazepan-2-yl, 1,4-dioxanyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, thiomorpholinyl, and 1,1-dioxidothiomorpholinyl.
The heterocycles of the present invention are substituted with 0, 1, 2, 3, or 4 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, oxo, -NRGRH, (NRGRH) alkoxy, (NRGRH) lkyl, and (NRcRH)carbonyl. The heterocycles of the present invention may be optionally substituted with one aryl group, as defined herein. The aryl group may be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NRGRH, (NRGRH)alkoxy, (NRGRH)alkyl, (NRGRH)carbonyl, and (NRGRH)sulfonyl.
The term "heterocyclealkoxy" as used herein, means a heterocycle, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of heterocyclealkoxy include, but are not limited to, 4-morpholinylmethoxy, 2-(4-morpholinyl)ethoxy, 4-thiomorpholinylmethoxy, 2-(4-thiomorpholinyl)ethoxy, 1 -piperidinylmethoxy, 2-(l-piperidinyl)ethoxy, 4-hydroxy-l- piperidinylmethoxy , 2-(4-hydroxy- 1 -piperidinyl)ethoxy, 3-hydroxy- 1 -pyrrolidinylmethoxy, 3-hydroxy- 1-azetidinylmethoxy, and 4-hydroxy-l-azepanylmethoxy.
The term "heterocyclealkyl" as used herein, means a heterocycle, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of heterocyclealkyl include, but are not limited to, 4-morpholinylmethyl, 2-(4-morpholinyl)ethyl, 4-thiomorpholinylmethyl, 2-(4-thiomorpholinyl)ethyl, 1-piperidinylmethyl, 2-(l-piperidinyl)ethyl, 4-hydroxy-l- piperidinylmethyl, 2-(4-hydroxy- l-piperidinyl)ethyl, 3-hydroxy- 1-pyrrolidinylmethyl, 3-hydroxy-l-azetidinylmethyl, 3-hydroxy-l-azepanylmethyl, and 4-hydroxy-l-azepanylmethyl.
The term "heterocyclealkylcarbonyl" as used herein, means a heterocyclealkyl, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of heterocyclealkylcarbonyl include, but are not limited to, 4-(l- piperidinyl)butanoyl, 3-(l-piperidinyl)propanoyl, 4-(4-morpholinyl)butanoyl, and 3-(4-morpholinyl)propanoyl.
The term "heterocyclecarbonyl" as used herein, means a heterocycle, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of heterocyclecarbonyl include, but are not limited to, 4-morpholinylcarbonyl, 4-thiomorpholinylcarbonyl, 1-piperidinylcarbonyl, (4-hydroxy-l- piperidinyl)carbonyl, and 3-hydroxy-l-pyrrolidinylcarbonyl.
The term "heterocyclecarbonylalkyl" as used herein, means a heterocyclecarbonyl, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of heterocyclecarbonylalkyl include, but are not limited to, 2- (4-morpholinyl)-2-oxoethyl, 3-(4-morpholinyl)-3-oxopropyl, and 2-(l-piperidinyl)-2-oxoethyl.
The term "heterocyclecarbonylalkylcarbonyl" as used herein, means a heterocyclecarbonylalkyl, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of heterocyclecarbonylalkylcarbonyl include, but are not limited to, 5-(4-morpholinyl)-5- oxopentanoyl, 4-(4-morpholinyl)-4-oxobutanoyl, and 5-(l-piperidinyl)-5-oxopentanoyl.
The term "heterocycleoxy" as used herein, means a heterocycle group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of heterocycleoxy include, but are not limited to, 4-piperidinyloxy, 3-pyιτolidinyloxy, 3-azetidinyloxy, and tetrahydrofuran-3-yloxy.
The term "hydroxy" as used herein, means an -OH group.
The term "hydroxyalkoxy" as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of hydroxyalkoxy include, but are not limited to, 2-hydroxyethoxy, 3-hydroxypropoxy, 2,3-dihydroxypropoxy, 2,3-dihydroxypentoxy, and 3-hydroxy-2,2- dimethylpropoxy .
The term "hydroxyalkyl" as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2- hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypropyl, 2,3-dihydroxypentyl, 2-ethyl-4- hydroxyheptyl, and 3-hydroxy-2,2-dimethylpropyl.
The term "hydroxyalkynyl" as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkynyl group, as defined herein. Representative examples of hydroxyalkynyl include, but are not limited to, 4-hydroxy-4- methylpent-1-ynyl, 4-hydroxybut-l-ynyl, and 3-hydroxyprop-l-ynyl.
The term "hydroxyalkylcarbonyl" as used herein, means a hydroxyalkyl group, as defined herein, is appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of hydroxyalkylcarbonyl include, but are not limited to, glycoloyl, 3- hydroxypropanoyl, and 4-hydroxybutanoyl. The term "hydroxysulfonyl" as used herein, means a HOS(O)2- group.
The term "hydroxysulfonylalkyl" as used herein, means a hydroxysulfonyl group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxysulfonylalkyl include, but are not limited to, 4- sulfobutyl, 3-sulfopropyl, and 2-sulfoethyl.
The term "hydroxysulfonylalkylcarbonyl" as used herein, means a hydroxysulfonylalkyl group, as defined herein, is appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of hydroxysulfonylalkylcarbonyl include, but are not limited to, 4-sulfobutanoyl and 3-sulfopropanoyl.
The term " lower alkoxy" as used herein, is a subset of alkoxy as defined herein and means a lower alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom, as defined herein. Representative examples of lower alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, and 2-propoxy.
The term "lower alkyl" as used herein, is a subset of alkyl as defined herein and means a straight or branched chain hydrocarbon group containing from 1 to 3 carbon atoms. Examples of lower alkyl are methyl, ethyl, n-propyl, and iso-propyl.
The term "mercapto" as used herein, means a -SH group.
The term "mercaptoalkyl" as used herein, means a mercapto group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of mercaptoalkyl include, but are not limited to, hydroxymethyl, 2- mercaptoethyl, 3-mercaptopropyl, and 4-mercaptobutyl.
The term "nitro" as used herein, means a -N02 group.
The term "-NRARB" as used herein, means two groups, R and Rβ, which are appended to the parent molecular moiety through a nitrogen atom. RA and RB are each independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkoxyalkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylcarbonyl, alkoxysulfonyl, alkoxysulfonylalkyl, alkoxysulfonylalkylcarbonyl, alkyl, alkylcarbonyl, alkynyl, aryl, carboxyalkyl, carboxyalkylcarbonyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkylcarbonyl, cycloalkylcarbonyl, cycloalkylcarbonylalkyl, cycloalkylcarbonylalkylcarbonyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, heterocyclealkylcarbonyl, heterocyclecarbonyl, heterocyclecarbonylalkyl, heterocyclecarbonylalkylcarbonyl, hydroxyalkyl, hydroxyalkylcarbonyl, hydroxysulfonyl, hydroxysulfonylalkyl, hydroxysulfonylalkylcarbonyl, (NRERF)alkyl, (NRERF)alkylcarbonyl, (NRERF)carbonyl, (NRERF)carbonylalkyl, (NRERF)carbonylalkylcarbonyl, (NRERp)sulfonyl, (NRERF)sulfonylalkyl, and (NRERF)sulfonylalkylcarbonyl. Representative examples of -NRARB include, but are not limited to, amino, methylamino, dimethylamino, cyclohexylamino, (trans)-4-methylcyclohexylamino, (cis)-4-methylcyclohexylamino, (trans)-4-hydroxycyclohexylamino, and (cis)-4-hydroxycyclohexylamino.
The term "(NRARB)alkoxy" as used herein, means a -NRARB group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of (NRARβ) lko y include, but are not limited to aminomethoxy, 2- aminoethoxy, methylaminomethoxy, 2-(methylamino)ethoxy, dimethylaminomethoxy, 2- (dimethylamino)ethoxy, cyclohexylaminomethoxy, (trans)-4-methylcyclohexylaminomethoxy, (cis)-4-methylcyclohexylaminomethoxy, (trans)-4-hydroxycyclohexylaminomethoxy, and (cis)-4-hydroxycyclohexylaminomethoxy.
The term "(NRARB) alkyl" as used herein, means a -NRARB group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of (NRARβ)alkyl include, but are not limited to aminomethyl, 2- aminoethyl, methylaminomethyl, 2-(methylamino)ethyl, dimethylaminomethyl, 2- (dimethylamino)ethyl, cyclohexylaminomethyl, (trans)-4-methylcyclohexylaιτιinomethyl, (cis)- 4-methylcyclohexylaminomethyl, (1τans)-4-hydroxycyclohexylaminomethyl, and (cis)-4-hydroxycyclohexylaminomethyl.
The term "(NRARB) lkynyl" as used herein, means a -NRARB group, as defined herein, appended to the parent molecular moiety through an alkynyl group, as defined herein. Representative examples of (NRARβ)alkynyl include, but are not limited to 3-aminoprop-l-ynyl, 3-(dimethylamino)prop-l-ynyl, and 4-aminopent-l-ynyl.
The term "(NRARB)carbonyl" as used herein, means a -NRARB group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of (NRARB)carbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, and (ethylmethylamino)carbonyl. The term "(NRARβ)carbonylalkyr' as used herein, means a (NRARβ)carbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of (NRARβ)carbonylalkyl include, but are not limited to, aminocarbonylmethyl, (methylamino)carbonylmethyl, (dimethylamino)carbonylmethyl, and (ethylmethylamino)carbonylmethyl.
The term "-NRERF" as used herein, means two groups, RE and Rp, which are appended to the parent molecular moiety through a nitrogen atom. RE and RF are each independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, cycloalkyl, heteroarylalkyl, and hydroxyalkyl. Representative examples of -NRERF include, but are not limited to, amino, methylamino, dimethylamino, acetylamino, and acetylmethylamino.
The term "(NRεRF koxy" as used herein, means a -NRERF group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of (NRERp)alkoxy include, but are not limited to aminomethoxy, 2- aminoethoxy, methylaminomethoxy, 2-(methylamino)ethoxy, dimethylaminomethoxy, and 2- (dimethylamino)ethoxy.
The term "(NRERp)alkyl" as used herein, means a -NRERF group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of (NRERp)alkyl include, but are not limited to aminomethyl, 2- aminoethyl, 3-aminopropyl, methylaminomethyl, 2-(methylamino)ethyl, dimethylaminomethyl, and 2-(dimethylamino)ethyl.
The term "(NRERp)alkylcarbonyl" as used herein, means a (NRERρ)alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of (NRERp)alkylcarbonyl include, but are not limited to aminoacetyl, 3-aminopropanoyl, 3-dimethylaminopropanoyl, and 4-aminobutanoyl.
The term "(NRERF)carbonyl" as used herein, means a -NRERF group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of (NRERp)carbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, and (ethylmethylamino)carbonyl.
The term "(NRERF)carbonylalkyl" as used herein, means a (NRERp)carbonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of (NRERF)carbonylalkyl include, but are not limited to, 2- amino-2-oxoethyl, 3-amino-3-oxopropyl, and 4-amino-4-oxobutyl.
The term "(NRERF)carbonylalkylcarbonyl" as used herein, means a (NRERF)carbonylalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of (NRERF)carbonylalkylcarbonyl include, but are not limited to, 3-amino-3-oxopropanoyl and 4- amino-4-oxobutanoyl .
The term "(NRERF)sulfonyl" as used herein, means a -NRERF group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of (NRERp)sulfonyl include, but are not limited to, aminosulfonyl, (methylamino)sulfonyl, (dimethylamino)sulfonyl, and (ethylmethylamino)sulfonyl.
The term "(NRERF)sulfonylalkyl" as used herein, means a (NRERp)sulfonyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of (NR£RF)sulfonylalkyl include, but are not limited to, 2- (aminosulfonyl)ethyl, 2-(methylaminosulfonyl)ethyl, 3-(dimethylaminosulfonyl)propyl, and 4- (ethylmethylaminosulf onyl)butyl .
The term "(NRERp)sulfonylalkylcarbonyl" as used herein, means a (NRERp)sulfonylalkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of (NRERF)sulfonylalkylcarbonyl include, but are not limited to, 3-(aminosulfonyl)propanoyl, 4-(methylaminosulfonyl)butanoyl, 4-(dimethylaminosulfonyl)butanoyl, and 4-(ethylmethylaminosulfonyl)butanoyl.
The term "-NRGRH" as used herein, means two groups, RG and RH, which are appended to the parent molecular moiety through a nitrogen atom. RQ and RH are each independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl. Representative examples of -NRGRH include, but are not limited to, amino, methylamino, dimethylamino, acetylamino, and acetylmethylamino.
The term "(NRGRH)alkoxy" as used herein, means at least one -NRQRH group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of (NRϋR^ lkoxy include, but are not limited to aminomethoxy, 2- aminoethoxy, methylaminomethoxy, 2-(methylamino)ethoxy, dimethylaminomethoxy, 2-(dimethylamino)ethoxy, and 2-(dimethylamino)-l-[(dimethylamino)methyl]ethoxy.
The term "(NRGRH)alkyl" as used herein, means a -NRGRH group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of (NRϋR^ lkyl include, but are not limited to aminomethyl, 2- aminoethyl, 3-aminopropyl, methylaminomethyl, 2-(methylamino)ethyl, dimethylaminomethyl, and 2-(dimethylamino)ethyl.
The term "(NRGRH)carbonyl" as used herein, means a -NRGRH group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of (NRGRH)carbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, and (ethylmethylamino)carbonyl.
The term "(NRGRH)sulfonyl" as used herein, means a -NRGRH group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of (NRGRκ)sulfonyl include, but are not limited to, aminosulfonyl, (methylamino)sulfonyl, (dimethylamino)sulfonyl, and (ethylmethylamino)sulfonyl.
This invention is intended to encompass compounds having formula (I) when prepared by synthetic processes or by metabolic processes. Preparation of the compounds of the invention by metabolic processes include those occurring in the human or animal body (in vivo) or processes occurring in vitro.
The compounds of the present invention can exist as therapeutically acceptable salts. The term "therapeutically acceptable salt," as used herein, represents salts or zwitterionic forms of the compounds of the present invention which are water or oil-soluble or dispersible, which are suitable for treatment of diseases without undue toxicity, irritation, and allergic response; which are commensurate with a reasonable benefit/risk ratio, and which are effective for their intended use. The salts can be prepared during the final isolation and purification of the compounds or separately by reacting an amino group with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, formate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2- hydroxyethansulfonate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, succinate, tartrate, trichloroacetate,trifluoroacetate, phosphate, glutamate, bicarbonate, para-toluenesulfonate, and undecanoate. Also, amino groups in the compounds of the present invention can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. Examples of acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.
Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine. The cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethyla ine, diethylamine, ethylamine, tributylamine, pyridine, N,N- dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procame, dibenzyl amine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N - dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
The present compounds can also exist as therapeutically acceptable prodrugs. The term "therapeutically acceptable prodrug," refers to those prodrugs which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use. The term "prodrug," refers to compounds which are rapidly transformed in vivo to parent compounds of formula (I) for example, by hydrolysis in blood. A representative example of a prodrug of the present invention includes, but is not limited to, 4'-(6,7-dimethoxy-l,4-dihydroindeno[l,2- c]pyrazol-3-yl)- 1 , 1 '-biphenyl-4-yl 1 ,4'-bipiperidine-l '-carboxylate. Asymmetric centers exist in the compounds of the present invention. These centers are designated by the symbols "R" or "S," depending on the configuration of substituents around the chiral carbon atom. It should be understood that the invention encompasses all stereochemical isomeric forms, or mixtures thereof, which possess the ability to inhibit protein kinases. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, or direct separation of enantiomers on chiral chromatographic columns. Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the ait.
In accordance with methods of treatment and pharmaceutical compositions of the invention, the compounds can be administered alone or in combination with other anticancer agents. When using the compounds, the specific therapeutically effective dose level for any particular patient will depend upon factors such as the disorder being treated and the severity of the disorder; the activity of the particular compound used; the specific composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration; the route of administration; the rate of excretion of the compound employed; the duration of treatment; and drugs used in combination with or coincidently with the compound used. The compounds can be administered orally, parenterally, osmotically (nasal sprays), rectally, vaginally, or topically in unit dosage formulations containing carriers, adjuvants, diluents, vehicles, or combinations thereof. The term "parenteral" includes infusion as well as subcutaneous, intravenous, intramuscular, and intrasternal injection.
Parenterally administered aqueous or oleaginous suspensions of the compounds can be formulated with dispersing, wetting, or suspending agents. The injectable preparation can also be an injectable solution or suspension in a diluent or solvent. Among the acceptable diluents or solvents employed are water, saline, Ringer's solution, buffers, monoglycerides, diglycerides, fatty acids such as oleic acid, and fixed oils such as monoglycerides or diglycerides.
The anticancer effect of parenterally administered compounds can be prolonged by slowing their absorption. One way to slow the absorption of a particular compound is administering injectable depot forms comprising suspensions of crystalline, amorphous, or otherwise water-insoluble forms of the compound. The rate of absorption of the compound is dependent on its rate of dissolution which is, in turn, dependent on its physical state. Another way to slow absorption of a particular compound is administering injectable depot forms comprising the compound as an oleaginous solution or suspension. Yet another way to slow absorption of a particular compound is administering injectable depot forms comprising microcapsule matrices of the compound trapped within liposomes, microemulsions, or biodegradable polymers such as polylactide-polyglycolide, polyorthoesters or poly anhydrides. Depending on the ratio of drug to polymer and the composition of the polymer, the rate of drug release can be controlled.
Transdermal patches can also provide controlled delivery of the compounds. The rate of absorption can be slowed by using rate controlling membranes or by trapping the compound within a polymer matrix or gel. Conversely, absorption enhancers can be used to increase absorption.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound can optionally comprise diluents such as sucrose, lactose, starch, talc, silicic acid, aluminum hydroxide, calcium silicates, polyamide powder, tableting lubricants, and tableting aids such as magnesium stearate or microcrystalline cellulose. Capsules, tablets and pills can also comprise buffering agents, and tablets and pills can be prepared with enteric coatings or other release-controlling coatings. Powders and sprays can also contain excipients such as talc, silicic acid, aluminum hydroxide, calcium silicate, polyamide powder, or mixtures thereof. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons or substitutes therefore.
Liquid dosage forms for oral administration include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs comprising inert diluents such as water. These compositions can also comprise adjuvants such as wetting, emulsifying, suspending, sweetening, flavoring, and perfuming agents.
Topical dosage forms include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and transdermal patches. The compound is mixed under sterile conditions with a carrier and any needed preservatives or buffers. These dosage forms can also include excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Suppositories for rectal or vaginal administration can be prepared by mixing the compounds with a suitable non-irritating excipient such as cocoa butter or polyethylene glycol, each of which is solid at ordinary temperature but fluid in the rectum or vagina. Ophthalmic formulations comprising eye drops, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.
The total daily dose of the compounds administered to a host in single or divided doses can be in amounts from about 0.1 to about 200 mg/kg body weight or preferably from about 0.25 to about 100 mg/kg body weight. Single dose compositions can contain these amounts or submultiples thereof to make up the daily dose.
Determination of Biological Activity
The Chkl enzymatic assay was carried out using recombinant Chkl kinase domain protein covering amino acids from residue 1 to 289 and a polyhistidine tag at the C-terminal end. Human cdc25c peptide substrate contained a sequence from amino acid residue 204 to 225. The reaction mixture contained 25 mM of HEPES at pH 7.4, 10 mM MgCl2, 0.08 mM Triton X-100, 0.5 mM DTT, 5 μM ATP, 4 nM 33P ATP, 5 μM cdc25c peptide substrate, and 6.3 nM of the recombinant Chkl protein. Compound vehicle DMSO was maintained at 2% in the final reaction. After 30 minutes at room temperature, the reaction was stopped by addition of equal volume of 4M NaCl and 0. IM EDTA, pH 8. A 40 μL aliquot of the reaction was added to a well in a Flash Plate (NEN Life Science Products, Boston, MA) containing 160 μL of phosphate- buffered saline (PBS) without calcium chloride and magnesium chloride and incubated at room temperature for 10 minutes. The plate was then washed 3 times in PBS with 0.05% of Tween-20 and counted in a Packard TopCount counter (Packard BioScience Company, Meriden, CT).
Compounds of the present invention inhibited Chkl at IC50 alues between about 0.1 nM and about 10,0000 nM. Preferred compounds inhibited Chkl at IC50 values between about 0.1 nM and about 250 nM. Most preferred compounds inhibited Chkl at IC50 values between about 0.1 nM and about 50 nM. Thus, the compounds of the invention are useful in treating disorders which are caused or exacerbated by increased protein kinase levels.
The compounds of the invention, including but not limited to those specified in the examples, possess the ability to inhibit protein kinases. As protein kinase inhibitors, such compounds are useful in the treatment of both primary and metastatic solid tumors, including carcinomas of breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach, pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract (including kidney, bladder and urothelium), female genital tract (including cervix, uterus, and ovaries as well as choriocarcinoma and gestational trophoblastic disease), male genital tract (including prostate, seminal vesicles, testes and germ cell tumors), endocrine glands (including the thyroid, adrenal, and pituitary glands), and skin, as well as hemaiigiomas, melanomas, sarcomas (including those arising from bone and soft tissues as well as Kaposi's sarcoma) and tumors of the brain, nerves, eyes, and meninges (including astrocytomas, gliomas, glioblastomas, retinoblastomas, neuromas, neuroblastomas, Schwannomas, and meningiomas). Such compounds may also be useful in treating solid tumors arising from hematopoietic malignancies such as leukemias (i.e., chloromas, plasmacytomas and the plaques and tumors of mycosis fungicides and cutaneous T- cell lymphoma/leukemia) as well as in the treatment of lymphomas (both Hodgkin's and non- Hodgkin's lymphomas). In addition, these compounds may be useful in the prevention of metastases from the tumors described above either when used alone or in combination with radiotherapy and/or other chemotherapeutic agents.
Synthetic Methods
Abbreviations which have been used in the descriptions of the scheme and the examples that follow are: Bu for CH3CH2CH2CH2-; Et for CH3CH2-; Me for CH3-; PPh3 for triphenylphosphine; PCy3 for tricyclohexylphosphine; dba for dibenzylideneacetone; EDC or EDCI for l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; DCC for 1,3- dicyclohexylcarbodiimide; HOBt for 1-hydroxybenzotriazole; DMSO for dimethylsulfoxide; DME for 1,2-dimethoxyethane; THF for tetrahydrofuran; DMF for N,N-dimethylformamide; TFA for trifluoracetic acid; dppf for diphenylphosphinoferrocene; Ac for -C(0)CH3, TMS for trimethylsilyl; SEM for [2-(trimethylsilyl)ethoxy]methyl; DMA for dimethylacetamide; and DIEA for diisopropylethylamine.
The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes which illustrate the methods by which the compounds of the invention may be prepared. Starting materials can be obtained from commercial sources or prepared by well-established literature methods known to those of ordinary skill in the art.
Scheme 1
(3)
3,6-Disubstituted-l,4-dihydroindeno[l,2-c]pyrazoles of general formula (5) and (6), wherein RA, RB, R , R5, and Rg are as defined in formula (I), can be prepared as described in Scheme 1. l,4-Dihydroindeno[l,2-c]pyrazole-6-carbaldehyde, prepared using the procedure described in US 6,297,238, herein incorporated by reference, can be treated with N- iodosuccinimide to provide 3-iodo-l,4-dihydroindeno[l,2-c]pyrazole-6-carbaldehyde. 3-Iodo- l,4-dihydroindeno[l,2-c]pyrazole-6-carbaldehyde can be treated with amines of general formula (1) (or H2NOH) and a reducing agent, including but not limited to, sodium borohydride or sodium cyanoborohydride to provide amines of general formula (2). Amines of general formula (2) can be treated with boronic acids of general formula (4) (or 4,4,5,5-tetramethy-l,3,2- dioxaborolanes), a base, including but not limited to, cesium carbonate, sodium carbonate, or potassium carbonate, and a metal catalyst, including but not limited to, tetrakis(triphenylphoshine)palladium or bis(triphenylphoshine)palladium (II) chloride to provide 3,6-disubstituted-l,4-dihydroindeno[l,2-c]pyrazoles of general formula (5).
3-Iodo-l,4-dihydroindeno[l,2-c]pyrazole-6-carbaldehyde can also be treated with nitrogen containing heterocycles, including but not limited to, azetidine, azepane, aziridine, azocane, morpholine, mono-protected piperazine, piperidine, 4-hydroxypiρeridine, pyrrolidine, thiomorpholine, or 1,1-dioxidothiomorpholine, for example, to provide compounds of general formula (3). Compounds of general formula (3) can be treated with boronic acids of general formula (4), a base, including but not limited to, cesium carbonate, sodium carbonate, or potassium carbonate, and a metal catalyst, including but not limited to, tetrakis(triphenylphoshine)palladium or bis(triphenylphoshine)palladium (II) chloride to provide 3,6-disubstituted-l,4-dihydroindeno[l,2-c]pyrazoles of general formula (6).
It is to be understood that 3,7-disubstituted-l,4-dihydroindeno[l,2-c]pyrazoles can be prepared from l,4-dihydroindeno[l,2-c]pyrazole-7-carbaldehyde using the methodology described in Scheme 1.
Scheme 2
Compounds of general formula (10), wherein Xl5 X3, Ri, R2, R3, R , R5, and Rg are as defined in formula (I), can be prepared as described in Scheme 1. 1-Indanones or 5,6-dihydro- 7H-cyclopenta[b]pyridin-7-ones, purchased or prepared using methodology known to those of skill in the art, can be treated with esters of general formula (8), 1,1 -carbonyldiimidazole, and a base, including but not limited to, lithium diisopropylamide to provide compounds of general formula (9). Compounds of general formula (9) can be treated with hydrazine and an acid, including but not limited to, acetic acid, with heat to provide compounds of general foraiula (10).
Scheme 3
(13) Heck, Suzuki, ..„. or Stille conditions *• '
R =CI, Br, or I - R =aryl or heteroaryl l,4-Dihydroindeno[l,2-c]pyrazoles of general formula (13), wherein X3, R , R5, and R6 are as defined in formula (I), can be prepared as described in Scheme 3. 5,6-Dimethoxy-l- indanone, purchased from Aldrich Chemical Co., can be treated with sodium cyanide to provide 5-hydroxy-6-methoxy-l-indanone. 5-Hydroxy-6-methoxy-l-indanone can be treated with nitric acid and sodium nitrite to provide 5-hydroxy-6-methoxy-4-nitro-l-indanone. 5-Hydroxy-6- methoxy-4-nitro-l-indanone can be treated with iodomethane and then methodology described in Scheme 2 to provide compounds of general formula (12). Compounds of general formula (12) can be treated with a reducing agent, including iron metal in the presence of acetic acid, to provide amines of general formula (13). Compounds of general formula (13) where R4 is chlorine, bromine or iodine can be further elaborated under Heck, Suzuki, or Stille conditions to provide compounds of general formula (13) wherein R4 is aryl or heteroaryl as defined herein. An example of suitable Suzuki conditions is described in Example ID herein or Suzuki conditions as described in N. Miyaura, A. Suzuki, Chem. Rev., 2457-2483:95 (1995); A. Suzuki, J. Organomet. Chem., 147-168:576 (1999), N. Miyaura, In Advances in Metal-Organic Chemistry, L. S. Liebeskind, Ed., JAI: London, 1998; Vol. 6, pp 187-243; and A. Suzuki, In Metal-Catalyzed Cross-Coupling Reactions, F. Diederich, P. J. Stang, Eds., Wiley-VCH: New York, 1998; Chapter 2; S. P. Stanforth, Tetrahedron, 263-303:54 (1998); can be used to prepare compounds, including but not limited to, 4'-(5-amino-6,7-dimethoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)-l, -biphenyl-4-ol. Aryl and heteroaryl boronic acids and boronic esters are available commercially or can be prepared as described in the scientific literature of synthetic organic chemistry or as described in Example 11 herein.
Compounds of general formula (13), wherein R) is chlorine, bromine, or iodine, can be treated with aryl or heteroaryl stannanes (Me3SnR , Bu3SnR4), purchased or prepared using known mehodology, a palladium source such as tris(dibenzylidineacetone)dipalladium or palladium diacetate, and a ligand such as tri(2-furyl)phosphine or triphenyl arsine in a solvent such as DMF at 25-150 °C (Stille conditions) to provide compounds of general formula (13) wherein R4 is aryl or heteroaryl as defined herein. Organotin reagents can be prepared from arylhalides, aryltriflates, heteroarylhalides, or heteroaryltriflates by reaction with distannanes like (Me3Sn)2 (hexamethyl distannane) in the presence of a palladium source like Pd(Ph3P) as described in Krische, Lehn, et. al., Helvetica Chimica Acta, 1909-1920:81(11) (1998) and in Benaglia, et al., Tetrahedron Letters, 4737-4740:38 (1997) 38.
Compounds of general formula (13), wherein Rj is chlorine, bromine, or iodine, can be treated with aryl or heteroaryl halides, purchased or prepared using known mehodology, under Heck conditions as described in Tetrahedron 3327:36 (1980) to provide compounds of general formula (13) wherein R4 is aryl or heteroaryl as defined herein. Scheme 4
l,4,7,8-Tetrahydro[l,4]dioxino[2',3':5,6]indeno[l,2-c]pyrazoles of general formula (17), wherein X3, R3, Rt, R5, and Rg are as defined in formula (I), can be prepared as described in Scheme 4. 5,6-Dimethoxy indanones of general formula (15), purchased or prepared using known methodology, can be treated with tribromoborane and then 1,2-iodoethane to provide 2,3,7,8-tetrahydro-6H-indeno[5,6-b][l,4]dioxin-6-ones of general formula (16). 2,3,7,8- Tetrahydro-6H-indeno[5,6-b][l,4]dioxin-6-ones of general formula (16) can be treated under conditions as described in Scheme 2 to provide 1,4,7,8- tetrahydro[l,4]dioxino[2',3':5,6]indeno[l,2-c]pyrazoles of general formula (17), including but not limited to, 4-(l,4,7,8-tetrahydro[l,4]dioxino[2',3':5,6]indeno[l,2-c]pyrazol-3-yl)-l,l - biphenyl-4-ol.
The present invention will now be described in connection with certain preferred embodiments which are not intended to limit its scope. On the contrary, the present invention covers all alternatives, modifications, and equivalents as can be included within the scope of the claims. Thus, the following examples, which include preferred embodiments, will illustrate the preferred practice of the present invention, it being understood that the examples are for the purposes of illustration of certain preferred embodiments and are presented to provide what is believed to be the most useful and readily understood description of its procedures and conceptual aspects. Compounds of the present invention were named by ACD/ChemSketch version 5.0 (developed by Advanced Chemistry Development, Inc., Toronto, ON, Canada) or were given names consistent with ACD nomenclature.
Example 1 4-(6-{ [(trans-4-methylcvclohexyl)aminolmethyl 41 -dihvdroindenor 2-clpyrazol-3-yl benzoic acid
Example 1A 1 ,4-Dihydro-indeno \ 1 ,2-c1pyrazole-6-carbaldehyde To a solution of 6-bromo-l,4-dihydro-indeno[l,2-c]pyrazole (0.100 g, 0.425 mmol, see U.S. Patent 6297238 for preparation) in THF (3 mL) at -78 °C was added 1.8 M PhLi in cyclohexane/ether (0.71 mL, 1.28 mmol) followed by 1.3 M s-BuLi in cyclohexane (0.98 mL, 1.28 mmol) 30 minutes later. The reaction mixture was stirred at -78 °C for 60 minutes and DMF (0.33 mL, 4.25 mmol) was added. The dry ice bath was removed after 30 minutes. After an additional 30 minutes, the reaction was quenched with water. The reaction mixture was extracted with EtOAc, washed with 50% brine, dried over MgSO , filtered, and concentrated. The concentrate was purified by flash chromatography eluted with EtOAc/hexane (7:3 to 8:2) to give 0.053 g (68%) of the desired product as brown solid.. MS (DCI/NH ) m/z: 185.0 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 3.76 (s, 2 H), 7.63 (s, 1 H), 7.62-7.97 (m, 2 H), 8.04 (s, 1 H), 10.00 (s, 1 H).
Example IB 3-Iodo- 1.4-dihydro-indenof 1 ,2-clp yrazole-6-carbaldehyde A suspension of Example 1A (7.90 g, 0.0429 mol) and N-iodosuccinimide (11.6 g, 0.0515 mol) in DMF (150 mL) was heated at 80 °C for 5.5 hours. The reaction was cooled and the solvent was evaporated. The concentrate was triturated with EtOAc and ether to give 7.20 g of brown solid as the desired product. The filtrate was concentrated and purified by flash cliromatography eluted with EtOAc/hexane (7:3) to give 1.30 g of the desired product (combined yield: 64%). MS (DCI/NH3) m z: 310.9 (M+H)+; XH NMR (300 MHz, DMSO-dg) δ 3.63 (s, 0.8 H), 3.68 (s, 1.2 H), 7.72 (d, J=7.46 Hz, 0.5 H), 7.83 (d, J=7.80 Hz, 0.5 H), 7.96 (m, 1 H), 8.07 (m, 1 H), 10.03 (s, 1 H), 13.45 (s, 0.6 H), 13.72 (s, 0.4 H).
Example 1C N-|~(3-iodo- 1 -dihvdroindenor 2-clpyrazol-6-yl)methvn-N-(trans-4-methylcvclohexyl)amine and N-r(3-iodo-l,4-dihvdroindenori,2-clpyrazol-6-yl)methyll-N-(cis-4-methylcyclohexyl)amine To a suspension of Example IB (7.18 g, 0.0232 mol) in EtOH (500 mL) were added 4- methylcyclohexylamine hydrochloride (8.66 g, 0.0579 mol) and potassium carbonate (4.81 g, 0.0348 mol). The mixture was heated to reflux overnight and cooled to room temperature. To the above yellow suspension was added NaBH4 (1.76 g, 0.0464 mol) in two portions and the reaction mixture stirred overnight. After filtration of the solid, the filtrate was concentrated and purified by flash chromatography eluted with EtOAc/MeOH/NH4OH (10:0.2:0.02 to 10:1:0.1) to give 2.20 g of the cis product (higher Rf) as yellow solid and 3.60 g of the trans product as yellow solid, cis isomer: MS (DCI/NH3) m/z: 408.0 (M+H)+; !H NMR (300 MHz, CD3OD) δ 0.96 (d, J=6.78 Hz, 3 H), 1.35-1.70 (m, 9 H), 2.56 (m, 1 H), 3.53 (s, 2 H), 3.81 (s, 1 H), 7.35 (d, J=7.80 Hz, 1 H), 7.54 (s, 1 H), 7.58 (d, J=7.46 Hz, 1 H). trans isomer: MS (DCI/NH3) m/z: 408.0 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 0.88 (d, J=6.44 Hz, 3 H), 1.09-1.24 (m, 2 H), 1.28-1.53 (m, 2 H), 1.62 (m, 1 H), 1.67-1.79 (m, 2 H), 1.93-2.05 (m, 2H), 2.48 (m, 1 H), 3.53 (s, 2 H), 3.84 (s, 2 H), 7.34 (d, J=7.80 Hz, 1 H), 7.53 (s, 1 H), 7.58 (d, J=7.80 Hz, 1 H).
Example ID 4-(6- { T(1xans-4-methylcvclohexyl aminolmethyl } - 1.4-dihvdroindeno[ 1 ,2-clpyrazol-3-yl)benzoic acid A mixture of Example 1C (trans, 45.0 mg, 0.110 mmol), 4-carboxybenzene boronic acid (20.1 mg, 0.121 mmol), Na2C03 (1 M, 0.26 mL, 0.264 mmol), and Pd(PPh3)2Cl2 (7.70 mg, 0.0110 mmol) in DME/EtOH/H2O (7:2:3, 1.2 mL) in a capped 2 mL vial was heated at 160 °C for 450 seconds in a Smith Synthesizer (300 W). The reaction was cooled using 40 psi pressurized air. Solvents were evaporated and the crude product was purified using preparative HPLC to give 25.0 mg (26%) of the desired product as pale yellow foam. The purification was processed on a Waters Symmetry C8 column (25mm X 100mm, 7 μm particle size) using a gradient of 10% to 100% acetonitrile: 0.1% aqueous TFA over 8 min (lOmin run time) at a flow rate of 40 mL/min. MS (DCI/NH3) m/z:402.2 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 0.95 (d, J=6.44 Hz, 3 H), 1.00-1.20 (m, 2 H), 1.33-1.60 (m, 3 H), 1.81-1.98 (m, 2 H), 2.15-2.30 (m, 2 H), 3.15 (m, 1 H), 3.96 (s, 2 H), 4.31 (s, 2 H), 7.52 (m, 1 H), 7.71 (m, 1 H), 7.81 (d, J=7.80 Hz, 1 H), 7.90 (d, J=8.81 Hz, 2 H), 8.15 (d, J=8.48 Hz, 2 H).
Example 2 4-(6- { r(cis-4-methylcvclohexyl)aminolmethyl I - 1 ,4-dihydroindeno |~1 ,2-clpyrazol-3-yl)benzoic acid The desired product was prepared using the procudure in Example ID replacing the trans product from Example 1C with the cis product from Example lC. MS (DC-7NH3) m/z: 402 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 1.04 (d, J=7.12 Hz, 3 H), 1.50-1.98 (m, 9 H), 3.23 (m, 1 H), 3.98 (s, 2 H), 4.31 (s, 2 H), 7.53 (d, J=9.15 Hz, 1 H), 7.73 (s, 1 H), 7.82 (d, J=7.80 Hz, IH), 7.91 (d, J=8.81 Hz, 2 H), 8.15 (d, J=8.48 Hz, 2 H).
Example 3 ethyl 4-(6-( F(trans-4-methylcyclohexyl)aminolmethyl i-1 ,4-dihydroindeno IT ,2-c1pyrazol-3- yPbenzoate To a degassed suspension of Example 1C (trans, 45.0 mg, 0.110 mmol) in DME/EtOH/H20 (7:3:2) were added 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzoic acid ethyl ester (31.8 μL, 0.121 mmol), Na2C03 (IM, 0.11 mL), and Pd(PPh3)2Cl2 (7.7 mg, 0.0110 mmol). The reaction mixture was heated overnight at 85 °C in a sealed vial. The mixture was concentrated and the residue was extracted with EtOAc, washed with brine, dried over MgSO , filtered, and concentrated. The residue was purified using preparative HPLC (see condition in Example ID) to give 8.8 mg (12%) of the desired product as white foam. MS (DC17NH3) m/z: 430.2 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 0.95 (d, J=6.78 Hz, 3 H), 1.09 (m, 2 H), 1.42 (t, J=7.12 Hz, 3 H), 1.42-1.57 (m, 3 H), 1.82-1.94 (m, 2 H), 2.16-2.29 (m, 2 H), 3.15 (m, 1 H), 3.98 (s, 2 H), 4.30 (s, 2 H), 4.40 (q, J=7.12 Hz, 2 H), 7.52 (d, 1=7.80 Hz, 1 H), 7.72 (s, 1 H), 7.82 (d, J=7.80 Hz, 1 H), 7.92 (d, J=8.82 Hz, 2 H), 8.15 (d, 1=8.48 Hz, 2 H). Example 4 4-(6-( r(trans-4-hvdroxycvclohexyl)aminolmethyl 1 - 1 ,4-dihvdroindenori ,2-clpyrazoI-3- vDbenzoic acid
Example 4A frans-4-r(3-Iodo-l,4-dihydro-indenori,2-clpyrazol-6-ylmethyl)-aminol-cyclohexanol The desired product was prepared by replacing 4-methylcyclohexylamine hydrochloride with trans-4-hydroxycyclohexylamine hydrochloride in Example IC. MS (DCI/NH3) m/z: 410.0 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 1.09-1.35 (m, 4 H), 1.82-2.08 (m, 4 H), 2.48 (m, 1 H), 3.47-3.58 (m, 3H), 3.82 (s, 2H), 7.34 (m, 1 H), 7.52 (m, 1 H), 7.58 (d, J=7.80 Hz, 0.8 H), 7.65 (d, J=7.80 Hz, 0.2 H).
Example 4B 4-(6-{r(trans-4-hydroxycvclohexyl)aminolmethyl}-l,4-dihydroindenoπ,2-clpyrazol-3- vDbenzoic acid The desired product was prepared by replacing Example IC with Example 4A in Example ID. MS (DCI/NH3) m/z: 404.2 (M+H)+; lH NMR (300 MHz, CD3OD) δ 1.27-1.61 (m, 4 H), 2.02-2.16 (m, 2 H), 2.18-2.32 (m, 2 H), 3.07-3.25 (m, 1 H), 3.50-3.66 (m, 1 H), 3.97 (s, 2 H), 4.30 (s, 2 H), 7.51 (dd, J=7.80, 1.36 Hz, 1 H), 7.71 (s, 1 H), 7.81 (d, J=7.80 Hz, 1 H), 7.91 (d, J=8.48 Hz, 2 H), 8.15 (d, J=8.48 Hz, 2 H).
Example 5 N- 1"3-(6- { r(trans-4-hvdroxycvclohexyl)amino1mefhyl 1-1 ,4-dihydroindeno I" 1 ,2-c1pyrazol-3- vDphenyllacetamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 4A and 3-acetamidobenzene boronic acid in Example ID. MS (DCI/NH3) m/z: 417.2 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 1.28-1.69 (m, 4 H), 2.03-2.14 (m, 2 H), 2.19 (s, 3H), 2.21-2.33 (m, 2H), 3.17 (m, 1 H), 3.58 (m, 1 H), 3.92 (s, 2 H), 4.29 (s, 2 H), 7.34-7.59 (m, 4 H), 7.70 (s, 1 H), 7.80 (d, J=8.14 Hz, 1 H), 8.24 (m, 1 H). Example 6 4-(6-{ r(frans-4-hydroxycyclohexyl)aminolmethyli-1.4-dihvdroindenori,2-c1pyrazol-3- vPbenzamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 4A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID. MS (DCI/NH3) m z: 403.3 (M+H)+; 1H NMR (300 MHz, CD3CD) δ 1.29-1.59 (m, 4 H), 2.03-2.15 (m, 2 H), 2.20-2.32 (m, 2 H), 3.17 (m, IH), 3.56 (m, IH), 3.97 (s, 2 H), 4.30 (s, 2 H), 7.52 (dd, J=7.80, 1.36 Hz, 1 H), 7.72 (s, 1 H), 7.82 (d, J=7.80 Hz, 1 H), 7.90 (d, J=8.48 Hz, 2 H), 8.02 (d, J=8.48 Hz, 2 H).
Example 7 4-r6-(4-morpholinylmethyl)-l,4-dihydroindenori,2-clpyrazol-3-yl1benzoic acid
Example 7A 3-Iodo-6-morpholin-4-ylmethyl- 4-dihvdro-indenori,2-clpyrazole A mixture of Example IB (1.00 g, 3.22 mmol), morpholine (0.84 mL, 9.66 mmol), and TsOH.H2O (61.2 mg, 0.322 mmol) in toluene (50 mL) was heated to refluxing overnight. The solvent was evaporated. To the resulting residue were added EtOH (40 mL), THF (10 mL), and NaBH (0.182 g, 4.83 mmol) at room temperature. The mixture was stirred overnight and the resulting solid was filtered. The filtrate was concentrated, treated with IN HC1, and extracted with EtOAc. The aqueous layer was basified using 3N NaOH and extracted with EtOAc. The organic layer was dried over MgS0 , filtered, and concentrated. The residue was purified by flash chromatography eluted with EtOAc/MeOH (95:5) to give 0.387 g (32%) of the desired product as pale yellow solid. MS (DCI/NH3) m/z: 382.0 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 2.44-2.51 (m, 4 H), 3.53 (s, 2 H), 3.57 (s, 2 H), 3.66-3.72 (m, 4 H), 7.34 (d, J=8.14 Hz, 1 H), 7.54 (s, 1 H), 7.58 (d, J=7.80 Hz, 1 H).
Example 7B 4-r6-(4-morpholinylmethyl -l,4-dihydroindenori,2-clpyrazoI-3-yllbenzoic acid The desired product was prepared by replacing Example IC with Example 7 A in Example ID. MS (DCI/NH3) m z: 376.1 (M+H)+; 1H NMR (500 MHz, DMSO-dg) δ 3.06-3.17 (m, 2 H,) 3.26 (d, J=12.17 Hz, 2 H), 3.87 (t, J=11.54 Hz, 2 H), 3.91-3.99 (m, 4 H), 4.40 (d, J=4.37 Hz, 2 H), 7.66 (d, J=7.80 Hz, 1 H), 7.75 (d, J=7.80 Hz, 1 H), 7.89 (s, 1 H), 7.98 (d, J=8.42 Hz, 2 H), 8.06 (d, J=8.42 Hz, 2 H), 11.61 (s, 1 H).
Example 8 methyl 4- r6-(4-morpholinylmethyl)- 1 ,4-dihydroindeno [1 ,2-clpyrazol-3-yl1benzoate To Example 7B (28.8 mg, 0.0643 mmol) in MeOH (3 mL) was added concentrated HC1 (0.50 mL). The mixture was heated to 65 °C and stirred for 3 days. The reaction mixture was concentrated and purified using HPLC. The TFA salt of the desired product was converted into the HC1 (17.0 mg, 81%) using the procedure in Example 7B. The HPLC condition is indicated as the following: Dynamx C18 (5 μm, 21.4x250 mm) column was used containing a Rainin Dynamax solvent delivery system with a Dynamax UV-D II detector. The solvent system used was a 20% to 100% acetonitrile/water containing 0.1% TFA linear gradient. The elution rate was 10 mL/min and the UV detection wavelength was set at 254 nm). MS (DCI/NH3) m/z: 390 (M+H)+; H NMR (400 MHz, DMSO-dg) δ 3.05-3.18 (m, 2 H), 3.22-3.30 (m, 2 H), 3.77-3.87 (m, 2 H), 3.89 (s, 3 H), 3.91-4.00 (m, 4 H), 4.40 (d, J=4.60 Hz, 2 H), 7.63 (d, J=7.98 Hz, 1 H), 7.75 (d, J=7.67 Hz, 1 H), 7.86 (s, 1 H), 7.99 (d, J=8.29 Hz, 2 H), 8.08 (d, J=8.28 Hz, 2 H), 11.29 (s, 1 H).
Example 9 4-F6-(4-morpholinylmethyl)-l,4-dihydroindenori,2-clpyrazol-3-yllbenzamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 7A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID. The product was purified by flash chromatography eluted with EtOAc/MeOH NH4OH (10:1:0.1). MS (DCI/NH3) m/z: 375.2 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 2.34-2.44 (m, 4 H), 3.53 (s, 2 H,), 3.56-3.63 ( , 4 H), 3.91 (s, 2 H), 7.31 (d, J=7.46 Hz, 1 H), 7.42 (s, 1 H), 7.52 (s, 1 H), 7.64 (m, 1 H), 7.87 (d, J47.80 Hz, 2 H), 8.00 (d, J=8.48 Hz, 3 H), 13.29 (s, 1 H). Example 10 N-(3-r6-(4-morpholinylmethyl)-l,4-dihydroindenon,2-clpyrazol-3-vnphenyljacetamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 7A and 3-acetamidobenzeneboronic acid in Example ID. MS (DCI/NH3) m/z: 389.2 (M+H)+; 1H NMR (400 MHz, DMSO-dg) δ 2.10 (s, 3 H), 3.06-3.17 (m, 2H), 3.22-3.32 (m, 2H), 3.78-3.90 (m, 4 H), 3.95 (d, J=14.12 Hz, 2 H), 4.40 (d, J=3.68 Hz, 2 H), 7.41 (t, J=7.83 Hz, 1 H), 7.58 (m, 3 H), 7.74 (d, J=7.67 Hz, 1 H), 7.88 (s, 1 H), 8.13 (s, 1 H), 10.18 (s, I H), 11.37 (s, 1 H).
Example 11 2-(acetylamino)-4-r6-(4-morpholinylmethyl)-l,4-dihvdroindenori,2-c1pyrazol-3-yl1benzoic acid
Example 11 A N-(5-Bromo-2-methyl-phenyl)-acetamide To a solution of 3-bromo-6-mefhylaniline (1.00 g , 5.37 mmol) in pyridine (8 mL) was added acetyl chloride (0.76 mL, 10.7 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour and concentrated. The residue was extracted with EtOAc, washed with 5% citric acid, dried over MgSO4, concentrated, and triturated with ether to give 0.750 g (61%) of the desired product as off-white crystal. MS (DC17NH3) m/z: 227.9 (M+H)+, 229.9 (M+2+H)+; 1H NMR (300 MHz, CDC13) δ 2.21 (s, 6 H), 6.90 (m, 1 H), 7.04 (d, J=8.14 Hz, 1 H), 7.20 (d, J=7.80 Hz, 1 H), 8.06 (s, 1 H).
Example 1 IB 2-Acetylamino-4-bromo-benzoic acid To a solution of Example 11A (0.372 g, 1.63 mmol) in pyridine (6 mL) and H20 (6 mL) was added KMn04 (1.03 g, 6.52 mmol) in 2 portions at room temperature. The reaction mixture was heated to 90 °C for 4 hours and immediately filtered. The filter cake was rinsed with hot H2O. The filtrate was concentrated and treated with H 0. The solid material was filtered and filtrate acidified with 10% HC1 until pH=3. The white precipitate was filtered, rinsed with H2O, and dried in a vacuum oven to give 0.398 g (95%) of the desired product as white solid. MS (DCI/NH3) m/z: 257.9 (M+H)+, 259.9 (M+2+H)+; 1H NMR (300 MHz, CD3OD) δ 2.20 (s, 3 H), 7.30 (dd, J=8.48, 2.03 Hz, 1 H), 7.97 (d, J=8.48 Hz, 1 H), 8.84 (d, J=2.03 Hz, 1 H).
Example 11C 2-Acetylamino-4-(4,4,5,5-tetramethyl-Fl,3,21dioxaborolan-2-yl)-benzoic acid methyl ester To a solution of Example 1 IB (45.0 mg, 0.174 mmol) in CH2Cl2/MeOH (2 mL/ 0.3 mL) was added TMSCHN . After the disappearance of strong bubbling, the reaction mixture was concentrated. The crude methyl ester product was taken into the next step without purification. A mixture of the above crude product, Pd2(dba)3 (3.2 mg, 0.0034 mmol), PCy3 (3.9 mg, 0.014 mmol), KOAc (25.6 mg, 0.261 mmol), and bis(pinacolato) diboron (53.0 mg, 0.209 mmol) in 1,4-dioxane (1.5 mL) was heated at 85 °C overnight in a capped vial. The solvent was evaporated and the residue was extracted with EtOAc, washed with brine, dried over MgSO4, filtered, concentrated, and purified by flash chromatography eluted with hexane/EtOAc (8:2 to 7:3) to give 31.0 mg (56%) of the desired product as off-white solid. MS (DCI7NH3) m/z: 320.1 (M+H)+; 1H NMR (300 MHz, DMSO-d6) δ 1.31 (s, 12 H), 2.11 (s, 3 H), 3.85 (s, 3 H), 7.45 (d, J=8.82 Hz, 1 H), 7.87 (d, J=7.80 Hz, 1 H), 8.42 (s, 1 H), 10.42 (s, 1 H).
Example 1 ID 2-(acetylamino)-4-r6-(4-morpholinylmethyl)-l,4-dihvdroindenori,2-clpyrazol-3-yllbenzoic acid
The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 7A and Example 1 IC in Example ID. The product was purified using the HPLC condition in Example 8. MS (DCI/NH3) m/z: 433.2 (M+H)+; 1H NMR (500 MHz, CD3OD) δ 2.17 (s, 3 H), 3.09-3.36 (m, 2H), 3.88 (s, 2 H,) 3.56-4.06 (m, 6H), 4.35 (s, 2 H), 7.44 (d, J=7.80 Hz, 1 H), 7.50 (d, J=6.55 Hz, 1 H), 7.65 (s, 1 H), 7.74 (d, J=7.80 Hz, 1 H), 7.83 (d, J=8.73 Hz, 1 H), 8.09 (d, J=8.11 Hz, 1 H), 8.99 (s, 1 H).
Example 12 4- f 6- r(4-h ydroxy- 1 -piperidinypmethyll- 1 ,4-dihydroindeno [" 1 ,2-clpyrazol-3-yl Ibenzoic acid Example 12A l-(3-Iodo-l,4-dihvdro-indenoπ.2-clpyrazol-6-ylmethyl)-piperidin-4-ol The desired product was prepared by replacing morpholine with 4-hydroxypiperidine in Example 7A. MS (DCI/NH3) m z: 396.0 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 1.48-1.65 (m, 2 H), 1.77-1.91 (m, 2 H), 2.12-2.31 ( , 2 H), 2.74-2.89 (m, 2 H), 3.54 (s, 2 H), 3.57-3.69 (m, IH), 3.57 (s, 2 H), 7.33 (d, J=9.15 Hz, 1 H), 7.52 (s, 1 H), 7.58 (d, J=7.80 Hz, 1 H).
Example 12B 4- { 6- r(4-hvdroxy- 1 -piperidinvDmethyll- 1 ,4-dihydroindeno I" 1 ,2-c1pyrazol-3-yl Ibenzoic acid The desired product was prepared by replacing Example IC with Example 12A in Example ID. MS (DCI/NH3) m/z: 390.2 (M+H)+; 1H NMR (400 MHz, DMSO-dg) δ 1.66-1.82 (m, 2H), 1.89-2.07 (m, 2H), 2.94 (m, IH), 3.09-3.23 (m, 2H), 3.34 (m, IH), 3.64 (m, 1 H), 3.97 (s, 2 H), 4.34 (dd, J=15.04, 4.60 Hz, 2 H), 6.78-6.90 (m, 2 H), 7.56-7.67 (m, 0.5 H), 7.71-7.81 (m, 2 H) 7.84 (d, J=13.81 Hz, 0.5 H,) 7.97 (d, J=8.29 Hz, 1 H), 8.06 (d, J=8.59 Hz, 1 H), 10.55 (s, 1 H).
Example 13 4- ( 6-r(4-hydroxy- 1 -piperidinvDmethyll- 1 ,4-dihydroindenor 1 ,2-c1pyrazol-3-yl Ibenzamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 12A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID. MS (DCI/NH3) m/z: 389.2 (M+H)+; 1H NMR (400 MHz, DMSO-dg) δ 1.64- 1.80 (m, 2 H), 1.88-2.09 (m, 2 H), 2.96 (m, 1 H), 3.08-3.22 (m, 2 H), 3.33 (m, 1 H), 3.63 (m, 1 H), 3.95 (s, 2 H), 4.33 (dd, J=14.58, 5.06 Hz, 2 H), 7.40 (s, 1 H), 7.62 (dd, J=13.20, 7.67 Hz, 1 H), 7.74 (d, J=7.67 Hz, 1 H), 7.84 (d, J=13.20 Hz, 1 H), 7.91 (d, J=8.59 Hz, 2 H), 8.01 (m, 2 H), 10.65 (s, 1 H).
Example 14 N-(3 - { 6- r(4-hydroxy- 1 -piperidmvDmethyl] - 1 ,4-dihydroindeno [" 1 ,2-clpyr azol-3- yl 1 phenyl) acetamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 12A and 3-acetamidobenzeneboronic acid in Example ID. MS (DCI/NH3) m/z: 403.2 (M+H)+; 1H NMR (400 MHz, DMSO-dg) δ 1.65-1.80 (m, 2 H), 1.88-2.04 (m, 2 H), 2.95 (m, 1 H), 3.09-3.23 (m, 2 H), 3.35 (m, 1 H), 3.62 (m, 1 H), 3.88 (s, 2 H) 4.33 (dd, J=15.50, 5.06 Hz, 2 H), 7.41 (t, J=7.83 Hz, 1 H), 7.50-7.64 (m, 3 H), 7.73 (d, J=7.67 Hz, 1 H), 7.84 (d, J=14.12 Hz, 1 H), 8.13 (s, 1 H), 10.15 (s, 1 H), 10.46 (s, 1 H).
Example 15 4-{6-[(neopentylamino)methyl1-l,4-dihydroindenoFl,2-c1pyrazol-3-yl}benzoic acid
Example 15 A (2,2-Dimethyl-propyl)-(3-iodo-l,4-dihydro-indenori,2-c1pyrazol-6-ylmethyl)-amine The desired product was prepared by replacing morpholine with neopentylamine in Example 7A. MS (DC17NH3) m/z: 382.1 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 0.92 (s, 9H), 2.34 (s, 2 H), 3.53 (s, 2 H), 3.82 (s, 2 H), 7.35 (d, J=7.80 Hz, 1 H), 7.52-7.61 (m, 2 H).
Example 15B 4-16-f (neopentylamino)methyn- 1 ,4-dihydroindeno F 1 ,2-c1pyrazol-3-yl Ibenzoic acid The desired product was prepared by replacing Example IC with Example 15 A in Example ID. MS (DCI/NH3) m/z: 376.2 (M+H)+; ]H NMR (500 MHz, DMSO-d6) δ 0.98 (s, 9 H), 2.62-2.77 (m, 2 H), 3.96 (s, 2 H), 4,23 (s, 2 H), 7.62 (d, J=7.80 Hz, 1 H), 7.74 (d, J=7.80 Hz, 1 H), 7.83 (s, 1 H), 7.96 (d, J=8.42 Hz, 2 H), 8.06 (d, J=8.42 Hz, 2 H), 8.94 (s, 1 H).
Example 16
4-{6-F(neopentylamino)methyl1-l,4-dihvdroindenoFl,2-clpyrazol-3-yl}benzamide
The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 15A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID. MS (DCI/NH3) m/z: 375.2 (M+H)+; 1H NMR (300 MHz, DMSO-d6) δ 0.97 (s,
9 H), 2.62-2.81 (m, 2 H), 3.97 (s, 2 H), 4.24 (s, 2 H), 7.42 (s, 1 H), 7.60 (d, J=8.48 Hz, 1 H), 7.74 (d, J=7.80 Hz, 1 H), 7.81 (s, 1 H), 7.90 (d, J=8.48 Hz, 2 H), 8.01 (d, J=8.48 Hz, 2 H), 8.86 (s, 1 H).
Example 17 4-(6- 1 F(3-hydroxy-2,2-dimethvIpropyl)aminolmethyl } - 1 ,4-dihvdroindenoF 1 ,2-c1ρyrazol-3- vDbenzoic acid
Example 17 A 3- F(3-Iodo- 1 ,4-dihydro-indenoF 1 ,2-clp yrazol-6-ylmethyl)-amino1-2,2-dimethyl-propan- 1 -ol The desired product was prepared by replacing morpholine with 3-amino-2,2-dimefhyl-l- propanol in Example 7A. MS (DCI/NH3) m/z: 398.1 (M+H)+; JH NMR (300 MHz, CD3OD) δ 0.90 (s, 6 H), 2.52 (s, 2 H), 3.36 (s, 2 H), 3.53 (s, 2 H), 3.80 (s, 2 H), 7.33 (d, J=6.78 Hz, 1 H), 7.52 (s, 1 H), 7.57 (d, J=7.80 Hz, 1 H).
Example 17B 4-(6- ( F(3-hydroxy-2,2-dimethylpropyl)amino1methyl 1-1 ,4-dihydroindeno F 1 ,2-clpyrazol-3- vDbenzoic acid The desired product was prepared by replacing Example IC with Example 17 A in Example ID. MS (DCI/NH3) m z: 391.3 (M+H)+; 1H NMR (500 MHz, DMSO-dg) δ 0.91 (s, 6 H), 2.77 (m, 2 H), 3.23 (s, 2 H), 3.96 (s, 2 H), 4.23 (s, 2 H,) 7.62 (d, J=7.80 Hz, 1 H), 7.73 (d, J=7.80 Hz, 1 H), 7.83 (s, 1 H), 7.97 (d, J=8.42 Hz, 2 H), 8.06 (d, J=8.42 Hz, 1 H), 8.91 (s, 2 H).
Example 18 4-(6-( F(3-hydroxy-2,2-dimethylpropyl)aminolmethyl}-l,4-dihydroindenoFl,2-clpyrazol-3- ypbenzamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 17A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID. MS (DCI/NH3) m z: 391.2 (M+H)+; 1H NMR (500 MHz, DMSO-d6) δ 0.90 (s, 6 H), 2.82 (m, 2 H), 3.24 (d, J=4.99 Hz, 2 H), 3.96 (s, 2 H), 4.23 (d, J=17.47 Hz, 2 H), 7.49 (d, J=8.42 Hz, 0.5 H) 7.54 (d, J=8.11 Hz, 0.5 H), 7.66 (s, 1 H), 7.75 (s, 1 H), 7.90 (d, J=8.42 Hz, 1 H), 8.01 (d, J=8.11 Hz, 3 H), 8.53 (s, 2 H).
Example 19 4-F6-(hydroxymethyl)- 1 ,4-dihydroindeno F 1 ,2-c]pyrazol-3-yllbenzoic acid
Example 19A (3-Iodo-l,4-dihydro-indenoFl,2-clpyrazol-6-yl)-methanol To a suspension of Example IB (0.500 g, 1.61 mmol) in a mixture of MeOH (9 mL) and THF (3 mL) was added NaBH (73.0 mg, 1.93 mmol) at room temperature. The mixture was stirred for 2 hours and the solvent was evaporated. The resulting concentrate was dissolved in hot CH2CI2 with a small amount of MeOH and the desired product was recrystalized to give 0.324 g (65%) of the desired product as brown solid. MS (DCI NH3) m/z: 312.9 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 3.54 (s, 2 H), 4.66 (s, 2 H), 7.35 (d, J=7.80 Hz, 1 H), 7.55 (s, 1 H), 7.59 (d, J=7.80 Hz, 1 H).
Example 19B 4-F6-(hvdroxymethyl)-l,4-dihvdroindenoFl,2-c1pyrazol-3-vnbenzoic acid The desired product was prepared by replacing Example IC with Example 19A in Example ID. MS (DC17NH3) m/z: 307.1 (M+H)+; 1H NMR (500 MHz, DMSO-dg) δ 3.90 (s, 2 H), 4.57 (s, 2 H), 7.33 (d, J=7.49 Hz, 1 H), 7.54 (s, 1 H), 7.61 (d, J=7.80 Hz, 1 H), 7.94 (d, J=8.42 Hz, 2 H), 8.05 (d, J=8.42 Hz, 2 H).
Example 20 4-F6-(hvdroxymethyl)-l,4-dihydroindenoFl,2-clpyrazol-3-yllbenzamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 19A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID. MS (DCI/NH3) m/z: 306.1 (M+H)+; 1H NMR (500 MHz, DMSO-dg) δ 3.90 (s, 2 H), 4.57 (s, 2 H), 7.32 (d, J=7.49 Hz, 1 H), 7.54 (s, 1 H), 7.61 (d, J=7.80 Hz, 1 H), 7.89 (d, J=8.42 Hz, 2 H), 8.00 (d, J=8.42 Hz, 2 H). Example 21 4- F6-(methoxymethyl)- 1.4-dihydroindeno Fl ,2-c]pyrazol-3-yl]benzoic acid
Example 21 A 3-Iodo-6-methoxymethyl-l ,4-dihydro-indenoFl ,2-clpyrazole A mixture of Example 19A (0.294 g, 0.942 mmol), LiBr (0.090 g, 1.04 mmol), and PBr3 (0.14 mL, 11.49 mmol) in DMF (5 mL) was stirred at room temperature for 2 hours. Ice was added to the reaction mixture and the resulting precipitate was filtered. The solid was suspended in MeOH and treated with Et3N (1 mL). The mixture was concentrated and purified by flash chromatography eluted with EtOAc/CH2Cl2 (2:98 to 5:95) to give 0.0422 g (12%) of the desired product. MS (DC17NH3) m/z: 327.0 (M+H)+; 1H NMR (500 MHz, CD3OD) δ 3.38 (s, 3 H), 3.53 (s, 2 H), 4.50 (s, 2 H), 7.33 (d, J=7.80 Hz, 1 H), 7.52 (s, 1 H), 7.59 (m, 1 H).
Example 2 IB 4- F6-(methoxymethyl)- 1 ,4-dihydroindeno F 1 ,2-c1pyrazol-3-yllbenzoic acid The desired product was prepared by replacing Example IC with Example 21 A in Example ID. MS (DCI NH3) m/z: 321.0 (M+H)+; 1H NMR (400 MHz, DMSO-dg) δ 3.31 (s, 3 H), 3.89 (s, 2 H), 4.46 (s, 2 H), 7.31 (d, J=7.67 Hz, 1 H), 7.52 (s, 1 H), 7.63 (d, J=7.67 Hz, 1 H), 7.92 (d, J=8.59 Hz, 2 H), 8.04 (d, J=8.59 Hz, 2 H).
Example 22 4-F6-(allyloxy)-1.4-dihydroindenoFl,2-c]pyrazol-3-yllbenzoic acid
Example 22A 5-Allyloxy-indan- 1 -one To a solution of 5 -hydroxy- 1-indanone (4.27 g, 0.0288 mol) in THF/DMF (5 mL/10 mL) at 0°C was added NaH (60%, 1.21 g, 0.0303 mol) followed by allyl bromide (2.7 mL, 0.0317 mol). The reaction was warmed to room temperature and stirred overnight. The reaction mixture was quenched with water and extracted with EtOAc, washed with brine, dried over MgSO , filtered, and concentrated. The residue was purified by flash chromatography eluted with EtOAc/hexane (1:1) to give 4.29 g (79%) of the desired product as brown oil. MS (DCI/NH3) m/z: 189.1 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 2.53-2.64 (m, 2 H), 2.96-3.11 (m, 2 H), 4.64-4.72 (m, 2 H), 5.29 (dd, J=10.51, 1.36 Hz, 1 H), 5.42 (dd, J=17.29, 1.70 Hz, 1 H), 6.06 (m, 1 H), 6.98 (dd, J=8.48, 2.37 Hz, 1 H), 7.10 (d, J=2.03 Hz, 1 H) 7.56 (d, J=8.48 Hz, 1 H).
Example 22B methyl 4-F(5-(allyloxy)-l-oxo-l,3-dihydro-2H-inden-2-ylidene)(hvdroxy)methyllbenzoate To a solution of Example 22A (0.222 g, 1.18 mmol) in THF (5 mL) at -78°C was added LDA (2.0M, 0.65 mL, 1.30 mmol). After 40 minutes, a pre-mixed suspension of CDI (0.191 g, 1.18 mmol) and terephthalic acid monomethyl ester (0.213 g, 1.18 mmol) in THF/DMF (4mL/lmL) was added to the above reaction mixture at -78°C. The dry ice bath was removed after 15 minutes and the reaction mixture stirred for 1 hour. The reaction was quenched with NH4C1 solution and extracted with EtOAc. The organic layer was dried over MgS0 , filtered, and concentrated. The concentrate was triturated with ether to give 0.132 g (32%) of the desired product as yellow solid. MS (DCI/NH3) m/z: 351.1 (M+H)+; 1H NMR (300 MHz, CDC13) δ 3.90 (s, 2 H), 3.96 (s, 3 H), 4.60-4.69 (m, 2 H), 5.34 (dd, J=10.51, 1.36 Hz, 1 H), 5.45 (dd, J=17.29, 1.36 Hz, 1 H), 6.07 (m, 1 H), 6.97-7.04 (m, 2 H), 7.83 (d, J=9.16 Hz, 1 H), 7.97 (d, J=8.48 Hz, 2 H), 8.10-8.23 (m, 2 H).
Example 22C methyl 4-F6-(allyloxy)-l,4-dihydroindenoFl,2-c|pyrazol-3-yl1benzoate A mixture of Example 22B (1.70 g, 4.85 mmol), hydrazine monohydrate (0.28 mL, 5.82 mmol), and AcOH (0.33 mL, 5.82 mmol) in EtOH (120 mL) was heated at 90 °C overnight. The reaction was cooled and the precipitate was filtered. The filter cake was rinsed with ether to give 1.56 g (93%) of the desired product as a white solid. MS (DCI/NH3) m/z: 347.1 (M+H)+; 1H NMR (300 MHz, DMSO-d6) δ 3.88 (s, 5 H), 4.58-4.67 (m, 2 H), 5.28 (dd, J=10.51, 1.36 Hz, 1 H), 5.43 (dd, J=17.12, 1.87 Hz, 1 H), 6.09 ( , 1 H), 6.97 (d, J=8.48 Hz, 1 H), 7.21 (s, 1 H), 7.59 (d, J=8.48 Hz, 1 H), 7.87-8.01 (m, 2 H), 8.02-8.14 (m, 2 H), 13.25 (s, 1 H). Example 22D 4-F6-(allyloxy)-l,4-dihydromdenoFl,2-clpyrazol-3-vHbenzoic acid A mixture of Example 22C (0.300 g, 0.866 mmol), LiOH.H2O (0.109 g, 2.60 mmol) in THF/MeOH/H2O (20/5/3 mL) was heated at 60 °C for 2 hours. After cooling, the reaction mixture was treated with TFA until pH=3. Solid material was filtered, rinsed with water, and dried in a vacuum oven to give 0.290 g (100%) of the desired product as white solid. MS (DCI/NH3) m z: 333.1 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 3.87 (s, 2 H), 4.63 (d, J=5.09 Hz, 2 H), 5.28 (dd, J=10.51, 1.70 Hz, 1 H), 5.43 (dd, J=17.12, 1.53 Hz, 1 H), 6.08 (m, 1 H), 6.97 (dd, J=8.48, 2.37 Hz, 1 H), 7.21 (d, J=2.37 Hz, 1 H), 7.56 (d, J=8.48 Hz, 1 H), 7.91 (d, J=8.48 Hz, 2 H), 8.04 (d, J=8.48 Hz, 2 H) 13.11 (s, 1 H).
Example 23 4-F6-(allyloxy)-l,4-dihvdroindenoFl,2-clpyrazol-3-vnbenzamide A mixture of Example 22D (50.0 mg, 0.150 mmol), HOBt (28.5 mg, 0.211 mmol), EDC (40.4 mg, 0.211 mmol), NH4C1 (40.1 mg, 0.750 mmol), and Et3N (0.14 mL, 0.975 mmol) in DMF (3 mL) in a capped flask was stirred at room temperature for 24 hours. The reaction mixture was diluted with EtOAc and washed with NaHCO3 and brine. The organic layer was dried over MgSO4, filtered, concentrated, and triturated with EtOAc to give 28.6 mg (58%) of the desired product as white powder. MS (DCITNH,) m/z: 332.1 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 3.87 (s, 2 H), 4.54-4.69 (m, 2 H) 5.28 (dd, J=10.51, 1.70 Hz, 1 H), 5.43 (dd, J=17.29, 1.70 Hz, 1 H), 6.09 (m, 1 H), 6.97 (d, J=8.48 Hz, 1 H), 7.20 (s, 1 H), 7.41 (m, 1 H), 7.58 (m, 1 H), 7.79-7.92 (m, 2 H), 4.94-8.06 (m, 3 H), 13.15 (s, 1 H).
Example 24 methyl 4-(6-hydroxy- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-3-yl)benzoate A suspension of Example 22C (0.200 g, 0.577 mmol) in THF (16 mL) was heated until a clear solution appeared and cooled to room temperature. To this solution was added Pd(PPh3)4 (0.0130 g, 2%). A suspension of NaBH in THF (2 mL) was added to the above reaction mixture in three portions at 0°C. The reaction was warmed to room temperature and stirred overnight. The reaction mixture was treated with acetone and the solvent was evaporated. The residue was treated with warm MeOH and the solid was filtered. The filtrate was concentrated and triturated with warm EtOAc. After cooling, the solid was filtered and rinsed with EtOAc to give 0.179 g (100%) of the desired product as yellow solid. MS (DC-7NH3) m/z: 307.0 (M+H)+; 1H NMR (300 MHz, DMSO-d6) δ 3.60 (s, 3 H), 3.86 (s, 2 H), 6.43 (d, J=7.46 Hz, 1 H), 6.67 (s, 1 H), 7.17 (d, J=8.14 Hz, 1 H), 7.89 (d, J=8.48 Hz, 2 H), 7.99 (d, J=8.48 Hz, 2 H).
Example 25
4-(6-hydroxy-l,4-dihvdroindenoFl,2-clpyrazol-3-yl)benzoic acid
The desired product was prepared by replacing Example 22C with Example 24 in
Example 22D. MS (DCI/NH3) m/z: 292.9 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 3.82 (s, 2
H), 6.77 (dd, J=8.14, 2.03 Hz, 1 H), 7.00 (s, 1 H), 7.44 (d, J=8.14 Hz, 1 H), 7.90 (d, J=8.48 Hz, 2
H), 8.03 (d, J=8.48 Hz, 2 H).
Example 26 4-(6-{ F(trans-4-hydroxycvclohexyl)aminolcarbonyl}-l,4-dihydroindenoFl,2-clpyrazol-3- vDbenzoic acid
Example 26A 3-Iodo- 1 ,4-dihydro-indeno F 1 ,2-clpyrazole-6-carboxylic acid A mixture of Example IB (3.00 g, 9.67 mmol), KH2P04 (5.26 g , 0.0387 mol), and H2NS03H (1.41 g, 0.0145 mol) in l,4-dioxane/H2O (100/30 mL) was stirred at 0 °C for 15 minutes. To this mixture was added NaC102 (1.14 g, 0.0126 mol) in H20 (15 mL) dropwise. The reaction mixture was stirred for 15 minutes at 0 °C followed by the addition of NaHSO3 (1.11 g, 0.0106 mol). The resulting suspension was warmed to room temperature and stirred for 1 hour. The reaction mixture was treated with Na2S2O3 solution and concentrated under reduced pressure. The residue was treated with water and stirred for 1 hour. The mixture was filtered and the filter cake was rinsed with water and dried in a vacuum oven to provide the title compound which was used in the next step without further purification. MS (DCI/NH3) m/z: 327.0 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 3.57 (s, 2 H), 7.67 (m, 1 H), 7.98 (d, J=7.80 Hz, 1 H), 8.10 (s, 1 H). Example 26B 3-Iodo-l,4-dihvdro-indenoFl,2-clpyrazole-6-carboxylic acid (4-hydroxy-cyclohexyl)-amide The desired product was prepared by replacing NH4C1 and Example 22D with trans-4- amino-cyclohexanol and Example 26A in Example 23. MS (DCI/NH3) m/z: 424.0 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 1.12-1.48 (m, 4 H), 1.71-1.93 (m, 4 H), 3.41 (m, 1 H), 3.55 (s, 0.5 H), 3.60 (s, 0.5 H), 3.74 (m, 1 H), 4.55 (d, J=4.41 Hz, 1 H), 7.56 (d, J=8.14 Hz, 0.5 H), 7.66 (d, J=7.80 Hz, 0.5 H), 7.86 (t, J=7.97 Hz, 1 H), 8.01 (d, J=5.76 Hz, 1 H), 8.20 (d, J=7.80 Hz, 1 H).
Example 26C 4-(6-{F(trans-4-hydroxycyclohexyl aminolcarbonyl)-l,4-dihydroindenori,2-clpyrazol-3- yDbenzoic acid The desired product was prepared by replacing Example IC with Example 26B in Example ID. MS (DCI NH3) m/z: 418.2 (M+H)+; 1H NMR (500 MHz, DMSO-dg) δ 1.20-1.32 (m, 2 H), 1.33-1.46 (m, 2 H), 1.76-1.92 (m, 4 H), 3.76 (m, 1 H), 3.97 (s, 2 H), 7.71 (d, J=7.80 Hz, 1 H), 7.88 (d, J=7.18 Hz, 1 H), 7.95 (d, J=8.11 Hz, 2 H), 8.03-8.08 (m, 3 H), 8.20 (d, J=7.80 Hz, 1 H).
Example 27 4-{6-F(neopentylamino)carbonyl1-l,4-dihvdroindenori,2-c1pyrazol-3-yl}benzoic acid
Example 27A 3-Iodo- 1 ,4-dihy dro-indenoF 1 ,2-c]pyrazole-6-carboxylic acid (2,2-dimethyl-propyP-amide The desired product was prepared by replacing NH C1 and Example 22D with neopentylamine and Example 26A in Example 23. MS (DCI/NH3) m/z: 396.0 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ 0.91 (s, 9 H), 3.12 (d, J=6.44 Hz, 2 H), 3.59 (s, 2 H), 7.64 (m, 1 H), 7.88 (d, J=8.14 Hz, 1 H), 8.06 (m, 1 H), 8.37 (t, J=6.27 Hz, 1 H).
Example 27B 4-(6-F(neopentylamino)carbonyll-l,4-dihvdroindenoFl,2-clpyrazol-3-yllbenzoic acid The desired product was prepared by replacing Example IC with Example 27 A in Example ID. MS (DCI/NH3) m/z: 390.1 (M+H)+; 1H NMR (500 MHz, DMSO-D6) δ 0.93 (s, 9 H), 3.14 (d, J=6.24 Hz, 2 H, 3.99 (s, 2 H), 7.73 (d, J=8.11 Hz, 1 H), 7.91 (d, J=7.80 Hz, 1 H), 7.96 (d, J=8.42 Hz, 2 H), 8.04-8.10 (m, 3 H), 8.37 (t, J=6.24 Hz, 1 H).
Example 28 3-F4-(ar nocarbonyl)phenyll-N-neopentyl-l,4-dihvdroindenoFl,2-clpyrazole-6-carboxamide The desired product was prepared replacing Example IC and 4-carboxybenzene boronic acid with Example 27A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID. MS (DCI/NH3) m/z: 389.2 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ 0.93 (s, 9 H), 3.14 (d, J=6.10 Hz, 2 H) 3.99 (s, 2 H), 7.41 (s, 1 H), 7.73 (d, J=8.14 Hz, 1 H), 7.90 (d, J=8.48 Hz, 2 H), 7.97-8.10 (m, 3 H), 8.39 (t, J=6.27 Hz, 1 H).
Example 29 4'-(6-{ F(cis-4-methylcvclohexyl)aminolmethyl l-l,4-dihydroindenoFl,2-c1pyrazol-3-yl)-l,r- biphenyl-4-ol
Example 29A 4'-(4,4,5,5-Tetramethyl-Fl,3,21dioxaborolan-2-vP-biρhenyl-4-ol A mixture of 4'-bromo-biphenyl-4-ol (0.300 g, 1.20 mmol), bis(pinacolato)- diboron (0.336 g, 1.32 mmol), PdCl2(dppf).CH2Cl2 (0.0293 g, 3%), dppf (0.0199 g, 3%), and KOAc (0.353 g, 3.60 mmol) in 1,4-dioxane (6 mL) was heated at 90 °C overnight. The reaction mixture was concentrated and the residue was extracted with EtOAc, washed with brine, dried over MgS04, filtered, concentrated, and purified by flash chromatography eluted with hexane/EtOAc (1:1) to give 0.278 g (78%) of the desired product as white foam. MS (DCI/NH3) m/z: 296.1 (M+H)+; 1H NMR (300 MHz, CDC13) δ 1.36 (s, 12H), 6.90 (d, J=8.48 Hz, 2 H), 7.53 (dd, J=12.72, 8.65 Hz, 4 H), 7.85 (d, J=8.14 Hz, 2 H).
Example 29B 4-(6-{ F(cis-4-methylcyclohexyPaminolmethyl)-l,4-dihvdroindenoFl,2-clpyrazol-3-yP-l,r- biphenyl-4-ol The desired product was prepared by replacing Example IC (trans) and 4-carboxybenzene boronic acid with Example IC (cis) and Example 29A in Example ID. MS (DCI NH3) m/z: 450.2 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 1.04 (d, J=7.12 Hz, 3 H), 1.47-2.01 (m, 9 H), 3.28 (m, 1 H), 3.96 (s, 2 H), 4.31 (s, 2 H), 6.89 (d, J=8.82 Hz, 2 H), 7.46-7.59 (m, 3 H), 7.67- 7.76 (m, 3 H), 7.78-7.89 (m, 3 H).
Example 30 4'-(6-{F(trans-4-hvdroxycyclohexyl)aminolmethyll-l,4-dihvdroindenoπ,2-clpyrazol-3-yl)-3- methoxy-1 , 1 '-biphenyl-4-ol
Example 30A 4 -Bromo-3 -methox y-biphenyl-4-ol A mixture of 2-methoxy-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol (0.250 g, 1.00 mmol), 1,4-dibromo benzene (0.259 g, 1.10 mmol), Pd(PPh3) (0.0580 g, 5%), and CsF (0.456 g, 3.00 mmol) in DME/MeOH (25 mL, 1:1) was heated at 70 °C overnight. The reaction mixture was concentrated and the residue was extracted with CH2C12 , washed with water, dried over MgS04, filtered, concentrated, and purified by flash chromatography eluted with hexane/CH2Cl2 (1:9) to give 0.151g (54%) of the desired product. MS (DCI/NH3) m/z: 279.9 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 3.91 (s, 3 H), 6.86 (d, J=8.14 Hz, 1 H), 7.06 (m, 1 H), 7.14 (d, J=2.03 Hz, 1 H), 7.44-7.58 (m, 3 H).
Example 30B
3-Methoxy-4'-(4,4,5,5-tetramethyl-Fl,3,21dioxaborolan-2-yl)-biρhenyl-4-ol
The desired product was prepared by replacing 4 -bromo-biphenyl-4-ol with Example
30A in Example 29A. MS (DCI/NH3) m/z: 326.1 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 1.36
(s, 12 H), 3.92 (s, 3 H), 6.87 (d, J=8.14 Hz, 1 H), 7.11 (d, J=8.14 Hz, 1 H), 7.19 (d, J=2.37 Hz, 1
H), 7.57 (d, J=8.14 Hz, 2 H), 7.76 (d, J=8.48 Hz, 2 H). Example 30C 4-(6-f r(tians-4-hvdroxycvclohexyl)aminolmethyl)-l,4-dihydroindenori,2-clpyrazol-3-yl)-3- methox y- 1 , 1 -biphenyl-4-ol The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 4A and Example 30B in Example ID. MS (DCI/NH3) m/z: 482.2 (M+H)+; 1H NMR (500 MHz, CD3OD) δ 1.31-1.43 (m, 2 H), 1.46-1.59 (m, 2 H), 2.01-2.14 (m, 2 H), 2.19- 2.32 (m, 2 H), 3.15 (m, 1 H), 3.59 (m, 1 H), 3.93 (s, 5 H), 4.28 (s, 2 H), 6.89 (d, J=8.11 Hz, 1 H), 7.14 (d, J=8.11 Hz, 1 H), 7.22 (d, J=1.87 Hz, 1 H), 7.50 (d, 1=7.49 Hz, 1 H), 7.66-7.75 (m, 3 H), 7.79-7.88 (m, 3 H).
Example 31 4-(6-{F(tians-4-hydroxycyclohexyPaminolmethyll-l,4-dihvdroindenoFl,2-clpyrazol-3-yl)-3-
(hydroxymethvP- 1 , 1 -biphenyl-4-ol
Example 31A 4 -Bromo-3-hvdroxymethyl-biphenyl-4-ol The desired product was prepared by replacing 2-methoxy-4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenol with 2-hydroxymethyl-4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenol in Example 30A. MS (DCI/NH3) m/z: 278.0, 279.8 (M, M+2). 1H NMR (500 MHz, CD3OD) δ 4.61 (s, 2 H), 6.75 (d, J=8.42 Hz, 1 H), 7.26 (d, J=10.92 Hz, 1 H), 7.37 (d, J=8.42 Hz, 2 H), 7.40-7.49 (m, 3 H).
Example 3 IB 3-HvdroxymethvI-4 -(4,4,5,5-tetramethyl-Fl,3,21dioxaborolan-2-yl)-biphenyl-4-ol The desired product was prepared by replacing 4-bromo-biphenyl-4-ol with Example 31 A in Example 29A. MS (DCI/NH3) m/z: 326.1 (M+l)+; *H NMR (300 MHz, CD3OD) δ 1.36 (s, 12 H), 4.71 (s, 2 H), 6.85 (d, J=8.48 Hz, 1 H), 7.35-7.46 (m, 1 H), 7.54-7.62 (m, 3 H) 7.76 (d, 1=8.14 Hz, 2 H).
Example 31C 4,-(6-(F(trans-4-hvdroxycvclohexyl)aminolmethyl)-l,4-dihvdroindenoFl,2-clpyrazol-3-yP-3-
(hvdroxymethyP-1 , 1 -biρhenyl-4-ol The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 4A and Example 3 IB in Example ID. MS (ESI) m/z: 482.0 (M+H)+; 1H NMR (500 MHz, CD3OD) δ 1.30-1.43 (m, 2 H), 1.45-1.61 (m, 2 H), 2.00-2.13 (m, 2 H), 2.16-2.32 (m, 2 H), 3.17 (m, 1 H), 3.58 (m, 1 H), 3.93 (s, 2 H), 4.27 (s, 2 H), 4.73 (s, 2 H), 6.88 (d, J=8.42 Hz, 1 H), 7.40-7.52 (m, 2 H), 7.63 (s, 1 H), 7.67-7.75(m, 3 H), 7.77-7.86 (m, 3 H).
Example 32 3-methoxy-4 -{6-F(neopentylamino)methyll-l,4-dihydroindenoFl,2-clpyrazol-3-yll-l,l - biphenyl-4-ol The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 15A and Example 30B in Example ID. MS (DC17NH3) m/z: 454.2 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 1.04 (s, 9 H), 3.95 (s, 3 H), 3.96 (s, 2 H), 4.33 (s, 2 H), 6.90 (d, J=8.14 Hz, 1 H), 7.15 (dd, J=8.31, 2.20 Hz, 1 H), 7.23 (d, J=2.03 Hz, 1 H), 7.56 (m, 1 H), 7.69- 7.77 (m, 3 H), 7.80-7.88 (m, 3 H).
Example 33 4-(6-f F(3-hydroxy-2,2-dimethylpropyl)aminolmethyl}-l,4-dihydroindenoFl,2-clpyrazol-3-yP-3- methoxy- 1 , 1 -biphenyl-4-ol The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 17A and Example 30B in Example ID. MS (DCI NH3) m z: 470.2 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 1.02 (s, 6 H), 3.00 (s, 2 H), 3.45 (s, 2 H), 3.95 (s, 5 H), 4.30 (s, 2 H), 6.89 (d, J=8.14 Hz, 1 H), 7.15 (dd, J=8.14, 2.03 Hz, 1 H), 7.23 (d, J=2.03 Hz, 1 H), 7.50 (d, J=1.36 Hz, 1 H), 7.68-7.76 (m, 3 H) 7.78-7.91 (m, 3 H).
Example 34 3-(4'-hydroxy-l, -biphenyl-4-yP-l,4-dihydroindenoFl,2-clpyrazol-6-ol
Example 34A 5-(allyloxy)-2-F(4-bromophenvP(hydroxy methylenel-l-indanone The desired product was prepared by replacing terephthalic acid monomethyl ester with 4- bromo-benzoic acid in Example 22B. MS (DCI/NH3) m/z: 371.4 (M+H)+; 1H NMR (300 MHz, CDCI3) δ 3.86 (s, 2 H), 4.64 (d, J=5.43 Hz, 2 H), 5.29-5.52 (m, 2 H), 6.08 (m, 1 H), 6.92-7.04 (m, 2 H), 7.63 (d, J=8.82 Hz, 2 H), 7.73-7.86 (m, 3 H).
Example 34B 6-Allyloxy-3-(4-biOmo-phenyP-l,4-dihvdro-indenoFl,2-clpyrazole The desired product was prepared by replacing Example 22B with Example 34A in Example 22C. MS (DCI/NH3) m/z: 367.0 (M+l)+, 367.9 (M+l+2)+; 1H NMR (400 MHz, CDC13) δ 3.71 (s, 2 H), 4.59 (d, 3=5.22 Hz, 2 H), 5.24-5.53 (m, 2 H), 6.07 (m, 1 H), 6.90 (d, J=8.29 Hz, 1 H), 7.09 (m, 1 H), 7.46-7.61 (m, 6 H).
Example 34C 3-(4 -hydroxy- 1 , 1 -biphenyl-4-yP- 1 ,4-dihydroindeno F 1 ,2-c1pyrazol-6-ol The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 34B and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol in Example ID. MS (DCI NH3) m/z: 341.1 (M+H)+; XH NMR (500 MHz, DMSO-dg) δ 3.80 (s, 2 H), 6.77 (d, J=10.29 Hz, 1 H), 6.87 (d, J=8.73 Hz, 2 H), 6.99 (s, 1 H), 7.45 (d, J=8.42 Hz, 1 H), 7.56 (d, J=8.42 Hz, 2 H), 7.70 (d, J=8.11 Hz, 2 H), 7.82 (d, J=8.42 Hz, 2 H), 9.45 (s, 1 H)? 9.57 (s, 1 H).
Example 35 3-(4'-hvdroxy-3 -mefhoxy- 1 , 1 '-biphenyl^-yP- 1 ,4-dihvdroindenoF 1.2-clpyrazol-6-ol The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 34B and 2-methoxy-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol in Example ID. MS (DCI/NH3) m z: 371.1 (M+H)+; 1H NMR (500 MHz, CD3OD) δ 3.88 (s, 2 H), 3.95 (s, 3 H), 6.78-6.98 (m, 2 H), 7.02-7.29 (m, 3 H), 7.55 (m, 1 H), 7.69-7.89 (m, 4 H).
Example 36 4 -F6-(hvdroxymethyl)-l,4-dihvdroindenoFl,2-clpyrazol-3-vn-l, -biphenyl-4-ol The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 19A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol in Example ID. MS (DCI/NH3) m/z: 355.1 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 3.89 (s, 2 H), 4.68 (s, 2 H), 6.88 (d, J=8.82 Hz, 2 H), 7.37 (d, J=6.78 Hz, 1 H), 7.53 (d, J=8.82 Hz, 2 H), 7.60 (s, 1 H), 7.65- 7.74 (m, 3 H), 7.83 (d, J=8.48 Hz, 2 H).
Example 37 4 '-( 1 ,4-dihydroindeno Fl ,2-c1pyrazol-3-yP- 1 , 1 -biphenyl-4-ol
Example 37A 3 -Iodo- 1 ,4-dihydro-indeno [ 1 ,2-clpyr azole The desired product was prepared by replacing Example 1 A with l,4-dihydro-indeno[l,2- cjpyrazole, prepared according to procedure described in U.S. Patent 6297238, in Example IB.
MS (DCI/NH3) m/z: 282.9 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 3.54 (s, 2 H), 7.23-7.42 (m, 2 H), 7.54 (d, J=7.12 Hz, 1 H), 7.62 (d, J=6.44 Hz, IH).
Example 37B 4 '-( 1 ,4-dihydroindeno fl ,2-clpyrazol-3-yP- 1 , 1 -biphenyl-4-ol The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 37 A and Example 29A in Example ID. MS (DCI/NH3) m/z: 325.1 (M+H)+; 1H NMR (300 MHz, DMSO-d6) δ 3.90 (s, 2 H), 6.87 (d, J=8.82 Hz, 2 H), 7.23-7.45 (m, 2 H), 7.53- 7.63 (m, 3 H), 7.65-7.79 (m, 3 H), 7.85 (d, J=7.80 Hz, 2 H), 9.60 (s, 1 H), 13.22 (s, 1 H).
Example 38 4 '- l"6-(h ydrox ymeth yl)- 1 ,4-dihydroindeno I" 1 , 2-clp yrazol-3 -yll -3 -methoxy- 1 , 1 -biphen yl-4-ol The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 19A and Example 30B in Example ID. MS (DCI/NH3) m/z: 385.1 (M+H)+; 1H NMR (500 MHz, DMSO-d6) δ 3.88 (s, 5 H), 4.58 (s, 2 H), 6.88 (d, J=8.11 Hz, 1 H), 7.16 (dd, J=8.27, 2.03 Hz, 1 H), 7.27 (d, J=2.18 Hz, 1 H, 7.32 (d, J=7.80 Hz, 1 H), 7.55 (s, 1 H), 7.62 (d, J=7.49 Hz, 1 H), 7.76 (d, J=8.42 Hz, 2 H), 7.86 (d, J=8.42 Hz, 2 H). Example 39 3-(3 -fluoro-4-hvdroxy-l, -biphenyl-4-vP-l,4-dihvdroindenon,2-c1pyrazol-6-ol The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 34B and 2-fluoro-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol in Example ID. MS (DCI/NH3) m/z: 359.0 (M+H)+; 1H NMR (400 MHz, CD3OD) δ 3.84 (s, 2 H), 6.83 (dd, J=8.29, 2.45 Hz, 1 H), 6.96-7.07 (m, 2 H), 7.33 (m, 1 H), 7.40 (dd, J=12.27, 2.15 Hz, 1 H), 7.54 (d, J=8.29 Hz, 1 H), 7.70 (d, J=8.59 Hz, 2 H), 7.78-7.88 (m, 2H).
Example 40 3-(3,-amino-4 -hydroxy-l,r-biphenyl-4-vP-l,4-dihydroindenori,2-c1pyrazol-6-ol
Example 40A 2-Amino-4-(4,4,5,5-tetramethyl-ri,3,21dioxaborolan-2-vP-phenol A mixture of Pd2(dba)3 (0.0765 g) and Cy-MAP (0.165 g) in degassed 1,4-dioxane (6 mL) was stirred at room temperature for 30 minutes. To the above mixture was added 2-amino- 4-chloro-phenol (0.300 g, 2.09 mmol), bis(pinacolato) diboron (0.557 g, 2.19 mmol), and KOAc (0.308 g, 3.14 mmol). The reaction mixture was heated at 85 °C overnight, allowed to cool to room temperature, concentrated under reduced pressure and the residue was treated with EtOAc. The ethyl acetate layer was washed with brine, dried over MgS04, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with hexanes/EtOAc (7:3 to 1:1) to give 0.273g (69%) of the desired product as brown solid. MS (DCI/NH3) m/z: 235.8 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 1.24 (s, 12 H), 3.92 (s, 1 H), 6.62 (d, J=7.80 Hz, 1 H), 6.78 (dd, J=7.63, 1.53 Hz, 1 H), 6.96 (d, J=1.36 Hz, 1 H).
Example 40B
3-(3 -amino-4 -hydroxy- 1,1 -biphenyl-4-yl)-l,4-dihvdroindenori,2-clpyrazol-6-ol
The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 34B and 40A in Example ID. MS (DCI/NH3) m/z: 356.1 (M+H)+; 1H NMR (300
MHz, CD3OD) δ 3.84 (s, 2 H), 6.83 (dd, J=8.31, 2.20 Hz, 1 H), 7.05 (d, J=2.37 Hz, 1 H), 7.12 (d, J=8.48 Hz, 1 H,) 7.53 (d, J=8.14Hz, 1 H), 7.60 (d, J=2.37 Hz, 1 H), 7.63-7.68 (m, 1 H), 7.71 (d, J=8.48 Hz, 2 H), 7.87 (d, J=8.48 Hz, 2 H).
Example 41 4-hydroxy-4 - r6-(hydroxymethvP- 1 ,4-dihydroindeno [" 1 ,2-clp yrazol-3 - yll -5 -methox v- 1,1 - biphenyl-2-carbaldehyde
Example 41 A 4-Bromo-4-hvdroxy-5-methoxy-biphenyl-2-carbaldehvde A mixture of 2-bromo-5-hydroxy-4-methoxy-benzaldehyde (1.00 g, 4.32 mmol), 4- bromophenyl boronic acid (1.04 g, 5.18 mmol), Pd(PPh3) (0.250 g), and CsF (1.97 g, 12.6 mmol) in DME/MeOH (1:1, 65 mL) was heated at 70 °C overnight. The mixture was diluted with CH2C12 and washed with water. The organic layer was dried over MgSO , filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography eluting with hexane/CH2Cl2 (1:9) to give 0.809g (60%) of the desired product which was carried into the next step without further purification. MS (DCI/NH3) m/z: 307.4 (M+H)+.
Example 41B 4-Hvdroxy-5-methoxy-4'-(4,4,5,5-tetramethyl-n,3,21dioxaborolan-2-vP-biphenyl-2- carbaldehyde The desired product was prepared by replacing 4'-bromo-biphenyl-4-ol with Example 41 A in Example 29A. The product was carried into the next step without further purification. MS (DCI/NH3) m/z: 372.2 (M+NH4)+.
Example 41C 4-hvdroxy-4'-r6-(hvdroxymethyl)-l,4-dihydroindenori,2-clpyrazol-3-yll-5-methoxy-l,r- biphenyl-2-carbaldehyde The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 19A and 41B in Example ID. MS (DCI/NH3) m/z: 413.1 (M+H)+; !H NMR (500 MHz, DMSO-dg) δ 3.90 (s, 2 H), 3.94 (s, 3 H), 4.58 (s, 2 H), 7.03 (s, 1 H), 7.33 (d, J=7.80 Hz, 1 H), 7.36 (s, 1 H), 7.55-7.58 (m, 3 H), 7.62 (d, J=7.80 Hz, 1 H), 7.92 (d, J=8.11 Hz, 2 H), 9.76 (s, I H).
Example 42 3-(4-hvdroxy-l,r-biphenyl-4-vP-N-(trans-4-hydroxycvclohexyP-l,4-dihvdroindenori,2- clpyrazole-6-carboxamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 26B and Example 29A in Example ID. The microwave assisted reaction was run for 450 to 2000 seconds at 160 to 180 °C. MS (DCI/NH3) m/z: 466.2 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 1.38-1.52 (m, 4 H), 1.93-2.10 (m, 4 H), 3.58 (m, 1 H), 3.883 (m, 1 H), 3.94 (s, 2 H), 6.88 (d, 3=8.81 Hz, 2 H), 7.52 (d, 3=8.48 Hz, 2 H), 7.69 (d, 3=8.48 Hz, 2 H), 7.75-7.87 (m, 4 H), 8.02 (s, 1 H).
Example 43 3-(4 '-hydroxy- 1 , 1 -biphenyl-4-vP-N-neopentyl- 1 ,4-dihydroindeno IT ,2-e1pyrazole-6-carboxamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 27A and Example 29A in Example ID. MS (DCI/NH3) m/z: 438.2 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 0.93 (s, 9 H), 3.14 (d, J=6.10 Hz, 2 H), 3.97 (s, 2 H), 6.88 (d, J=8.48 Hz, 2 H), 7.58 (d, 3=8.82 Hz, 2 H), 7.73 (d, J=8.48 Hz, 3 H), 7.83-7.96 (m, 3 H), 8.07 (s, 1 H), 8.39 (t, 3=6.44 Hz, 1 H), 9.60 (s, 1 H).
Example 44 4-r7-(hvdroxymethvP-l,4-dihydroindenori,2-clpyrazol-3-yllbenzoic acid
Example 44A l,4-dihvdroindenon,2-c1pyrazole-7-carbaldehvde The desired product was prepared by replacing 6-bromo-l,4-dihydro-indeno[l,2-c]pyrazole with 7-bromo-l,4-dihydro-indeno[l,2-c]pyrazole in Example 1 A.
Example 44B 3-iodo-l,4-dihydroindenoFl,2-c]pyrazole-7-carbaldehyde The desired product was prepared by replacing Example 1A with Example 44 A in Example IB. MS (DCI/NH3) m/z: 310.9 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 3.64 (s, 0.8 H), 3.69 (s, 1.2 H), 7.78 (t, J=8.82 Hz, 1 H), 7.88 (t, J=7.97 Hz, 1 H), 8.02 (s, 0.4 H), 8.11 (s, 0.6 H), 10.08 (s, 1 H).
Example 44C
(3-Iodo-l ,4-dihvdro-indenoFl ,2-clpyrazol-7-yl)-methanol
The desired product was prepared by replacing Example IB with Example 44B in Example 19 A.
MS (DCI/NH3) m/z: 312.9 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 3.52 (s, 2 H), 4.67 (s, 2 H),
7.30 (d, J=9.49 Hz, 1 H), 7.51 (d, 3=7.80 Hz, 1 H), 7.64 (s, 1 H).
Example 44D 4-F7-(hvdroxynιethvP-l,4-dihydroindenoFl,2-clρyrazol-3-vnbenzoic acid The desired product was prepared by replacing Example IC with Example 44C in Example ID. MS (DCI/NH3) m/z: 307.0 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 3.89 (s, 2 H), 4.70 (s, 2 H), 7.33 (d, J=7.80 Hz, 1 H), 7.56 (d, J=8.48 Hz, 1 H), 7.74 (s, 1 H), 7.91 (d, 3=8.81 Hz, 2 H), 8.09- 8.18 (m, 3 H).
Example 45 4- F7-(hydroxymethvP- 1 ,4-dihydroindeno F 1 ,2-clpyr azol-3 -yllbenzamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 44C and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID. MS (DCI/NH3) m/z: 306.0 (M+H)+; 1H NMR (500 MHz, DMSO-dg) δ 3.88 (s, 2 H), 4.59 (s, 2 H), 5.22 (s, 1 H), 7.25 (d, 3=7.80 Hz, 1 H), 7.32-7.45 (m, 1 H), 7.52 (d, J=7.80 Hz, 1 H), 7.65 (s, 1 H), 7.88 (s, 2 H), 7.99 (d, 3=7.80 Hz, 2 H), 13.29 (s, 1 H).
Example 46 4 -r7-(hydroxymethyl)-l,4-dihvdiOindenoFl,2-clpyrazol-3-yll-3-methoxy-l, -biphenyl-4-ol The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 44C and Example 30B in Example ID. MS (DCI/NH3) m/z: 385.1 (M+H)+; 1H NMR (300 MHz, DMSO-d6) δ 3.87 (s, 2 H), 3.88 (s, 3 H), 4.59 (s, 2 H), 6.88 (d, J=8.14 Hz, 1 H), 7.16 (dd, J=8.14, 2.03 Hz, 1 H), 7.21-7.29 (m, 2 H), 7.54 (m, 1 H), 7.65 (s, 1 H), 7.76 (d, J=8.48 Hz, 2 H), 7.86 (d, 3=8.48 Hz, 2 H), 9.14 (s, brd, 1 H).
Example 47 N-{3-F7-(hvdroxymethyP-l,4-dihvdroindenoFl,2-clpyrazol-3-yllphenyl|acetamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 44C and 3-acetamidobenzene boronic acid in Example ID. MS (DCI/NH3) m z: 320.0 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 2.18 (s, 3 H), 3.86 (s, 2 H), 4.69 (s, 2 H), 7.34 (dd, J=7.80, 1.36 Hz, 1 H), 7.42-7.47 (m, 2 H, 7.52-7.58 (m, 2 H), 7.73 (d, 3=0.68 Hz, 1 H), 8.15 (m, 1 H).
Example 48 4-F7-(4-morpholinylmethvP-l,4-dihvdroindenoFl,2-c1pyrazol-3-yllbenzoic acid
Example 48 A 3-Iodo-7-morpholin-4-ylmethyl-l,4-dihvdro-indenoFl,2-c1pyrazole The desired product was prepared by replacing Example IB with Example 44B in Example 7A. MS (DCI/NH3) m/z: 382.0 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 2.39-2.55 (m, 4 H), 3.52 (s, 2 H), 3.59 (s, 2 H), 3.66-3.74(m, 4 H),7.29 (dd, 3=7.80, 1.70 Hz, 1 H), 7.50 (d, 3=7.80 Hz, 1 H), 7.63 (m, 1 H).
Example 48B 4-F7-(4-morpholinylmethyl)-l,4-dihydroindenoFl,2-c1pyrazol-3-yllbenzoic acid The desired product was prepared by replacing Example IC with Example 48A in Example ID. MS (DCI/NH3) m/z: 376.2 (M+H)+; 1H NMR (400 MHz, CD3OD) δ 3.33-3.52 (m, 4 H), 3.65- 3.86 (m, 2 H), 3.97 (s, 2 H), 3.99-4.14 (m, 2 H), 4.46 (s, 2 H), 7.47 (d, J=7.67 Hz, 1 H), 7.73 (d, J=7.67 Hz, 1 H), 7.82-7.96 (m, 3 H), 8.14 (d, J=8.59 Hz, 2 H). Example 49
4- F7-(4-morpholinylmethyP- 1 ,4-dihydroindeno F 1 , 2-c1pyrazol-3 -yllbenzamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 48A and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID. MS (DCI NH3) m/z: 375.1 (M+H)+; 1H NMR (400 MHz, CD3OD) δ 3.21-3.33 (m, 2 H), 3.38-3.49 (m, 2 H), 3.67-3.81 (m, 2 H), 3.95 (s, 2 H), 4.01-4.12 (m, 2 H), 4.46 (s, 2 H), 7.47 (dd, 3=7.67, 1.53 Hz, 1 H), 7.72 (d, J=7.98 Hz, 1 H), 7.84-7.91 (m, 3 H), 8.00 (d, J=8.29 Hz, 2 H).
Example 50 4-f 7- { F(2-hvdroxyethyl)aminolmethyl 1-1 ,4-dihydroindeno F 1 ,2-clpyrazol-3-yl)benzoic acid
Example 50A 2-F(3-Iodo- 1 ,4-dihydro-indenoFl ,2-clpyrazol-7-ylmethyl)-aminol-ethanol The desired product was prepared by replacing Example IB and morpholine with Example 44B and 2-amino-ethanol in Example 7A. MS (DC-7NH3) m/z: 356.0 (M+H)+; !H NMR (300 MHz, CD3OD) δ 2.81 (t, J=5.77 Hz, 2 H), 3.54 (s, 2 H), 3.70 (t, J=5.77 Hz, 2 H), 3.92 (s, 2 H), 7.33 (dd, 3=7.80, 1.70 Hz, 1 H), 7.54 (d, 3=7.80 Hz, 1 H), 7.64 (s, 1 H).
Example 50B 4-(7-(F(2-hydroxyethyl)amino1methyl|-l,4-dihydroindenoFl,2-clpyrazol-3-yPbenzoic acid The desired product was prepared by replacing Example IC with Example 50A in Example ID. MS (DCI/NH3) m/z: 350.1 (M+H)+; 1H NMR (400 MHz, CD3OD) δ 3.09 (t, J=5,52 Hz, 2 H), 3.74 (t, J=5,52 Hz, 2 H), 3.87 (s, 2 H), 4.25 (s, 2 H), 7.36 (dd, J=7.67, 1.84 Hz, 1 H), 7.60 (d, 3=7.98 Hz, 1 H), 7.76 (d, 3=1.23 Hz, 1 H), 7.80 (d, 3=8.59 Hz, 2 H), 8.05 (d, J=8.90 Hz, 2 H).
Example 51 4 -r7-(hydroxymethyl)-l ,4-dihydroindenoFl ,2-clpyrazol-3-yl1-l , 1 -biphenyl-4-ol The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 44C and Example 29A in Example ID. MS (DCI/NH3) m/z: 355.1 (M+H)+; 1H NMR (500 MHz, DMSO-dg) δ 3.86 (s, 2 H), 4.59 (s, 2 H), 6.87 (d, 3=8.42 Hz, 2 H), 7.24 (d, 3=7.80 Hz, 1 H), 7.52 (d, 3=7.80 Hz, 1 H), 7.57 (d, J=8.42 Hz, 2 H), 7.64 (s, 1 H), 7.71 (d, J=8.42 Hz, 2 H), 7.85 (d, J=8.42 Hz, 2 H), 9.56 (s, 1 H).
Example 52 4-{7-F(neopentylamino)methvn-l,4-dihvdroindenori,2-c1pyrazol-3-yl)benzamide
Example 52A (2,2-Dimethyl-propyP-(3-iodo-l,4-dihydro-indenoFl,2-clpyrazol-7-ylmethyP-amine The desired product was prepared by replacing Example IB and morpholine with Example 44B and neopentylamine in Example 7A. MS (DCI/NH3) m/z: 382.0 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 0.92 (s, 9 H), 2.35 (s, 2 H), 3.52 (s, 2 H), 3.84 (s, 2 H), 7.30 (dd, 3=7.80, 1.70 Hz, 1 H), 7.50 (d, 3=7.80 Hz, 1 H), 7.62 (s, 1 H).
Example 52B 4- { 7-F(neopentylamino)methyll- 1 ,4-dihydroindenoF 1 ,2-clpyrazol-3-yl Ibenzamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 52A and 4-(4,4,5,5-teti"amethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID. MS (DCI/NH3) m/z: 375.2 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 0.95 (s, 9 H), 2.74 (s, 2 H), 3.97 (s, 2 H), 4.28 (s, 2 H), 7.37-7.50 (m, 2 H), 7.66 (d, J=7.80 Hz, 1 H), 7.84-7.94 (m, 3 H), 7.98-8.06 (m, 3 H), 8.60 (s, brd, 1 H).
Example 53 4 - { 7-r(neopentylamino)methyll- 1 ,4-dihydroindeno Fl ,2-clpyrazol-3-yl }- 1 , 1 -biphenyl-4-ol The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 52A and Example 29 A in Example ID. MS (DCI/NH3) m/z: 424.2 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 0.97 (s, 9 H), 2.67-2.81 (m, 2 H), 3.95 (s, 2 H), 4.20-4.38 (m, 2 H), 6.88 (d, J=8.48 Hz, 2 H), 7.46 (dd, J=7.97, 1.53 Hz, 1 H), 7.57 (d, J=8.81 Hz, 2 H), 7.66 (d, J=7.80 Hz, 1 H), 7.73 (d, 3=8.48 Hz, 2 H), 7.82-7.88 (m, 2 H), 7.91 (s, 1 H), 8.57 (s, brd, 1 H).
Example 54 4-{7-F(methylamino)carbonyll-l,4-dihvdroindenoFl,2-c1pyrazol-3-yl|benzoic acid
Example 54A 3-Iodo- 1 ,4-dihvdro-indeno F 1 ,2-clpyrazole-7-carboxylic acid The desired product was prepared by replacing Example 2B with Example 44B in Example 26A. MS (DC-7NH3) m/z: 326.9 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 3.62 (s, 2 H), 7.66 (d, 3=7.80 Hz, 1 H), 7.90 (dd, J=7.97, 1.53 Hz, 1 H, 8.12 (d, J=1.36 Hz, 1 H).
Example 54B 3 -Iodo-1 ,4-dihvdro-indeno Fl ,2-clpyrazole-7-carboxylic acid methylamide The desired product was prepared by replacing Example 22D and NH C1 with Example 54 A and methylamine in Example 23. MS (DCI/NH3) m/z: 339.9 (M+H)+; 1H NMR (300 MHz, DMSO- dg) δ 2.79 (s, 1.2 H), 2.81 (s, 1.8 H), 3.55 (s, 0.8 H), 3.60 (s, 1.2 H), 7.60 (d, 3=7.12 Hz, 1 H), 7.77 (m, 1 H), 8.08 (m, 1 H), 8.52 (d, J=3.73 Hz, 1 H), 13.21 (s, 0.6 H), 13.54 (s, 0.4 H).
Example 54C 4-(7-Ffmethylamino)carbonyll-l,4-dihydroindenoFl,2-c1pyrazol-3-yl}benzoic acid The desired product was prepared by replacing Example IC with Example 54B in Example ID. The microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID. MS (DCI/NH3) m/z: 334.1 (M+H)+; !H NMR (500 MHz, DMSO-dg) δ 2.82 (d, J=4.41 Hz, 3 H), 3.98 (s, 2 H), 7.66 (d, 3=7.80 Hz, 1 H), 7.81 (d, 3=8.73 Hz, 1 H), 7.94 (d, 3=8.11 Hz, 2 H), 8.06 (d, J=8.11 Hz, 2 H), 8.16 (s, 1 H), 8.53 (d, J=4.37 Hz, 1 H), 12.99 (s, 0.4 H), 13.49 (s, 0.6 H).
Example 55 3- F4-(aminocarbonypphenyll -N-methyl- 1 ,4-dihydroindeno F 1 ,2-c1pyrazole-7-carboxamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 54B and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzamide in Example ID. The microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID. MS (DCI/NH3) m/z: 333.6 (M+H)+; !H NMR (500 MHz, DMSO-dg) δ 2.82 (d, 3=4.41 Hz, 3 H), 3.98 (s, 2 H), 7.65 (d, 3=7.80 Hz, 1 H), 7.81 (dd, 3=7.80, 1.56 Hz, 1 H), 7.89 (d, J=8.42 Hz, 2 H), 8.00 (d, J=8.42 Hz, 2 H), 8.16 (s, 1 H), 8.53 (d, J=4.68 Hz, 1 H).
Example 56 3-(4 -hydroxy- 1 , 1 -biphenyl-4-yl)-N-methyl- 1 ,4-dihvdroindeno F 1 ,2-clpyrazole-7-carboxamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 54B and Example 29A in Example ID. The microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID. MS (DCI/NH3) m/z: 382.1 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 2.82 (d, 3=4.41 Hz, 3 H), 3.96 (s, 2 H), 6.87 (d, J=8.48 Hz, 2 H), 7.57 (d, J=8.48 Hz, 2 H), 7.65 (d, J=7.80 Hz, 1 H), 7.73 (d, 3=8.48 Hz, 2 H), 7.81 (dd, 3=7.97, 1.53 Hz, 1 H), 7.86 (d, J=8.48 Hz, 2 H), 8.17 (s, 1 H), 8.55 (d, J=4.75 Hz, 1 H), 9.60 (s, brd, 1 H).
Example 57 4-{7-F(neopentylamino)carbonvn-l,4-dihvdroindenoFl,2-c1pyrazol-3-yl)benzoic acid
Example 57 A 3 -Iodo- 1 ,4-dihy dro-indeno \ 1 ,2-clp yrazole-7-carboxylic acid (2, 2-dimethyl-prop vP-amide The desired product was prepared by replacing Example 22D and NH4C1 with Example 54A and neophentylamine in Example 23. MS (DCI NH3) m/z: 396.0 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 0.92 (s, 9 H), 3.11 (s, 0.8 H), 3.13 (s, 1.2 H), 3.56 (s, 0.8 H), 3.61 (s, 1.2 H), 7.61 (d, J=7.80 Hz, 1 H), 7.79 (d, J=7.80 Hz, 1 H), 7.99 (s, 0.4 H), 8.13 (s, 0.6 H), 8.44 (s, brd, 1 H), 13.22 (s, brd, 0.6 H), 13.53 (s, brd, 0.4 H).
Example 57B 4-(7-F(neopentylamino)carbonyl1-l,4-dihydroindenoFl,2-c1pyrazol-3-yl)benzoic acid The desired product was prepared by replacing Example IC with Example 57A in Example ID. The microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID. MS (DCI/NH3) m/z: 390.1 (M+H)+; 1H NMR (300 MHz, DMSO-d6) δ 0.93 (s, 9 H), 3.15 (d, J=6.44 Hz, 2 H), 3.99 (s, 2 H), 7.66 (d, J=8.14 Hz, 1 H), 7.76-7.90 (m, 1 H), 7.95 (d, J=8.14 Hz, 2 H), 8.06 (d, 3=8.14 Hz, 2 H), 8.18 (s, 1 H), 8.47 (t, 3=6.44 Hz, 1 H).
Example 58 3-(4 -hydroxy- 1 , 1 '-biphenyl-4-vP-N-neopentyl- 1 ,4-dihydroindeno Fl ,2-clpyrazole-7-carboxamide The desired product was prepared by replacing Example IC and 4-carboxybenzene boronic acid with Example 57A and Example 29A in Example ID. The microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID. MS (DCI/NH3) m/z: 438.2 (M+H)4 1H NMR (500 MHz, DMSO-d6) δ 0.94 (s, 9 H), 3.15 (d, J=6.24 Hz, 2 H), 3.96 (s, 2 H), 6.88 (d, 3=8.42 Hz, 2 H), 7.57 (d, J=8.74 Hz, 2 H), 7.65 (d, J=8.11 Hz, 1 H), 7.73 (d, 3=8.11 Hz, 2 H), 7.82 (d, J=9.36 Hz, 1 H), 7.86 (d, J=8.42 Hz, 2 H), 8.19 (s, 1 H), 8.45 (t, 3=6.24 Hz, 1 H), 9.57 (s, brd, 1 H).
Example 59 4-(7- { r(trans-4-hvdroxycyclohexyPamino1carbonyl 1-1 ,4-dihydroindenoF 1 ,2-clpyrazol-3- vPbenzoic acid
Example 59A 3-Iodo- 1 ,4-dihydro-indenoFl ,2-clpyrazole-7-carboxylic acid (trans-4-hydroxy-cvclohexyP- amide The desired product was prepared by replacing Example 22D and NH4CI with Example 54A and trans-4-amino-cyclohexanol in Example 23. MS (DCI/NH3) m/z: 424.0 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 1.09-1.50 (m, 2 H), 1.72-1.92 (m, 4 H), 3.39 (m, 1 H), 3.55 (s, 0.8 H), 3.60 (s, 1.2 H), 3.66-3.82 (m, 1 H), 4.55 (d, J=4.41 Hz, 1 H), 7.59 (m, 1 H), 7.77 (t, 3=7.46 Hz, 1 H), 7.98 (s, 0.4 H), 8.12 (s, 0.6 H), 8.28 (d, J=8.14 Hz, 1 H), 13.21 (s, 0.6 H) 13.53 (s, 0.4 H).
Example 59B 4-(7-{ F( frans-4-hvdroxycyclohexyDaminolcarbonyl 1-1 ,4-dihvdroindenoF 1 ,2-clpyrazol-3- y benzoic acid The desired product was prepared by replacing Example IC with Example 59A in Example ID. The microwave-assisted reaction was run for 900 seconds instead of 450 seconds in Example ID. MS (DCI/NH3) m/z: 418.1 (M+H)+; 1H NMR (500 MHz, DMSO-dg) δ 1.20-1.32 (m, 2 H), 1.35-1.47 (m, 2 H), 1.79-1.90 (m, 4 H), 3.36 (m, 1 H), 3.76 (m, 1 H), 3.97 (s, 2 H), 7.64 (d, 3=7.80 Hz, 1 H), 7.81 (d, 3=7.80 Hz, 1 H), 7.94 (d, 3=8.11 Hz, 2 H), 8.05 (d, J=8.42 Hz, 2 H), 8.17 (s, 1 H), 8.29 (d, J=7.80 Hz, 1 H).
Example 60 6-F6-(allyloxy -l ,4-dihydroindenoFl ,2-clpyrazol-3-yllnicotmic acid
Example 60A methyl 6-FF5-(allyloxy)-l-oxo-l,3-dihvdro-2H-inden-2-ylidene1(hydroxy)methyllnicotinate The desired product was prepared by replacing terephthalic acid monomethyl ester with 5- (methoxycarbonyl)-2-pyridinecarboxylic acid in Example 22B.
Example 60B methyl 6-r6-(allyloxy)-l,4-dihydroindenoFl,2-clpyrazol-3-yl1meotmate The desired product was prepared by replacing Example 22B with Example 60A in Example
22C.
Example 60C 6-r6-(allyloxy -l,4-dihvdroindenoFl,2-clpyrazolC3-vnnicotinic acid The desired product was prepared by replacing Example 22C with Example 60B in Example 22D. MS (DCI/NH3) m/z: 334.0 (M+H)+; *H NMR (500 MHz, DMSO-dg) δ 3.88 (s, 2 H), 4.63 (d, J=4.99 Hz, 2 H), 5.28 (d, J=10.61 Hz, 1 H), 5.43 (d, J=17.47 Hz, 1 H), 6.08 (m, 1 H), 6.97 (dd, J=8.27, 2.03 Hz, 1 H), 7.22 (s, 1 H), 7.56 (d, J=8.11 Hz, 1 H), 7.94 (s, 1 H), 8.36 (d, J=8.11 Hz, 1 H), 9.12 (s, 1 H), 13.40 (s, brd, 1 H). Example 61 6-(6-hydroxy- 1 ,4-dihvdroindeno F 1 ,2-c1pyrazol-3 -vPnicotinic acid
Example 61 A methyl 6-(6-hydroxy-l,4-dihvdroindenoFl,2-clpyrazol-3-yl)nicotinate
The desired product was prepared by replacing Example 22C with Example 60B in Example 24.
Example 6 IB 6-(6-hydroxy- 1 ,4-dihydroindeno Fl ,2-c1pyrazol-3-yl)nicotinic acid The desired product was prepared by replacing Example 22C with Example 61 A in Example 22D. MS (DCI/NH3) m/z: 294.0 (M+H)+; 1H NMR (300 MHz, DMSO-d6) δ 3.83 (s, 2 H), 6.78 (dd, J=8.14, 2.37 Hz, 1 H), 7.00 (d, J=2.03 Hz, 1 H), 7.45 (d, J=8.14 Hz, 1 H), 7.92 (d, J=8.14 Hz, 1 H), 8.36 (dd, 3=8.14, 2.03 Hz, 1 H), 9.11 (d, J=2.03 Hz, 1 H), 9.50 (s, brd, 1 H).
Example 62 6-(allyloxy)-3- F4-( lH-tetraazol-5-vPphen yll- 1 ,4-dihvdroindeno F 1 ,2-clp yrazole
Example 62A 4-FF5-(allyloxy)-l-oxo-l,3-dihydro-2H-inden-2-ylidenel(hydroxy)methyllbenzonitrile The desired product was prepared by replacing terephthalic acid monomefhyl ester with 4- cyanobenzoic acid in Example 22B.
Example 62B 4-(6-Allyloxy-l,4-dihydro-indenoFl,2-clpyrazol-3-yl)-benzonitrile The desired product was prepared by replacing Example 22B with Example 62A in Example 22C. MS (DCI/NH3) m/z: 314.1 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 3.85 (s, 0.8 H), 3.90 (s, 1.2 H), 4.46-4.68 (m, 2 H), 5.28 (dd, 3=10.51, 1.70 Hz, 1 H), 5.43 (dd, 3=17.29, 2.03 Hz, 1 H), 6.09 (m, 1 H), 6.97 (m, 1 H), 7.16-7.28 (m, 1 H), 7.46-7.65 (d, J=8.48 Hz, 1 H), 7.87-8.08 (m, 4 H), 13.31 (s, brd, 1 H). Example 62C 6-(allyloxy)-3-r4-(lH-tetraazol-5-yl)phenvn-l,4-dihydroindenoFl,2-clpyrazole A mixture of Example 62B (61.5 mg, 0.196 mmol), NaN3 (19.1 mg, 0.294 mmol), and Et3N.HCl (40.5 mg, 0.294 mmol) in DMF (2 mL) was heated at 140 °C for 4 hours. To this mixture were added more NaN3 (60.0 mg) and Et3N.HCl (120 mg). The reaction mixture was stirred overnight, cooled, and concentrated. The crude material was purified using the HPLC condition in Example 8 to give 20.0 mg (29%) of the desired product as brown solid. MS (DCI/NH3) m/z: 357.1 (M+H)+; 1H NMR (300 MHz, DMSO-dg) δ 3.90 (s, 2 H), 4.53-4.71 (m, 2 H), 5.29 (dd, J=10.51, 1.70 Hz, 1 H), 5.44 (dd, 3=17.29, 2.03 Hz, 1 H), 6.07 (m, 1 H), 6.98 (dd, J=8.31, 2.20 Hz, 1 H), 7.22 (d, J=2.03 Hz, 1 H), 7.57 (d, J=8.14 Hz, 1 H), 8.02 (d, 3=8.14 Hz, 2 H), 8.16 (d, J=8.48 Hz, 2 H), 13.22 (s, brd, 1 H).
Example 63 4-(6-{F(trans-4-methylcvclohexyPaminolmethyll-l,4-dihvdroindenori,2-clpyrazol-3-yl)phenol The desired product was prepared by replacing 4-carboxybenzene boronic acid with 4-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol in Example ID. MS (DCI/NH3) m/z: 374.2 (M+H)+; 1H NMR (300 MHz, CD3OD) δ 0.95 (d, 3=6.44 Hz, 3 H), 1.00-1.18 (m, 2 H), 1.35- 1.56 (m, 3 H), 1.81-1.95 (m, 2 H), 2.15-2.30 (m, 2 H), 3.12 (m, 1 H), 3.88 (s, 2 H), 4.28 (s, 2 H), 6.91 (d, 3=8.82 Hz, 2 H), 7.49 (d, 3=7.80 Hz, 1 H), 7.63 (d, 3=8.82 Hz, 2 H), 7.69 (s, 1 H), 7.79 (d, J=7.80 Hz, 1 H).
Example 64 4'-(6,7-dimethoxy-l,4-dihydroindenoFl,2-clpyrazol-3-yl)-l, -biphenyl-4-ol
Example 64A (4-Bromophenyl)-imidazol- 1 -yl-methanone 4-Bromobenzoic acid (lOg, 50 mmol) in 50 ml of DMF was treated with carbonyl- 1,1'- dii idazole (18 g, 112.5 mmol). The mixture was stirred for 3 hours and poured into water. The mixture was filtered and the filter cake washed with water and dried to provide the title compound. MS (DCI/NH3) m/z: 252.9 (M+H)+. 1H NMR (300 MHz, DMSO-Dg) δ ppm 7.17 (dd, J=1.65, 0.81 Hz, 1 H) 7.69 (t, J=1.48 Hz, 1 H) 7.77 (m, 2 H) 7.83 (m, 2 H) 8.21 (dd, 3=1.36, 0.85 Hz, 1 H).
Example 64B 2-(4-Bromobenzoyl)-5 ,6-dimethoxy-indan- 1 -one 5,6-Dimethoxy-indan-l-one (2 g, 10.4 mmol) in 25 ml of THF was treated with NaH (60%, 624 mg, 15.6 mmol) at 0 °C. After the suspension was stirred at room temperature for 1 hour, the mixture was treated with Example 64A (2.61 g, 10.4 mmol) in 5 ml of THF dropwise. After stirring for 3 hours at room temperature, the mixture was poured into water and acidified with hydrochloric acid. The mixture was filtered and the filter cake was washed with water and recrystallized from ethanol to provide the title compound. MS (DCI/NH3) m/z: 375.0 (M+H)+.
Example 64C 3-(4-Bromophenyl)-6,7-dimethoxy- 1 ,4-dihydroindeno F 1 ,2-clpyrazole Example 64B (820 mg, 2.18 mmol), hydrazine monohydrate (0.127mL, 2.63 mmol), and acetic aicd (0.15 ml, 2.63 mmol) were combined in 30 ml of ethanol and heated at 90 °C for 6 hours. The mixture was allowed to cool to room temperature and filtered. The filter cake was dried to provide the title compound. MS (DCI/NH3) m/z: 373.0 (M+H)+. 1H NMR (300 MHz, DMF-D7) δ ppm 3.84 (s, 2 H), 3.89 (s, 3 H), 3.93 (s, 3 H), 7.31 (s, 1 H), 7.34 (s, 1 H), 7.71 (d, J = 8.48 Hz, 2 H), 7.89 (d, J = 8.48 Hz, 2 H), 13.17 (s, 1 H).
Example 64D 4'-(6,7-dimethoxy- 1 ,4-dihydroindenoFl ,2-c|pyrazol-3-yl)- 1 , 1 -biphenyl-4-ol Example 64C (50 mg, 0.14 mmol)), 4-hydroxylphenyl boronic acid (23.3 mg, 0.17 mmol), Na2C03 (1 M, 0.3 mL), and Pd(PPh3)2Cl2 (9.9 mg, 0.014mmol) were combined in DME:EtOH:H20 (7:2:3, 1.5 mL) in a capped 2 mL vial and heated at 160 °C for 600 seconds in a Smith Synthesizer. The mixture was cooled using 40 psi pressurized air, the solvents were evaporated, and the residue was purified using preparative HPLC (for conditions, see Example ID) to provide the title compound. MS (DCI/NH3) m/z: 385.1 (M+H)+. 1H NMR (500 MHz, DMSO-D6) δ ppm 3.79 (s, 2 H), 3.82 (s, 3 H), 3.85 (s, 3 H), 6.87 (d, 3=8.66 Hz, 2 H), 7.23 (s, IH), 7.25 (s, IH), 7.57 (d, 3=8.66 Hz, 2 H), 7.71 (d, 3=8.34 Hz, 2 H), 7.82 (d, J=8.42 Hz, 2 H), 9.55 (s, 1 H).
Example 65 6,7-dimethoxy-3 - F4-( 1 H-tetraazol-5 -yDphenyll - 1 ,4-dihvdroindeno F 1 ,2-clpyrazole Example 64C (50 mg, 0.14 mmol)), zinc cyanide (17.4 mg, 1.48 mmol), and Pd(PPh3)4 (15.6 mg, 0.014mmol) were combined in DMF (3 mL) in a capped 5 mL vial and heated at 180 °C for 300 seconds in a Smith Synthesizer. The mixture was cooled using 40 psi and then treated with sodium azide (105.3 mg, 1.62 mmol) and NH4C1 (87 mg, 1.62 mmol). The vial was recapped and heated at 220 °C for 15 minutes. After the reaction mixture was cooled using 40 psi pressurized air, the solvent was removed and the residue was purified using preparative HPLC (for conditions, see Example ID) to provide the title compound. MS (DCI/NH3) m/z: 361.0 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.83 (s, 2 H), 3.84 (s, 3 H), 3.85 (s, 3 H), 7.24 (s, 1 H), 7.26 (s, 1 H), 8.01 (d, 3=8.42 Hz, 2 H), 8.15 (d, J=8.42 Hz, 2 H).
Example 66 4-(6,7-dimethoxy-l,4-dihydroindenoFl,2-e]pyrazol-3-yl)benzoic acid Example 64C (78 mg, 0.21 mmol), PdCl2(dppf)-CH2Cl2 (18 mg), triethyl amine (0.088 mL), were combined in THF (98 mL) and H 0 (1 mL) and stirred under a CO atmosphere (500 psi) at 120 °C for 16 hours. The mixture was allowed to cool to room temperature, concentrated under reduced pressure and the residue was purified by HPLC (for conditions, see Example ID) to provide the title compound. MS (DCI/NH3) m/z: 337.0 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.81 (s, 2 H), 3.82 (s, 3 H), 3.84 (s, 3 H), 7.23 (s, 1 H), 7.25 (s, 1 H), 7.91 (d, J=8.30Hz, 2 H), 8.04 (d, J=8.30 Hz, 2 H).
Example 67 4-(4-hydroxy- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-3-yl)benzoic acid
Example 67A 2-(4-bromobenzoyl)-lH-indene-l,3(2H)-dione Methanol (8.5 ml) was treated with sodium (4.8 g) in benzene (90 mL). The reaction mixture was refluxed overnight, allowed to cool to room temperature, and treated with phthalic acid dimethyl ester (38.84 g) and l-(4-bromophenyl)ethanone (39.81 g) in benzene (50 mL). Distillation of the reaction mixture was performed at 80 °C overnight to remove methanol. The reaction mixture was poured into diluted HC1 and filtered. The filter cake was collected and recrystallized from ethanol to provide the title compound.
Example 67B 3 -(4-bromophenyl)indeno F 1 ,2-clp yrazol-4( 1 H)-one Example 67A (5.8 g) and hydrazine monohydrate (0.982 ml, 20.24 mmol) were combined in ethanol (300 mL) and refluxed at 90 °C overnight. The mixture was allowed to cool to room temperature and was filtered. The filter cake was dried to provide the title compound. MS (DCI/NH3) m/z: 327.3 (M+H)+.
Example 67C butyl 4-(4-oxo- 1 ,4-dihydroindeno Fl ,2-clpyrazol-3-vPbenzoate Pd(OAc)2 (3.5 mg), Ph3P (16 mg), DIEA (2.6 ml), and Example 67B (100 mg) were combined in butanol and treated with a stream of CO for 5 minutes. The mixture was stirred at 120 °C overnight under a CO atmosphere. The mixture was allowed to cool to room temperature, concentrated, and the residue was purified by silicon gel chromatography using a mixture of hexane and ethyl acetate as eluent to provide the title compound. MS (DCI/NH3) m/z: 347.0 (M+H)+.
Example 67D 4-(4-hydroxy- 1 ,4-dihvdroindeno F 1 ,2-clpyrazol-3-vPbenzoic acid Example 67C (51 mg) in 2 ml of THF/MeOH (1:1) was treated with NaBH4 (5.6 mg) at 0 °C. The reaction mixture was allowed to warm to room temperature and stir for 1 hour. The mixture was concentrated and the residue was suspended in THF (1 mL), MeOH (2 mL), and aqueous NaOH (IN, 1 mL). After stirring at 60 °C for 2 hours, the mixture was concentrated and the residue was purified by HPLC to provide the title compound. MS (DCI/NH3) m/z: 293.3 (M+H)+. 1H NMR (400 MHz, DMSO-Dg) δ ppm 5.59 (d, 3=8.67 Hz, 1 H), 5.84 (d, 3=8.67 Hz, IH), 7.33 (m, 2 H), 7.54 (d, J=7.13 Hz, 1 H), 7.59 (d, J=7.29 Hz, 1 H), 8.03 (d, 3=8.44 Hz, 2H), 8.10 (d, J=8.44, 2H), 13.19 (s, IH).
Example 68 4-F6-(mo holin-4-ylmethyP-l,4-dihydroindenoFl,2-c1pyrazol-3-yn-l,r-biphenyl-4-ol
Example 68A l,4-dihvdroindenoF1.2-c1pyrazole-6-carbaldehyde To a solution of 6-bromo-l,4-dihydro-indeno[l,2-c]pyrazole (0.100 g, 0.425 mmol, see U.S. Patent 6297238 for preparation) in THF (3 mL) at -78 °C was added PhLi in cyclohexane/ether (1.8 M, 0.71 mL, 1.28 mmol) followed by s-BuLi in cyclohexane (1.3 M, 0.98 mL, 1.28 mmol) 30 minutes later. The reaction mixture was stirred at -78 °C for 60 minutes and DMF (0.33 mL, 4.25 mmol) was added. The dry ice bath was removed after 30 minutes. After an additional 30 minutes, the reaction was quenched with water. The reaction mixture was extracted with EtOAc, washed with 50% brine, dried over MgS0 , filtered, and concentrated. The concentrate was purified by flash chromatography eluted with EtOAc/hexane (7:3 to 8:2) to give 0.053 g (68%) of the desired product as brown solid. MS (DCI NH3) m/z: 185.0 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 3.76 (s, 2 H), 7.63 (s, 1 H), 7.62-7.97 (m, 2 H), 8.04 (s, 1 H), 10.00 (s, 1 H).
Example 68B 3-iodo-1.4-dihvdromdenoFl,2-elpyrazole-6-earbaldehyde A suspension of Example 68A (7.90 g, 0.0429 mol) and N-iodosuccinimide (11.6 g, 0.0515 mol) in DMF (150 mL) was heated at 80 °C for 5.5 hours. The reaction was cooled and the solvent was evaporated. The concentrate was triturated with EtOAc and ether to give 7.20 g of brown solid as the desired product. The filtrate was concentrated and purified by flash chromatography eluted with EtOAc/hexane (7:3) to give 1.30 g of the desired product (combined yield: 64%). MS (DCI/NH3) m/z: 310.9 (M+H)+; !H NMR (300 MHz, DMSO-Dg) δ ppm 3.63 (s, 0.8 H), 3.68 (s, 1.2 H), 7.72 (d, 3=7.46 Hz, 0.5 H), 7.83 (d, J=7.80 Hz, 0.5 H), 7.96 (m, 1 H), 8.07 (m, 1 H), 10.03 (s, 1 H), 13.45 (s, 0.6 H), 13.72 (s, 0.4 H).
Example 68C 3-iodo-6-(morpholin-4-ylmethvP- 1 ,4-dihvdroindeno Fl ,2-clpyrazole A mixture of Example 68B (1.00 g, 3.22 mmol), morpholine (0.84 mL, 9.66 mmol), and TsOH.H2O (61.2 mg, 0.322 mmol) in toluene (50 mL) was heated to refluxing overnight. The solvent was evaporated. To the resulting residue were added EtOH (40 mL), THF (10 mL), and NaBH4 (0.182 g, 4.83 mmol) at room temperature. The mixture was stirred overnight and the solid was filtered. The filtrate was concentrated, treated with IN HC1, and extracted with EtOAc. The aqueous layer was basified using 3N NaOH and extracted with EtOAc. The organic layer was dried over MgSO4, filtered, and concentrated. The residue was purified by flash chromatography eluted with EtOAc/MeOH (95:5) to give 0.387 g (32%) of the desired product as pale yellow solid. MS (DCI/NH3) m/z: 382.0 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 2.44-2.51 (m, 4 H), 3.53 (s, 2 H), 3.57 (s, 2 H), 3.66-3.72 (m, 4 H), 7.34 (d, 3=8.14 Hz, 1 H), 7.54 (s, 1 H), 7.58 (d, 3=7.80 Hz, 1 H).
Example 68D 4'-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-vP-l,l -biphenyl-4-ol A mixture of 4'-bromo-biphenyl-4-ol (0.300 g, 1.20 mmol), bis(pinacolato)diboron (0.336 g, 1.32 mmol), PdCl2(dppf).CH2Cl2 (0.0293 g, 3%), dppf (0.0199 g, 3%), and KOAc (0.353 g, 3.60 mmol) in 1,4-dioxane (6 mL) was heated at 90 °C overnight. The reaction mixture was concentrated and the residue was extracted with EtOAc, washed with brine, dried over MgS0 , filtered, concentrated, and purified by flash chromatography eluted with hexane/EtOAc (1:1) to give 0.278 g (78%) of the desired product as white foam. MS (DCI/NH3) m/z: 296.1 (M+H)+; 1H NMR (300 MHz, CDC13) δ ppm 1.27 (s, 4 H), 1.36 (s, 8 H), 6.90 (d, J=8.48 Hz, 2 H), 7.53 (dd, 3=12.72, 8.65 Hz, 4 H), 7.85 (d, J=8.14 Hz, 2 H).
Example 68E 4'-(6-morpholin-4-ylmethyl- 1 ,4-dihydro-indenoF 1 ,2-c1pyrazol-3-yl)-biphenyl-4-ol A mixture of Example 68C (60.0 mg, 0.157 mmol), Example 68D (51.2 mg, 0.173 mmol), Na2CO3 (1 M, 0.22 mL, 0.220 mmol), and Pd(PPh3)2Cl2 (11.0 mg, 0.0157 mmol) in DME/EtOH/H2O (7:2:3, 1.4 mL) in a capped 2 mL vial was heated to 160 to 170 °C for 450 to 600 seconds in a Smith Synthesizer (300W). The reaction was cooled using 40 psi pressurized air. Solvents were evaporated and the crude product was purified using preparative HPLC to give 22.9 mg (22%) of the desired product as TFA salt. The purification was processed on a Phenomenex® C18 column (250 mm X 21.2mm, 5 μm particle size) using a gradient of 0% to 70% acetonitrile : 0.1% aqueous TFA over 46 min at a flow rate of 25 mL/min.
Examples 69 to 83, represented by Figure (I) and listed in Table 1, were synthesized in a similar fashion as that described in Example 68E.
Figure (I) Table 1
Example 84 4'-[6-(morpholin-4-ylcarbonyl)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]-l, -biphenyl-4-ol
Example 84A 3-iodo-l,4-dihydroindenoFl,2-clpyrazole-6-carboxylic acid A mixture of Example 68B (3.00 g, 9.67 mmol), KH2PO4 (5.26 g, 0.0387 mol), and H2NSO3H (1.41 g, 0.0145 mol) in l,4-dioxane/H2θ (100/30 mL) was stirred at 0 °C for 15 minutes. To this mixture was added NaC102 (1.14 g, 0.0126 mol) in H20 (15 mL) dropwise. The reaction mixture was stirred for 15 minutes at 0 °C followed by the addition of NaHS03 (1.11 g, 0.0106 mol). The resulting suspension was warmed to room temperature and stirred for 1 hour. The reaction mixture was treated with N 2S203 solution and concentrated to remove most of the solvents. Water was added to the resulting slurry and the suspension was stirred for 1 hour. The solid material was filtered, rinsed with water, and dried in a vacuum oven to give 3.49 g of the desired product as yellow solid. This product was used in the following step without further purification. MS (DCI/NH3) m/z: 327.0 (M+H)+; 1H NMR (300 MHz, DMSO- Dg) δ ppm 3.57 (s, 2 H), 7.67 (m, 1 H), 7.98 (d, J=7.80 Hz, 1 H), 8.10 (s, 1 H). Example 84B 3-iodo-6-(morpholin-4-ylcarbonyl)-l,4-dihydroindenoFl,2-clpyrazole A mixture of Example 84A (0.210 g, 0.644 mmol), PyBOP (0.503 g, 0.966 mmol), morpholine (0.084 mL, 0.966 mmol), and diisopropylethylamine (0.39 mL, 2.25 mmol) in DMF (5 mL) was stirred at room temperature overnight. The reaction mixture was diluted with EtOAc and washed with water and NaHCO3. The organic layer was dried over MgSO , filtered, concentrated, and purified by flash chromatography eluted with EtOAc to give 0.122 g (48%) of the desired product as red solid. MS (DCI/NH3) m/z: 396.0 (M+H)+; 1H NMR (300 MHz, DMSO-Dg) δ ppm 3.46-3.67 (m, 10 H) 7.41 (m, 1 H) 7.59 (s, brd, 1.5 H) 7.67 (d, J=7.46 Hz, 0.5 H).
Example 84C 4 - F6-(morpholin-4-ylcarbonvP- 1 ,4-dihvdroindeno F 1 ,2-clpyrazol-3-yll- 1 , 1 '-biphenyl-4-ol The desired product was prepared by substituting Example 68C with Example 84B in Example 68E. The reaction temperature and time were raised to 180 °C and 1000 seconds, respectively.
Example 85 N-cyclohexyl-3-(4 -hydroxy- 1 , 1 '-biphenyl-4-vP- 1 ,4-dihydroindeno Fl ,2-clpyrazole-6- carboxamide
Example 85A N-cyclohexyl-3-iodo- 1 ,4-dihydroindenoF 1 ,2-clpyrazole-6-carboxamide A mixture of Example 84A (0.359 g, 1.07 mmol), HOBt (0.218 g, 1.61 mmol), EDC (0.308, 1.61 mmol), cyclohexylamine (0.18 mL, 1.61 mmol), and Et3N (0.22 mL1.61 mmol) in DMF (8 mL) was stirred at room temperature overnight. The reaction mixture was diluted with EtOAc and washed with NaHC03 and brine. The organic layer was dried over MgSO , filtered, concentrated, and triturated with ether to give 0.216 g (50%) of the desired product as yellow solid. MS (DCI/NH3) m/z: 408.0 (M+H)+; 1H NMR (300 MHz, DMSO-Dg) δ ppm 1.09-1.44 (m, 5 H) 1.58-1.91 (m, 5 H) 3.48-3.67 (m, 2 H) 3.77 (m, 1 H) 7.61 (m, 1 H) 7.86 (d, 3=7.46 Hz, 1 H) 8.02 (s, 1 H) 8.23 (d, 3=8.14 Hz, 1 H) 13.27 (s, 0.5 H) 13.58 (s, 0.5 H).
Example 85B N-cyclohexyl-3-(4'-hydroxy- 1 , 1 '-biphenyl-4-vD- 1 ,4-dihydroindenoF 1 ,2-clpyrazole-6- carboxamide The desired product was prepared by substituting Example 68C with Example 85A in Example 68E. The reaction temperature and time were raised to 180 °C and 1000 seconds, respectively.
Examples 86 to 97, represented by Figure (II) and listed in Table 2, were synthesized in a similar fashion as described in Example 84C or 85B.
H
Figure (II)
Table 2
Example 98 N-F3-(4'-hydroxy-l,r-biphenyl-4-yl)-l,4-dihvdroindenoFl,2-clpyrazol-6-yll-2-moi'pholin-4- ylacetamide
Example 98A 6-bromo- 1 - ( F2-(trimethylsilvPethoxylmethyl I - 1 ,4-dihydroindeno F 1 ,2-clpyrazole and 6-bromo-2-{ r2-(trimethylsilyl)ethoxylmethyll-2,4-dihydroindenoFl,2-c1pyrazole To a solution of 6-bromo-l,4-dihydro-indeno[l,2-c]pyrazole (4.08 g, 0.0174 mol, see U.S. Patent 6297238 for preparation) in DMF (100 mL) at 0 °C was added NaH (60%, 0.764 g, 0.0191 mol). After 20 minutes, SEMC1 (3.4 mL, 0.0191 mol) was added to the above mixture and the ice bath was removed. The reaction was quenched with water 3.5 hours later. The reaction mixture was diluted with EtOAc and washed with brine. The organic layer was dried over MgS04, filtered, concentrated, and purified by flash chromatography eluted with EtOAc/hexane (2:8) to give 5.14 g (81%) of the desired products as brown oil. MS (DCI/NH3) m/z: 365.0 (M+H)+; 1H NMR (300 MHz, CDC13) δ ppm 0.00-0.02 (m, 9 H) 0.89-0.98 (m, 2 H) 3.59-3.68 (m, 4 H) 5.52 (s, 1.3 H) 5.68 (s, 0.7 H) 7.51 (m, 2.4 H) 7.67 (m, 1.6 H).
Example 98 B N-d - ( FΣ-ftrimethylsilvDethoxyl methyl 1-1 ,4-dihydroindeno Fl ,2-clpyrazol-6-yl)acetamide To a solution of Example 98A (5.77 g, 0.0158 mol) in degassed 1,4-dioxane (50 mL) were added Pd(OAc)2 (70.9 mg, 2 mol%), Xantphos (274 mg, 3 mol%), Cs2CO3 (7.72 g, 0.0237 mol), and acetamide (1.12 g, 0.0190 mol). The mixture was heated at 100 °C overnight and cooled. The solvent was evaporated and the residue was extracted with EtOAc, washed with water, brine, NaHCO3, dried over MgSO4, filtered, concentrated, and purified by flash chromatography eluted with EtOAc/hexane (6:4 to 8:2) to give 4.06 g (75%) of the desired product as yellow solid. MS (DCI/NH3) m/z: 344.1 (M+H)+; 1H NMR (300 MHz, CDC13) δ ppm 0.00-0.02 (m, 9 H) 0.94 (dd, 3=16.44, 8.31 Hz, 2 H) 2.23 (s, 3 H) 3.60-3.68 (m, 4 H) 5.51 (s, 1.3 H) 5.67 (s, 0.7 H) 7.35 (m, 1 H) 7.45 (d, 3=7.46 Hz, 1 H) 7.60 (d, J=8.14 Hz, 0.4 H) 7.73 (d, 3=8.14 Hz, 0.6 H) 7.91 (d, 3=12.21 Hz, 1 H)
Example 98C l,4-dihydroindenoFl,2-clpyrazol-6-amine To a solution of Example 98B (1.96 g, 5.71 mmol) in EtOH (25 mL) was added cone. HC1 (1.5 mL). The mixture was heated at 80 °C for 7 hours and cooled. The solvent was evaporated and the residue was dissolved in water and washed with EtOAc. The aqueous layer was basified with 3N NaOH until pH=9 and extracted with EtOAc (2X). The combined organic layers were dried and concentrated to give the desired product (0.920 g, quantitative yield) as yellow foam. MS (DCI/NH3) m/z: 172.0 (M+H)+;
1H NMR (300 MHz, DMSO-Dg) δ ppm 3.44 (s, 2 H) 5.10 (s, 2 H) 6.52 (dd, 3=8.14, 2.03 Hz, 1 H) 6.71 (s, 1 H) 7.26 (d, 3=8.14 Hz, 1 H) 7.48 (s, 1 H) 12.27 (s, 1 H).
Example 98D 2-chloro-N- 1 ,4-dihydroindeno Fl ,2-clpyrazol-6-ylacetamide To a solution of Example 98C (0.250 g, 1.46 mmol) in acetone (10 mL) were added saturated NaHCO3 solution (5 mL) and chloroacetyl chloride (0.13 mL, 1.61 mmol). The mixture was heated at 50 °C for 90 minutes and cooled. The solvent was partially evaporated and water was added to the suspension. The solid was filtered, washed with water, and dried to give the desired product (0.280 g, 78%) as off-white solid. A small amount of the product (30 mg) was further purified using reversed-phase HPLC to afford an analytical sample. MS (DCI/NH3) m/z: 248.0 (M+H)+; 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.62 (s, 2 H) 4.27 (s, 2 H) 7.52 (d, 3=8.42 Hz, 1 H) 7.58 (m, 1 H) 7.61 (s, 1 H) 7.85 (s, 1 H) 10.34 (s, 1 H).
Example 98E 2-chloro-N-(3-iodo-l,4-dihvdroindenoFl,2-c1pyrazol-6-vPacetamide To a solution of Example 98D (0.140 g, 0.565 mmol) in DMF (3 mL) was added NIS (0.153 g, 0.678 mmol) and the mixture was heated at 80 °C for 4 hours and cooled. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was washed water, brine, dried, filtered, and concentrated, and purified by flash chromatography eluted with EtOAc/hexane (7:3 to 9:1) to give 47 mg of the desired product as brown solid. MS (DCI/NH3) m/z: 373.9 (M+H)+; 1H NMR (300 MHz, DMSO-Dg) δ ppm 3.53 (s, 2 H) 4.26 (s, 2 H) 7.52 (s, brd, 2 H) 7.87 (s, 1 H) 10.38 (s, 1 H).
Example 98F N-O-iodo-l -dihydroindenoF ∑-clpyrazol-ό-yP^-morpholin^-ylacetamide To a solution of Example 98E (44.5 mg, 0.119 mmol) in EtOH (2 mL) was added morpholine (31.3 μL). The mixture was heated at 60 °C for 4 hours and cooled. The solvent was evaporated and the residue was purified by flash chromatography eluted with EtOAc to give 39.5 mg (78%) of the desired product as yellow foam.
MS (DCI/NH3) m/z: 425.0 (M+H)+; 1H NMR (300 MHz, DMSO-Dg) δ ppm 2.51-2.53 (m, 4 H) 3.14 (s, 2 H) 3.51 (s, 2 H) 3.64 (m, 4 H) 7.50 (m, brd, 1 H) 7.59 (m, 1 H) 7.90 (s, 1 H) 9.81 (s, 1 H).
Example 98G N- F3-(4 -hydroxy- 1 , 1 -biphenyl-4-vP- 1 ,4-dihydroindeno F 1 , 2-clpyrazol-6-yll-2-morpholin-4- ylacetamide The desired product was prepared by substituting Example 68C with Example 98F in Example 68E.
Examples 99 to 103, represented by Figure (III) and listed in Table 3, were synthesized in a similar fashion as described in Example 98G.
H
Figure (III)
Table 3
Example 104 3-(4 -hydroxy-l, -biphenyl-4-yl)-7-methoxy-N-(pyridin-4-ylmethvP-l,4-dihydroindenoFl,2- clpyrazole-6-carboxamide
Example 104 A 2-(hvdroxymethylene -6-n ethoxyindan- 1 -one To a mixture of ethyl formate (15.75 mL, 0.195 mol) and NaH (60%, 7.80 g, 0.195 mol) in benzene (550 mL) was added a suspension of 6-methoxy-indan-l-one (15.81 g, 0.0974 mol) in benzene (150 mL) dropwise at 0 °C. The reaction mixture was stirred at room temperature overnight and treated with water. The solid was filtered, washed with water, and oven dried to give the desired product (16.86 g, 91%). The product may exist in sodium salt form, however, it was carried into the next reaction without further characterization. MS (DCI/NH3) m/z: 191.1 (M+H)+; 1H NMR (300 MHz, DMSO-Dg) δ ppm 3.50 (s, 2 H) 3.80 (s, 3 H) 7.13-7.20 (m, 2 H) 7.47 (d, J=8.14 Hz, 1 H) 7.74 (s, brd, 1 H).
Example 104B 7-methoxy- 1 ,4-dihydroindeno F 1 ,2-clpyrazole A mixture of Example 104A (16.86 g, 0.0886 mol), hydrazine monohydrate (5.2 mL, 0.106 mol), and AcOH (6.1 mL, 0.106 mol) in EtOH (375 mL) was heated at 90 °C for 2 hours. The solvent was evaporated and the residue was triturated with water and filtered. The filtering cake was triturated again with NaHC03 solution, filtered, washed with water, and oven dried to give the desired product (13.9 g, 84%). MS (DCI/NH3) m/z: 187.0 (M+H)+; 1H NMR (300 MHz, DMSO-Dg) δ ppm 3.52 (s, 2 H) 3.81 (s, 3 H) 6.81 (dd, 3=8.31, 2.54 Hz, 1 H) 7.17 (s, 1 H) 7.40 (d, 3=8.14 Hz, 1 H) 7.62 (s, 1 H) 12.71 (s, 1 H).
Example 104C 6-bromo-7-methoxy- 1 ,4-dihydroindeno F 1 ,2-clpyr azole To a solution of Example 104B (8.91 g, 0.0478 mol) in AcOH (150 mL) was added Br (3.43 mL, 0.0669). The reaction mixture was concentrated after 5 minutes and the residue was triturated into EtOAc and hexane, and then filtered. The solid was stirred in NaHCO3 solution and filtered, washed with water, and oven dried to give the desired product (11.99 g, 95%). The material with slight impurity was used in the next step without further purification. MS (DCI/NH3) m/z: 265.0 (M+H)+; 266.9 (M+H+2)+.
Example 104D 7-methoxy-l,4-dihvdroindenoFl,2-c]pyrazole-6-carbaldehyde To a suspension of Example 104C (5.49 g, 0.0207 mol) in THF (300 mL) was added PhLi (1.9 M, 21.8 mL, 0.0414 mol) at -78 °C. s-BuLi (1.4 M, 29.6 mL, 0.0414 mol) and DMF (12.8 mL, 0.166 mol) were added to the reaction mixture after 30 and 60 minutes, respectively. The mixture was stirred at -78 °C for 1 hour and the cold bath was removed. The reaction was quenched with saturated NH4C1 solution after 1 hour at room temperature. The mixture was extracted with EtOAc, washed with water, brine, dried over MgS04, filtered, concentrated, and triturated with ether to give 3.62 g (81%) of the desired product. MS (DCI/NH3) m/z: 215.1 (M+H)+; 1H NMR (300 MHz, DMSO-Dg) δ ppm 3.62 (s, 2 H) 4.01 (s, 3 H) 7.45 (s, 1 H) 7.73 (s, 1 H) 7.80 (s, 1 H) 10.37 (s, 1 H) 13.07 (s, 1 H).
Example 104E
3-iodo-7-m.et.hoxy- 1 ,4-dihydroindeno Fl ,2-c1pyrazole-6-carbaldehyde
The desired product was prepared by substituting Example 68 A with Example 104D in
Example 68B. After the reaction, the solvent was evaporated and the residue was triturated with ether to give the crude product, which was used in the next step without further purification. MS
(DCI/NH3) m/z: 340.9 (M+H)+.
Example 104F 3-iodo-7-methoxy-l,4-dihydroindenoFl,2-clpyrazole-6-carboxylic acid The desired product was prepared by substituting Example 68B with Example 104E in Example 84A. The crude product was used in the next step without further purification. MS (DCI NH3) m/z: 374.0 (M+NH4)+.
Example 104G The desired product was prepared by substituting Example 84A and cyclohexylamine with Example 104F and 4-(aminomethyl)pyridine in Example 85 A. The slightly impure product was used in the next step without further purification. MS (DCI/NH3) m/z: 447.0 (M+H)+. The formation of tertiary amides in this step towards corresponding final compounds listed in Table 4 was done following the protocol in Example 84B.
Example 104H 3-(4'-hydroxy- 1 , 1 -biphenyl-4-yP-7-methoxy-N-(pyridin-4-ylmethyP-l ,4-dihydroindenoF 1 ,2- clpyrazole-6-carboxamide The desired product was prepared by substituting Example 68C with Example 104G in Example 68E.
Example 105 4-(6-I F(2-hydroxyethyl)arnino1methyl)-7-methoxy-l,4-dihvdroindenoFl,2-clpyrazol-3-yl)-l, - biphenyl-4-ol
Example 105 A 2-F(3-Iodo-7-methoxy-l,4-dihvdro-indenoFl,2-clpyrazol-6-ylmethyl)-amino1-ethanol The desired product was prepared by substituting Example 68B and morpholine with Example 104D and 2-aminoethanol in Example 68C. The slightly impure product was used in the next step without further purification. MS (DCI/NH3) m/z: 386.0 (M+H)+.
Example 105B 4 '-(6- { F(2-hydroxy ethyl) aminolmethyl I -7-methoxy- 1 ,4-dihydroindeno F 1 , 2-c1pyrazol-3-yP- 1,1 - biphenyl-4-ol The desired product was prepared by substituting Example 68C with Example 105 A in Example 68E.
Examples 106 to 116, represented by Figure (IV) and listed in Table 4, were synthesized in a similar fashion as described in Example 104H or Example 105B.
Figure (IV)
Table 4
Example 117 3-fluoro-4 - F6-(hvdroxymethvP- 1 ,4-dihvdroindeno F 1 ,2-clpyrazol-3 -yll- 1 , 1 '-biphenyl-4-ol
Example 117A (3-iodo- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-6-yl)methanol To a suspension of Example 68B (0.500 g, 1.61 mmol) in a mixture of MeOH (9 mL) and THF (3 mL) was added NaBH (73.0 mg, 1.93 mmol) at room temperature. The mixture was stirred for 2 hours and the solvent was evaporated. The desired product (0.324 g, 65%) was recrystalized from hot CH2C12 with a small amount of MeOH. MS (DCI/NH3) m/z: 312.9 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 3.54 (s, 2 H), 4.66 (s, 2 H), 7.35 (d, J=7.80 Hz, 1 H), 7.55 (s, 1 H), 7.59 (d, 3=7.80 Hz, 1 H).
Example 117B 3-fluoro-4 -F6-(hvdroxymethyl)-l,4-dihvdroindenoFl,2-clpyrazol-3-yll-l, -biphenyl-4-ol The desired product was prepared by substituting Example 68C and Example 68D with Example 117A and 2-fluoro-4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenol respectively in Example 68E. MS (DCI NH3) m/z: 373.1 (M+H)+; 1H NMR (400 MHz, DMSO- Dg) δ ppm 3.89 (s, 2 H) 4.57 (s, 2 H) 7.05 (t, 3=8.00 Hz, 1 H) 7.32 (d, 3=7.36 Hz, 1 H) 7.41 (d, J=8.29 Hz, 1 H) 7.54-7.59 (m, 2 H) 7.61 (d, J=7.67 Hz, 1 H) 7.76 (d, 3=8.29 Hz, 2 H) 7.86 (d, J=12.0 Hz, 2 H) 10.00 (s, brd, 1 H).
The intermediates leading to the compounds represented by Figure V and shown in Table 5 were prepared in the similar fashion as the examples shown in Table 1, Table 2, or Table 4. The final Suzuki coupling reaction was done similar to the procedure described in Example 117B.
Figure (V)
Table 5
Example 123 5-16- Ff 4-methylpiperazin- 1 -ypmethyll- 1 ,4-dihy droindeno F 1 ,2-c1pyrazol-3 -yl 1 p yridine-2- carbonitrile
Example 123 A 3-iodo-l-{F2-(trimethylsilvPethoxylmethyl)-l,4-dihydroindenoFl,2-c1pyrazole-6-carbaldehvde To a mixture of Example 68A (1.00 g, 3.22 mmol) and NaH (60%, 0.142 g, 3.55 mmol) in DMF (20 mL) was added SEMC1 (0.63 mL, 3.55 mmol). After 4 hours, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with NaHCO3, dried over MgS04, filtered, concentrated, and purified by flash chromatography eluted with hexane/EtOAc (8:2 to 1:1) to give 0.887 g (63%) of the desired product as yellow solid. MS (DCI/NH3) m/z: 440.9 (M+H)+; 1H NMR (300 MHz, CDC13) δ ppm -0.01 (m, 9 H) 0.75-1.10 (m, 2 H) 3.46-3.76 (m, 2 H) 5.61 (s, 1 H) 5.68 (s, 1 H) 7.80 (d, 3=7.80 Hz, 0.5 H) 7.87-7.97 (m, 1.5 H) 8.03 (d, J=5.76 Hz, 1 H) 10.06 (s, 1 H).
Example 123B 3-iodo-6- F(4-methylpiperazin- 1 -v methyll - 1 - { F2-(trimethylsilyl)ethoxylmethyl j - 1 ,4- dihydroindenoFl,2-clpyrazole The desired product was prepared by substituting Example 68B and morpholine with Example 123A and 1-methylpiperazine respectively in Example 68C. MS (ESI) m/z: 525.1 (M+H)+.
Example 123C 6-fluoropyridin-3-ylboronic acid To a mixture of 5-bromo-2-fluoro-pyridine (1.71 g, 6.20 mmol) in dry ether (100 mL) was added n-BuLi (1.6M in hexane, 41.4 mL, 0.0663 mol) at -78 °C. After 30 minutes, trimethyl borate (8.2 mL, 0.0722 mol) was added to the above mixture and the reaction was warmed to room temperature and stirred overnight. The reaction was quenched with water and brine and acidified with 10% HCl until pH=8. The mixture was extracted with EtOAc, washed with 50% brine, dried over MgSO4, filtered, concentrated to give 5.1 g (60%) of the desired product. The crude product was used in the next step without further purification.
Example 123D 3-(6-fluoropyridin-3 -yP-6- F(4-methylpiper azin- 1 -yPmethyll- 1 - { F2- (trimethylsilypethoxylmethyl } - 1 ,4-dihydroindeno F 1 ,2-clpyrazole The desired product was prepared by substituting Example 68C and Example 68D with Example 123B and Example 123C in Example 68E. The product was purified by flash chromatography instead of reversed-phase HPLC. MS (ESI) m/z: 494.3 (M+H)+.
Example 123E 5-{6-F(4-methylpiρerazin-l-yl methyn-1.4-dihydroindenoFl,2-clpyrazol-3-yl|pyridine-2- carbonitrile A mixture of Example 123D (70.6 mg, 0.142 mmol) and NaCN (9.7 mg, 0.199 mmol) in DMF (1.2 mL) in a capped vial was heated to 210 °C for 1200 seconds in a Smith Synthesizer (300 W). The reaction was cooled using 40 psi pressurized air. The mixture was extracted with EtOAc and the organic layer was washed with 50% brine, NaHCO3, dried over MgSO , filtered, concentrated. The crude product was treated with HCl (cone, 2 drops) and EtOH (3 mL) and the mixture was heated at 75 °C for 2.5 hours. The solvent was evaporated and the residue was purified using reversed-phase HPLC to give 7.5 mg of the desired product as TFA salt.
Example 124 3-(6-cyanopyridin-3-yP-N-(pyridm-2-ylmethyl)-l,4-dihydroindenoFl,2-clpyrazole-6- carboxamide Example 124 A 3-iodo-N-(pyridin-2-ylmethyl)-l,4-dihvdroindenoF1.2-c1pyrazole-6-carboxamide The desired product was prepared by substituting cyclohexylamine with 2- (aminomethyl)pyridine in Example 85A. CH2CI2 was used for trituration. MS (DCI/NH3) m/z: 417.0 (M+H)+; 1H NMR (300 MHz, DMSO-Dg) δ ppm 3.58 (s, IH) 3.63 (s, IH) 4.58 (d, 3=5.76 Hz, 2 H) 7.26 (m, 1 H) 7.33 (d, J=7.80 Hz, 1 H) 7.60 (d, J=8.14 Hz, 0.5 H) 7.74 (m, 1.5 H) 7.95 (t, J=7.97 Hz, 1 H) 8.10 (d, J=5.42 Hz, 1 H) 8.50 (m, 1 H) 9.14 (t, J=5.93 Hz, 1 H) 13.29 (s, 0.4 H) 13.61 (s, 0.6 H).
Example 124B l-Fbis(4-methoxyphenyl)methyll-3-iodo-N-(pyridin-2-ylmethvP-l,4-dihvdroindenoFl,2- clpyrazole-6-carboxamide A mixture of Example 124A (0.176 g, 0.423 mmol), bis-(4-methoxy-phenyl)-methyl chloride (0.122 g, 0.465 mmol), and Et3N (71 μL, 0.507 mmol) in DMF (2.0 mL) was stiπ-ed at room temperature for 4 hours. The reaction mixture was diluted with 50% brine and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO4, filtered, concentrated, and purified by flash chromatography eluted with EtOAc to give 0.166 g (61%) of the desired as pale yellow solid. MS (ESI) m/z: 643.1 (M+H)+.
Example 124C l-Fbis(4-methoxyphenyl)methyl1-3-(6-fluoropyridm-3-yP-N-(pyridin-2-ylmethvP-l,4- dihydroindeno F 1 ,2-clpyrazole-6-carboxamide The desired product was prepared by substituting Example 68C and Example 68D with Example 124B and Example 123C in Example 67E. The product was purified by flash chromatography instead of reversed-phase HPLC. MS (ESI) m/z: 612.2 (M+H)+.
Example 124D 3-(6-cyanopyridin-3-vP-N-(ρyridin-2-ylmethvP-1.4-dihydroindenoFl,2-clpyrazole-6- carboxamide The desired product was prepared by substituting Example 123D with Example 124C in Example 123E. Acidic deprotection was done in EtOH and 1,4-dioxane at 40 °C overnight.
Examples 125 to 129, represented by Figure (VI) and shown in Table 6, were synthesized in the similar fashion as described in Example 123E or Example 124D. The pyrazole nitrogen of the intermediates could also be protected by SEM group.
H
Figure (VI)
Table 6
Example 130 -F6-(hydroxymethyp-l,4-dihydroindenoFl,2-c'lpyrazol-3-yllpyridine-2-carbonitrile Example 130 A (3-iodo- 1 - ( F2-(trimethylsilyl)ethoxylmethyl 1 - 1 ,4-dihydroindeno Fl ,2-clpyrazol-6-vPmethanol To a solution of Example 123A (1.500 g, 3.41 mmol) in MeOH (18 mL) and THF (14 mL) was added NaBH4 (64.5 mg, 1.70 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 90 minutes and quenched with water. The solvents were evaporated and the residue was extracted with EtOAc, washed with NaHCO3, dried over MgSO4, filtered, concentrated, and purified by flash chromatography eluted with EtOAc/hexane (1:1) to give 1.195 g (79%) of the desired product as off white solid. MS (ESI) m/z: 443.0 (M+H)+.
Example 130B (3-(6-fluoropyridin-3-yl)-l-f r2-(trimethylsilyl)ethoxylmethyl|-l,4-dihydroindenoFl,2-clpyrazol-
6-yl)methanol The desired product was prepared by substituting Example 68C and Example 68D with Example 130A and Example 123C in Example 68E. The product was purified by flash chromatography instead of reversed-phase HPLC. MS (ESI) m/z: 412.1 (M+H)+.
Example 130C 5-F6-(hydroxymethvP-l,4-dihydroindenoFl,2-c1pyrazol-3-yllpyridine-2-carbonitrile The desired product was prepared by substituting Example 123D with Example 130B in Example 123E. MS (ESI) m/z: 289.0 (M+H)+. 1H NMR (300 MHz, DMSO-Dg) δ ppm 3.95 (s, 2 H) 4.57 (s, 2 H) 7.34 (d, 3=7.80 Hz, 1 H) 7.56 (s, 1 H) 7.62 (m, 1 H) 8.17 (m, 1 H) 8.39 (dd, 3=8.14, 2.37 Hz, 1 H) 9.18 (s, 1 H).
Example 131 5-{6-F(pyridin-3-yloxy methyll-l,4-dihydroindenoFl,2-clpyrazol-3-yl}pyridine-2-carbonitrile
Example 131 A 5-(6-(hvdroxymethvP-l-{ F2-(trimethylsilvPethoxylmethyl)-l,4-dihvdroindenoFl,2-c1pyrazol-3- yl)pyridine-2-carbonitrile The desired product was prepared by substituting Example 123D with Example 130B in Example 123E except that the final removal of SEM protecting group using HCl was not performed. MS (ESI) m/z: 419.1 (M+H)+.
Example 13 IB 5-16- F(pyridin-3-yloxy)methyll- 1 ,4-dihydroindeno F 1 ,2-c]pyrazol-3-yl lpyridine-2-carbonitrile A mixture of Example 131 A (60.0 mg, 0.143 mmol), di-t-butyl azodicarboxylate (39.6 mg, 0.172 mmol), Ph3P on solid support (3mmol/g, 57.3 mg, 0.172 mmol), and 3- hydroxypyridine (16.4 mg, 0.172 mmol) in THF (2 mL) was stirred at room temperature overnight. The solid was filtered and the solvent was evaporated. The crude product was treated with HCl (concentrated, 4 drops) and EtOH (4 mL). The mixture was heated in a capped vial at 75 °C for 2 hours. The solvent was evaporated and the residue was purified using reversed-phase HPLC to give the desired product (12.4 mg) as TFA salt. MS (ESI) m/z: 366.0 (M+H)+. ]H NMR (300 MHz, DMSO-D6) δ ppm 4.01 (s, 2 H) 5.83 (s, 2 H) 7.58 (d, J=7.80 Hz, 1 H) 7.74 (m, 1 H) 7.80 (s, 1 H) 7.93-8.05 (m, 2 H) 8.18 (d, 3=8.14 Hz, 1 H) 8.40 (dd, 3=8.14, 2.37 Hz, 1 H) 8.62- 8.84 (m, 2 H) 9.19 (s, 1 H) 12.14 (s, 1 H).
Example 132 5-{6-F(pyridin-4-yloxy)methvn-l,4-dihvdroindenoFl,2-clpyrazol-3-yllpyridine-2-carbonitrile The desired product was prepared by substituting 3-hydroxypyridine with 4- hydroxypyridine in Example 13 IB. MS (ESI) m/z: 366.0 (M+H)+. 1H NMR (300 MHz, DMSO- Dg) δ ppm 3.99 (s, 2 H) 5.56 (s, 2 H) 7.10 (d, 3=7.46 Hz, 2 H) 7.46 (d, 3=7.80 Hz, 1 H) 7.67-7.83 (m, 2 H) 8.17 (d, J=8.14 Hz, 1 H) 8.39 (dd, 3=8.14, 2.03 Hz, 1 H) 8.62 (d, J=7.12 Hz, 2 H) 9.18 (d, 3=2.03 Hz, 1 H).
Example 133 3-(6-fluoropyridin-3-yl)-7-methoxy-4,4-dimethyl-l,4-dihvdroindenoFl,2-c1pyrazol-6-ol Example 133 A 6-methoxy-3 ,3-dimethyl-5- { F2-(trimethylsilyl)ethoxylmethoxy 1 indan- 1 -one To a solution of 5-hydroxy-6-methoxy-3,3-dimethyl-indan-l-one (40.0 g, 0.194 mol, see preparation in J. Chem. Soc. Perkin Trans. 1 1982, p2013-2017) in CH2C12 (400 mL) were added diisopropylethylamine (35.5 mL, 0.204 mol) and SEMC1 (34.9 mL, 0.198 mol). The reaction mixture was stirred at room temperature for 3 hours and concentrated. The residue was purified by flash chromatography eluted with EtOAc/hexane (2:8) to give 60.5 g (93%) of the desired product as brown oil. MS (DCI/NH3) m/z: 337.1 (M+H)+; 1H NMR (300 MHz, CDC13) δ ppm 0.00 (s, 9 H) 0.96 (t, 3=8.10 Hz, 2 H) 1.39 (s, 6 H) 2.56 (s, 2 H) 3.83 (t, 3=8.10 Hz, 2 H) 3.90 (s, 3 H) 5.39 (s, 2 H) 7.15 (s, 1 H) 7.20 (s, 1 H).
Example 133B 2-(hvdroxymethylene)-6-methoxy-3 ,3-dimethyl-5- { F2-(trimethylsilvPethoxylmethoxy 1 indan- 1 - one To a solution of Example 133 A (2.41 g, 7.15 mmol) in THF (15 mL) was added NaH (60%, 0.343 g, 8.58 mmol) at 0 °C. After 1 hour, ethyl formate (0.73 mL, 8.58 mmol) was added. The reaction mixture was heated at 50 °C for 2 hour, cooled, quenched with water, and extracted with EtOAc. The organic layer was washed with 5% citric acid, brine, dried over MgS04, filtered, concentrated, and purified by flash chromatography eluted with EtOAc/hexane (1 : 1) to give 1.17 g of the desired product as purple gel. MS (DCI NH3) m/z: 365.2 (M+H)+. 1H NMR (300 MHz, CDC13) δ ppm 0.00 (s, 9 H) 0.96 (t, 3=8.10 Hz, 2 H) 1.43 (s, 6 H) 3.83 t, t, 3=8.10 Hz, 2 H) 3.93 (s, 3 H), 7.18 (s, 1 H) 7.27 (d, 3=2.37 Hz, 2 H).
Example 133C 7-methoxy-4,4-dimethyl-6- { F2-C trimethylsilypethoxylmethoxy ) - 1 ,4-dihvdroindeno F 1 ,2- clpyrazole A mixture of Example 133B (0.886 g, 2.43 mol), hydrazine monohydrate (0.14 mL, 2.92 mol), and AcOH (38 μL, 0.729 mmol) in EtOH (20 mL) was heated at 85 °C for 1.5 hours. The solvent was evaporated and the residue was purified by flash chromatography eluted with EtOAc/hexane (1:1) to give 0.865 g of the desired product as yellow solid. MS (DCI/NH3) m/z: 362.1 (M+H)+; 1H NMR (300 MHz, DMSO-Dg) δ ppm 0.00 (s, 9 H) 0.91 (t, J=8.10 Hz, 2 H) 1.40 (s, 6 H) 3.78 (t, J=8.10 Hz, 2 H) 3.84 (s, 3 H) 5.22 (s, 2 H) 7.17 (s, 1 H) 7.20 (s, 1 H) 7.53 (s, 1 H).
Example 133D 3-iodo-7-methoxy-4,4-dimethyl-6-{ F2-(trimethylsilvPethoxy1methoxy)-l,4-dihvdroindenoFl,2- clpyrazole A suspension of Example 133C (10.4 g, 0.0290 mol) and N-iodosuccinimide (7.82 g, 0.0348 mol) in 1,4-dioxane (300 mL) was heated at 90 °C for 7.5 hours. The reaction was cooled and the solvent was evaporated. The concentrate was purified by flash chromatography eluted with EtOAc/hexane (1:1) to give 8.79 g of the desired product. MS (DCI NH3) m/z: 487.1 (M+H)+; 1H NMR (300 MHz, CDCI3) δ ppm 0.00 (s, 9 H) 0.97 (t, 3=8.10 Hz, 2 H) 1.48 (s, 6 H) 3.85 (t, 3=8.10 Hz, 2 H) 3.92 (s, 3 H) 5.32 (s, 2 H) 7.21 (s, 1 H) 7.22 (s, 1 H).
Example 133E 3-(6-fluorop yridin-3-yl)-7-methoxy-4,4-dimethyl- 1 ,4-dihydroindenoF 1 ,2-c1pyrazol-6-ol The desired product was prepared by substituting Example 68C and Example 68D with Example 133D and Example 123C in Example 68E. The product was purified by flash chromatography instead of reversed-phase HPLC. This intermediate was treated with HCl (concentrated, 3 drops) and EtOH (2 mL). The mixture was stirred at room temperature for 2 hours. The solvent was evaporated and the residue was purified using reversed-phase HPLC to give the desired product (13.0 mg) as TFA salt. MS (ESI) m/z: 326.0 (M+H)+. 1H NMR (300 MHz, CD3OD) δ ppm 1.52 (s, 6 H) 3.93 (s, 3 H) 6.93 (s, 1 H) 7.14-7.31 (m, 2 H) 8.16 (m, 1 H) 8.56 (d, J=1.70 Hz, 1 H).
Example 134 5-f6-hvdroxy-7-methoxy-4,4-dimethyl-l,4-dihydroindenoFl,2-c1pyrazol-3-yl)pyridine-2- carbonitrile Example 134A 3-iodo-7-methoxy-4,4-dimethyl-6- { F2-(trimethylsilvPethoxylmethoxy I - 1 - ( F2- (trimethylsilyPethoxylmethyl I- 1 ,4-dihvdroindeno Fl ,2-clpyrazole To a mixture of Example 133D (0.475 g, 0.977 mmol) and NaH (60%, 0.043 g, 1.07 mmol) in THF (10 mL) was added SEMCl (0.19 mL, 1.07 mmol). After 2 hours, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with NaHC03, dried over MgS04, filtered, concentrated, and purified by flash chromatography eluted with hexane/EtOAc (8:2) to give 0.455 g (75%) of the desired product as yellow gel. MS (DCI/NH3) m/z: 617.2 (M+H)+.
Example 134B 3-iodo-7-methoxy-4,4-dimethyl-l-f F∑-CtrimethylsilyPethoxylmethyll-l -dihydroindenoFl^- clpyrazol-6-ol A mixture of Example 134A (0.450 g, 0.730 mmol) and HCl (concentracted, 0.4 mL) in EtOH (10 mL) was stirred at room temperature for 3 hours. The solvent was evaporated at room temperature and the residue was purified by flash chromatography eluted with hexane/EtOAc/CH2Cl2 (7:3:1 to 1:1:0) to give 0.321 g (90%) of the desired product as pale yellow gel. MS (DCI NH3) m/z: 487.1 (M+H)+.
Example 134C 346-fluoropyridm-3-yP-7-methoxy-4,4-dimethyl- 1 - { F2-(trimethylsilyl)ethoxylmethyl 1 - 1 ,4- dihvdroindeno F 1 ,2-clp yr azol-6-ol The desired product was prepared by substituting Example 68C and Example 68D with Example 134B and Example 123C in Example 68E. The product was purified by flash chromatography instead of reversed-phase HPLC. MS (ESI) m/z: 456.1 (M+H)+.
Example 134D
5-(6-hydroxy-7-methoxy-4,4-dimethyl- 1 - ( F2-(trimethylsilyl)ethoxylmethyl 1-1,4- dihvdroindenoFl,2-clpyrazol-3-vPpyridine-2-carbonitrile The desired product was prepared by substituting Example 123D with Example 134C in Example 123E. The product was purified by flash chromatography instead of reversed-phase HPLC. MS (ESI) m/z: 463.1 (M+H)+.
Example 134E 5-(6-hydroxy-7-methoxy-4,4-dimethyl-l,4-dihydroindenoFl,2-clpyrazol-3-yl)pyridine-2- carbonitrile A mixture of Example 134D (23.0 mg, 0.0497 mmol) and HCl (concentrated, 2 drops) in EtOH (2 mL) was stirred at 75 °C for 1.5 hours. The solvent was evaporated and the residue was purified using reversed-phase HPLC to give the desired product (4.0 mg) as TFA salt. MS (ESI) m/z: 333.0 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 1.56 (s, 6 H) 3.93 (s, 3 H) 6.94 (s, 1 H) 7.20 (s, 1 H) 7.99 (d, 3=8.14 Hz, 1 H) 8.32 (dd, J=8.14, 2.37 Hz, 1 H) 9.11 (d, J=2.37 Hz, 1 H).
Example 135 5- F7-methoxy-4,4-dimethyl-6-(pyridin-3-ylmethoxy)- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-3- yllpyridine-2-carbonitrile
Example 135 A 3-iodo-7-methoxy-4 ,4-dimethyl-6-(pyridin-3-ylmethoxy)-l-{ F2-(trimethylsilyl)ethoxylmethyl }- l,4-dihvdroindenoF1.2-clpyrazole A mixture of Example 134B (200.0 mg, 0.411 mmol), di-t-butyl azodicarboxylate (0.189 g, 0.822 mmol), PI13P on solid support (3mmol/g, 0.274 g, 0.822 mmol), and 3-pyridylcarbinol (80 μL, 0.822 mmol) in THF (3 mL) was stirred at room temperature overnight. The solid was filtered and the solvent was evaporated. The crude product was purified by flash chromatography eluted with EtOAc to give 0.242g (100%) of the desired product as yellow gel. MS (DCI/NH3) m/z: 578.1 (M+H)+.
Example 135B
3-(6-fluoropyridin-3-yl)-7-methoxy-4,4-dimethyl-6-(pyridin-3-ylmethoxy)-l-( F2-
(trimethylsilyl)ethoxylmethyll-l,4-dihvdroindenoFl,2-clpyrazole The desired product was prepared by substituting Example 68C and Example 68D with Example 135A and Example 123C in Example 68E. The product was purified by flash chromatography instead of reversed-phase HPLC. MS (ESI) m/z: 547.2 (M+H)+.
Example 135C 5-F7-methoxy-4,4-dimethyl-6-(pyridin-3-ylmethoxy)- 1 ,4-dihydroindeno Fl ,2-clpyrazol-3- yllpyridine-2-carbonitrile The desired product was prepared by substituting Example 123D with Example 135B in Example 123E.
Examples 136 to 142, represented by Figure (VII) and shown in Table 7, were synthesized in a similar fashion as Example 135C.
H
Figure (VII)
Table 7
Example 143 5-r7-methoxy-6-(pyridin-2-ylmethoxy)-l,4-dihvdroindenoFl,2-c1pyrazol-3-vnpyridine-2- carbonitrile
Example 143A 6-methoxy-5-( F2-(trimethylsilyl)ettιoxylmethoxy 1 indan- 1 -one To a solution of 5-hydroxy-6-methoxy-indan-l-one (21.1 g, 0.118 mol, see preparation in 3. Org. Chem. 57, 1992, 589-594) and N,N-diisopropylethylamine (21.6 mL, 0.124 mol) in CH2C12 (200 mL) was added SEMCl (21.3 mL, 0.121 mol). The mixture was stirred at room temperature for 2 hours and diluted with NaHCO3 solution. After separation, the organic layer was dried over MgS04, filtered, concentrated, and purified by flash chromatography eluted with EtOAc/hexane (3:7 to 1:1) to give 26.3 g (72%) of the desired product as brown oil. MS (ESI) m/z: 309.0 (M+H)+; 1H NMR (300 MHz, CDC13) δ ppm -0.01 (s, 9 H) 0.96 (t, 3=8.25 Hz, 2 H) 2.66 (t, J=5.70 Hz, 2 H) 3.03 (t, J=5.70 Hz, 2 H) 3.80 (t, J=8.25 Hz, 2 H) 3.90 (s, 3 H) 5.36 (s, 2 H) 7.20 (s, 1 H) 7.22 (s, 1 H).
Example 143B phenyl 6-chloronicotinate A mixture of 6-chloronicotinic acid (68.0 g, 0.431 mol), phenol (40.6 g, 0.431 mol), DCC (93.6 g, 0.453 mol), and DMAP (1.60 g, 0.0129 mol) in ether (1 L) was stirred at room temperature overnight. The solvent was evaporated and the residue was stirred in CH2C12. The solid was filtered and the filtrate was purified by flash chromatography eluted with CH2CI210 give 88.0 g (88%) of the desired product. MS (DCI/NH3) m/z: 234.0 (M+H)+; 1H NMR (300 MHz, CDCI3) δ ppm 7.22 (d, J=8.14 Hz, 2 H) 7.31 (t, J=7.29 Hz, 1 H) 7.47 (dd, 3=17.12, 7.97 Hz, 3 H) 8.40 (m, 1 H) 9.17 (d, 3=1.70 Hz, 1 H).
Example 143C 3-(6-chloropyridin-3-yl)-7-methoxy-6-{ F2-(trimethylsilyl)ethoxylmethoxy 1-1,4- dihydroindenoF 1 ,2-clpyrazole To a solution of Example 143A (24.1 g, 0.0781 mol) in THF (400 mL) was added NaH (60%, 9.37 g, 0.234 mol) in 2 portions at room temperature. After 20 minutes, Example 143B (21.0 g, 0.0898 mol) was added. The reaction mixture was stirred for 3 hours, treated with EtOH, and concentrated. To the resulting residue were added EtOH (400 mL), glacial acetic acid (22.4 mL, 0.391mol), and hydrazine monohydrate (11.4 mL, 0.234 mol). The mixture was heated at 90 °C for 2 hours, cooled, and concentrated. The residue was extracted with EtOAc and washed with NaHC03. The organic layer was dried over MgS04, filtered, concentrated, and triturated with ether to give 23.8 g (69%) of the desired product as off-white solid. MS (ESI) m/z: 444.1 (M+H)+; 1H NMR (300 MHz, DMSO-Dg) δ ppm 0.00 (s, 9 H) 0.92 (t, 3=8.09 Hz, 2 H) 3.77 (m, J=7.94 Hz, 2 H) 3.86 (s, 3 H) 5.24 (s, 2 H) 6.70 (m, 1 H) 7.30 (d, J=10.51 Hz, 2 H) 7.66 (d, J=8.14 Hz, 1 H) 8.23 (dd, 3=8.31, 2.54 Hz, 1 H) 8.83 (d, J=3.05 Hz, 1 H).
3-(6-chloropyridin-3-vP-7-methoxy-6-{F2-(trimethylsilvPethoxy1methoxyl-l-{F2- (trimethylsilyPethoxylmethyl 1 - 1 ,4-dihydroindeno r 1 ,2-clpyrazole
Example 143D The desired product was prepared by substituting Example 68A with Example 143C in Example 123A. MS (ESI) m/z: 574.2 (M+H)+.
Example 143E 5-(7-methoxy-6- { F2-(trimethylsilyl)ethoxylmethoxy I - 1 - { F2-(trimethylsilyPethoxylmethyl 1-1,4- dihydroiiidenoFl,2-clpyrazol-3-yPpyridine-2-carbonitrile A mixture of Example 143D (1.500 g, 2.61 mmol), Pd2(dba)3 (71.7 mg, 3 mol%), dppf (86.8 mg, 6 mol%), Zn (20.5 mg, 12 mol%), and Zn(CN)2 (0.460 g, 3.92 mmol) in N,N- dimethylacetamide (40 mL) was degassed and heated at 120 °C overnight. The mixture was cooled and filtered through celite. The filtrate was diluted with 50% brine and extracted with EtOAc twice. The combined organic layers were washed with NaHC03 and brine, dried over MgS04, filtered, concentrated, and purified by flash chromatography eluted with EtOAc/hexane (4:6) to give 1.17 g (80%) of the desired product as pale yellow solid. MS (ESI) m/z: 565.2 (M+H)+.
Example 143F 5-(6-hydroxy-7-methoxy-l-{ F2-(trimethylsilyl)ethoxylmethyl)-l,4-dihydroindenoFl,2-clpyrazol-
3-yl)pyridine-2-carbonitrile A mixture of Example 143E (9.96 g, 0.0176 mmol) and HCl (concentrated, 4.0 mL) in MeOH (200 mL) and CH2CI2 (100 mL) was stirred at room temperature for 1.5 hours. Most of the solvents were evaporated at room temperature. The residue was extracted with EtOAc, washed with NaHCO , dried over MgS0 , filtered, concentrated to give 7.63 g (quantitative yield) of the desired product as pale yellow solid. MS (ESI) m/z: 435.2 (M+H)+.
Example 143G 5-F7-methoxy-6-(pyridin-2-ylmethoxy)-l,4-dihvdroindenoFl,2-c1pyrazol-3-yllpyridine-2- carbonitrile The desired product was prepared by first substituting Example 134B and 3- pyridylcarbinol with Example 143F and 2-pyridylcarbinol in Example 135A. The intermediate was treated with HCl and EtOH at about 75 °C for about 2 hours. The suspension was cooled and the solid was filtered, washed with ether, and dried to give the desired product as HCl salt. Alternatively, the intermediate after acidic treatment was purified using reversed-phase HPLC to give the desired product as TFA salt.
Example 144 5-{7-F(6-chloropyridin-3-vPmethoxyl-6-methoxy-l,4-dihydroindenoFl,2-clpyrazol-3- yl lpyridine-2-carbonitrile
Example 144A 5 ,6-dihydroxyindan- 1 -one To a solution of 5,6-dimethoxy-indan-l-one (40.0 g, 0.208 mol) in CH2CI2 (800 mL) at - 78 °C was added BBr3 (59.0 mL, 0.624 mol) dropwise. The dry ice bath was removed after the addition. The mixture was stirred at room temperature for 1 hour and poured into a large amount of ice/water and stirred vigorously. The pink solid was filtered, washed with water, and vacuum oven dried to give 33.3 g (98%) of the desired product.MS (DCI/NH3) m/z: 165.0 (M+H)+; !H NMR (300 MHz, CD3OD) δ ppm 2.58-2.61 (m, 2 H) 2.98 (t, J=5.55 Hz, 2 H) 6.85 (s, 1 H) 7.04 (s, 1 H).
Example 144B 6-hy droxy-5 -methox yindan- 1 -one A mixture of Example 144A (28.5 g, 0.173 mol), Mel (27.0 mL, 0.433 mol), and Li2CO3 (32.0 g, 0.519 mol) in DMF (800 mL) was heated at 55 °C overnight. DMF was evaporated and the residue was treated with water (IL) and HCl (concentrated, 60 mL). The solid was filtered, washed with water until the filtrate became neutral, and dried to give 21.0 g (68%) of the desired product. MS (DCI/NH3) m/z: 179.0 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 2.58-2.67 (m, 2 H) 3.05 (t, 3=5.55 Hz, 2 H) 3.96 (s, 3 H) 7.04 (s, 2 H).
Example 144C 5-{7-F(6-chloropyridin-3-yl)methoxyl-6-methoxy-l,4-dihydroindenoFl,2-clpyrazol-3- yl lpyridme-2-carbonitrile The desired product was prepared by substituting 6-hydroxy-5-methoxyindan-l-one with Example 144B in Example 143A followed by the similar procedures in Examples 143C, 143D, 143E, 143F, and 143G.
Examples 145 to 163 represented by Figure (VIII) and shown in Table 8 were synthesized in a similar fashion as described in Example 143G or 144C.
H
Figure (VIII)
Table 8
Example 164 4'-(6,7-dimethoxy-l,4-dihydromdenoFl,2-c1pyrazol-3-yl)-3-methoxy-l, -biphenyl-4-ol Example 64C (50 mg, 0.14 mmol), 2-methoxy-4-(4,4,5,5-tetramethyl[l,3,2] dioxaborolan-2-yl)-phenol (42.3 mg, 0.17 mmol), Na2CO3 (1 M, 0.3 mL), and Pd(PPh3)2Cl2 (9.9 mg, 0.014mmol) were combined in DME/EtOH/H2O (7:2:3, 1.5 mL) in a capped 2 mL vial and heated to 160 °C for 600 seconds in a Smith Synthesizer. The reaction was cooled using 40 psi pressurized air, the solvents were evaporated, and the residue was purified using preparative HPLC. MS (DCI/NH3) m z: 415.06 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.79 (s, 2 H) 3.82 (s, 3 H) 3.85 (s, 3 H) 3.88 (s, 3 H) 6.87 (d, J=8.11 Hz, 1 H) 7.16 (dd, 3=8.11, 2.18 Hz, 1 H) 7.23 (s, 1 H) 7.25 (s, 1 H) 7.27 (d, J=1.87 Hz, 1 H) 7.75 (d, J=8.42 Hz, 2 H) 7.83 (d, 3=8.42 Hz, 2 H).
Example 165 4-(6,7-dimethoxy- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-3-yPphenol
Example 165 A 4-Benzyloxybenzoic acid (2 g, 8.76 mmol) and Ll'-carbonyldiimidazole (2.3 g, 14 mmol) were combined in DMF. The reaction mixture was stirred overnight and poured into ice- water. The resulting precipitate was collected by filtration, washed with water, and dried. The title product (2.4 g) was obtained at 99% yield. MS (DCI/NH3) m/z: 279.08 (M+H)+.
Example 165B 2-F4-(benzyloxy)benzovn-5 ,6-dimethoxyindan- 1-one 5,6-Dimethoxyindanone (1 g, 5.2 mmol) in 45 mL of THF was treated with NaH (60%, 312 mg, 7.8 mmol). After the addition of Example 165A (1.45 g, 5.2 mmol), the reaction mixture was stirred overnight and poured into ice water. The resulting mixture was acidified with concentrated HCl. Yellow solid was collected by filtration, washed with water and hot ethanol. The title product (1.2 g) was obtained at 57% yield. MS (DCI/NH3) m/z: 403.11 (M+H)+. Example 165C 3 - F4- (benzyloxy)phenvn -6,7-dimethoxy- 1 ,4-dihydroindeno F 1 ,2-clpyrazole Example 165B (500 mg, 1.24 mmol), hydrazine monohydrate (72 μL), and acetic acid (85 μL) were combined in 20 mL of ethanol, heated at 90°C overnight and cooled. The precipitates were collected by filtration to give the title compound. MS (DCI/NH3) m/z: 399.11 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.73 (s, 2 H) 3.81 (s, 3 H) 3.84 (s, 3 H) 5.17 (s, 2 H) 7.14 (d, J=7.49 Hz, 2 H) 7.21 (d, J=8.11 Hz, 2 H) 7.34 (t, 3=7.18 Hz, 1 H) 7.41 (t, 3=7.49 Hz, 2 H) 7.48 (d, J=7.18 Hz, 2 H) 7.71 (d, 3=8.11 Hz, 2 H) 12.85 (s, 1 H).
Example 165D 4-(6,7-dimethoxy-l ,4-dihydroindenoF 1 ,2-clpyrazol-3-yl)phenol Example 165C (57 mg, 0.14 mmol) and Pd/C (10%, 15.2 mg) were combined in THF (20 mL) and stirred under hydrogen atmosphere for 24 hours. Pd/C was removed by filtration and the filtrate was concentrated. The residue was purified by HPLC to give the title compound. MS (DCI/NH3) m z: 309.03 (M+H)+. 1H NMR (400 MHz, DMSO-Dg) δ ppm 3.71 (s, 2 H) 3.81 (s, 3 H) 3.83 (s, 3 H) 6.87 (d, 3=8.59 Hz, 2 H) 7.20 (s, 1 H) 7.22 (s, 1 H) 7.60 (d, 3=8.59 Hz, 2 H)
Example 166 3-(4 -hydroxy- 1 , 1 -biphenyl-4-yl)- 1 ,4-dihvdroindeno F 1 ,2-c1pyrazole-6,7-diol
Example 166 A 3-(4-bromophenyl)-l,4-dihydroindenoFl,2-clpyrazole-6,7-diol Example 64C (142 mg, 0.38 mmol) in 1,2-dichloroethane (50 mL) was treated with BBr3*SMe2 (597 mg, 1.91 mmol), heated at 80°C for 30 hours and cooled. Reaction was quenched with water (20 mL), and the resulting mixture was treated with ether (100 mL). The precipitate was collected by filtration and further purified by HPLC. MS (DCI/NH3) m/z: 344.94 (M+H)+. Example 166B 3-(4 -hydroxy- 1 , 1 -biphenyl-4-vP- 1 ,4-dihydroindeno F 1 ,2-clpyrazole-6,7-diol Example 166A (35 mg, 0.10 mmol), 4-hydroxylρhenyl boronic acid (18 mg), Na2CO3 (1 M, 0.25 mL), and Pd(PPh3)2Cl2 (9.9 mg, 0.014mmol) were combined in DME/EtOH/H20 (7:2:3, 1.5 mL) in a capped 2 mL vial and heated to 160 °C for 600 seconds in a Smith Synthesizer. The reaction was cooled using 40 psi pressurized air, the solvents were evaporated, and the residue was purified using preparative HPLC to give the title compound. MS (DCI/NH3) m/z: 357.04 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.69 (s, 2 H) 6.87 (d, J=8.54 Hz, 2 H) 6.96 (s, 1 H) 7.04 (s, 1 H) 7.56 (d, 3=8.54 Hz, 2 H) 7.70 (d, 3=8.54 Hz, 2 H) 7.81 (d, 3=8.54 Hz, 2 H).
Example 167 4-(6,7-dimethoxy-l,4-dihvdroindenoFl,2-clpyrazol-3-yl)benzonitrile A mixture of Example 64C (50 mg, 0.14 mmol), zinc cyanide (17.4 mg, 1.48 mmol), Pd(PPh3)4 (15.6 mg, 0.014mmol) in DMF (3 mL) in a capped 5 mL vial was heated to 180 °C for 300 seconds in a Smith Synthesizer. The reaction was cooled using 40 psi pressurized air, and the solvent was evaporated. The residue was purified by preparative HPLC to give the title product. MS (DCI/NH3) m/z: 318.04 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.81 (s, 2 H) 3.82 (s, 3 H) 3.84 (s, 3 H) 7.23 (s, 1 H) 7.25 (s, 1 H) 7.96 (s, 4 H).
Example 168 3-(6-hydroxy-2-naphthyl)- 1 ,4-dihvdroindeno F 1 ,2-clpyrazol-6-ol
Example 168A l-(6-methoxy-2-naphthovP-lH-imidazole 6-Methoxynanphthalene-2-carboxylic acid (2 g, 9.9 mmol) and i'-carbonyldiimidazole (2.4 g, 14.8 mmol) were combined in DMF ( 10 mL) and stirred overnight. The white solid was collected by filtration, washed with water and dried to give the title compound. Example 168B 5-(benzyloxy)-2-(6-methoxy-2-naphthoyPindan-l-one 5-Benzyloxyindanone (1.5 g, 6.29 mmol) was treated with NaH (60%, 377 mg) in THF (50 mL), and then Example 168A (1.59 g) was added. The reaction was stirred for 6 hours at room temperature. The precipitates were collected by filtration and dissolved in water, acidified with concentrated HCl, and the resulting precipitates were collected, washed with water and dried to give the title compound.
Example 168C 6-(benzyloxy)-3-(6-methoxy-2-naphthvP-l,4-dihydroindenoFl,2-clpyrazole The desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 168B. MS (DCI/NH3) m/z: 419.14 (M+H)+.
Example 168D 3-(6-hydroxy-2-naphthyl)- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-6-ol The desired product was prepared using the procudure in Example 166A replacing Example 64C with Example 168C. MS (DCI/NH3) m/z: 315.04 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.89 (s, 2 H) 6.84 (dd, 3=8.24, 2.14 Hz, 1 H) 7.07 (d, J=1.53 Hz, 1 H) 7.13-7.14 (m, 2 H) 7.54 (d, J=8.24 Hz, 1 H) 7.75-7.79 (m, 2 H) 7.82 (d, 3=9.76 Hz, 1 H) 8.14 (s, 1 H).
Example 169 6,7-dimethoxy-3-F4-(lH-pyrrol-2-yl)phenyll-l,4-dihydroindenoπ,2-clpyrazole The desired product was prepared using the procedure in Example 164 replacing 2- methoxy-4-(4,4,5,5-tertramethyyl[l,3,2] dioxaborolan-2-yl)-phenol with l-tert-Bocpyrrolyl-2- boronic acid. MS (DCI/NH3) m/z: 358.12 (M+H)+. 1H NMR (400 MHz, DMSO-Dg) δ ppm 3.79 (s, 2 H) 3.82 (s, 3 H) 3.84 (s, 3 H) 6.14 (q, 3=2.35 Hz, 1 H) 6.59 (s, 1 H) 6.88 (s, 1 H) 7.23 (d, J=9.21 Hz, 2 H) 7.72-7.77 (m, 4 H) 11.32 (s, 1 H)
Example 170 6,7-dimethoxy-3-F4-( lH-pyrazol-4-yl)phenyll-l ,4-dihydroindenoFl ,2-clpyrazole
Example 170 A l-Fchloro(4-methoxyphenyl)methyll-4-methoxybenzene Bis(4-methoxyphenyl)methanol (30 g) was treated with thionyl chloride (40 mL). The resulting mixture was refluxed for 2.5 hours and concentrated to give the desired product.
Example 170B 1 - rbis(4-methoxyphenyl)methyH-4-iodo- lH-pyrazole 4-Iodo-lH-pyrazole (1 g, 5.15 mmol), Example 170A (1.49 g, 5.67 mmol), and triethylamine (0.79 mL) were combined in THF (20 mL), and refluxed for 1.5 hour. The inorganic salts were removed by filtration, and the filtrate was concentrated. The residue was recrystalized from a mixture of ethyl acetate and hexane to give 1.56 g of product at 72% yield. MS (DCI/NH3) m/z: 420.0 (M+H)+. 1H NMR (400 MHz, DMSO-Dg) δ ppm 3.72 (s, 6 H) 6.78 (s, 1 H) 6.90 (d, J=8.59 Hz, 4 H) 7.06 (d, 3=8.59 Hz, 4 H) 7.58 (s, 1 H) 7.81 (s, 1 H)
Example 170C 1 - rbis(4-methoxyphenvPmethvn-3-(4-bromophenyl)-6,7-dimethoxy- 1 ,4-dihvdroindeno F 1 ,2- clpyrazole The desired product was prepared using the procedure in Example 170B replacing 4- iodo-lH-pyrazole with Example 64C. The title product (2.0 g) was obtained at 83% yield. MS (DCI/NH3) m/z: 597.12 (M+H)+. 1H NMR (400 MHz, DMSO-D6) δ ppm 3.60 (s, 3 H) 3.73 (s, 6 H) 3.75 (s, 2 H) 3.78 (s, 3 H) 6.61 (s, 1 H) 6.94 (d, 3=8.59 Hz, 4 H) 7.14 (s, 1 H) 7.20 (s, 1 H) 7.25 (d, 3=8.59 Hz, 4 H) 7.62 (d, J=8.59 Hz, 2 H) 7.72 (d, J=8.59 Hz, 2 H).
Example 170D 1 -Fbis(4-methoxyphenyPmethyl1 -6,7-dimethoxy-3-F4-(4,4,5 ,5 -tetramethyl- 1 ,3,2-dioxaborolan-2- yPphenyll - 1 ,4-dihydroindeno F 1 ,2-clpyrazole Example 170C (1 g, 1.67 mmol), bis(pinacolato)diborane (467 mg, 1.84 mmol), PdCl2(dppf CH2Cl2 (41 mg, 0.05 mmol), dppf (28 mg), and K OAc were combined in 1,4- dioxane (35 mL) and purged with a stream of nitrogen. The reaction was heated at 90°C overnight and concentrated. The residue was purified by flash chromatography eluting with hexane:ethyl acetate (2:1). The desired product (950 mg) was obtained at 88% yield. *H NMR (500 MHz, DMSO-Dg) δ ppm 1.31 (s, 12 H) 3.58 (s, 3 H) 3.73 (s, 6 H) 3.77 (s, 2 H) 3.78 (s, 3 H) 6.54 (s, 1 H) 6.95 (d, J=8.73 Hz, 4 H) 7.14 (s, 1 H) 7.22 (s, 1 H) 7.24 (d, J=8.73 Hz, 4 H) 7.74 (d, 3=8.11 Hz, 2 H) 7.80 (d, J=8.11 Hz, 2 H).
Example 170E l-Fbis(4-methoxyphenyl)methyll-3-(4-{l-Fbis(4-methoxyphenyPmethyn-lH-pyrazol-4- yl}phenvP-6,7-dimethoxy-l,4-dihydroindenoFl,2-c1pyrazole Example 170B (67 mg, 0.159 mmol), Example 170D (84 mg, 0.13 mmol), Na2Cθ3 (1 M, 0.3 mL), and Pd(PPh3)2Cl2 (9.9 mg, 0.014 mmol) were combined in DME/EtOH/H2O (7:2:3, 1.5 L) in a capped 2 mL vial and heated to 160 °C for 1000 seconds in a Smith Synthesizer. The reaction was cooled using 40 psi pressurized air, the solvents were evaporated, and the residue was purified using flash chromatography eluting with hexane:ethyl acetate (1:1). The title product (84 mg) was obtained at 65% yield. MS (DCI/NH3) m/z: 811.37 (M+H)+. 1H NMR (400 MHz, DMSO-Dg) δ ppm 3.57 (s, 3 H) 3.73 (s, 6 H) 3.75 (s, 6 H) 3.76 (s, 2 H) 3.78 (s, 3 H) 6.51 (s, 1 H) 6.79 (s, 1 H) 6.92-6.96 (m, 8 H) 7.12 (s, 1 H) 7.14 (d, J=8.90 Hz, 4 H) 7.21 (s, 1 H) 7.25 (d, J=8.59 Hz, 4 H) 7.64 (d, 3=8.29 Hz, 2 H) 7.75 (d, J=8.59 Hz, 2 H) 7.99 (s, 1 H) 8.14 (s, 1 H). Example 170F 6 ,7-dimethox y-3 - F4-( 1 H-pyr azol-4-ypphen yll - 1 ,4-dihvdroindeno F 1 ,2-clpyrazole
Example 170E (60 mg, 0.078 mmol) was treated with 4 M HCl in dioxane (5 mL). The reaction was stirred overnight and concentrated. The residue was washed with a mixture of hexane and ethyl acetate to give light yellow product. MS (DCI/NH3) m/z: 359.07 (M+H)+. 1H NMR (400 MHz, DMSO-Dg) δ ppm 3.82 (s, 2 H) 3.83 (s, 3 H) 3.85 (s, 3 H) 7.25 (s, 1 H) 7.27 (s, 1 H) 7.76 (d, 3=8.29 Hz, 2 H) 7.81 (d, 3=8.29 Hz, 2 H) 8.16 (s, 2 H).
Example 171 4'-(6,7-dimethoxy-l,4-dihydroindenoFl,2-clpyrazol-3-yP-l, -biphenyl-4-yl l,4'-bipiperidine- - carboxylate
Example 171 A 4 - { l-Fbis(4-methoxyphenyPmethyll-6,7-dimethoxy- 1 ,4-dihydroindenoF l,2-clpyrazol-3-yl 1-1,1' biphenyl-4-ol The desired product was prepared using the procedure in Example 166B replacing Example 166A with Example 170C. However, the product was purified by flash chromatography instead of HPLC. The title product (168 mg) was obtained at 82% yield. MS (DCI/NH3) m/z: 611.24 (M+H)+.
Example 17 IB 4 - { 1 - Fbis(4-methoxyphenyl)methyll -6,7-dimethoxy- 1 ,4-dihydroindeno r 1 ,2-clp yrazol-3-yl 1-1,1'- biphenyl-4-yl l,4'-bipiperidine-l -carboxylate Example 171A (150 mg, 0.25 mmol) in pyridine (4 mL) was treated with [l,4']bipiperidinyl-l'-carbonyl chloride (190 mg, 3 mmol) and stirred for 3 days. Reaction mixture was poured into water and extracted with dichloromethane and ethyl acetate. The organic layer was dried over MgSO , and evaporated. The residue was purified by flash chromatography eluting with ethyl acetate :MeOH:NH4OH (100:5:0.5). The title compound (160 mg) was obtained at 81% yield.
Example 17 IC 4'-(6.7-dimethoxy-l,4-dihydroindenoFl,2-c1pyrazol-3-vP-l, -biphenyl-4-yl l,4'-bipiperidine-r- carboxylate Example 171B (90 mg, 0.11 mmol) in dichloromethane was treated with TFA (4.5 mL), and the reaction was stirred overnight and concentrated. The residue was purified by preparative HPLC. The title product (50 mg) was obtained at 56% yield. MS (DCIΛNH3) m/z: 579.30 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.65-1.73 (m, 6 H) 1.86-1.89 (m, 2 H) 2.08- 2.10 (m, 2 H) 2.93-3.02 (m, 4 H) 3.09 (m, 1 H) 3.43-3.49 (m, 4 H) 3.81 (s, 2 H) 3.83 (s, 3 H) 3.85 (s, 3 H) 7.23-7.26 (m, 4 H) 7.77 (d, 3=8.54 Hz, 2 H) 7.81 (d, 3=8.54 Hz, 2 H) 7.89 (3=8.86 Hz, 2 H) 9.11 (s, I H).
Example 172 3-(4-bromophenyl)-7-methoxy- 1 ,4-dihydroindeno F 1 ,2-c1pyrazol-6-ol
Example 172 A 5 -hydroxy-6-methoxyindan- 1 -one 5,6-Dimethoxy-l-indanone (1 g, 5.20 mmol) and NaCN (2.55g, 52 mmol) were combined in DMSO (10 mL). The reaction was stirred at 100°C for two days, cooled, diluted with water and extracted with dichloromethane. The aqueous solution was acidified with concentrated HCl, and extracted with dichloromethane. The organic layer was dried over MgSO and evaporated to give the title compound (500 mg). MS (DCI/NH3) m/z: 178.99 (M+H)+. 1H NMR (500 MHz, CD2C12) δ ppm 2.59 (t, 3=5.62 Hz, 2 H) 3.01 (t, J=5.62 Hz, 2 H) 3.93 (s, 3 H) 6.33 (s, 1 H) 6.95 (s, 1 H) 7.17 (s, 1 H).
Example 172B 6-methoxy-5-F(4-methoxybenzvPoxylindan-l-one Example 172A (1.4 g, 7.86 mmol), 4-methoxybenzyl chloride (2.13 g, 15.72 mmol), Na2CO3 (1.67 g, 15.72) and sodium iodide (1.18 g, 7.86) were combined in acetone (50 mL). The reaction was stirred for 3 days, and then the solvent was removed. The residue was mixed with water (300 mL) and ethyl acetate (100 mL). The precipitate was collected by filtration, washed with a mixture of hexane and ethyl acetate (2:1) and dried to give the title product (1.4 g). MS (DCI/NH3) m/z: 299.14 (M+H)+.
Example 172C 2-(4-bromobenzoyl)-6-methoxy-5-F(4-methoxybenzyl)oxylindan-l-one Example 172B (1.2 g, 4.0 mmol) in 40 mL of THF was treated with NaH (60%, 240 mg, 6.0 mmol). After the addition of Example 64A (1.31 g), the reaction mixture was stirred overnight and poured into ice water. The resulting mixture was acidified with concentrated HCl. The precipitate was collected by filtration and recrystallized from ethanol. The title product (1.7 g) was obtained at 88% yield. MS (DCI/NH3) m/z: 481.04 (M+H)+.
Example 172D 3-(4-bromophenvP-7-methoxy-6-F(4-methoxybenzvPoxy1-l,4-dihydroindenoFl,2-clpyrazole The desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 172C. The title compound (1.45 g) was obtained at 92% yield. MS (DCI/NH3) m/z: 479.05 (M+H)+.
Example 172E 3-(4-bromophenvP-7-methoxy-l,4-dihydroindenoFl,2-c1pyrazol-6-ol Example 172D (280 mg, 0.59 mmol) in HO Ac (35 mL) was heated at 90°C for 24 hours, and the solvent was evaporated. The residue was triturated with a mixture of hexane and ethyl acetate to give the title product (220 mg) at 90% yield. MS (DCI/NH3) m/z: 357.98 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.69 (s, 2 H) 3.85 (s, 3 H) 7.01 (s, 1 H) 7.20 (s, 1 H) 7.67 (d, 3=8.42 Hz, 2 H) 7.73 (d, J=8.42 Hz, 2 H). Example 173 3-(4 -hydroxy- 1 , 1 '-biphenyl-4-yl)-7-methoxy- 1 ,4-dihydroindenoFl ,2-clpyrazol-6-ol The desired product was prepared using the procedure in Example 166B replacing Example 166A with Example 172E. MS (DCI/NH3) m/z: 371.14 (M+H)+. 1H NMR (400 MHz, DMSO-Dg) δ ppm 3.72 (s, 2 H) 3.84 (s, 3 H) 6.86 (d, 3=8.59 Hz, 2 H) 7.00 (s, 1 H) 7.20 (s, 1 H) 7.55 (d, 3=8.59 Hz, 1 H) 7.69 (d, J=8.59 Hz, 2 H) 7.80 (d, J=8.59 Hz, 2 H) 8.96 (s, 1 H) 9.53 (s, I H).
Example 174 3-(4 -hydroxy-3 -methoxy- 1 , 1 '-biphenyl-4-yl)-7-methoxy-l ,4-dihydroindeno Fl ,2-c1pyrazol-6-ol
The desired product was prepared using the procedure in Example 164 replacing Example 64C with Example 172E. MS (DCI/NH3) m/z: 400.14 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.73 (s, 2 H) 3.86 (s, 3 H) 3.88 (s, 3 H) 6.87 (d, 3=8.11 Hz, 1 H) 7.02 (s, 1 H) 7.15 (dd, 3=8.11, 2.18 Hz, 1 H) 7.21 (s, 1 H) 7.26 (d, 3=1.87 Hz, 1 H) 7.74 (d, 3=8.42 Hz, 2 H) 7.81 (d, J=8.42 Hz, 2 H) 9.00 (s, 1 H) 9.12 (s, 1 H)
Example 175 4 '- F7-methoxy-6-(pyridin-2-ylmethoxy)- 1 ,4-dihvdroindeno F 1 ,2-c1pyrazol-3-yll -1,1 -biphenyl-4- ol
Example 175A 5-(benzyloxy)-6-methoxyindan-l-one Example 172A (15 g, 84.3 mmol), benzyl bromide (15 mL, 126.3 mmol), and K2CO3 (23.25 g, 168.5 mmol) were combined in acetone (50 mL). The reaction was stirred for 2 days, and the inorganic salt was removed by filtration. The filtrate was concentrated, and the residue was recrystallized from a mixture of hexane and ethyl acetate to give the title product (17.1 g) at 76% yield. MS (DCI/NH3) m/z: 269.11 (M+H)+.
Example 175B 5-(benzyloxy)-2-(4-bromobenzoyl)-6-methoxyindan- 1 -one The desired product was prepared using the procedure in Example 172C replacing Example 172B with Example 175A. MS (DCI/NH3) m/z: 450.98 (M+H)+.
Example 175C 6-(benzyloxy -3-(4-bromophenyP-7-methoxy-l,4-dihydroindenoFl,2-clpyrazole The desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 175B. MS (DCI/NH3) m/z: 449.08 (M+H)+.
Example 175D 6-(benzyloxy)-3-(4-bromophenyP-7-methoxy-l-{ F2-(trimethylsilvPethoxylmethyl|-l,4- dihydroindenoF 1 ,2-clpyrazole To a suspension of NaH (60%, 1.21 g, 30.25 mmol) in DMF (150 mL) was added Example 175C (12.3 g, 27.50 mmol). The mixture was stirred for 30 min and then SEMCl (5.35 mL, 30.25 mmol) was added dropwise. The reaction was stirred for 2 hours and poured into ice- water. The precipitate was collected by filtration and dried to give the title product (15.0 g) at 94% yield.
Example 175E 4'-(6-(benzyloxy)-7-methoxy- 1 -{ F2-(trimethylsilyl)ethoxy1methyl }-l ,4-dihydroindeno Fl ,2- clpyrazol-3-yl)-l , 1 -biphenyl-4-ol The desired product was prepared using the procedure in Example 166B replacing Example 166A with Example 175D. MS (DC-yNH3) m/z: 591.27 (M+H)+.
Example 175F
6-(benzyloxy)-7-methoxy-3-(4'-{ F2-(trimethylsilyl)ethoxy1methoxy 1-1,1 -biphenyl-4-yl)-l-( F2-
(trimethylsilypethoxylmethyl 1 - 1 ,4-dihydroindeno F 1 ,2-clpyrazole Example 175E (2.97 g, 5.03 mmol) was treated with NaH (60%, 221 mg, 5.53 mmol) in DMF for 1 hour, and then SEMCl (0.98 mL, 5.53 mmol) was added dropwise. The reaction was stirred at room temperature for 1 hour, poured into ice water, and extracted with ethyl acetate. The organic layer was dried over MgS0 , and concentrated. The residue was purified by flash chromatography eluting with hexane:ethyl acetate (4:1). The title product (3.02 g) was obtained at 88% yield. MS (DCI/NΗ3) m/z: 721.35 (M+H)+.
Example 175G 7-methoxy-3-(4 -(F2-(trimethylsilyl)ethoxylmethoxyl-l,l'-biphenyl-4-vP-l-(F2-
(trimethylsilvPethoxylmethyl 1 - 1 ,4-dihvdroindeno F 1 ,2-clp yr azol-6-ol Example 175F (3.0 g, 4.16 mmol) and Pd/C (10%, 443 mg, 0.416 mmol) were combined in THF (350 mL) and stirred under hydrogen atmosphere for 4 days. The solid was removed by filtration through Celite. The filtrate was concentrated, and the residue was purified by flash chromatography eluting with hexane:ethyl acetate (2:1). The title product (2.3 g) was obtained at 88% yield. MS (DCI/NH3) m z: 631.24 (M+H)+.
Example 175H 4'-r7-methoxy-6-(pyridin-2-ylmethoxy)-l,4-dihydroindenoFl,2-c1pyrazol-3-vn-l,r-biphenyl-4- ol Example 175G (50 mg, 0.0792 mmol), Cs2CO (103 mg, 0.317 mmol) and 2-chloromethylpyridine*HCl (14.3 mg, 0.087 mmol) were combined in DMF (2 mL). The reaction mixture was purged with a stream of nitrogen, stirred at 50 °C under nitrogen atmosphere overnight and concentrated. The residue was suspended in methanol (2 mL), treated with 4 N HCl in dioxane (2 mL) and heated at 50°C for 5 hours. Solvent was removed, and the residue was purified by preparative HPLC to give the title compound (11.6 mg, 2TFA salt) at 22.3 % yield. Examples 176 to 188 represented by Figure (IX) and shown in Table 9 were synthesized in a similar fashion as described in Example 175H, except substituting the appropriate organic chloride or bromide for 2-chloromethylpyridine»HCl.
Figure (IX)
Table 9
Example 189 4 -F7-methoxy-6-(pyridin-3-ylmethoxy)-l,4-dihydroindenoFl,2-clpyrazol-3-yll-l, -biphenyl-4- pi
Example 175G (50 mg, 0.0792 mmol), di-tert-butyl azodicarboxylate (44 mg, 0.19 mmol), polymer-supported Ph3P (3 mmol/g, 63 mg, 0.19 mmol) and pyridin-3-yl-methanol (22 mg, 0.20 mmol) were combined in THF (3 mL). The reaction was stirred at room temperature for 3 days, and the insoluble material was removed by filtration and washed with THF thoroughly. The filtrate was concentrated, and the residue was suspended in methanol (2 mL), treated with 4 N HCl in dioxane (2 mL) and heated at 50°C for 5 hours. The precipitate was collected by filtration to give the title compound. The filtrate was concentrated, and the residue was purified by HPLC to give another portion of the title compound.
Examples 190 to 204 represented by Figure (X) and shown in Table 10 were synthesized in a similar fashion as described in Example 189, except substituting the appropriate alcohol for pyridin-3-yl-methanol.
Figure (X) Table 10
Example 205 4-(6-hydroxy-7-methoxy- 1 ,4-dihydroindenoF 1 ,2-clpyrazol-3-yPbenzonitrile
Example 205A 6-methoxy-5-(F2-(trimethylsilyl)ethoxy1methoxylindan-l-one Example 172A (1 g, 5.62 mmol) and N,N-diisopropylethylamine (2.94 mL, 16.86 mmol) were combined in dichloromethane and treated with SEMCl (1.49 mL, 8.43 mmol). The reaction mixture was stirred for 1 hour, diluted with dichloromethane, washed with cold water and saturated NaHCO3. The organic layer was dried over MgSO and concentrated. The residue was purified by flash chromatography eluting with hexane:ethyl acetate (2:1). The title product (1.3 g) was obtained at 75% yield. MS (DCI/NH3) m/z: 309.1 (M+H)+.
Example 205B 4-(lH-imidazol-l-ylcarbonyl)benzonitrile The desired product was prepared using the procedure in Example 165A replacing 4- benzyloxybenzoic acid with 4-cyanobenzoic acid.
Example 205C 4-F(6-methoxy-l-oxo-5-f F2-(trimethylsilvPethoxylmethoxyl-2,3-dihvdro-lH-inden-2- vPcarbonyllbenzonitrile Example 205A (5.4 g, 17.51 mmol) in 250 mL of THF was treated with NaH (60%, 1.06 g, 26.37 mmol). After the addition of Example 205B (5.2 g, 26.37 mmol), the reaction mixture was stirred overnight and poured into ice water. The resulting mixture was acidified with concentrated HCl. Yellow solid was collected, washed with water and dried. MS (DCI/NH3) m/z: 438.17 (M+H)+.
Example 205D 4-(7-methoxy-6- 1 F2-(trimethylsilyl)ethoxy1methoxy i - 1 ,4-dihvdroindeno F 1 ,2-clpyrazol-3- yPbenzonitrile The desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 205C. The title compound (6.5 g) was obtained at 88% yield. MS (DCI/NH3) m z: 434.19 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 0.00 (s, 9 H) 0.92 (t, 3=8.11 Hz, 2 H) 3.77 (t, 3=8.11 Hz, 2 H) 3.81 (s, 2 H) 3.86 (s, 3 H) 5.24 (s, 2 H) 7.32 (s, 2 H) 7.96 (s, 4 H) 13.32 (s, 1 H).
Example 205E 4-(7-methoxy-6-{F2-(trimethylsilyl)ethoxylmethoxy)-l-{ F2-(trimethylsilyl)ethoxylmethyl 1-1,4- dihydroindenoFl,2-clpyrazol-3-yl)benzonitrile The desired product was prepared using the procedure in Example 175D replacing Example 175C with Example 205D. The title compound (6.5 g) was obtained at 83% yield. MS (DCI/NH3) m/z: 564.28 (M+H)+.
Example 205F 4-(6-h ydroxy-7-methoxy- 1 ,4-dihydroindeno F 1 ,2-clpyr azol-3 - vDbenzonitrile Example 205E (50 mg, 0.089 mmol) in ethanol (2 mL) was treated with 4 N HCl in dioxane (2 mL) and heated at 50°C for 5 hours. The precipitate was collected by filtration to give the title compound (22 mg) at 82% yield. MS (DCI/NH3) m/z: 304.06 (M+H)+. 1H NMR (400 MHz, DMSO-Dg) δ ppm 3.74 (s, 2 H) 3.84 (s, 3 H) 7.01 (s, 1 H) 7.20 (s, 1 H) 7.93 (s, 4 H).
Example 206 4-F7-methoxy-6-('pyridin-2-ylmethoxy)-1.4-dihvdroindenoFl,2-c1pyrazol-3-vnbenzonitrile
Example 206A 4-(6-hydroxy-7-methoxy-l-{F2-(trimethylsilyl)ethoxy1methyll-l,4-dihvdroindenoFl,2-c1pyrazol-
3-vPbenzonitrile Example 205E (1.5 g, 2.66 mmol) in ethanol (40 mL) was treated with 4 N HCl in dioxane (1 mL). The reaction was stirred at room temperature for 30 min. The precipitate was collected by filtration to give the title compound (0.98g) at 85% yield. MS (DCI/NH3) m/z: 434.21 (M+H)+.
Example 206B 4-F7-methoxy-6-(pyridin-2-ylmethoxy)-l,4-dihydroindenoFl,2-c1pyrazol-3-yllbenzonitrile Example 206A (50 mg, 0.115 mmol), di-tert-butyl azodicarboxylate (53.1 mg, 0.23 mmol), polymer-supported PI13P (3 mmol/g, 77 mg, 0.23 mmol) and pyridin-2-yl-methanol (25.2 mg, 0.23 mmol) were combined in THF (3 mL). The reaction was stiπ-ed at room temperature overnight, and the insoluble material was removed by filtration and washed with THF thoroughly. The filtrate was concentrated, and the residue was suspended in methanol (2 mL), treated with 4 N HCl in dioxane (2 mL) and heated at 50°C for 5 hours. The reaction mixture was concentrated, and the residue was purified by preparative HPLC to give the title compound (32.4 mg) at 71% yield. Examples 207 to 219 represented by Figure (XI) and shown in Table 11 were synthesized in a similar fashion as described in Example 206B, except substituting the appropriate alcohol for pyridin-3-yl-methanol.
Figure (XI) Table 11
Example 220 3-(4-cyanophenyP-N-(4-hydroxycyclohexyl)-7-methoxy-l,4-dihydroindenoFl,2-clpyrazole-6- carboxamide
Example 220A 6-methoxy- 1 -oxo-2,3-dihydro- lH-inden-5-yl trifluoromethanesulfonate Example 172A (6 g, 33.67 mmol), 2,6-lutidine (5.88 mL, 50.52 mmol), and 4- dimethylaminopyridine (822 mg, 6.72 mmol) were combined at -35°C - -30°C and then dropwise treated with triflic anhydride (8.52 mL, 50.64 mmol). The reaction mixture was slowly warmed to room temperature with stirring and concentrated. The residue was purified by flash chromatography eluting with hexane:ethyl acetate (2:1). The title product (9.8 g) was obtained at 94% yield. MS (DCIZNH3) m/z: 328.01(M+NH4)+.
Example 220B methyl 6-methoxy-l-oxomdane-5-carboxylate Example 220A (5.7 g, 18.37 mmol), PdCl2(dppi CH2Cl2 (1.5 g) and triethylamine (7.7 mL) were combined in methanol (50 mL) and stirred for 16 hours at 110°C under carbon monoxide atmosphere (500 psi). The solvent was removed, and the residue was purified by flash chromatography eluting with hexane:ethyl acetate (2:1). The title product (3.1 g) was obtained at 77% yield. MS (DCI/NH3) m/z: 221.02(M+H)+.
' Example 220C methyl 2-(4-cyanobenzoyl)-6-methoxy- 1 -oxoindane-5-carboxylate The desired product was prepared using the procedure in Example 205 C replacing Example 205 A with Example 220B. MS (DCI/NH3) m z: 350.07(M+H)+.
Example 220D methyl 3-(4-cyanophenyl)-7-methoxy-l,4-dihvdroindenoFl,2-c1pyrazole-6-carboxylate The desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 220C. The title compound (3.7 g) was obtained at 81% yield. MS (DCI/NH3) m/z: 346.08 (M+H)+. !H NMR (400 MHz, DMSO-Dg) δ ppm 3.80 (s, 3 H) 3.90 (s, 2 H) 3.91 (s, 3 H) 7.44 (s, 1 H) 7.83 (s, 1 H) 7.95 (d, 3=8.59 Hz, 2 H) 7.99 (d, 3=8.59 Hz, 2 H) 13.69 (s, 1 H).
Example 220E 3-(4-cyanophenyl)-7-methoxy- 1 ,4-dihvdroindeno F 1 ,2-c1pyrazole-6-carboxylic acid Example 220D (1 g, 2.90 mmol), 2 N NaOH (10 mL), THF(20 mL) and ethanol (20 mL) were combined and stirred overnight. The reaction mixture was concentrated, diluted with water and acidified with HCl. The precipitate was collected by filtration to give the title product (905 mg) at 85% yield. MS (DCI/NH3) m/z: 349.06 (M+NH4)+. 1H NMR (500 MHz, DMSO-D6) δ ppm 3.89 (s, 2 H) 3.92 (s, 3 H) 7.39 (s, 1 H) 7.85 (s, 1 H) 7.98 (s, 4 H).
Example 220F 3-(4-cvanophenyl)-N-(4-hvdroxycvclohexyl)-7-methoxy-l,4-dihydroindenoFl,2-c1pyrazole-6- carboxamide Example 220E (50 mg, 0.15 mmol), 4-aminocyclohexanol (52 mg, 0.45 mmol), BOP Reagent (100 mg, 0.23 mmol) and triethylamine (0.063 mL) were combined in DMF (2.5 mL) and stirred overnight. The precipitate was collected by filtration to give the title compound (44 mg) at 68% yield. MS (DCI/NH3) m/z: 429.2 (M+H)+.
Examples 221 to 227 represented by Figure (XII) and shown in Table 12 were synthesized in a similar fashion as described in Example 220F, except substituting the appropriate amine for 4-aminocyclohexanol.
Figure (XII) Table 12
Example 228 4-(6-{Ftrans (4-hvdroxycyclohexyl)aminolmethyl|-7-methoxy-l,4-dihydroindenoFl,2-c1pyrazol-
3-yl)benzonitrile
Example 228A (trans) 4-1 F(3-iodo-7-methoxy-l,4-dihvdroindenoFl,2-clpyrazol-6- yPmethyll amino I c vclohexanol Example 104E (150 mg, 0.44 mmol), trans-4-aminocyclohexanol hydrochloride (100 mg, 0.66 mmol) and K2CO3 (91 mg, 0.66 mmol) were combined in ethanol (20 mL) and heated at 100°C for 3 hours and cooled. After addition of NaBH4 (16.6 mg, 0.44 mmol), the reaction was stirred at room temperature overnight and concentrated. The residue was purified by flash chromatography eluting with CH2Cl2:CH3θH:NH4θH (100:10:1). The title compound (110 mg) was obtained at 57% yield. MS (ESI) m/z: 439.98 (M+H)+.
Example 228B 446-1 rtrans (4-hvdroxycyclohexyl)aminolmethyl}-7-methoxy-l,4-dihydroindenoFl,2-clpyrazol-
3-yl)benzonitrile Example 228 A (40 mg, 0.091 mmol), 4-cyanophenylboronic acid (16 mg, 0.11 mmol), Na2C03 (1 M, 0.25 mL), and Pd(PPh3)2Cl2 (6.4mg, 0.009mmol) were combined in DME/EtOH/H2O (7:2:3, 1.5 mL) in a capped 2 mL vial and heated to 160 °C for 600 seconds in a Smith Synthesizer. The reaction was cooled using 40 psi pressurized air, the solvents were evaporated, and the residue was purified using preparative HPLC. The title compound (20 mg) was obtained at 36% yield (based on 2TFA salt). MS (DCI/NH3) m/z: 415.19 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.14-1.23 (m, 2 H) 1.38-1.45 ( , 2 H) 1.89-1.91 (m, 2 H) 2.07-2.10 (m, 2 H) 3.00-3.05 (m, 2 H) 3.88 (s, 2 H) 3.94 (s, 3 H) 4.14-4.17 (m, 2 H) 7.39 (s, 1 H) 7.60 (s, 1 H) 7.96 (d, J=8.42 Hz, 2 H) 7.99 (d, J=8.42 Hz, 2 H) 8.45 (s, 2 H) Example 229 4- F6-( lH-imidazol- 1 -ylmethyl)-7-methoxy- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-3-yllbenzonitrile
Example 229 A methyl 3 -(4-cyanophenvP-7-methoxy- 1-1 F2-(trimethylsilyl)ethoxy]methyl I - 1 ,4- dihvdroindeno F 1 ,2-clpyrazole-6-carboxylate The desired product was prepared using the procedure in Example 175D replacing Example 175C with Example 220D. The title compound (1.5 g) was obtained at 91% yield. MS (DCI/NH3) m/z: 476.20 (M+H)+.
Example 229B 4-(6-(hydroxymethyl)-7-methoxy- 1 - { F2-(trimethylsilyPethoxy1methyl } - 1 ,4-dihvdroindeno F 1 ,2- c1pyrazol-3-yl)benzonitrile Example 229A (200 mg, 0.42 mmol) and NaBH (160 mg, 4.2 mmol) were combined in THF-MeOH (1:1), heated at 50°C overnight, and concentrated. The residue was purified by flash chromatography eluting with a mixture of ethyl acetate and hexane. MS (DCI/NH3) m/z: 448.19 (M+H)+.
Example 229C 4- r6-( lH-imidazol- 1 -ylmethyl)-7-methoxy- 1 ,4-dihydroindenoF 1 ,2-clpyrazol-3-yllbenzonitrile Example 229B (20 mg, 0.045 mmol) and l,l'-carbonyldiimidazole (30 mg, 0.18 mmol) were combined in acetonitiile (3 mL), heated at 80°C for 24 hours and concentrated. The residue was treated with ethanol (2 mL) and 4 N HCl in dioxane (2 mL), and the reaction mixture was stirred overnight. White precipitates was collected by filtration and dried to give the title compound (14.4 mg, HCl salt) at 80% yield. MS (DCI/NH3) m/z: 368.14 (M+H)+. H NMR (400 MHz, DMSO-Dg) δ ppm 3.86 (s, 2 H) 3.93 (s, 3 H) 5.43 (s, 2 H) 7.33 (s, 1 H) 7.39 (s, 1 H) 7.61 (s, 1 H) 7.67 (s, 1 H) 7.73 (s, 1 H) 7.95-8.00 (m, 4 H) 9.23 (s, 1 H)
Example 230 3-(6-chloropyridin-3-vP-6,7-dimethoxy-l,4-dihydroindenoFl,2-clpyrazole
Example 230A 2-chloro-5-( lH-imidazol- 1 -ylcarbonvPpyridine The desired product was prepared using the procedure in Example 165 A replacing 4- benzyloxybenzoic acid with 6-chloronicotinic acid.
Example 230B 2-F(6-chloropyridin-3-yl)earbonyll-5,6-dimethoxyindan-l-one The desired product was prepared using the procedure in Example 165B replacing Example 165A with Example 230A. MS (DCI/NH3) m/z: 331.98 (M+H)+.
Example 230C 3-(6-chloropyridin-3-vP-6,7-dimethoxy-l,4-dihydroindenoFl,2-c1pyrazole The desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 230B. The title product (937 mg) was obtained at 95% yield. MS (DCI/NH3) m/z: 328.01 (M+H)+. 1H NMR (400 MHz, DMSO-D6) δ ppm 3.80 (s, 2 H) 3.82 (s, 3 H) 3.84 (s, 3 H) 7.23 (s, 2 H) 7.65 (s, 1 H) 8.21 (d, J=7.37 Hz, 1 H) 8.82 (d, J=2.45 Hz, 1 H) 13.22 (s, 1 H).
Example 231
4-F5-(6,7-dimethoxy-l,4-dihydroindenoFl,2-c1pyrazol-3-yPpyridin-2-yllphenol
The desired product was prepared using the procedure in Example 166B replacing
Example 166A with Example 230C. MS (DCI/NH3) m/z: 386.09 (M+H)+. XR NMR (500 MHz, DMSO-Dg) δ ppm 3.82 (s, 3 H) 3.83 (s, 2 H) 3.84 (s, 3 H) 6.89 (d, 3=8.73 Hz, 2 H) 7.24 (d, J=7.80 Hz, 2 H) 7.98-8.01 (m, 3 H) 8.23 (dd, J=8.42, 2.18 Hz, 1 H) 8.99 (d, J=1.56 Hz, 1 H).
Example 232 4-F5-(6,7-dimethoxy-l,4-dihvdroindenoFl,2-clpyrazol-3-yl)pyridin-2-yll-2-methoxyphenol The title product was prepared using the procedure in Example 164 replacing Example 64C with Example 230C at 83% yield. MS (ESI) m/z: 416.08 (M+H)+. 1H NMR (500 MHz, DMSO-D6) δ ppm 3.82 (s, 3 H) 3.83 (s, 2 H) 3.84 (s, 3 H) 3.88 (s, 3 H) 6.89 (d, 3=8.42 Hz, 1 H) 7.24 (s, 1 H) 7.25 (s, 1 H) 7.59 (dd, J=8.26, 2.03 Hz, 1 H) 7.74 (d, 3=1.87 Hz, 1 H) 8.04 (d, J=8.42 Hz, 1 H) 8.21 (dd, 3=8.42, 2.18 Hz, 1 H) 9.00 (d, 3=1.87 Hz, 1 H).
Example 233 4-F5-(6,7-dimethoxy-l,4-dihydroindenoFl,2-clpyrazol-3-yl)pyridin-2-yll-2-fluorophenol The title product was prepared using the similar procedure in Example 232 replacing 2- methoxy-4-(4,4,5,5-tetramethyl[l,3,2] dioxaborolan-2-yl)-phenol with 2-fluoro-4-(4,4,5,5- tetramethyl[l,3,2] dioxaborolan-2-yl)-phenol. MS (ESI) m/z: 404.07 (M+H)+. JH NMR (500 MHz, DMSO-Dg) δ ppm 3.83 (s, 3 H) 3.84 (s, 2 H) 3.85 (s, 3 H) 7.07 (t, J=8.89 Hz, 1 H) 7.24 (s, 1 H) 7.26 (s, 1 H) 7.84 (dd, 3=8.42, 1.87 Hz, 1 H) 7.94 (dd, 3=12.79, 2.18 Hz, 1 H) 8.04 (d, 3=8.42 Hz, 1 H) 8.21 (dd, 3=8.42, 2.18 Hz, 1 H) 9.02 (d, 3=2.18 Hz, 1 H)
Example 234 5-(6,7-dimethoxy-l,4-dihydroindenoFl,2-clpyrazol-3-vPpyridine-2-carbonitrile The title product was prepared using the procedure in Example 167 replacing Example 64C with Example 230C. MS (DCI/MH3) m z: 319.06 (M+H)+. 1H NMR (500 MHz, DMSO- Dg) δ ppm 3.81 (s, 3 H) 3.83 (s, 5 H) 7.23 (s, 1 H) 7.24 (s, 1 H) 8.13 (d, J=8.11 Hz, 1 H) 8.34 (dd, J=8.42, 2.18 Hz, 2 H) 9.14 (d, 3=1.56 Hz, 1 H)
Example 235 6-(6,7-dimethoxy-l,4-dihvdiOindenoFl,2-clpyrazol-3-vPnicotinonitrile Example 235A methyl 5-bromopyridine-2-carboxylate 2,5-Dibromopyridine (9.5 g, 40.10mmol), PdCl2(PPh3)2 (844 mg), triethylamine (8.36 mL), methanol (38 mL), and acetonitrile (114 mL) were combined, heated under carbon monoxide atmosphere (75 psi) at 60°C for 16 hours and concentrated. The residue was purified by flash chromatography eluting with 25% ethyl acetate in hexane. The title compound (5.02 g) was obtained at 58% yield. MS (DCI/MH3) m z: 215.95 (M+H)+. 1H NMR (500 MHz, DMSO- Dg) δ ppm 3.91 (s, 3 H) 8.00 (d, J=8.11 Hz, 1 H) 8.27 (dd, 3=8.42, 2.49 Hz, 1 H) 8.86 (d, 3=1.56 Hz, 1 H)
Example 235B 2-F(5-bromopyridin-2-yl)carbonyn-5,6-dimethoxyindan-l-one The desired product was prepared using the procedure in Example 165B replacing Example 165A with Example 235A. The title compound (1.65 g) was obtained at 95% yield. MS (DCI/NH3) m/z: 375.98 (M+H)+.
Example 235 C 3-(5-bromopyridin-2-yl)-6,7-dimethoxy-l,4-dihydroindenoFl,2-c1pyrazole The desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 235B. The title compound (1.35 g) was obtained at 85% yield. MS (DCI/NH3) m/z: 373.94 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.76 (s, 2 H) 3.80 (s, 3 H) 3.83 (s, 3 H) 7.20 (s, 1 H) 7.25 (s, 1 H) 7.72 (d, 3=8.42 Hz, 1 H) 8.17 (d, J=6.86 Hz, 1 H) 8.76 (s, 1 H) 13.25 (s, 1 H)
Example 235D 6-(6,7-dimethoxy-l,4-dihvdroindenoFl,2-clpyrazol-3-yl)nicotinonitriIe The title product was prepared using the procedure in Example 167 replacing Example 64C with Example 235C at 70% yield. MS (DCI/MH3) m/z: 319.06 (M+H)+. 1H NMR (500 MHz, DMSO-D6) δ ppm 3.81 (s, 2 H) 3.82 (s, 3 H) 3.84 (s, 3 H) 7.24 (s, 1 H) 7.26 (s, 1 H) 7.98 (s, 1 H) 8.39 (d, 3=7.49 Hz, 1 H) 9.08 (d, J=1.25 Hz, 1 H)
Example 236 4 '- F6-( 1 -hydroxy- 1 -methylethvP- 1 ,4-dihydroindeno Fl ,2-c1pyrazol-3-yll- 1 , 1 -biphenyl-4-ol
Example 236A methyl l,4-dihydroindenoFl,2-clpyrazole-6-carboxylate The desired product was prepared using the procedure in Example 220B replacing Example 220A with 6-bromo- l,4-dihydro-indeno[l,2-c]pyrazole (for preparation, see U.S. Patent 6297238). MS (DCI/NH3) m/z: 215.05 (M+H)+.
Example 236B methyl 3-iodo- 1 ,4-dihydroindeno F 1 ,2-c1pyrazole-6-carboxylate The desired product was prepared using the procedure in Example 68B replacing Example 68A with 236A. MS (DCI NH3) m/z: 340.92 (M+H)+.
Example 236C 2-(3 -iodo- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-6-yl)propan-2-ol To a solution of Example 236B (1 g, 2.94 mmol) in THF (145 mL) was dropwise added 1.4 M MeMgBr in THF-toluene (8.4 mL, 11.76 mmol). The reaction mixture was slowly warmed to room temperature, stirred for 24 hours, quenched with aqueous NH4CI, and extracted with ethyl acetate. The organic layer was dried over MgS04 and concentrated. The residue was purified by flash chromatography eluting with 50% ethyl acetate in hexane. The title compound (700 mg) was obtained at 70% yield. MS (DC- H3) m/z: 340.95 (M+H)+. *H NMR (500 MHz, DMSO-Dg) δ ppm 1.44 (s, 6 H) 3.48 (s, 2 H) 5.02 (s, 1 H) 7.44 (dd, 3=7.80, 1.25 Hz, 1 H) 7.48 (m, 1 H) 7.65 (s, 1 H).
Example 236D 4-F6-(l-hvdroxy-l-methylethvP-l,4-dihydroindenoFl,2-c1pyrazol-3-yll-l, -biphenyl-4-ol Example 236C (45 mg, 0.13 mmol), Example 68D (47mg, 0.16 mmol), Na2CO3 (1 M, 0.3 mL), and Pd(PPh3)2Cl2 (9.9 mg, 0.014mmol) were combined in DME/EtOH/H2O (7:2:3, 1.5 mL) in a capped 2 mL vial and heated to 160 °C for 600 seconds in a Smith Synthesizer. The reaction was cooled using 40 psi pressurized air, the solvents were evaporated, and the residue was purified using preparative HPLC. The title compound (26.7 mg, TFA salt) was obtained at 42% yield. MS (DCI/NH3) m/z: 383.1 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.47 (s, 6 H) 3.86 (s, 2 H) 6.86 (d, 3=8.73 Hz, 2 H) 7.45 (d, 3=8.11 Hz, 1 H) 7.55-7.58 (m, 3 H) 7.69-7.72 (m, 3 H) 7.84 (d, 3=8.42 Hz, 2 H)
Example 237 4-F6-f 1 -hydroxy- 1 -methylethvP- 1 ,4-dihydroindenoF 1 ,2-clpyrazol-3-ynbenzonitrile The desired product was prepared using the procedure in Example 236D replacing Example 68D with 4-cyanophenyl boronic acid. The title compound (27.8 g) was obtained at 51% yield. MS (DCI/NH3) m/z: 316.09 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.47 (s, 6 H) 3.89 (s, 2 H) 7.47 (dd, 3=7.95, 1.40 Hz, 1 H) 7.57 (d, 3=8.11 Hz, 1 H) 7.69 (s, 1 H) 7.95 (d, 3=8.42 Hz, 2 H) 7.98 (d, 3=8.42 Hz, 2 H)
Example 238 2-F3-(6-chloropyridin-3-yl)-l,4-dihydroindenori,2-c1pyrazol-6-yllpropan-2-ol
Example 238A methyl l-oxoindane-5-carboxylate The desired product was prepared using the procedure in Example 220B replacing Example 220A with 5-bromoindanone. The title product was obtained at 85% yield. MS (DCI/NH3) m/z: 208.06(M+NH4)+. *H NMR (400 MHz, DMSO-Dg) δ ppm 2.69-2.72 (m, 2 H) 3.16-3.19 (m, 2 H) 3.90 (s, 3 H) 7.75 (d, 3=7.98 Hz, 1 H) 7.96 (dd, J=7.98, 1.53 Hz, 1 H) 8.15 (s, I H)
Example 238B methyl 2-r(6-chloropyridm-3-yl)carbonyll-l-oxoindane-5-carboxylate Example 238A (2.7 g, 14.2 mmol) in 45 mL of THF was treated with NaH (60%, 1.14 g, 28.4 mmol). After the addition of Example 230A (7.4 g, 35.5 mmol), the reaction mixture was stirred overnight and poured into ice water. The resulting mixture was acidified with concentrated HCl. Yellow solid was collected by filtration, washed with water and hot ethanol. The title product (4.3 g) was obtained at 92% yield. MS (DCI/NH3) m/z: 330.01 (M+H)+.
Example 238C methyl 3-(6-chloropyridin-3-yl)- 1 ,4-dihvdroindenoF 1 ,2-clpyrazole-6-carboxylate The desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 238B. The title compound (600 mg) was obtained at 74% yield. MS (DC-7NH3) m/z: 325.98 (M+H)+. 1H NMR (400 MHz, DMSO-Dg) δ ppm 3.88 (s, 3 H) 3.98 (s, 1 H) 4.01 (s, 1 H) 7.60-7.83 (m, 2 H) 8.00 (d, J=8.29 Hz, 1 H) 8.14 (s, 1 H) 8.25 (t, 3=9.97 Hz, 1 H) 8.85 (s, 1 H) 13.66 (s, 1 H)
Example 238D 2-F3-(6-chloropyridin-3-yl)-l,4-dihvdroindenoFl,2-c1pyrazol-6-yllpropan-2-ol The desired product was prepared using the procedure in Example 236C replacing Example 236B with Example 238C. The title compound (250 mg) was obtained at 83% yield. MS (ESI) m/z: 326.02 (M+H)+. H NMR (300 MHz, DMSO-D6) δ ppm 1.47 (s, 6 H) 3.89 (s, 2 H) 5.06 (s, 1 H) 7.48 (d, 3=8.48 Hz, 1 H) 7.58 (d, 3=7.80 Hz, 1 H) 7.66 (d, J=7.80 Hz, 1 H) 7.70 (s, 1 H) 8.24 (dd, 3=8.48, 2.37 Hz, 1 H) 8.85 (d, 3=2.03 Hz, 1 H) 13.37 (s, 1 H)
Example 239 4-{5-F6-(l-hvdroxy-l-methylethvP-l,4-dihydroindenoFl,2-c1pyrazol-3-yllpyridin-2-yl}phenol The desired product was prepared using the procedure in Example 166B replacing Example 166A with Example 238D. The title compound (25.1 mg) was obtained at 28% yield. MS (DCI/NH3) m z: 384.2 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.49 (s, 6 H) 3.93 (s, 2 H) 6.92 (d, 3=8.73 Hz, 2 H) 7.49 (dd, J=8.11, 1.56 Hz, 1 H) 7.60 (d, J=8.11 Hz, 1 H) 7.72 (s, 1 H) 8.00 (d, 3=9.04 Hz, 2 H) 8.04 (d, 3=8.42 Hz, 1 H) 8.29 (dd, 3=8.42, 2.18 Hz, 1 H) 9.03 (d, J=1.56 Hz, I H).
Example 240 3-(5,6-dichloropyridin-3-yP-6,7-dimethoxy-l,4-dihvdroindenoFl,2-clpyrazole
Example 240A 2,3-dichloro-5-(lH-imidazol-l-ylcarbonvPpyridine The desired product was prepared using the procedure in Example 165 A replacing 4- benzyloxybenzoic acid with 5, 6-chloronicotinic acid.
Example 240B 2-F(5,6-dichloropyridin-3-yl)carbonyll-5,6-dimethoxyindan-l-one The desired product was prepared using the procedure in Example 165B replacing Example 165 A with Example 240A.
Example 240C
3-(5,6-dichloropyridin-3-yP-6,7-dimethoxy-l,4-dihvdroindenoFl,2-clpyrazole
The desired product was prepared using the procedure in Example 165C replacing
Example 165B with Example 240B. MS (DCI/NH3) m/z: 361.98 (M+H)+. 1H NMR (400 MHz, DMSO-Dg) δ ppm 3.82 (s, 3 H) 3.83 (s, 2 H) 3.84 (s, 3 H) 7.23 (s, 1 H) 7.24 (s, 1 H) 8.42 (d, J=2.15 Hz, 1 H) 8.78 (d, J=2.15 Hz, 1 H).
Example 241 2-F3-(6-fluoropyridm-3-yl)-l,4-dihydroindenoFl,2-clpyrazol-6-yllpropan-2-ol The desired product was prepared using the procedure in Example 236D replacing Example 68D with 6-fluoronicotinic boronic acid. The title compound (350 g) was obtained at 96% yield. MS (DCI/NH3) m/z: 310.08 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.48 (s, 6 H) 3.88 (s, 2 H) 5.07 (s, 1 H) 7.35 (d, 3=6.71 Hz, 1 H) 7.48 (d, J=7.93 Hz, 1 H) 7.58 (d, J=6.71 Hz, 1 H) 7.70 (s, 1 H) 8.38 (m, 1 H) 8.67 (d, J=2.14 Hz, 1 H) 13.31 (s, 1 H)
Example 242 6,7-dimethoxy-3 -pyrazin-2-yl- 1 ,4-dihvdroindeno F 1 ,2-clpyrazole
Example 242A 5,6-dimethoxy-2-(pyrazin-2-ylcarbonyl)indan-l-one The desired product was prepared using the procedure in Example 165B replacing Example 165A with methyl pyrazine-2-carboxylate. MS (DCI/NH3) m/z: 299.06 (M+H)+.
Example 242B
6,7-dimethoxy-3-pyrazin-2-yl-l,4-dihydiOindenoFl,2-clpyrazole
The desired product was prepared using the procedure in Example 165C replacing
Example 165B with Example 242A. MS (DCI/NH3) m/z: 295.05 (M+H)+. !H NMR (500 MHz,
DMSO-Dg) δ ppm 3.82 (s, 3 H) 3.85 (s, 5 H) 7.23 (s, 1 H) 7.28 (s, 1 H) 8.59 (s, 1 H) 8.72 (s, 1
H) 9.05 (s, I H) 13.41 (s, 1 H). Example 243 6,7-dimethoxy-3-pyridin-3-yl-l,4-dihvdroindenoF1.2-clpyrazole
Example 243A 6,7-dimethoxy- 1 ,4-dihvdroindeno Fl ,2-clpyrazole A mixture of 5,6-dimethoxyindanone (6.0 g, 31 mmol), formic acid ethyl ester (5.04 mL, 62 mmol), 95% NaH (2.35 g, 93 mmol) and benzene (100 mL) was stirred at room temperature overnight. The solvent was removed. To the residue was added slowly ethanol (200 mL), acetic acid (20 mL) and hydrazine monohydrate (20 mL). The mixture was heated to reflux for 3 hours and cooled. The solvents were removed. The residue was suspended in water (100 mL), and the solid was collected by filtration, washed with water (100 mL) and CC (100 mL), and dried to give the desired product as light yellow solid powder (5.80 g, 87%). MS (ESI) m/z 217 (M+H)+. H NMR (300 MHz, DMSO-Dg) δ ppm 3.51 (s, 2 H) 3.79 (s, 3 H) 3.82 (s, 3 H) 7.17 (s, 1 H) 7.20 (s, I H) 7.56 (s, l H) 12.51 (s, l H).
Example 243B 3-iodo-6,7-dimethoxy-l,4-dihydroindenoFl,2-clpyrazole Example 243 A (5.80 g, 26.8 mmol), N-iodosuccinimide (7.84 g, 34.9 mmol), and anhydrous DMF (100 mL) were mixed, stirred at 80°C for 4 hours and concentrated. The residue was dissolved in dichloromethane (200 mL), washed with water (200 mLx3), dried over MgSO4 and concentrated. The residue was purified by flash chromatography to give the title product as brown solid (5.84 g, 64%). MS (ESI) m/z 343 (M+H)+. !H NMR (300 MHz, DMSO-Dg) δ ppm 3.42 (s, 2 H) 3.79 (s, 3 H) 3.81 (s, 3 H) 7.15 (s, 1 H) 7.19 (s, 1 H)
Example 243C 6,7-dimethoxy-3-pyridin-3-yl-l,4-dihydroindenoFl,2-clpyrazole Example 243B (100 mg, 0.29 mmol), pyridyl-3-boronic acid (43 mg, 0.35 mmol), Na2C03 (1 M, 0.35 mL), and Pd(PPh3)2Cl2 (20 mg, 0.014mmol) were combined in DME/EtOH/H2O (7:2:3, 4 mL) in a capped 5 mL vial and heated to 160 °C for 600 seconds in a Smith Synthesizer. The reaction was cooled using 40 psi pressurized air, the solvents were evaporated, and the residue was purified using preparative HPLC. MS (DCI/NH3) m/z: 294.1 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.83 (s, 5 H) 3.85 (s, 3 H) 7.24 (s, 1 H) 7.25 (s, 1 H) 7.73 (dd, J=7.95, 5.15 Hz, 1 H) 8.39 (d, 3=8.11 Hz, 1 H) 8.65 (dd, 3=4.99, 1.25 Hz, 1 H) 9.07 (d, 3=1.56 Hz, 1 H)
Example 244
6,7-dimethoxy-3-pyrimidin-5-yl-l,4-dihydroindenoFl,2-clpyrazole
The desired product was prepared using the procedure in Example 243C replacing pyridyl-3-boronic acid with pyrimidyl-5 -boronic acid. MS (DCI/NH3) m/z: 295.06 (M+H)+. 1H
NMR (500 MHz, DMSO-D6) δ ppm 3.82 (s, 3 H) 3.85 (s, 5 H) 7.24 (s, 1 H) 7.25 (s, 1 H) 9.16 (s,
1 H) 9.20 (s, 2 H).
Example 245 3-(6-chloropyridin-3-yl)-7-ethyl-6-methoxy-l,4-dihvdroindenoFl,2-c1pyrazole
Example 245A 6-methoxy-3-oxo-2,3-dihydro-lH-inden-5-yl trifluoromethanesulfonate Example 144B (3.5 g, 19.64 mmol) and NaH (60%, 496 mg, 19.64 mmol) were combined and stirred at 40°C until no bubble came out from the reaction mixture. After addition of N-phenyltrifluoromethanesulfonimide (8.41 g, 23.57 mmol), the reaction mixture was further stirred at 40°C for 30 min and concentrated. The residue was purified by flash chromatography eluting with 50% ethyl acetate in hexane. The title compound (5.5 g) was obtained at 90% yield. MS (DCI/NH3) m/z: 327.99 (M+NH4)+. 1H NMR (400 MHz, DMSO-Dg) δ ppm 2.65-2.68 (m, 2 H) 3.11-3.14 (m, 2 H) 4.01 (s, 3 H) 7.52 (s, 1 H) 7.62 (s, 1 H) Example 245B 5-methoxy-6-vinylindan- 1 -one Example 245A (4.5 g, 14.5 mmol), tributylvinyltin (5.54 g, 17.4 mmol), Pd(PPh3)2Cl2 (1.02 g, 1.45 mmol) and lithium chloride (4.9 g, 116 mmol), were combined in DMF (60 mL) and heated at 80°C for 2 hours, cooled. After addition of saturated potassium fluoride (100 L), the resulting mixture was stirred for 30 min, and diluted with ethyl acetate (800 mL). Precipitates were removed by filtration, and the filtrate was washed with water extensively, then with 10% HCl. The organic layer was dried over MgSO4 and concentrated. The residue was purified by flash chromatography eluting with 30% ethyl acetate in hexane. The title compound (1.65 g) was obtained at 60% yield. MS (DCI/NH3) m/z: 189.04 (M+H)+. 1H NMR (500 MHz, DMSO- Dg) δ ppm 2.47-2.49 (m, 2 H) 2.94-2.96 (m, 2 H) 3.81 (s, 3 H) 5.19 (dd, J=l 1.23, 1.25 Hz, 1 H) 5.74 (dd, 3=17.78, 1.25 Hz, 1 H) 6.83 (dd, 3=17.78, 11.23 Hz, 1 H) 7.06 (s, 1 H) 7.60 (s, 1 H).
Example 245 C 6-ethyl-5 -methoxyindan- 1 -one Example 245B (1.59 g, 8.46 mmol) and Pd-C (10%, 159 mg) were combined in THF (70 mL) and stirred under hydrogen atmosphere for 6 hours. Insoluble material was removed by filtration through Celite, the filtrate was evaporated to give the title product at quantitative yield.
Example 245D 2-F(6-chloropyridin-3-ypcarbonyll-6-ethyl-5-methoxymdan-l-one The desired product was prepared using the procedure in Example 238B replacing Example 238 A with Example 245C. The title compound (325 mg) was obtained at 71% yield.
Example 245E
3-(6-chloropyridin-3-yl)-7-ethyl-6-methoxy-l,4-dihvdroindenoF1.2-c1pyrazole
The desired product was prepared using the procedure in Example 165C replacing
Example 165B with Example 245D. MS (DCI/NH3) m/z: 326.04 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.04 (t, 3=7.49 Hz, 3 H) 2.50 (q, 3=7.49 Hz, 2 H) 3.69 (s, 2 H) 3.71 (s, 3 H) 7.06 (s, 1 H) 7.27 (d, J=8.42 Hz, 1 H) 7.48 (d, J=8.42 Hz, 1 H) 8.07 (s, 1 H) 8.67 (d, 3=2.18 Hz, 1 H) 13.04 (s, 1 H)
Example 246 5-(7-ethyl-6-methoxy- 1 ,4-dihydroindenoFl ,2-c1pyrazol-3-yl)pyridine-2-carbonitrile The title product was prepared using the procedure in Example 167 replacing Example 64C with Example 245E at 65% yield. MS (DCI MH3) m/z: 317.04 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.18 (t, 3=7.48 Hz, 3 H) 2.64 (q, J=7.63 Hz, 2 H) 3.86 (s, 3 H) 3.89 (s, 2 H) 7.23 (s, 1 H) 7.43 (s, 1 H) 8.15 (d, J=8.24 Hz, 1 H) 8.35 (dd, 3=8.24, 2.14 Hz, 1 H) 9.15 (d, 3=1.83 Hz, I H).
Example 247 3-(6-chloropyridin-3-yl)-7-ethyl-6-(tetrahydro-2H-pyran-4-yloxy)- 1 ,4-dihydroindeno F 1 ,2- clpyrazole
Example 247A 6-ethyl-5-hydroxyindan- 1 -one Example 245C (1 g, 5.31 mmol) in dichloromethane (25 mL) at -78°C was treated with BB1-3 (2 mL, 21.24 mmol). The reaction mixture was warmed to room temperature and stirred for 24 hours. The reaction was quenched with water and extracted with ethyl acetate. Organic layer was dried over MgSO4 and concentrated. The residue was purified by flash chromatography eluting with 50% ethyl acetate in hexane. The title compound (0.8 g) was obtained at 85% yield.
Example 247B 6-ethyl-5-(tetrahydro-2H-pyran-4-yloxy)indan- 1 -one Example 247A (150 mg, 0.85mmol), polymer supported Ph3P (3 mmol/g, 0.57 g, 1.7 mmol), di-tert-butyl azodicarboxylate (392 mg, 1.70 mmol) and tetrahydropyran-4-ol (174 mg, 1.70 mmol) were combined in THF (4 mL) and stirred overnight. Insoluble material was removed by filtration, and the filtrate was concentrated. The residue was purified by flash chromatography eluting with a mixture of ethyl acetate and hexane. The title compound was obtained at quantitative yield. MS (DCI/MH3) m/z: 261.1 (M+H)+.
Example 247C 2-F(6-chloropyridin-3-yl)carbonyn-6-ethyl-5-(tetrahvdro-2H-pyran-4-yloxy)indan-l-one The desired product was prepared using the procedure in Example 238B replacing Example 238 A with Example 247B.
Example 247D 3-(6-chloropyridin-3-yl)-7-ethyl-6-(tetrahvdro-2H-pyran-4-yloxy)-1.4-dihydroindenoFl,2- clpyrazole The desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 247C. MS (DCI/NH3) m/z: 396.1 (M+H)+. JH NMR (500 MHz, DMSO-Dg) δ ppm 1.19 (t, 3=7.49 Hz, 3 H) 1.61-1.68 (m, 2 H) 1.98-2.01 (m, 2 H) 2.66 (q, 3=7.49 Hz, 2 H) 3.51-3.55 (m, 2 H) 3.81 (s, 2 H) 3.84-3.87 (m, 2 H) 4.63-4.68 (m, 1 H) 7.26 (s, 2 H) 7.42 (s, 1 H) 7.63 (d, 3=8.11 Hz, 1 H) 8.20 (dd, 3=8.11, 2.49 Hz, 1 H) 8.80 (d, 3=2.18 Hz, 1 H) 13.17 (s, 1 H)
Example 248 4-{5-F7-ethyl-6-(tetrahvdro-2H-pyran-4-yloxy)-l,4-dihydroindenoFl,2-clpyrazol-3-ynpyridin-2- yl} phenol The desired product was prepared using the procedure in Example 166B replacing Example 166A with Example 247D. The title compound (35.2 mg) was obtained at 43% yield. MS (DCI/NH3) m/z: 454.17 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.21 (t, J=7.49 Hz, 3 H) 1.63-1.70 (m, 2 H) 2.00-2.03 (m, 2 H) 2.68 (q, 3=7.49 Hz, 2 H) 3.52-3.57 (m, 2 H) 3.86 (s, 3 H) 3.84-3.89 (m, 2 H) 4.65-4.69 (m, 1 H) 6.90 (d, 3=8.73 Hz, 2 H) 7.28 (s, 1 H) 7.45 (s, 1 H) 8.00 (d, 3=8.73 Hz, 3 H) 8.22 (dd, 3=8.26, 2.03 Hz, 1 H) 9.00 (d, J=2.18 Hz, 1 H)
Example 249 5-F7-ethyl-6-(3-morpholin-4-ylpropoxy)-l,4-dihydroindenoFl,2-clpyrazol-3-yllpyridine-2- carbonitrile
Example 249A 6-ethyl-5 - ( F2-(trimethylsilyl)ethoxy1methoxy j indan- 1 -one The desired product was prepared using the procedure in Example 205A replacing Example 172A with Example 247A.
Example 249B 2- F(6-chloropyridm-3-yl)carbonyll-6-ethyl-5- { F2-(trimethylsilyl)ethoxy1methoxy 1 indan- 1 -one The desired product was prepared using the procedure in Example 238B replacing Example 238 A with Example 249A.
Example 249C 3-(6-chloropyridin-3-yl)-7-ethyl-6- { F2-(trimethylsilyl)ethoxylmethoxy I- 1 ,4-dihydroindeno Fl ,2- clpyrazole The desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 249B. The title compound (1.35 g) was obtained at 69% yield (for 3 steps).
Example 249D
3-(6-chloropyridin-3-yl)-7-ethyl-6- 1 F2-(trimethylsilyl)ethoxylmethoxy 1-1-172-
(trimethylsilvPethoxylmethyl } - 1 ,4-dihydroindeno f 1 ,2-clpyrazole The desired product was prepared using the procedure in Example 175D replacing Example 175C with Example 249C. The title compound (1.05 g) was obtained at 81% yield.
Example 249E 5 -(7 -ethyl -6- 1 F2-(trimethylsilyPethoxylmethoxy ) - 1 - { F2-( trimethylsilyPethoxylmethyl 1-1,4- dihvdroindenoFl,2-clpyrazol-3-yl)pyridine-2-carbonitrile Example 249D (900 mg, 1.57 mmol), Pd2(dba)3 (36 mg, 0.039 mmol), dppf (43.5 mg, 0.078 mmol), zinc (204 mg, 0.39 mmol) and Zn(CN)2 were combined in DMA (75 mL), heated at 130°C for 3 hours and concentrated. The residue was purified by flash chromatography eluting with 20% ethyl acetate in hexane. The title product (872 mg) was obtained at 98.5 % yield. MS (DCI/NH3) m/z: 563.26 (M+H)+.
Example 249F 5-("7-ethyl-6-hvdroxy-l-{ F2-(trimethylsilyl)ethoxy1methyl|-l,4-dihvdroindenoFl,2-clpyrazol-3- vDpyridine-2-earboι.itrile The desired product was prepared using the procedure in Example 206A replacing Example 205E with Example 249E. The title compound (250 mg) was obtained at 81% yield. MS (DCI/NH3) m/z: 433.19 (M+H)+.
Example 249G 5-F7-ethyl-6-(3-morpholin-4-ylpropoxy)-l,4-dihydroindenoFl,2-clpyrazol-3-yllpyridine-2- carbonitrile Example 249F (40 mg, 0.092mmol), polymer supported PI13P (3 mmol/g, 46 mg, 0.139 mmol), di-tert-butyl azodicarboxylate (32 mg, 0.139 mmol) and 3-morpholin-4-ylpropan-l-ol (27 mg, 0.184 mmol) were combined in THF (3 mL) and stirred overnight. Insoluble material was removed by filtration, and the filtrate was concentrated. The residue was dissolved in a mixture of EtOH (5 mL) and CH2C12 (2 mL), treated with 4 N HCl in dioxane (0.5 mL), stirred at 50°C overnight and concentrated. The residue was purified by preparative HPLC. The title compound (33 mg) was obtained at 50% yield. MS (DCI/MH3) m/z: 430.2 (M+H)+.
Examples 250 to 254 represented by Figure (XIII) and shown in Table 13 were synthesized in a similar fashion as described in Example 249G, except substituting the appropriate alcohol for 3-morpholin-4-ylpropan-l-ol.
Figure (XIII) Table 13
Example 255 5-(6J-diethyl-l,4-dihvdroindenoFl,2-clpyrazol-3-vPpyridiιιe-2-carbonitrile
Example 255A 6-ethyl-l-oxo-2,3-dihydro-lH-inden-5-yl trifluoromethanesulfonate The desired product was prepared using the procedure in Example 245 A replacing Example 144B with Example 247A. The title compound (8.5 g) was obtained at 72% yield. MS (DCI/NH3) m/z: 325.99 (M+NH4)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.22 (t, 3=7.49 Hz, 3 H) 2.68-2.70 (m, 2 H) 2.74 (q, J=7.49 Hz, 2 H) 3.13-3.15 (m, 2 H) 7.64 (s, 1 H) 7.74 (s, 1 H)
Example 255B 6-ethyl-5-vinylindan-l -one The desired product was prepared using the procedure in Example 245B replacing Example 245A with Example 255A. The title compound (430 mg) was obtained at 52% yield. MS (DCI/NH3) m/z: 187.05 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.13 (t, 3=7.63 Hz, 3 H) 2.60-2.63 (m, 2 H) 2.74 (q, J=7.43 Hz, 2 H) 3.05-3.08 (m, 2 H) 5.49 (dd, 3=11.14, 1.07 Hz, 1 H) 5.90 (dd, J=17.39, 1.22 Hz, 1 H) 7.07 (dd, 3=17.39, 10.98 Hz, 1 H) 7.44 (s, 1 H) 7.71 (s, I H)
Example 255 C 2-F(6-chloropyridin-3-yPcarbonyll-6-ethyl-5-vinylindan-l-one The desired product was prepared using the procedure in Example 238B replacing Example 238A with Example 255B. The title compound was directly used for the preparation of Example 255D.
Example 255D 3-(6-chloropyridin-3-vP-7-ethyl-6-vinyl-l,4-dihydroindenoFl,2-clpyrazole The desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 255C. The title compound (250 mg) was obtained at 46% yield (for 2 steps). MS (DCI/NH3) m/z: 322.04 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.19 (t, 3=7.64 Hz, 3 H) 2.77 (q, 3=7.49 Hz, 2 H) 3.88 (s, 2 H) 5.34 (d, J=12.17 Hz, 1 H) 5.79 (d, 3=17.16 Hz, 1 H) 7.07 (dd, 3=17.31, 11.07 Hz, 1 H) 7.48 (s, 1 H) 7.65 (d, 3=7.80 Hz, 1 H) 7.74 (s, 1 H) 8.24 (dd, J=8.42, 2.50 Hz, 2 H) 8.84 (d, 3=2.50 Hz, 1 H) 13.41 (s, 1 H).
Example 255E l-rbis(4-methoxyphenyl)methyll-3-(6-chloropyridin-3-yP-7-ethyl-6-vinyl-l,4- dihydroindenori ,2-clpyrazole The desired product was prepared using the procedure in Example 170B replacing 4- iodo-lH-pyrazole with Example 255D. The title product (220 mg) was obtained at 79% yield.
Example 255F l-Fbis(4-methoxyphenyPmethyll-3-(6-chloropyridin-3-yP-6,7-diethyl-l,4-dihvdroindenoFl,2- clpyrazole Example 255E (130 mg) and Pt/C (5%, 13 mg) were combined in THF and stirred for 4 hours under hydrogen atmosphere. The insoluble material was removed by filtration, and the filtrate was evaporated. The title compound was obtained at quantitative yield.
Example 255G 5-{ l-Fbis(4-methoxyphenvPmethyll-6,7-diethyl-l,4-dihydroindenoFl,2-clpyrazol-3-yl)pyridine-
2-carbonitrile The title product was prepared using the procedure in Example 167 replacing Example 64C with Example 255F. The title product (62 mg) was obtained at 67% yield.
Example 255H 5-(6,7-diethyl-l,4-dihvdroindenoFl,2-clpyrazol-3-yl)pyridine-2-carbonitrile Example 255G (60 mg, 0.11 mmol) in a mixture of ethanol (10 mL) and THF (5 mL) was treated with 4 N HCl in dioxane (1 mL). The reaction was stirred for 4 hour, and the precipitate was collected, dried. The title product (30 mg) was obtained at 86% yield. MS (DCI/NH3) m/z: 315.11 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.20-1.25 (m, 6 H) 2.66-2.73 (m, 4 H) 3.87 (s, 2 H) 7.38 (s, 1 H) 7.46 (s, 1 H) 8.14 (d, J=8.11 Hz, 1 H) 8.37 (dd, J=8.11, 2.18 Hz, 1 H) 9.16 (d, J= 1.56 Hz, 1 H)
Example 256 3-(6-chloropyridm-3-yP-6,7-bis(2-methoxyethoxy -l,4-dihydiOindenoFl,2-c1pyrazole Example 256 A 5 ,6-bis(2-methoxyethoxy)indan- 1 -one Example 144A (800 mg, 4.88 mmol), 2-bromoethyl methyl ether (8 mL, 85.1 mmol), CS2CO3 (9 g, 27.6 mmol) were combined in DMF and heated at 100°C for 2 hours. Inorganic salts were removed by filtration, and the filtrate was concentrated. The residue was purified by flash chromatography eluting with 50% ethyl acetate in hexane. The title product (600 mg) was obtained at 44% yield. MS (DCI/NH3) m/z: 281.00 (M+H)+.
Example 256B 2-F(6-chloropyridin-3-yPcarbonyll-5,6-bis(2-methoxyethoxy)indan-l-one The desired product was prepared using the procedure in Example 238B replacing Example 238 A with Example 256 A.
Example 256C 3-(6-chloropyridin-3-yl)-6,7-bis(2-methoxyethoxy -l,4-dihydroindenoFl,2-clpyrazole The desired product was prepared using the procedure in Example 165C replacing Example 165B with Example 256B. The title compound (617 mg) was obtained at 82% yield (for 2 steps). MS (DCI/NH3) m/z: 416.1 (M+H)+. JH NMR (500 MHz, DMSO-Dg) δ ppm 3.34 (s, 3 H) 3.35 (s, 3 H) 3.68-3.71 (m, 4 H) 3.78 (s, 2 H) 4.14-4.18 (m, 4 H) 7.24 (s, 1 H) 7.26 (s, 1 H) 7.64 (d, 3=7.80 Hz, 1 H) 8.20 (dd, J=8.42, 2.50 Hz, 1 H) 8.81 (d, 3=2.18 Hz, 1 H) 13.22 (s, 1 H).
Example 257 5-F6,7-bis(2-methoxyethoxy)- 1 ,4-dihvdroindeno Fl ,2-clpyrazol-3-yllpyridine-2-carbonitrile The title product was prepared using the procedure in Example 167 replacing Example 64C with Example 256C. The title product was obtained at 85% yield. MS (DC17NH3) m/z: 424.16 (M+NH )+. 1H NMR (400 MHz, DMSO-Dg) δ ppm 3.34 (s, 3 H) 3.35 (s, 3 H) 3.68- 3.71(m, 4 H) 3.85 (s, 2 H) 4.15-4.19 (m, 4 H) 7.26 (s, 1 H) 7.27 (s, 1 H) 8.14 (d, 3=8.29 Hz, 1 H) 8.35 (dd, 3=8.29, 2.15 Hz, 1 H) 9.15 (d, 3=1.53 Hz, 1 H). Example 258 6-hydroxy-3-('4'-hydroxy-l, -biphenyl-4-yl)-7-methoxyindenoFl,2-clpyrazol-4(lH)-one
Example 258A 6-hydroxy-7-methoxy-3-(4'- 1 F2-(trimethylsilvPethoxylmethoxy 1-1,1 -biphenyl-4-vD- 1 - { F2- (trimethylsilypethoxylmethyl I indeno F 1 ,2-clp yrazol-4( 1 H)-one Example 175G (310 mg, 0.49 mmol) and CS2CO3 (640 mg, 1.96 mmol) were combined in DMF and heated under air at 90°C for 24 hours. Inorganic salt was removed by filtration, and the filtrate was concentrated. The residue was purified by flash chromatography eluting with 33% ethyl acetate in hexane. The title product (282 mg) was obtained at 89% yield. MS (DCI/NH3) m/z: 645.29 (M+NH4)+.
Example 258B 6-hydroxy-3-(4'-hydroxy-l, -biphenyl-4-yl)-7-methoxyindenoFl,2-c1pyrazol-4(lH)-one Example 258A (30 mg, 0.46 mmol) in ethanol (2 mL) was treated with 4 N HCl in dioxane (2 mL). The reaction mixture was heated at 50°C overnight and concentarted. The residue was purified by preparative HPLC. The title compound (19 mg) was obtained at 85% yield. MS (DCI/NH3) m/z: 385.09 (M+NH4)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.92 (s, 3 H) 6.88 (d, J=8.73 Hz, 2 H) 7.01 (s, 1 H) 7.14 (s, 1 H) 7.62 (d, 3=8.73 Hz, 2 H) 7.78 (d, 3=8.42 Hz, 2 H) 8.22 (d, 3=8.42 Hz, 2 H) 9.53 (s, 1 H) 9.63 (s, 1 H) 13.46 (s, 1 H)
Example 259 3-(4 -hydroxy- 1 , 1 '-biphenyl-4-yl)-7-methoxy-6-(2-piperidin- 1 -ylethoxy)indenoFl ,2-clpyrazol-
4(7H)-one Example 258A (40 mg, 0.0465 mmol), di-tert-butyl azodicarboxylate (21.4 mg, 0.093 mmol), polymer-supported Ph3P (3 mmol/g, 31 mg, 0.093 mmol) and 2-piperidin-l-ylethanol (15 mg, 0.116 mmol) were combined in THF (3 mL). The reaction was stirred at room temperature for 2 days, and the insoluble material was removed by filtration and washed with THF thoroughly. The filtrate was concentrated, and the residue was treated with 4 N HCl in dioxane (2 mL) and methanol (2 mL), and heated at 50°C for 3 hours and concentrated. The residue was purified by HPLC to give title compound (14.4 mg) at 45% yield. MS (DC-7NH3) m/z: 496.2 (M+H)+.
Examples 260 and 261 represented by Figure (XIV) and shown in Table 14 were synthesized in a similar fashion as described in Example 259, except substituting the appropriate alcohol for 2-piperidin-l-ylethanol.
Figure (XIV) Table 14
Example 262 4-{6-F3-(dimethylamino)propoxy1-7-methoxy-4-oxo-l,4-dihvdroindenoFl,2-clpyrazol-3- yllbenzonitrile
Example 262A 4-(7-methoxy-4-oxo-6-{ r2-(trimethylsilvPethoxylmethoxy}-l-{r2- (trimethylsilypethoxylmethyl 1-1 ,4-dihydroindeno F 1 ,2-clpyr azol-3 -ypbenzonitrile Example 205E (1.8 g, 3.19 mmol) and CS2CO3 (4.16 g, 12.76 mmol) were combined in DMF (50 mL) and heated under air at 50°C overnight. Inorganic salt was removed by filtration, and the filtrate was concentrated. The residue was purified by flash chromatography eluting with 25% ethyl acetate in hexane. The title product (1.82 g) was obtained at 99% yield. MS (DCI/NH3) m/z: 578.25 (M+H)+.
Example 262B 4-(6-hydroxy-7-methoxy-4-oxo- 1 - { F2-(trimethylsilyl)ethoxy1methyl } - 1 ,4-dihvdroindeno F 1 ,2- c1pyrazol-3-yl)benzonitrile The desired product was prepared using the procedure in Example 206A replacing Example 205E with Example 262A. The title compound was obtained at quantitative yield.
Example 262C 4- { 6- F3 -(dimethylamino)propoxyl -7-methox v-4-oxo- 1 ,4-dihvdroindeno \ 1 , 2-clpyrazol-3 - yllbenzonitrile Example 262B (40 mg, 0.089 mmol), di-tert-butyl azodicarboxylate (42 mg, 0.18 mmol), polymer-supported PI13P (3 mmol/g, 60 mg, 0.18 mmol) and 3-dimethylaminopropanol (18.6 mg, 0.18 mmol) were combined in THF (3 mL). The reaction was stirred at room temperature overnight, and the insoluble material was removed by filtration and washed with THF thoroughly. The filtrate was concentrated, and the residue was treated with 4 N HCl in dioxane (2 mL) and methanol (2 mL), and heated at 50°C for 5 hours. The reaction mixture was concentrated, and the residue was purified by HPLC to give the title compound (41 mg) at 77% yield. MS (DCI/NH3) m/z: 403.14 (M+H)+. Example 263 4-(6-hydroxy-7-methoxy-4-oxo-l,4-dihvdroindenoFl,2-clpyrazol-3-vPbenzonitrile The desired product was prepared using the procedure in Example 205F replacing
Example 205E with Example 262A. The title compound was obtained at quantitative yield. MS
(ESI) m/z: 315.99 (M-HV.
Examples 264 and 265 represented by Figure (XV) and shown in Table 15 were synthesized in a similar fashion as described in Example 262C, except substituting the appropriate alcohol for 3-dimethylaminopropanol.
Figure (XV) Table 15
Example 266 3-(6-chloropyridm-3-yl)-6,7-dimethoxy-4-methyl-l,4-dihydroindenoFl,2-clpyrazol-4-ol
Example 266A 3-(6-chloropyridin-3-yl)-6,7-dimethoxyindenori,2-c1pyrazol-4(lH)-one Example 230C (300 mg, 0.91 mmol) and CS2CO3 (1.5 g, 4.6 mmol) were combined in DMF (30 mL), heated under air at 90°C for 3 hours and concentrated. The residue was suspended in water, and the orange solid were collected by filtration and dried. The title product (287 mg) was obtained at 92% yield. MS (DCI/NH3) m/z: 342.20 (M+H)+. 1H NMR (400 MHz, DMSO-Dg) δ ppm 3.82 (s, 3 H) 3.90 (s, 3 H) 7.15 (s, 1 H) 7.16 (s, 1 H) 7.75 (d, J=8.59 Hz, 1 H) 8.48 (dd, 3=8.44, 2.30 Hz, 1 H) 9.14 (d, 3=2.15 Hz, 1 H).
Example 266B 3-(6-chloroρyridin-3-yl)-6,7-dimethoxy-4-methyl- 1 ,4-dihydroindeno n ,2-clpyrazol-4-ol To a suspension of 266A (100 mg, 0.29 mmol) in THF (15 mL) at 0°C was added 1.4 M GEbMgCl in toluene:THF (1:1, 1.3 mL). The reaction was warmed to room temperature, stirred for 1 day, quenched with water and concentrated. The residue was purified by preparative HPLC. MS (DCI/NH3) m/z: 358.03 (M+H)+. 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.57 (s, 3 H) 3.83 (s, 6 H) 3.86 (d, J=2.81 Hz, 1 H) 7.10 (s, 1 H) 7.17 (d, J=3.74 Hz, 1 H) 7.69 (d, J=8.42 Hz, 1 H) 8.37 (dd, 3=8.42, 2.50 Hz, 1 H) 9.01 (d, 3=2.50 Hz, 1 H).
Example 267 4 '- F6-methoxy-7-(2-pyrrolidin- 1 -ylethoxy)- 1 ,4-dihvdroindeno F 1 , 2-clpyrazol-3-yll -1,1 -biphenyl-
4-ol
Example 267A 1 -(4-bromobenzoyD- lH-imidazole To a solution of 4-bromo-benzoic acid (19.55 g, 97.3 mmol) in DMF (100 mL) was added l,l'-carbonyldiimidazole (39.42 g, 243.2 mmol) slowly at room-temperature under N2. After 2 hours, the reaction was completed and poured into ice water (1 L). The precipitate was filtered, washed with water (2 L), and dried in vacuo to give the desired product (16.7 g, 68%). MS (DCI NH3) m/z 252 (M+H)+; 1H NMR (300 MHz, DMSO-Dg) 6 ppm 7.02 (s, 1 H) 7.17 (s, 1 H) 7.63-7.90 (m, 4 H) 8.21 (s, 1 H)
Example 267B 6-(benzyloxy -5 -methoxyindan- 1 -one Example 144B (8.65 g, 48.5 mmol), benzyl bromide (12 mL, 97.1 mmol), K2CO3 (20.2 g, 146.2 mmol) and anhydrous acetone (500 mL) were mixed and refluxed overnight. Acetone was removed, and the concentrate was treated with water (300 mL). The precipitate was filtered, washed with water (300 mLx2), and dried to give the desired product (11.80 g, 91%). MS (DCI/NH3) m/z 269 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 2.61-2.67 (m, 2 H) 3.04-3.10 (m, 2 H) 3.95 (s, 3 H) 5.12 (s, 2 H) 7.10 (s, 1 H) 7.21 (s, 1 H) 7.28-7.39 (m, 3 H) 7.41-7.47 (m, 2 H)
Example 267C 6-(penzyloxy)-2-(4-bromobeιιzoyl)-5-methoxyindan- 1 -one To a solution of Example 267B (11.50 g, 42.9 mmol) in anhydrous THF (200 mL) was added 95% NaH (3.25 g, 128.7 mmol). The mixture was stirred at room-temperature for 0.5 hour. Example 267A (16.2 g, 64.35 mmol) in THF (50 mL) was added dropwise to the above mixture. The reaction was run overnight, and poured into water (1.5 L). Concentrated hydrochloric acid (30 mL) was added dropwise to neutralize the mixture. The precipitate was filtered, recrystallized in ethanol (100 mL), and dried in vacuo to give the desired product (14.08 g, 73%). MS (APCI) m/z 451 (M+H)+; 1H NMR (300 MHz, CDCI3) δ ppm 3.82 (s, 2 H) 3.98 (s, 3 H) 5.21 (s, 2 H) 6.99 (s, 1 H) 7.30-7.42 (m, 5 H) 7.44-7.50 (m, 2 H) 7.59-7.65 (m, 2 H) 7.74- 7.81 (m, 2 H)
Example 267D 7-(benzylo y)-3-(4-bromophenyl)-6-methoxy-l,4-dihydroindenori,2-clpyrazole Example 267C (14.08 g, 31.2 mmol), hydrazine monohydrate (3.03 mL, 62.4 mmol), absolute ethanol (300 mL), and glacial acetic acid (3.57 mL, 62.4 mmol) were mixed and refluxed for 24 hours. The reaction was cooled. The precipitate was filtered, washed with water (30 mLx2) and ethanol (30 mLx2), and dried in vacuo overnight to give the desired product (11.66 g, 84%). MS (ESI) m/z 448 (M+H)+
Example 267E 7-(benzyloxy)-3-(4-bromophenyl)-6-methoxy- 1 - 1 r2-(trimethylsilyl)ethoxylmethyl I - 1 ,4- dihvdroindeno F 1 ,2-clpyrazole To a mixture of Example 267D ( 11.66 g, 26.1 mmol) and DMF (500 mL) in ice bath was added 95% NaH (0.69 g, 27.41 mmol). The mixture was stirred at room temperature for 0.5 hour and then cooled at 0°C. 2-(trimethylsilyl)ethoxymethyl chloride (4.85 mL, 27.41 mmol) was added to the mixture. After 0.5 hour, the ice bath was removed. The reaction was run at room temperature for another hour, and then poured into water. Ethyl acetate (200 mLx3) was used to extract the product. The organic solution was dried with MgS04, concentrated, and purified by flash chromatography to give the desired product (10.84 g 72%). MS (DCI/NH3) m/z 577 (M+H)+
Example 267F 4'-(7-(benzyloxy)-6-methoxy- 1 - ( F2-(trimethylsilyl)ethoxylmethyl 1-1 ,4-dihydroindeno 1 ,2- clpyrazol-3-yP- 1 , 1 '-biphenyl-4-ol Example 267E (518 mg, 0.896mmol), dichlorobis(triphenylphosphine)palladium(II) (63 m g, 0.090 mmol), 4-(hydroxyphenyl)boronic acid (147.3 mg, 1.07 mmol), IM Na2CO3 solution (1 mL), DME/EtOH/H20 (7:2:3, 3 mL) and a stirrerbar were mixed together in a capped tube. The mixture was heated to I6O0C for 5 minutes in a Smith Synthesizer. The reaction was repeated 19 times. The solution was combined, and concentrated. The residue was purified by flash chromatography to give the desired product (4.69 g, 47%). MS (DCI/NH3) m/z 591 (M+H)+ Example 267G 7-(benzyloxy)-6-methoxy-3-(4 '-{ F2-(trimethylsilyl)ethoxylmethoxy)-l, 1 '-biphenyl-4-yl)-l-( F2- (trimethylsilypethoxylmethyl I - 1 ,4-dihvdroindeno F 1 ,2-clpyrazole To the solution of Example 267F (4.66 g, 7.9 mmol) in DMF (200 mL) was added 95 % NaH (0.21 g, 8.28 mmol). The mixture was stirred at room temperature for 0.5 hour. 2- (trimethylsilyl)ethoxymethyl chloride (1.49 mL, 8.28 mmol) was added dropwise. The reaction was stirred for 1 hour. DMF was removed. The residue was treated with water (200 mL) and extracted with ethyl acetate (200 mL). The organic phase was dried with MgSO , and purified by flash chromatography to give the desired product (4.31 g, 76%). MS (DCI NH3) m/z 722 (M+H)+
Example 267H 6-methoxy-3-(4'-{F2-(trimethylsilyl)ethoxylmethoxyl-l,r-biphenyl-4-yl)-l-(r2-
(trimethylsilyPethoxylmethyl 1 - 1 ,4-dihydroindeno Fl ,2-clpyrazol-7-ol Example 267G (4.20 g, 5.82 mmol), 10% Pd/C (2.1 g, 2 mmol), and THF (100 mL ) were mixed. The reaction was shaken under H2 (60 psi) at room temperature for 3 days. Flash chromatography was used to purify the desired product (2.67 g 71%). MS (DCI/NH3) m/z 631 (M+H)+
Example 2671 4'-F6-methoxy-7-(2-pyrrolidin-l-ylethoxy)-l,4-dihydroindenoFl,2-c1pyrazol-3-yll-l, -biphenyl-
4-ol Example 267H (50 mg, 0.079 mmol), l-(2-chloroethyl)pyrolidine hydrochloride (20 mg, 0.118 mmol), CS2CO3 (77 mg, 0.238 mmol), and DMF (2 mL) were mixed in a vial and stirred at 60°C overnight. LC-MS indicated the reaction was completed. The mixture was filtered and concentrated. To the residue was added ethanol (2 mL) and concentrated hydrochloric acid (2 mL). The reaction was heated at 50°C for 5 hours. The mixture was concentrated, and purified with HPLC to give the dsesired product. Examples 268 and 284 represented by Figure (XVI) and shown in Table 16 were synthesized in a similar fashion as described in Example 267.
Figure (XVI) Table 16
Example 285 3 -(4 -hydroxy- 1 , 1 -biphenyl-4-yl)-6-methoxy- 1 ,4-dihydroindeno r 1 ,2-clpyrazol-7-ol To Example 267H (33.3 mg, 0.053 mmol) were added ethanol (2 mL) and concentrated hydrochloric acid (2 mL). The reaction was shaken at 50°C for 5 hours. The mixture was concentrated, and purified by HPLC to give the desired product (18 mg, 57%). MS (ESI) m/z 371 (M+H)+; H NMR (400 MHz, DMSO-Dg) δ ppm 3.74 (s, 2 H) 3.82 (s, 3 H) 6.86 (d, J=8.90 Hz, 2 H) 7.07 (s, 1 H) 7.16 (s, 1 H) 7.55 (d, J=8.59 Hz, 2 H) 7.69 (d, J=8.29 Hz, 2 H) 7.81 (d, 3=8.59 Hz, 2 H) 9.56 (s, 1 H)
Example 286
3-(4'-hydroxy-l, -biphenyl-4-vP-6-methoxy-N-F2-(4-methylpiperazin-l-vPethyll-l,4- dihvdroindenoFl,2-clpyrazole-7-carboxamide
Example 286A
6-methoxy-3-(4'-{ F2-(trimethylsilyl)ethoxylmethoxy 1-1,1 '-biphenyl-4-yl)-l-( F2-
(trimethylsilyl)ethoxylmethyl|-l,4-dihvdroindenoFl,2-clpyrazol-7-yl trifluoromethanesulfonate
To the solution of Example 267H (1.29 g, 2.04 mmol) in THF (10 mL) at room temperature was added 95% NaH (51.6 mg, 2.04 mmol). The mixture was stirred for half an hour, and N-phenyltrifluoromethane sulphonamide (0.88 g, 2.45 mmol) was added. The reaction mixture was stirred at 40°C overnight. The reaction mixture was purified by flash chromatography to give the desired product (1.80 g, 100%). MS (APCI) m/z 763 (M+H)+ Example 286B 3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-6-methoxy-N-F2-(4-methylpiperazin- 1 -yl)ethyll- 1 ,4- dihydroindenoF 1 ,2-clpyrazole-7-carboxamide Example 286A (40 mg, 0.0524 mmol), 2-(4-methylpiperazin-l-yl)ethylamine (75 mg, 0.524 mmol), triethylamine (143μL, 1.048 mmol), PdCl2(dppf) (10 mg, 0.00132 mmol), and dichloromethane (5 mL) were mixed under CO (100 psi) at 100°C for 5 days. The reaction was cooled, and the pressure was released. The solution was concentrated. Ethanol (2 mL) and concentrated hydrochloric acid (2 mL) were added. The reaction was shakenat 50°C for 5 hours. The mixture was concentrated, and purified by HPLC to give the desired compound.
Examples 287 to 299 represented by Figure (XVII) and shown in Table 17 were synthesized in a similar fashion as described in Example 286B using the appropriate amine instead of 2-(4-methylpiperazin- 1 -yl)ethylamine.
FIGURE (XVII) TABLE 17
Example 300 4'-{6-methoxy-7-F(4-methyl- 1 ,4-diazepan- 1 -yl)carbony!1- 1 ,4-dihydroindeno \ 1 ,2-c|pyrazol-3- yl> - 1 , 1 '-biphenyl-4-ol The title compound was synthesized in a similar fashion as described in Example 286B using l-methyl-l,4-diazepane instead of 2-(4-methylpiperazin-l-yl)ethylamine, 22 mg 85% yield. MS (ESI) m/z 495 (M+H)+; 1HNMR (500 MHz, DMSO-D6) δ ppm 1.92-2.10 (m, 2 H) 2.92 (s, 3 H) 3.14-3.30 (m, 4 H) 3.35-3.60 (m, 4 H) 3.89 (s, 2 H) 3.94 (s, 3 H) 6.88 (d, J=8.42 Hz, 2 H) 7.38 (s, 1 H) 7.54-7.60 (m, 3 H) 7.73 (d, 3=8.42 Hz, 2 H) 7.84 (d, J=8.42 Hz, 2 H) 9.69 (s, 1 H).
Example 301 6-methoxy-3- {4- \3-( 1 -methylpyrrolidin-2-yl)propoxylphenyl}-7-(2-piperidin- 1 -ylethoxy)- 1 ,4- dihydroindenoFl ,2-clpyrazole
Example 301 A phenyl 4-(benzyloxy)benzoate 4-Hydroxy-benzoic acid phenyl ester (5 g, 23.3 mmol), benzyl bromide (5.54 mL, 46.7 mmol), K2CO3 (9.6 g, 70.0 mmol), and anhydrous acetone (200 mL) were mixed and reflux overnight. All acetone was removed. To the mixture was added water (300 mL). The solid was filtered, washed with methanol (50 mL <3), and dried to give the desired compound (6.63 g, 93%). MS (DCI) m/z 305 (M+H)+; Η NMR (300 MHz, CDCl3)δ ppm 5.17 (s, 2 H) 7.30-7.09 (m, 2 H) 7.17-7.23 (m, 2 H) 7.27 (m, 1 H) 7.34-7.48 (m, 7 H) 8.13-8.19 (m, 2 H)
Example 30 IB 5-methoxy-6-(2-piperidin- 1 -ylethoxy)indan- 1 -one Example 144B (5.34g, 30 mmol), l-(2-chloro-ethyl)-piperidine hydrochloride (11.0 g, 60 mmol), K2CO3 (16.6 g, 120 mmol), and acetonitrile (150 mL) were mixed and refluiεd 3 days. The reaction mixture was filtered. The filtrate was concentrated, and purified by flash chromatography to give the desired product (6.92 g, 80%). MS (ESI) m/z 290 (M+H)+; H NMR (300 MHz, CDCI3) δ ppm 1.40-1.49 (m, 2 H) 1.55-1.65 (m, 4 H) 2.45-2.57 (m, 4 H) 2.63-2.70 (m, 2 H) 2.84 (t, 3=6.27 Hz, 2 H) 3.01-3.08 (m, 2 H) 3.94 (s, 3 H) 4.18 (t, J=6.44 Hz, 2 H) 6.88 (s, 1 H) 7.20 (s, 1 H)
Example 30 IC 3-r4-(benzyloxy)phenyll-6-methoxy-7-(2-piperidin- 1 -ylethoxy)- 1 ,4-dihydroindeno Fl ,2- clpyrazole Example 301A (7.16 g, 24.00 mmol), Example 301B (6.92 g, 23.92 mmol), 95% NaH (1.82 g, 72 mmol) and benzene (100 mL) were mixed and refluxed overnight. The reaction mixture was cooled to room temperature, and benzene was removed. Acetic acid (10 mL), ethanol (100 mL) and hydrazine monohydrate (10 mL) were added. The mixture was heated to reflux for 2 hours, and then cooled. All the solvents were removed. The residue was treated with water (200 mL). The precipitate was filtered, washed with water (100 mLx3) and ethyl acetate (100 mLx3), and dried to give the desired product (7.71 g, 85%). MS (ESI) m/z 496 (M+H)VH NMR (300 MHz, CD3OD) δ ppm 1.44-1.55 (m, 2 H) 1.59-1.70 (m, 4 H) 2.60-2.67 (m, 4 H) 2.87 (t, 3=5.76 Hz, 2 H) 3.75 (s, 2 H) 3.89 (s, 3 H) 4.23 (t, J=5.76 Hz, 2 H) 5.15 (s, 2 H) 7.11 (d, J=8.81 Hz, 2 H) 7.24 (s, 1 H) 7.29-7.41 (m, 4 H) 7.43-7.48 (m, 2 H) 7.69 (d, 3=9.15 Hz, 2 H)
Example 30 ID 3- F4-(benzyloxy)phenyll -6-methoxy-7-(2-piperidin- 1 -ylethoxy)- 1 - { F2- (trimethylsilyl)ethoxylmethyl}-l,4-dihydroindenoFl,2-clpyrazole To the solution of Example 301C (7.71 g, 15.56 mmol) in DMF (200 mL) was added 95% NaH (0.412 g, 16.34 mmol). After 0.5 hour, 2-(trimethylsilyl)ethoxymethyl chloride (2.89 mL, 16.34 mmol) was added dropwise. Then the reaction was run at room temperature for 2 hours. All the DMF was removed. The residue was purified by flash chromatography to give the desired product (5.50 g, 56%). MS (APCI) m z 626 (M+H)+
Example 30 IE 4-(6-methoxy-7-(2-piperidin- 1 -ylethoxy)- 1 - { F2-(trimethylsilyl)ethoxylmethyl } - 1 ,4- dihydroindeno F 1 ,2-clpyrazol-3 -yl)phenol The mixture of Example 301D (5.50 g, 8.79 mmol) and 10% Pd/C (1.15 g, 1.09 mmol) in THF (100 mL) was treated with H2 (60 psi) at room temperature for 2 days. The mixture was filtered. The solution was concentrated, and purified by flash chromatography to give the desired product (4.0 g, 85%). MS (ESI) m/z 536 (M+H)+ Example 30 IF 6-methoxy-3- { 4- [3 -( 1 -methylpyrrolidin-2-yl)propoxyl phenyl} -7-(2-piperidin- 1 -ylethoxy)- 1 ,4- dihydroindenori,2-c1pyrazole Example 301E (54 mg, 0.10 mmol), (l-methyl-pyrrolidin-2-yl)-propan-l-ol (29 mg, 0.20 mmol), PPh3-polymer supported (50 mg, 0.15 mmol), di-tert-butyl azodicarboxylate (34.5 mg, , 0.15 mmol), and THF (3 mL) were mixed and stirred at room-temperature for 4 days. The resin was filtered, and the solution was concentrated. To the residue were added 2N HCl solution (1 mL) and ethanol (1 mL). The reaction was at 50°C for 8 hours, and concentrated. The residue was purified by HPLC give the desired product (24 mg, 46%). MS (ESI) m/z 517 (M+H)+;1H NMR (500 MHz, CD3OD) δ ppm 1.58 (m, 1 H) 1.79-1.91 (m, 5 H) 1.96-2.05 (m, 3 H) 2.06-2.20 (m, 3 H) 3.08-3.15 (m, 3 H) 3.35 (s, 3 H) 3.55-3.62 (m, 4 H) 3.10-3.11 (m, 4 H) 3.82 (s, 2 H) 3.94-3.98 (m, 3 H) 4.39-4.44 (m, 2 H) 7.08-7.13 (m, 2 H) 7.34 (s, 1 H) 7.40 (s, 1 H) 7.71-7.75 (m, 2 H)
Example 302 l-{4-F6-methoxy-7-(2-piperidin-l-ylethoxy)-l,4-dihydroindenoFl,2-c1pyrazol-3- y 11 phenoxy } acetone Example 302 was synthesized in a similar fashion as Example 30 IF, substituting (1- methyl-pyrrolidin-2-yl)-propan-l-ol with l-hydroxy-propan-2-one (19 mg, 41%). MS (ESI) m z 462 (M+H)+; !H NMR (500 MHz, CD3OD)δ ppm 1.58 (m, 1 H) 1.79-1.91 (m, 3 H) 1.97-2.06 (m, 2 H) 2.25 (s, 3 H) 3.06-3.16 (m, 2 H) 3.56-3.63 (m, 2 H) 3.75 (d, 3=12.16 Hz, 2 H) 3.81 (s, 2 H) 3.95 (s, 3 H) 4.39-4.44 (m, 2 H) 4.79 (s, 2 H) 7.06 (d, J=9.04 Hz, 2 H) 7.33 (s, 1 H) 7.40 (s, 1 H) 7.71 (d, J=8.73 Hz, 2 H)
Example 303 F4-(6,7-dimethoxy- 1 ,4-dihydroindeno \ 1 ,2-clpyrazol-3-yl)phenyl1methanol Example 243B (70 mg, 0.20 mmol), bis(triphenylphosphine)dichloropalladium (14.3 mg, 0.020 mmol), 3-hydroxymethyl-phenylboronic acid (36 mg, 0.24 mmol), DME EtOH/H2O (7:2:3, 3 mL), and IM Na2CO3 solution (1 mL) were mixed under N2. The reaction mixture was heated to 160°C for 600s in a Smith Synthesizer. After the reaction, the mixture was dried, and purified by HPLC to give the desired product (17 mg, 26%). MS (ESI) m/z 323 (M+H)VH NMR (400 MHz, DMSO-D6) δ ppm 3.76 (s, 2 H) 3.82 (s, 3 H) 3.84 (s, 3 H) 4.54 (s, 2 H) 7.21 (s, 1 H) 7.24 (s, 1 H) 7.61 (d, 3=8.29 Hz, 2 H) 7.74 (d, J=8.29 Hz, 2 H)
Example 304 3-(4-cyanophenyl)-6-methoxy-N-(pyridin-4-ylmethyl)- 1 ,4-dihydroindeno F 1 ,2-clpyrazole-7- carboxamide
Example 304 A phenyl 4-cyanobenzoate 4-Cyano-benzoic acid (10.0 g, 68.0 mmol), phenol (6.40 g, 68.0 mmol), DCC (14.73 g, 71.4 mmol), DMAP (0.25 g, 2.04 mmol) and ether (200 mL) were mixed, and stirred at room temperature for 3 days. Ether was removed. To the residue was added CH2C12 (200 mL). The solid was filtered. The filtrate was concentrated, and purified by flash chromatography to give the desried product (12.41 g, 82%). MS (DCI NH3) m/z 224 (M+H)+; 1H NMR (300 MHz, CDC13) δ ppm 7.19-7.25 (m, 2 H) 7.31 (m, 1 H) 7.41-7.50 (m, 2 H) 7.80-7.85 (m, 2 H) 8.29-8.34 (m, 2 H)
Example 304B 6-methoxy-3-oxo-2,3-dihydro-lH-inden-5-yl trifluoromethanesulfonate To the solution of Example 144B (4.86 g, 27.3 mmol) in THF (136 mL) at room temperature was added 95% NaH (0.690 g, 27.3 mmol). The temperature was raised to 40°C. After 0.5 hour, N-phenyltrifluoromethanesulfonimide (11.69 g, 27.3 mmol) was added. The temperature was maintained at 40°C overnight under N2. THF was removed. The residue was purified by flash chromatography to give the title compound (8.47 g, 100%). MS (DCI/NH3) m/z 311 (M+H)+; 1H NMR (300 MHz, CDC13) δ ppm 2.69-2.76 (m, 2 H) 3.11-3.18 (m, 2 H) 4.01 (s, 3 H) 7.07 (s, 1 H) 7.60 (s, 1 H)
Example 304C 6-methoxy-3-oxoindane-5-carboxylic acid Example 304B (8.47 g, 27.3 mmol), PdCl2(dppf) ( 0.21 g, 0.331 mmol), triethylamine (19.0 mL, 136.5 mmol), THF (200 mL) and water (50 mL) were mixed and stirred at room temperature under N2 for 10 minutes. Then the reaction system was charged with CO (500 psi). The temperature was raised to 110°C for 16 hours. The solvents were removed, and the residue was purified by flash chromatography to give the desired product (5.35 g, 95%). MS (ESI) m/z 207 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 2.63-2.69 (m, 2 H) 3.10-3.16 (m, 2 H) 3.99 (s, 3 H) 6.99 (s, 1 H) 8.26 (s, 1 H)
Example 304D methyl 6-methoxy-3-oxoindane-5-carboxylate Example 304C (5.35g, 25.94 mmol) was dissolved into methanol (100 mL). Concerirated H2SO4 (10 drops) was added. The mixture was refluxed overnight. The reaction was cooled, and methanol was removed. Saturated NaHCθ3 solution (100 mL) and CH2C1 (100 mL) were added. The organic layer was separated, and dried with MgSOψ The organic solution was concentrated, and purified by flash chromatography to give the desired product (3.00 g, 48%). MS (DCI/NH3) m/z 221 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 2.66-2.73 (m, 2 H) 3.15- 3.22 (m, 2 H) 3.87 (s, 3 H) 3.98 (s, 3 H) 7.26 (s, 1 H) 8.05 (s, 1 H)
Example 304E methyl 3-(4-cyanophenyl)-6-methoxy-l,4-dihydroindenori,2-clpyrazole-7-carboxylate Example 304D (0.92 g, 4.18 mmol), Example 304A (1.74 g, 6.27 mmol), 95% NaH (0.32 g, 12.54 mmol) and benzene (50 mL) were mixed, and heated to reflux overnight. Benzene was removed. Eethanol (50 mL), acetic acid (3 mL) and hydrazine monohydrate (3 mL) was added. The mixture was heated to reflux for 2 hours. The mixture was cooled, and the solvents were removed. To the residue was added water (50 mL). The precipitate was filtered, washed with water (10 mLx3) and ethyl acetate (10 mLx3), and dried to give the above intermediate (0.925 g, 64%). MS (ESI) m/z 346 (M+H)+; 1H NMR (400 MHz, DMSO-Dg) δ ppm 3.82 (s, 3 H) 3.90 (s, 3 H) 3.97 (s, 2 H) 7.44 (m, 1 H) 7.87-8.05 (m, 5 H) 13.42 (m, 1 H)
Example 304F 3-(4-cyanophenyl)-6-methoxy-l,4-dihydroindenoFl,2-clpyrazole-7-carboxylic acid Example 304E (0.925 g, 2.66moles) was dissolved in DMF (90 mL). To this solution was added a solution of LiOH (1.28 g, 54 mmol) in water (10 mL). The solution was stirred at room temperature for 4 days. All the solvents were removed with vacuum pump. 2N HCl solution was added until pH equals 2. Yellow precipitate was filtered, washed with water (2 mLx2), and dried to give the above intermediate (0.75 g, 72%). MS (ESI) m/z 332 (M+H)+; lE NMR (500 MHz, DMSO-Dg) δ ppm 3.90 (s, 3 H) 3.96 (s, 2 H) 7.41 (s, 1 H) 7.92 (s, 1 H) 7.94-8.00 (m, 4 H)
Example 304G 3-(4-cyanophenyl)-6-methoxy-N-(pyridin-4-ylmethyl)- 1 ,4-dihydroindeno F 1 ,2-c1pyrazole-7- carboxamide Example 304F (50 mg, 0.136 mmol), PyBrop (65.3 mg, 0.140 mmol), O-pyridin-4-yl- methylamine (15 m g, 0.14 mmol), DIEA (49μL, 0.28 mmol) and DMF (2 mL) were mixed, and stirred overnight. The solvent was removed. The residue was washed with water (2 mLχ2), methanol (2 mLx2) and ethyl acetate (2 mLx2), and dried to givethe title compound (20 mg, 35%). MS (ESI) m/z 422 (M+H)+; Η NMR (500 MHz, DMSO-D6) δ ppm 3.89 (s, 2 H) 3.99 (s, 3 H) 4.56 (d, 3=5.93 Hz, 2 H) 7.34 (d, J=5.30 Hz, 2 H) 7.45 (s, 1 H) 7.948.00 (m, 5 H) 8.52 (d, 3=4.05 Hz, 2 H) 8.86 (s, 1 H) 13.39 (s, 1 H)
Example 305 3-(4-cyanophenyl)-N-(trans-4-hydroxycyclohexyl)-6-methoxy-l,4-dihydroindenoFl,2- clpyrazole-7-carboxamide Example 305 was synthesized in similar fashion as Example 304G, substituting O- pyridin-4-yl-methylamine with trans-4-amino-cyclohexanol (9 mg, 15%). MS (ESI) m/z 429 (M+H)+; 1H NMR (500 MHz, DMSO-D6) δ ppm 1.22-1.40 (m, 4 H) 1.81-1.93 (m, 4 H) 3.43 (m, 1 H) 3.75 (m, 1 H) 3.90-4.05 (m, 5 H) 7.40 (m, 1 H) 7.94-8.00 (m, 5 H) 13.37 (m, 1 H)
Example 306 4-F6-methoxy-7-(pyridin-3-ylmethoxy)-l,4-dihydroindenoFl,2-clpyrazol-3-yllbenzonitrile
Example 306 A phenyl 4-bromobenzoate 4-Bromo-benzoic acid (32.83 g, 163.3 mmol), phenol (15.37 g, 163.3 mmol), DCC (35.38 g, 171.46 mmol), DMAP (0.40 g, 4.9 mmol) and ether (500 mL) were mixed, and stirred at room temperature for 3 days. Ether was removed. CH2C-2 (1 L) was added. The suspension was filtered. The filtrate was concentrated, and purified by flash chromatography to give the above intermediate (33.14 g, 73%). MS (DCI/NH3) m/z 278 (M+H)+; Η NMR (300 MHz, CDCI3) δ ppm 7.18-7.23 (m, 2 H) 7.29 (d, J=7.46 Hz, 1 H) 7.40-7.47 (m, 2 H) 7.63-7.69 (m, 2 H) 8.04-8.09 (m, 2 H)
Example 306B 5-methoxy-6-(pyridin-3-ylmethoxy)indan- 1 -one Example 144B (1.00 g, 5.61 mmol), 3-chloromethyl-pyridine hydrochloride (1.84 g, 11.22 mmol), K2CO3 (3.88 g, 28.10 mmol) and acetone (50 mL) were mixed, stirred, and heated to reflux overnight. The reaction mixture was then filtered. The filtrate was concentrated, and purified by flash chromatography to give the above intermediate (1.23 g, 81%). MS (ESI) m/z 270 (M+H)+; 'H NMR (300 MHz, CD3OD)δ ppm 2.62-2.67 (m, 2H) 3.04-3.11 (m, 2 H) 3.95 (s, 3 H) 5.19 (s, 2 H) 7.13 (s, 1 H) 7.27 (s, 1 H) 7.46 (dd, 3=7.80, 4.07 Hz, 1 H) 7.96 (m, 1 H) 8.50 (dd, 3=4.92, 1.53 Hz, 1 H) 8.65 (d, J=1.36 Hz, 1 H)
Example 306C 3-(4-bromophenyl)-6-methoxy-7-(pyridin-3-ylmethoxy)-l,4-dihydroindenoFl,2-c]pyrazole Example 306B (1.10 g, 4.08 mmol), Example 306A (2.26 g, 8.17 mmol), 95% NaH (0.41 g, 16.34 mmol) and benzene (100 mL) were mixed, stirred, and heated to reflux for 3 hours. The solvent was removed. Ethanol (100 mL), acetic acid (3 mL) and hydrazine monohydrate (3 mL) was added. The mixture was refluxed for another 2 hours. All the solvents were removed. To the residue was added water (100 mL). The suspension was filtered, washed with water (30 mLχ3), ethyl acetate (30 mLx3), and dried to give the above product (1.70 g, 93%). MS (ESI) m/z 449 (M+H)+; 1H NMR (400 MHz, DMSO-D6) δ ppm 3.76 (s, 2 H) 3.83 (s, 3 H) 5.22 (s, 2 H) 7.25 (s, 1 H) 7.35 (s, 1 H) 7.43 (dd, J=7.83, 4.76 Hz, IH) 7.60-7.80 (m, 4 H) 7.88 (d, 3=7.98 Hz, 2 H) 8.54 (dd, J=4.91, 1.53 Hz, 1 H) 8.68 (d, J=1.84 Hz, 1 H) 13.08 (s, 1 H)
Example 306D 4- F6-methoxy-7-(pyridin-3 -ylmethoxy)- 1 ,4-dihydroindeno F 1 ,2-cl pyrazol-3-yllbenzonitrile Example 306C (75 mg, 0.167 mmol), Pd(PPh3)4 (20 mg, 0.0167 mmol), Zn(CN)2 (230 mg, 2.00 mmol) and DMF (4 mL) were mixed, pumped with N2, stirred, and heated to 18tfC for 5 minutes in a Smith Synthesizer. The reaction mixture was filtered, and the filtrate was concentrated. The residue was purified by HPLC to give the title compound (40.0 mg, 61%). MS (ESI) m/z 395 (M+H)+; Η NMR (400 MHz, DMSO-Dg) δ ppm 3.84 (s, 2 H) 3.86 (s, 3 H) 5.36 (s, 2 H) 7.30 (s, 1 H) 7.41 (s, 1 H) 7.92 (dd, J=7.82, 5.37 Hz, 1 H) 7.96 (s, 4 H) 8.44 (d, J=7.98 Hz, 1 H) 8.81 (d, 3=4.91 Hz, 1 H) 8.93 (s, 1 H)
Example 307 4- { 7- F2-(dimethylamino)ethoxyl -6-methoxy- 1 ,4-dihydroindeno \ 1 ,2-c1 yrazol-3 -yl } benzonitrile
Example 307 A 6-F2-(dimethylamino)ethoxyl-5-methoxyindan- 1 -one Example 144B (1.00 g, 5.61 mmol), (2-chloro-ethyl)-dimethyl-amine hydrochloride (1.62 g, 11.22 mmol), K2CO3 (3.88 g, 28.10 mmol) and acetone (50 mL) were mixed, stirred, and heated to reflux overnight. The reaction mixture was then filtered. The filtrate was concentrated, and purified by flash chromatography to give the above intermediate (1.20 g, 86%). MS (ESI) m/z 250 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 2.37 (s, 6 H) 2.62-2.68 (m, 2 H) 2.82 (t, 3=5.43 Hz, 2 H) 3.05-3.10 (m, 2 H) 3.93 (s, 3 H) 4.14 (t, 3=5.43 Hz, 2 H) 7.09 (s, 1 H) 7.19 (s, 1 H)
Example 307B N-(2-{F3-(4-bromophenyl)-6-methoxy-l,4-dihydroindenoFl,2-clpyrazol-7-ylloxy}ethyl)-N,N- dimethylamine Example 307A (0.67g, 2.69 mmol), Example 306A (1.49g, 5.38 mmol), 95% NaH (0.27 g, 10.7 mmol) and benzene (100 mL) were mixed, stirred, and heated to reflux for 3 hours. The solvent was removed. Ethanol (100 mL), acetic acid (3 mL) and hydrazine monohydrate (3 mL) were added. The mixture was refluxed for another 2 hours. All the solvents were removed by vacuum pump. To the residue was added methanol (100 mL) and K2C03 (10 g). The suspension was stirred for 1 hour, and filtered. The filtrate was concentrated, and purified by flash chromatography to give the above intermediate (0.94 g, 82%). MS (ESI) m/z 429 (M+H)YH NMR (500 MHz, CD3OD) δ ppm 2.39 (s, 6 H) 2.83 (t, J=5.46 Hz, 2 H) 3.71 (s, 2 H) 3.88 (s, 3 H) 4.18 (t, J=5.61 Hz, 2 H) 7.20 (s, 1 H) 7.30 (s, 1 H) 7.61 (d, 3=8.42 Hz, 2 H) 7.65 (d, J=8.42 Hz, 2 H)
Example 307C 4-{7-F2-(dimethylamino)ethoxy1-6-methoxy-l,4-dihydroindenoFl,2-clpyrazol-3-yl}benzonitrile
Example 307B (73 mg, 0.170 mmol), Pd(PPh 4 (20 mg, 0.0167 mmol), Zn(CN)2 (230 mg, 2.00 mmol) and DMF (4 mL) were mixed, purged withN2, stirred, and heated to 180°C for 5 minutes in a Smith Synthesizer. The reaction mixture was filtered. The filtrate was concentrated. The residue was purified by HPLC to give the title compound (38.0 mg, 60%). MS (ESI) m/z 375 (M+H)+; !H NMR (400 MHz, CD3OD) δ ppm 3.07 (s, 6 H) 3.61-3.67 (m, 2 H) 3.88 (s, 2 H) 3.97 (s, 3 H) 4.40-4.47 (m, 2 H) 7.37 (s, 1 H) 7.43 (s, 1 H) 7.85 (d, 3=8.29 Hz, 2 H) 7.94 (d, J=8.29 Hz, 2 H)
Example 308 4-F6-methoxy-7-(pyridin-4-ylmethoxy)- 1 ,4-dihydroindeno r 1 ,2-c1pyrazol-3-yllbenzonitrile
Example 308 A 5-methoxy-6-(pyridin-4-ylmethoxy)indan- 1 -one Example 144B (1.00 g, 5.61 mmol), 4-chloromethyl-pyridine hydrochloride (1.84 g, 11.22 mmol), K2CO3 (3.88 g, 28.10 mmol) and acetone (50 mL) were mixed, stirred, and heated to reflux overnight. The reaction mixture was then filtered. The filtrate was concentrated, and purified by flash chromatography to give the above intermediate (1.44 g, 95%). MS (ESI) m/z 270 (M+H)+; JH NMR (300 MHz, CD3OD) δ ppm 2.62-2.68 (m, 2 H) 3.06-3.10 (m, 2 H) 3.98 (s, 3 H) 5.22 (s, 2 H) 7.14 (s, 1 H) 7.21 (s, 1 H) 7.54 (d, 3=6.10 Hz, 2 H) 8.518.55 (m, 2 H)
Example 308B 3-(4-bromophenyl)-6-methoxy-7-(pyridin-4-ylmethoxy)-l,4-dihydroindenori,2-c1pyrazole Example 308A (0.54 g, 2.00 mmol), Example 306A (1.11 g, 4.00 mmol), 95% NaH (0.38 g, 16.0 mmol) and benzene (70 mL) were mixed, stirred, and heated to reflux overnight. The solvent was removed. Ethanol (70 mL), acetic acid (3 mL) and hydrazine monohydrate (3 mL) was added. The mixture was refluxed for another 2 hours. All the solvents were removed by vacuum pump. To the residue was added water (100 mL). The suspension was filtered, washed with water (20 mLx3) and ethyl acetate (20 mLχ3), and dried to give the above product (0.82 g, 91%). MS (ESI) m/z 449 (M+H)+; H NMR (400 MHz, DMSO-Dg) δ ppm 3.76 (s, 2 H) 3.87 (s, 3 H) 5.27 (s, 2 H) 7.25-7.33 (m, 2 H) 7.47 (d, 3=6.14 Hz, 2 H) 7.71 (s, 4 H) 8.55-8.62 (m, 2 H) 13.08 (s, 1 H)
Example 308C 4- F6-methoxy-7-(pyridin-4-ylmethoxy)- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-3-yllbenzonitrile Example 308B (75 mg, 0.167 mmol), Pd(PPh3)4 (20 mg, 0.0167 mmol), Zn(CN)2 (0.230 g, 2.00 mmol) and DMF (4 mL) were mixed, purged with N2, stirred, and heated to 180°C for 5 minutes in a Smith Synthesizer. The reaction mixture was filtered. The filtrate was concentrated. DMSO (2.5 mL) was added, and the suspension was stirred for 0.5 hour. The precipitate was then filtered, washed by water (5 mLx3) and ethyl acetate (5 mLx3), and dried in vacuo to give the title compound (35 mg, 53%). MS (ESI) m/z 395 (M+H)+; 1H NMR (300 MHz, DMSODg) δ ppm 3.84 (s, 2 H) 3.88 (s, 3 H) 5.28 (s, 2 H) 7.28 (s, 1 H) 7.33 (s, 1 H) 7.47 (d, 3=6.10 Hz, 2 H) 7.92-8.01 (m, 4 H) 8.60 (d, J=5.76 Hz, 2 H) 13.30 (s, 1 H)
Example 309 4'-F6-methoxy-7-(trifluoromethoxy)- 1 ,4-dihydroindeno \ 1 ,2-clpyrazol-3-yl1- 1 , 1 '-biphenyl-4-ol
Example 309A O-(6-methoxy-3-oxo-2,3-dihydro- lH-inden-5-yl) S-methyl dithiocarbonate To a stirred solution of Example 144B (1.18 g, 6.6 mmol) in DMF (60 mL) was slowly added 95% NaH (0.20 g, 7.95 mmol) at 0°C. After the resulting mixture was stirred at room temperature for 1 hour, CS2 (0.79 mL, 13.2 mmol) was added dropwise at 0°C. The resulting mixture was stirred for 10 hours at room temperature before iodomethane (0.49 mL, 7.92 mmol) was added dropwise to the reaction mixture at 0°C. The resulting mixture was stirred for 1 hour at room temperature. All solvents were removed. The residue was separated by flash chromatography to give the desired intermediate (0.80 g, 45%). MS (DCI/NH3) m/z 269 (M+H)+; 1H NMR (300 MHz, CDC13) δ ppm 2.65-2.74 (m, 5 H) 3.09-3.17 (m, 2 H) 3.90 (s, 3 H) 7.01 (s, l H) 7.44 (s, 1 H)
Example 309B 5-methoxy-6-(trifluoromethoxy)indan- 1 -one To the suspension of l,3-dibromo-5,5-dimethylhydantoin (0.83 g, 2.91 mmol) in CH2C12 in a flame-dried flask at -78°C was added 70% HF/pyridine (2 mL) dropwise. To this mixture was added Example 309A (0.26 g, 0.97 mmol) in dichloromethane (5 mL). Then the dry-ice bath was replaced with ice-cold NaCl solution bath. The red-brown mixture was stirred for 0.5 hour, and diluted with ethyl ether. NaHSO3/NaHCO3/NaOH was used to adjust pH to 10. Ethyl ether (100 mL) was added to extract the product. The extraction solution was dried with MgSO^ concentrated, and separated by flash chromatography to give the above intermediate (79.7 mg, 33%). MS (APCI) m/z 247 (M+H)+
Example 309C 3-(4-bromophenyl)-6-methoxy-7-(trifluoromethoxy)-l,4-dihydroindenoFl,2-clpyrazole Example 309B (80 mg, 0.325 mmol), Example 306A(180 mg, 0.65 mmol), 95% NaH (66 mg, 2.60 mmol), and benzene (10 mL) were mixed and reflux overnight. Then all the solvent was removed. To the residue were added ethanol (10 mL), acetic acid (2 mL), and hydrazine monohydrate (2 mL). The mixture was heated to reflux for 2 hours. Flash chromatography purification was used to give the above intermediate (45.3 mg, 33%). MS (APCI) m/z 425 (M+H)+; 1H NMR (300 MHz, DMSO-D6) δ ppm 3.89 (s, 2 H) 3.92 (s, 3 H) 7.68-7.75 (m, 4 H) 7.83-7.89 (m, 2 H)
Example 309D 4'-F6-methoxy-7-(trifluoromethoxy)-l ,4-dihydroindeno Fl ,2-clpyrazol-3-y 11-1 , 1 '-biphenyl-4-ol Example 309C (41.6 mg, 0.098 mmol), dichlorobis(triphenylphosphine)palladium (6.9 mg, 0.0098 mmol), (4-hydroxyphenyl)boronic acid (16.2 mg, 0.118 mmol), DME/EtOH/H20 (7:2:3, 3 mL), and IM N^COs solution (1 mL) were mixed, heated to 160°C for 10 minutes in a Smith Synthesizer. All the solvents were removed. The residue was purified by HPLC to give the title compound (9.0 mg, 42%). MS (ESI) m/z 439 (M+H)+; 1H NMR (400 MHz, DMSODg) δ ppm 3.88-3.95 (m, 5 H) 6.87 (d, 3=8.90 Hz, 2 H) 7.52 (s, 1 H) 7.557.58 (m, 3 H) 7.72 (d, 3=8.59 Hz, 2 H) 7.84 (d, J=8.61 Hz, 2 H)
Example 312 4'-(6-morpholin-4-yl- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-3 -yl)- 1 , 1 '-biphenyl-4-ol Example 312A 5-morpholin-4-ylindan- 1 -one A mixture of 5-bromo-l-indanone (0.76 g, 3.60 mmol), Cs2CO3 (1.64 g, 5.04 mmol), Pd2(dba)3 (82 mg, 0.09 mmol), BINAP (112 mg, 0.18 mmol), morpholine (0.94 mL, 10.8 mmol) and THF (15 mL) was pumped with N2 for 0.5 hour and then heated to reflux overnight. The reaction mixture was concentrated, and purified by flash chromatography to give the above intermediate (0.40 g, 51.1%). MS (ESI) m/z 218 (M+H)+; Η NMR (300 MHz, CD3OD) δ ppm 2.59-2.65 (m, 2 H) 3.03-3.10 (m, 2 H) 3.34-3.40 (m, 4 H) 3.79-3.85 (m, 4 H) 6.95 (s, 1 H) 6.99 (m, 1 H) 7.57 (d, J=8.48 Hz, 1 H)
Example 312B 3-(4-bromophenyl)-6-morpholin-4-yl- 1 ,4-dihydroindeno F 1 ,2-clpyrazole Example 312A (0.390 g, 1.80 mmol), Example 306A (0.746 g, 2.69 mmol), 95% NaH (0.136 g, 5.38 mmol) and bezene (40 mL) were mixed and reflux for 3 hours. Then all the benzene was removed. To the residue were added ethanol (30 mL), acetic acid (2.5 mL) and hydrazine monohydrate (2.5 mL). The mixture was refluxed for 2 hours. Once again, all the liquid reagents were removed using vacuum pump. Water (50 mL) was added. The precipitate was washed with water (20 mLx2) and ethyl acetate (10 mLx2), and dried in vacuo to give the above intermediate (0.464 g, 65%). MS (ESI) m/z 396 (M+H)+; 1H NMR (300 MHz, DMSO-Dg) δ ppm 3.13-3.20 (m, 4 H) 3.73-3.81 (m, 6 H) 6.95 (dd, 3=8.48, 2.37 Hz, 1 H) 7.19 (d, 3=2.03 Hz, 1 H) 7.49 (d, 3=8.14 Hz, 1 H) 7.68 (d, 3=8.48 Hz,2 H) 7.65-7.80 (m, 2 H) 13.03 (s, 1 H)
Example 312C 4'-(6-morpholin-4-yl- 1 ,4-dihydroindenoF 1 ,2-cl yrazol-3-yl)- 1 , 1 '-biphenyl-4-ol Example 312B (60 mg, 0.151 mmol), (4-hydroxyphenyl)boronic acid (25 mg, 0.182 mmol), Pd(PPh3)2Cl2 (10.6 mg, 0.015 mmol), DMEΕtOH/H2O (7:2:3, 3 mL) and lM Na2CO3 solution (1 mL) were mixed, capped, and heated to 160°C for 10 minutes in a Smith Synthesizer. All the solvents were removed. The residue was purified by HPLC to give the title compound (29 mg, 47%). MS (ESI) m/z 410 (M+H)+; Η NMR (500 MHz, DMSODg) δ ppm 3.14-3.21 (m, 4 H) 3.73-3.81 (m, 4 H) 3.83 (s, 2 H) 6.87 (d, 3=8.73 Hz, 2 H) 6.96 (dd, 3=8.42, 2.18 Hz, 1 H) 7.21 (s, 1 H) 7.51 (d, 3=8.42 Hz, 1 H) 7.56 (d, 3=8.73 Hz, 2 H) 7.71 (d, 3=8.42 Hz, 2 H) 7.82 (d, J=8.42 Hz, 2 H) 9.56 (s, 1 H)
Example 313 3-methoxy-4'-(6-morpholin-4-yl- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-3-yl)- 1 , 1 '-biphenyl-4-ol Example 313 was synthesized in similar fashion as Example 312C, submitting (4- hydroxyphenyPboronic acid with 2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- phenol. (41 mg, 62%) MS (ESI) m/z 440 (M+H)+; 1H NMR (500 MHz, DMSO-D6) δ ppm 3.14- 3.21 (m, 4 H) 3.73-3.81 (m, 4 H) 3.83 (s, 2 H) 3.88 (s, 3 H) 6.87 (d, J=8.11 Hz, 1 H) 6.97 (dd, J=8.58, 2.03 Hz, 1 H) 7.16 (dd, 3=8.11, 2.18 Hz, 1 H) 7.21 (s, 1 H) 7.26 (d, 3=1.87 Hz, 1 H) 7.52 (d, 3=8.42 Hz, 1 H) 7.75 (d, J=8.42 Hz, 2 H) 7.83 (d, J=8.42 Hz, 2 H)
Example 314 4-(6-morpholin-4-yl-l,4-dihydroindenori,2-clpyrazol-3-yl)benzonitrile Example 312B (60 mg, 0.151 mmol), Pd(PPh3) (17.5 mg, 0.015 mmol), Zn(CN)2(213 mg, 1.82 mmol), and DMF (4 mL) were mixed, and purged withN2 for 10 minutes. The reaction mixture was capped, stirred, and heated to 180°C for 5 minutes in a Smith Synthesizer. After the reaction, the reaction mixture was filtered, and the filtrate was concentrated. The residue was purified by HPLC to give the title compound (33 mg, 64%). MS (ESI) m/z 343 (M+H)+; 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.17-3.24 (m, 4 H) 3.74-3.82 (m, 4 H) 3.85 (s, 2 H) 7.00 (dd, 3=8.42, 1.87 Hz, 2 H) 7.23 (s, 1 H) 7.52 (d, J=8.42 Hz, 1 H) 7.9Θ8.01 (m, 4 H)
Example 315 4-F5-(6-morpholin-4-yl-l,4-dihydroindenoFl,2-clpyrazol-3-yl)pyridin-2-yllphenol
Example 315A 3 -(6-chloropyridin-3 -yl)-6-morpholin-4-yl- 1 ,4-dihydroindeno \ 1 ,2-clpyrazole Example 312A (403 mg, 1.85 mmol), Example 230A (963 mg, 4.63 mmol), 95% NaH (187 mg, 7.40 mmol) and THF (20 mL) were mixed and stirred under N2 overnight. THF was removed. To the residue was added ethanol (60 mL), acetic acid (3 mL) and hydrazine monohydrate (3 mL). The mixture was heated to reflux for 2 hours, and then cooled. The reaction mixture was concentrated. Water (30 mL) was added. The light yellow precipitate was washed with water (20 mLx2) and ethyl acetate (5 mLx2), and dried in vacuo to give the above intermediate (0.514 g, 79%). MS (ESI) m/z 353 (M+H)+; 1H NMR (400 MHz, DMSO-Dg) δ ppm 3.13-3.19 (m, 4 H) 3.72-3.78 (m, 4 H) 3.82 (s, 2 H) 6.95 (dd, J=8.59, 1.53 Hz, 1 H) 7.18 (s, 1 H) 7.48 (s, 1 H) 7.64 (s, 1 H) 8.20 (d, 3=8.29 Hz, 1 H) 8.81 (d, J=2.15 Hz, 1 H) 13.17 (s, 1 H)
Example 315B 4- F5-(6-morpholin-4-yl- 1 ,4-dihydroindeno F 1 ,2-dpyrazol-3 -yl)pyridin-2-yl1phenol Example 315A (60 mg, 0.151 mmol), (4-hydroxyphenyl)boronic acid (25 mg, 0.182 mmol), Pd(PPh3)2Cl2 (10.6 mg, 0.015 mmol), DME/EtOH/H2O (7/2/3, 3 mL) and lMNa2CO3 (1 mL) were mixed, and heated to 160°C for 10 minutes in a Smith Synthesizer. The solvents were removed. The residue was purified by HPLC to give the title compound (29 mg, 47%). MS (ESI) m/z 411 (M+H)+; Η NMR (500 MHz, DMSO-Dg) δ ppm 3.14-3.21 (m, 4 H) 3.73-3.81 (m, 4 H) 3.88 (s, 2 H) 6.90 (d, J=8.73 Hz, 2 H) 6.98 (dd, J=8.26, 2.03 Hz, 1 H) 7.23 (s, 1 H) 7.52 (d, 3=8.42 Hz, 1 H) 8.00 (t, J=9.04 Hz, 3 H) 8.24 (dd, J=8.42, 2.18 Hz, 1 H) 9.00 (d, J=1.87 Hz, 1 H) 9.85 (s, 1 H)
Example 316 2-methoxy-4-F5-(6-morpholin-4-yl-l,4-dihydroindenoFl,2-clpyrazol-3-yl)pyridin-2-yllphenol Example 316 was synthesized in similar fashion as Example 315B, submitting (4- hydroxyphenyl)boronic acid with 2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- phenol. (76 mg, 61%) MS (ESI) m/z 441 (M+H)VH MR (500 MHz, DMSO-D6) δ ppm 3.14- 3.21 (m, 4 H) 3.73-3.81 (m, 4 H) 3.88 (s, 2 H) 3.89 (s, 3 H) 6.91 (d, 3=8.11 Hz, 1 H) 6.98 (dd, 3=8.42, 1.87 Hz, 1 H) 7.23 (s, 1 H) 7.52 (d, J=8.42 Hz, 1 H) 7.60 (dd, 3=8.26, 2.03 Hz, 1 H) 7.74 (d, 3=1.87 Hz, 1 H) 8.05 (d, J=8.42 Hz, 1 H) 8.23 (dd, J=8.42, 2.18 Hz, 1 H) 9.01 (d, 3=2.18 Hz, I H)
Example 317 5-(6-morpholin-4-yl-l,4-dihydroindenoFl,2-c1pyrazol-3-yl)pyridine-2-carbonitrile Example 315A (100 mg, 0.283 mmol), Pd(PPh3) (33 mg, 0.0283 mmol), 2h(CN)2 (332 mg, 2.83 mmol), and DMF (4 mL) were mixed, and pumped with N2for 10 minutes. The reaction mixture was stirred, and heated to 180°C for 5 minutes in a Smith Synthesizer. After the reaction, the solution was filtered, and the solvent was removed. The residue was purified by HPLC to give the title compound (39 mg, 40%). MS (ESI) m/z 344 (M+H)+; H NMR (500 MHz, DMSO-Dg) δ ppm 3.14-3.21 (m, 4 H) 3.73-3.81 (m, 4 H) 3.89 (s, 2 H) 6.98 (dd, 3=8.42, 2.18 Hz, 1 H) 7.22 (d, J=1.56 Hz, 1 H) 7.51 (d, J=8.42 Hz, 1 H) 8.13 (d, 3=8.11 Hz, 1 H) 8.35 (dd, 3=8.11, 2.18 Hz, 1 H) 9.15 (d, 3=1.56 Hz, 1 H)
Example 318 5-(6,7-diisopropoxy-l,4-dihydroindenoFl,2-clpyrazol-3-yl)pyridine-2-carbonitrile
Example 318A 5,6-diisopropoxyindan- 1 -one Example 144A (0.445 g, 2.70 mmol), 2-bromo-propane (0.64 mL, 6.77 mmol), CS2CO3 (2.20 g, 6.77 mmol) and DMF (20 mL) were mixed, stirred, and heated to 60°C for 8 hours. The reaction mixture was then filtered. The solution was concentrated, and dried to give the desired intermediate (0.67g, 100%). MS (DCI/NH3) m/z 249 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 1.32 (d, J=6.10 Hz, 6 H) 1.38 (d, 3=6.10 Hz, 6 H) 2.61-2.68 (m, 2 H) 3.03-3.09 (m, 2 H) 4.51 (m, 1 H) 4.75 (m, 1 H) 7.08 (s, 1 H) 7.18 (s, 1 H)
Example 318B 3-(6-chloropyridin-3-yl)-6,7-diisopropoxy-l,4-dihydroindenoFl,2-clpyrazole Example 318A (0.67 g, 2.70 mmol), Example 230A (1.12 g, 5.40 mmol), 95% NaH (0.26 g, 10.8 mmol) and benzene (30 mL) were mixed, stirred, and heated to reflux for 4 hours. All the solvent was removed. To the residue were added ethanol (70 mL), acetic acid (5 mL) and hydrazine monohydrate (5 mL). The reaction mixture was heated to reflux for 2 hours. Then the solvents were removed. Water (50 mL) was added. The precipitate was filtered, washed with water (20 mLx3) and ethyl acetate (20 mLx3), and dried in vacuo to give the above intermediate (0.60 g, 58%). MS (ESI) m/z 384 (M+H)+; 1H NMR (500 MHz, DMSO-D6) δ ppm 1.25-1.33 (m, 12 H) 3.72-3.85 (m, 2 H) 4.45-4.60 (m, 2 H) 7.15-7.28 (m, 2 H) 7.63 (m, 1 H) 8.21 (m, 1 H) 8.81 (s, 1 H) 13.23 (s, 1 H)
Example 318C 5 -(6,7-diisopropoxy- 1 ,4-dihydroindeno \ 1 ,2-clpyrazol-3-yl)ρyridine-2-carbonitrile Example 318B (100 mg, 0.261 mmol), Pd(PPh3) (30.1 mg, 0.0261 mmol), Zn(CN)2 (0.367 g, 3.126 mmol) and DMF (5 mL) were mixed, purged WM N2, stirred, and heated to 180°C for 5 minutes in the Smith Synthesizer. The reaction mixture was filtered. The solution was concentrated. DMSO (2.5 mL) was added. The suspension was filtered. The precipitate was washed with ethyl acetate (2 mLx3), and dried to give the title compound (19.4 mg, 20%). MS (ESI) m/z 375 (M+H)+; ]H NMR (500 MHz, DMSO-Dg) δ ppm 1.25-1.31 (m, 12 H) 3.86 (s, 2 H) 4.45-4.60 (m, 2 H) 7.17-7.30 (m, 2 H) 8.13 (m, 1 H) 8.34 (m, 1 H) 9.13 (m, 1 H) 13.39 (m, 1 H)
Example 319 4-F5-(6,7-diisopropoxy-l,4-dihydroindeno[l,2-clpyrazol-3-yl)pyridin-2-ynphenol Example 318B (100 mg, 0.26 mmol), (4-hydroxyphenyl)boronic acid (43 mg, 0.313 mmol), Pd(PPh3)2Cl2 (18 mg, 0.026 mmol), DME/EtOH/H2O (7:2:3, 3 mL) and lM Na2CO3 solution (1 mL) were mixed, capped, and heated to 160°C for 10 minutes in a Smith Synthesizer. Then all the solvents were removed. The residue was purified by HPLC to give the title compound (16.4 mg, 14%). MS (ESI) m/z 442 (M+H)+; 1H NMR (500 MHz, DMSO-D6) δ ppm 1.24-1.31 (m, 12 H) 3.81 (s, 2 H) 4.46-4.57 (m, 2 H) 6.89 (d, 3=8.73 Hz, 2 H) 7.22 (d, 3=9.36 Hz, 2 H) 7.95-8.01 (m, 3 H) 8.20 (dd, 3=8.42, 2.18 Hz, 1 H) 8.99 (d, J=1.87 Hz, 1 H) 9.80 (s, 1 H)
Example 320 4-r5-(6,7-diisopropoxy-l,4-dihydroindenoFl,2-c1pyrazol-3-yl)pyridin-2-yll-2-methoxyphenol Example 320 was synthesized in similar fashion as Example 319, submitting (4-hydroxyphenyl)boronic acid with 2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- phenol (65.4 mg, 53%). MS (ESI) m/z 472 (M+H)+; 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.23-1.30 (m, 12 H) 3.82 (s, 2 H) 3.88 (s, 3 H) 4.46-4.57 (m, 2 H) 6.89 (d, 3=8.42 Hz, 1 H) 7.22 (d, J=9.04 Hz, 2 H) 7.56-7.62 (m, 3 H) 7.73 (d, J=2.18 Hz, 1 H) 8.03 (d, 3=8.42 Hz, 1 H) 8.20 (dd, J=8.42, 2.18 Hz, 1 H) 8.99 (d, J=2.18 Hz, 1 H)
Example 321 5 -F6-(tetrahydro-2H-pyran-4-yloxy)- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-3-yllpyridine-2- carbonitrile
Example 321 A 5-(tetrahydro-2H-pyran-4-yloxy)indan- 1 -one 5 -Hydroxy- 1-indanone (0.636 g, 4.30 mmol), tetrahydro-pyran-4-ol (1.22 mL, 12.80 mmol), PPh3-polymer supported (2.864 g, 8.59 mmol), DBAD (1.978 g, 8.59 mmol) and THF (40 mL) were mixed, and shaken overnight. The mixture was filtered, and washed with THF (10 mLx3). The filtrate was concentrated. The residue was purified by flash chromatography to give the above intermediate (0.85 g, 85%). MS (APCI) m/z 233 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 1.79-1.89 (m, 2 H) 2.01-2.12 (m, 2 H) 2.62-2.69 (m, 2 H) 3.07-3.15 (m, 2 H) 3.85-4.00 (m, 4 H) 4.75 (m, 1 H) 6.97 (dd, J=8.65, 2.20 Hz, 1 H) 7.08 (s, 1 H) 7.63 (d, J=8.48 Hz, 1 H)
Example 32 IB 3-(6-chloropyridin-3-yl)-6-(tetrahydro-2H-pyran-4-yloxy)- 1 ,4-dihydroindeno \ 1 ,2-clpyrazole Example 321 A (0.85 g, 3.66 mmol), Example 230A (1.52 g, 7.32 mmol), 95% NaH (0.37 g, 14.64 mmol) and benzene (40 mL) were mixed, stirred, and heated to reflux for 4 hours. The mixture was concentrated. To the residue was added ethanol (40 mL), acetic acid (5 mL) and hydrazine monohydrate (5 mL). The reaction mixture was heated to reflux for 2 hours. All the solvents were removed. To the residue was added water (50 mL). The precipitate was filtered, washed with water (30 mLx3) and ethyl acetate (30 mLx3), and dried in vacuo to give the desired intermediate (0.70 g, 28%). MS (ESI) m/z 368 (M+H)+; 1H NMR (400 MHz, DMSODg) δ ppm 1.56-1.62 (m, 2 H) 1.95-2.04 (m, 2 H) 3.46-3.55 (m, 2 H) 3.82-3.91 (m, 4 H) 4.62 (m, 1 H) 6.99 (dd, 3=8.59, 2.15 Hz, 1 H) 7.23 (d, J=1.84 Hz, 1 H) 7.54 (d, J=7.98 Hz, 1 H) 7.64 (d, J=8.29 Hz, 1 H) 8.22 (dd, 3=8.29, 2.45 Hz, 1 H) 8.82 (d, 3=2.15 Hz, 1 H) 13.25 (s, 1 H)
Example 32 IC 5- F6-(tetrahydro-2H-pyran-4-yloxy)- 1 ,4-dihydroindeno r 1 ,2-clpyrazol-3-yl1pyridine-2- carbonitrile Example 321B (100 mg, 0.27 mmol), Pd(PPh 4 (31 mg, 0.027 mmol), Zn(CN)2(0.383 g, 3.26 mmol) and DMF (5 mL) were mixed, purged withH, stirred, and heated to 180°C for 5 minutes in a Smith Synthesizer. The reaction mixture was filtered. The solution was concentrated. DMSO (2.5 mL) was added. The suspension was filtered. The precipitate was washed with ethyl acetate (2 mLχ3), and dried to give the title compound (19.4 mg, 20%). MS (ESI) m/z 359 (M+H)+; *H NMR (500 MHz, DMSO-Dg) δ ppm 1.56-1.62 (m, 2 H) 1.94-2.03 (m, 2 H) 3.46-3.54 (m, 2 H) 3.82-3.91 (m, 4 H) 4.62 (m, 1 H) 7.00 (d, 3=7.49 Hz, 1 H) 7.23 (s, 1 H) 7.52 (m, 1 H) 8.10 (m, 1 H) 8.35 (d, J=7.49 Hz, 1 H) 9.14 (s, 1 H) 13.42 (m, 1 H)
Example 322 4-{ 5-F6-(tetrahydro-2H-pyran-4-yloxy)- 1 ,4-dihydroindeno \ 1 ,2-clpyrazol-3-yI|pyridin-2- yljphenol Example 321B (100 mg, 0.27 mmol), (4-hydroxyphenyl)boronic acid (45 mg, 0.326 mmol), Pd(PPh3)2Cl2 (19 mg, 0.027 mmol), DME/EtOH/H2O (7:2:3, 3 mL) and lM Na2CO3 (1 mL) were mixed, and heated to 160°C for 10 minutes in a Smith Synthesizer. All the solvents were removed. The residue was purified by HPLC to give the title compound (31.7 mg, 28%). MS (ESI) m/z 426 (M+H)+; 1HNMR (300 MHz, DMSO-D6) δ ppm 1.57-1.64 (m, 2 H) 1.95- 2.04 (m, 2 H) 3.47-3.54 (m, 2 H) 3.82-3.91 (m, 4 H) 4.63 (m, 1 H) 6.876.71 (m, 2 H) 6.99 (dd, J=8.48, 2.37 Hz, 1 H) 7.24 (d, 3=2.03 Hz, 1 H) 7.55 (d, J=8.14 Hz, 1 H) 7.94-8.02 (m, 3 H) 8.19 (dd, 3=8.48, 2.37 Hz, 1 H) 9.01 (d, J=1.70 Hz, 1 H)
Example 323 2-methoxy-4-{5-F6-(tetrahydro-2H-pyran-4-yloxy)-l,4-dihydroindenoFl,2-c1pyrazol-3- yllpyridin-2-yl}phenol Example 323 was synthesized in similar fashion as Example 322, submitting (4- hydroxyphenyl)boronic acid with 2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- phenol (56 mg, 46%). MS (ESI) m/z 456 (M+H)+; H NMR (300 MHz, DMSO-D6) δ ppm 1.58- 1.66 (m, 2 H) 1.94-2.04 (m, 2 H) 3.46-3.53 (m, 2 H) 3.84-3.92 (m, 4 H) 4.63 (m, 1 H) 6.90 (d, J=8.48 Hz, 1 H) 6.99 (dd, J=8.48, 2.37 Hz, 1 H) 7.25 (d, J=2.37 Hz, 1 H) 7.56 (d, J=8.48 Hz, 1 H) 7.60 (dd, 3=8.14, 2.03 Hz, 1 H) 7.75 (d, 3=2.03 Hz, 1 H) 8.04 (d, 3=8.48 Hz, 1 H) 8.20 (dd, 3=8.65, 2.15 Hz, 1 H) 9.01 (d, 3=2.37 Hz, 1 H) 9.35 (s, 1 H)
Example 324 5-(6-isopropoxy-l,4-dihydroindenoFl,2-clpyrazol-3-yl)pyridine-2-carbonitrile
Example 324A phenyl 6-chloronicotinate 6-Chloro-nicotinic acid (31.67 g, 201 mmol), phenol (18.92 g, 201 mmol), DCC (43.55 g, 211 mmol), DMAP (0.737 g, 6.03 mmol) and ether (500 mL) were mixed, and stirred under N at room temperature for 3 days. Then the ether was removed. To the residue was added CH2C12 (1000 mL). The urea precipitate was filtered. The solution was concentrated, and purified by flash chromatography to give the desired intermediate (37 g, 79%). MS (DCI/NH3) m/z 234 (M+H)+; 1H NMR (300 MHz, CDCl3)δ ppm 7.19-7.34 (m, 3 H) 7.41-7.53 (m, 3 H) 8.39 (dd, 3=8.14, 2.37 Hz, 1 H) 9.17 (d, J=2.03 Hz, 1 H)
Example 324B 5-isopropoxyindan- 1 -one 5-hydroxy-l-indanone (0.665 g, 4.68 mmol), 2-bromo-propane (0.88 mL, 9.36 mmol), Cs2CO3 (3.05 g, 9.36 mmol) and DMF (50 mL) were mixed, stirred, and heated to 60°C overnight. The reaction was filtered. The solution was concentrated, and dried to give the above intermediate (0.89 g, 100%). MS (DCI/NH3) m/z 191 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 1.35 (d, 3=6.10 Hz, 6 H) 2.62-2.69 (m, 2 H) 3.07-3.15 (m, 2 H) 4.75 (m, 1 H) 6.91 (dd, 3=8.48, 2.03 Hz, 1 H) 7.01 (s, 1 H) 7.61 (d, 3=8.48 Hz, 1 H)
Example 324C (A-833748.0) 3-(6-chloropyridin-3-yl)-6-isopiOpoxy-l,4-dihydroindenoFl,2-clpyrazole Example 324B (0.89 g, 4.68 mmol), Example 324A (1.64 g, 7.02 mmol), 95% NaH (0.355 g, 14.64 mmol) and benzene (50 mL) were mixed, stirred, and heated to reflux for 4 hours. The mixture was concentrated. To the residue was added ethanol (150 mL), acetic acid (10 mL) and hydrazine monohydrate (10 mL). The reaction mixture was heated to reflux for 2 hours. All the solvents were removed. To the residue was added water (100 mL). The precipitate was filtered out, washed with water (30 mLx3) and ethyl acetate (30 mLx3), and dried in vacuo to give the intermediate 58C (1.01 g, 66%). MS (ESI) m/z 326 (M+H)+;1H NMR (500 MHz, DMSO-D6) δ ppm 1.30 (d, J=6.24 Hz, 6 H) 3.85 (s, 2 H) 4.66 (m, 1 H) 6.93 (dd, J=8.11, 2.18 Hz, 1 H) 7.16 (d, J=2.18 Hz, 1 H) 7.53 (d, J=8.11 Hz, 1 H) 7.64 (d, J=8.11 Hz, 1 H) 8.22 (dd, 3=8.11, 2.50 Hz, 1 H) 8.82 (d, 3=2.50 Hz, 1 H) 13.24 (s, 1 H)
Example 324D 5-(6-isopropoxy- 1 ,4-dihydroindeno F 1 ,2-c1pyrazol-3-yl)pyridine-2-carbonitrile Example 324C (100 mg, 0.31 mmol), Pd(PPh3)4 (36 mg, 0.031 mmol), Zn(CN)2(0.43g, 3.68 mmol) and DMF (5 mL) were mixed, pumped with N2, stirred, and heated to 180°C for 5 minutes in the Smith Synthesizer. The reaction mixture was filtered. The filtrate was concentrated. To the residue was added DMSO (2.5 mL). The suspension was filtered. The precipitate was washed with ethyl acetate (2 mLx3), and dried to give the title compound (53.6 mg, 55%). MS (ESI) m/z 317 (M+H)+; 1H NMR (500 MHz, DMSODg) δ ppm 1.30 (d, J=6.24 Hz, 6 H) 3.89 (d, 3=14.66 Hz, 2 H) 4.67 (m, 1 H) 6.94 (d, 3=8.11 Hz, 1 H) 7.17 (s, 1 H) 7.54 (s, 1 H) 8.11 (s, 1 H) 8.36 (dd, J=8.11, 1.87 Hz, 1 H) 9.15 (s, 1 H) 13.43 (s, 1 H)
Example 325 4-F5-(6-isopropoxy-l,4-dihydroindenoFl,2-clpyrazol-3-yl)pyridin-2-yllphenol Example 324C (100 mg, 0.31 mmol), (4-hydroxyphenyl)boronic acid (51 mg, 0.37 mmol), Pd(PPh3)2Cl2 (22 mg, 0.031 mmol), DME/EtOH/H2O (7/2/3, 3 mL) and IM Na2CO3 (1 mL) were mixed, capped, and heated to 160°C for 10 minutes in a Smith Synthesizer. All the solvents were removed. The residue was purified by HPLC to give the title compound (43 mg, 36%). MS (ESI) m/z 384 (M+H)+; !H NMR (500 MHz, DMSO-D6) δ ppm 1.30 (d, J=5.93 Hz, 6 H) 3.89 (s, 2 H) 4.67 (m, 1 H) 6.89 (d, J=8.73 Hz, 2 H) 6.92 (dd, J=8.11, 2.18 Hz, 1 H) 7.17 (s, 1 H) 7.54 (d, 3=8.11 Hz, 1 H) 7.96 (d, J=8.42 Hz, 1 H) 8.00 (d, J=8.73 Hz, 2 H) 8.18 (dd, J=8.26, 2.34 Hz, 1 H) 9.01 (d, J=2.18 Hz, 1 H) 9.75 (s, 1 H)
Example 326 4-r5-(6-isopropoxy- 1 ,4-dihydroindeno F 1 ,2-clpyrazol-3-yl)pyridin-2-yl1-2-methoxyphenol Example 326 was synthesized in a similar fashion as Example 325, submitting (4- hydroxyphenyl)boronic acid with 2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- phenol (72 mg, 56%). MS (ESI) m/z 414 (M+H)+; 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.30 (d, J=5.93 Hz, 6 H) 3.89 (s, 5 H) 4.66 (m, 1 H) 6.90 (d, J=8.11 Hz, 1 H) 6.93 (dd, J=8.26, 2.34 Hz, 1 H) 7.17 (s, 1 H) 7.55 (d, J=8.42 Hz, 1 H) 7.60 (dd, 3=8.26, 2.03 Hz, 1 H) 7.74 (d, J=2.18 Hz, 1 H) 8.03 (d, 3=8.42 Hz, 1 H) 8.21 (dd, 3=8.42, 2.18 Hz, 1 H) 9.01 (d, 3=2.18 Hz, 1 H) 9.35 (s, 1 H)
Example 327 5-(6,7-diethoxy- 1 ,4-dihydroindeno \ 1 ,2-clpyrazol-3-yl)pyridine-2-carbonitrile
Example 327A 5,6-diethoxyindan-l-one Example 144A (0.56 g, 3.41 mmol), bromoethane (2.55 mL, 34.1 mmol), CS2CC5 (3.33 g, 10.23 mmol) and DMF (20 mL) were mixed, stirred, and heated to 60°C in a capped high- pressure tube overnight. The reaction was then filtered. The solution was concentrated, and dried to give the desired intermediate (0.75 g, 100%). MS (APCI) m/z 221 (M+H)+
Example 327B 3-(6-chloropyridin-3-yl)-6,7-diethoxy-l,4-dihydroindenoFl,2-clpyrazole Example 327A (0.75 g, 3.41 mmol), Example 324A (1.60 g, 6.82 mmol), 95% NaH (0.344 g, 13.64 mmol) and benzene (50 mL) were mixed, stirred, and heated to reflux for 4 hours. The mixture was then concentrated. To the residue were added ethanol (150 mL), acetic acid (10 mL) and hydrazine monohydrate (10 mL). The reaction mixture was heated to reflux for 2 hours. All the solvents were removed. To the residue was added water (100 mL). The precipitate was filtered, washed with water (30 mLx3) and ethyl acetate (30 mLx3), and dried in vacuo to give the above intermediate (0.57 g, 47%). MS (ESI) m/z 356 (M+H)+;Η NMR (500 MHz, DMSO-D6) δ ppm 1.36 (q, J=6.86 Hz, 6 H) 3.78 (s, 2 H) 4.0O4.13 (m, 4 H) 7.21 (d, J=9.04 Hz, 2 H) 7.64 (d, J=8.42 Hz, 1 H) 8.20 (dd, J=8.27, 2.34 Hz, 1 H) 8.81 (d, 3=2.18 Hz, 1 H) 13.17 (s, 1 H)
Example 327C 5-(6,7-diethoxy-l,4-dihydroindenoFl,2-c1pyrazol-3-yl)pyridine-2-carbonitrile Example 327B (100 mg, 0.281 mmol), Pd(PPh3) (32 mg, 0.028 mmol), Zn(CN)2 (0.40 g, 3.37 mmol) and DMF (5 mL) were mixed, pumped withN2, stirred, and heated to 180°C for 5 minutes in a Smith Synthesizer. The reaction mixture was filtered. The solution was concentrated. To the residue was added DMSO (2.5 mL). The suspension was filtered. The precipitate was washed with ethyl acetate (2 mLx3), and dried to give the title compound (82.1 mg, 84%). MS (ESI) m/z 347 (M+H)+; 1H NMR (400 MHz, DMSODg) δ ppm 1.32-1.41 (m, 6 H) 3.78-3.88 (m, 2 H) 4.04-4.14 (m, 4 H) 7.15-7.28 (m, 2 H) 7.57 (m, 1 H) 8.13 (m, 1 H) 8.34 (t, 3=7.52 Hz, 1 H) 9.15 (m, 1 H) 13.36 (s, 1 H)
Example 328 4- F5-(6,7-diethoxy- 1 ,4-dihydroindeno \ 1 ,2-clpyrazol-3-yl)pyridin-2-yl1phenol Example 327B (100 mg, 0.281 mmol), (4-hydroxyphenyl)boronic acid (46 mg, 0.34 mmol), Pd(PPh3)2C-2 (20 mg, 0.0281 mmol), DME/EtOH/H2O (7:2:3, 3 mL) and lM N<|CO3 solution (1 mL) were mixed, and heated to 160°C for 10 minutes in a Smith Synthesizer. All the solvents were removed. The residue was purified by HPLC to give the title compound (34 mg, 29%). MS (ESI) m/z 414 (M+H)+; 1H NMR (400 MHz, DMSO-Dg) δ ppm 1.33-1.40 (m, 6 H) 3.82 (s, 2 H) 4.05-4.15 (m, 4 H) 6.77-6.81 (m, 2 H) 7.23 (d, 3=6.14 Hz, 2 H) 7.988.02 (m, 3 H) 8.19 (dd, 3=8.29, 2.46 Hz, 1 H) 9.00 (d, J=1.53 Hz, 1 H) 11.13 (s, 1 H)
Example 329 4-r5-(6,7-diethoxy-l,4-dihydroindenoFl,2-clpyrazol-3-yl)pyridin-2-yn-2-methoxyphenol Example 329 was synthesized in a similar fashion as Example 328, submitting (4- hydroxyphenyl)boronic acid with 2-methoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- phenol (47 mg, 38%). MS (ESI) m/z 444 (M+H)+; 1H NMR (400 MHz, DMSO-D6) δ ppm 1.33- 1.40 (m, 6 H) 3.82 (s, 2 H) 3.89 (s, 3 H) 4.05-4.15 (m, 4 H) 6.90 (d, 3=8.29 Hz, 1 H) 7.23 (d, J=6.14 Hz, 2 H) 7.60 (dd, 3=8.29, 2.15 Hz, 1 H) 7.72 (m, 1 H) 8.03 (d, 3=8.29 Hz, 1 H) 8.19 (dd, 3=8.44, 2.30 Hz, 1 H) 9.01 (d, J=1.84 Hz, 1 H)
Example 330 5-F6,7-bis(difluoromethoxy)-l,4-dihydroindenori,2-clpyrazol-3-yllpyridine-2-carbonitrile
Example 330A 5,6-bis(difluoromethoxy)indan- 1 -one Example 144A (1.266 g, 7.71 mmol), K2CO3 (4.26 g, 30.84 mmol) and DMF (100 mL) were mixed and stirred. C1CHF2 (80psi) was introduced to the reaction. The temperature was set to 85°C for 2 hours. After the reaction, the high pressure was released. The solvent was removed. The residue was purified by flash chromatography to give the above intermediate (1.10 g, 54%). MS (ESI) m/z 265 (M+H)+; 1HNMR (300 MHz, CD3OD) δ ppm 2.69-2.76 (m, 2 H) 3.13-3.20 (m, 2 H) 6.61-7.27 (m, 2 H) 7.46 (s, 1 H) 7.55 (s, 1 H)
Example 330B (A-835801.0) 3-(6-chloropyridin-3-yl)-6,7-bis(difluoromethoxy)-l,4-dihydroindenoFl,2-clpyrazole Example 330A (0.55 g, 2.08 mmol), Example 324A (0.974 g, 4.16 mmol), 95% NaH (0.21 g, 8.32 mmol) and benzene (50 mL) were mixed, stirred, and heatedto reflux for 4 hours. The mixture was then concentrated. To the residue were added ethanol (50 mL), acetic acid (5 mL) and hydrazine monohydrate (5 mL). The reaction mixture was heated to reflux for 2 hours. All the solvents were removed. To the residue was added water (100 mL). The precipitate was filtered, and washed with water (30 mLχ3). The solid was further purified by flash chromatography to give the above intermediate (89 mg, 11%). MS (ESI) m/z 400 (M+H)+
Example 330C 5-F6,7-bis(difluoromethoxy)-l,4-dihydroindenori,2-c1pyrazol-3-yllpyridine-2-carbonitrile Example 330B (30 mg, 0.075 mmol), Pd(PPl3) (8.7 mg, 0.0075 mmol), Zn(CN)2(106 g, 0.901 mmol) and DMF (2 mL) were mixed, pumped withN2, stirred, and heated to 180°C for 5 minutes in a Smith Synthesizer. The reaction mixture was filtered. The solution was concentrated. To the residue was added DMSO (2.5 mL). The suspension was filtered. The precipitate was purified by flash chromatography to give the title compound (22.7 mg, 78%). MS (ESI) m/z 400 (M+H)+; H NMR (300 MHz, DMSO-Dg) δ ppm 4.02 (s, 2 H) 6.99-7.57 (m, 2 H) 7.62 (s, 2 H) 8.18 (d, J=7.80 Hz, 1 H) 8.39 (dd, J=8.14, 2.37 Hz, 1 H) 9.18 (d, J=2.03 Hz, 1 H) 13.74 (s, l H)
Example 331 4-{5-F6,7-bis(difluoromethoxy)-l,4-dihydroindenoFl,2-clpyrazol-3-yllpyridin-2-yl>phenol Example 330B (30 mg, 0.075 mmol), (4-hydroxyphenyl)boronic acid (12.4 mg, 0.090 mmol), Pd(PPh3)2Cl2 (5.2 mg, 0.0075 mmol), DME/EtOH/H2O (7/2/3, 2.25 mL) and IM Na2CO3 (0.75 mL) were mixed, and heated to 160°C for 10 minutes in a Smith Synthesizer. All the solvents were removed. The residue was purified by HPLC to give the title compound (24 mg, 70%). MS (ESI) m/z 458 (M+H)+; Η NMR (300 MHz, DMSODg) δ ppm 3.99 (s, 2 H) 6.85-6.92 (m, 2 H) 6.98-7.57 (m, 2 H) 7.60-7.64 (m, 2 H) 7.98-8.04 (m, 2 H) 8.18 (m, 1 H) 9.03 (d, J=2.71 Hz, 1 H) 9.79 (s, 1 H)
Example 332 5-F6-(lH-l,2,4-triazol-l-ylmethyl)-l,4-dihydroindenoFl,2-c1pyrazol-3-yllpyridine-2-carbonitrile
Example 332A 5'-bromo-2'3'-dihydrospiro[l,3-dioxolane-2,r-indenel A mixture of 5-bromo-l-indanone (13.0 g, 61.8 mmol), p-toluenesulfonic acid (23 mg, 0.12 mmol) and ethylene glycol (27.6 mL, 494.6 mmol) in benzene (140 mL) was refluxed for about 24 hours, using a Dean-Stark trap to remove water. The mixture was cooled, poured into excess 5% aqueous sodium bicarbonate and was extracted with toluene. The combined organic extracts were washed with brine, dried with MgSO4, filtered, and evaporated in vacuum. The residue was purified by flash column chromatography using dichloromethane as the mobile phase to give the above intermediate. MS (DCI/NH3): m/z 254, 256 (M)+.
Example 332B 2',3'-dihydrospirori,3-dioxolane-2,l'-inden1-5'-ylmethanol To a solution of Example 332A (13 g, 50.9 mmol) in tetrahydrofuran (150 mL) was added a 2.5M solution of n-butyllithium in hexanes (30.5 mL, 76.4 mmol) dropwise at about -78 °C. Then a solution of N,N-dimethylformamide (39.4 mL, 509.0 mmol) in tetrahydrofuran (40 mL) was added dropwise and the mixture was allowed to warm to ambient temperature. The mixture was poured into water and was extracted with ethyl acetate. The combined organic extracts were washed with brine, dried over MgSO4, filtered, and evaporated in vacuum. The residue was re-dissolved in a mixture of tetrahydrofuran (15 mL) and methanol (150 mL) and sodium borohydride (2.6 g, 68.7 mmol) was added inportions at about 0°C. The reaction mixture was stirred at room temperature for about 2 hours, then the mixture was concentrated in vacuum, diluted with water, and extracted with ethyl acetate. The combined organic extracts were washed with brine, dried (MgSO4), filtered and evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel using hexane/ethyl acetate (2:1) as the mobile phase to give the above intermediate. MS (DCI/NH3): m/z 207 (M+H)+.
Example 332C 5-(hydroxymethyl)indan- 1 -one A solution of Example 332B (8.0 g, 38.7 mmol) and p-toluenesulfonic acid (7.4 g, 38.7 mmol) in a mixture of water (20 mL) and acetone (85 mL) was refluxed for about 1 hour. The mixture was concentrated in vacuum, diluted with water and was neutralized by careful addition of potassium carbonate (2.7 g, 19.4 mmol). The precipitate was filtered off, washed with a minimum of water and diethyl ether and was dried in vacuum to give the above intermediate. MS (DCI/NH3): m/z 180 (M+NH )+.
Example 332D (1 -oxo-2,3-dihydro-lH-inden-5-yl)methyl methanesulfonate To a mixture of Example 332C (3.8 g, 23.6 mmol) and triethylamine (4.3 mL, 30.7 mmol) in tetrahydrofuran (50 mL) was added methanesulfonyl chloride (2.2 mL, 28.3 mmol) dropwise at about 0 °C. After about 30 min stirring at about 0 °C, the reaction mixture was diluted with water and was extracted with ethyl acetate. The combined organic extracts were washed with brine, dried (MgSO4), filtered and evaporated under reduced pressure to give the above intermediate. MS (DCI/NH3): m/z 258 (M+NH )+.
Example 332E 5-( 1 H- 1 ,2,4-triazol- 1 -ylmethyl)indan- 1 -one To a suspension of Example 332D (5.6 g, 23.3 mmol) and potassium carbonate (6.4 g, 46.6 mmol) in ethanol (200 mL) was added 1-methylpiperazine (5.2 mL, 46.6 mmol) dropwise at about 0 °C. The mixture was stirred at room temperature for about 3 hours, concentrated in vacuum, diluted with water and was extracted with ethyl acetate. The combined organic extracts were dried (MgSO ), filtered and evaporated under reduced pressure. The residue was purified by flash column chromatography on silica gel using dichloromethane/methanol (5:1) as the mobile phase to give the above intermediate. MS (DCI/NH3): m z 214 (M+H)+; Η NMR (500 MHz, CDC13) * ppm 2.62 (t, J = 8 Hz, 2H), 3.08 (t, J = 8 Hz, 2H), 5.55 (s, 2H), 7.28 (d, J = 9 Hz, IH), 7.42 (s, IH), 7.63 (d, J = 9 Hz, IH), 8.01 (s, IH), 8.75 (s, IH).
Example 332F 3-(6-chloropyridin-3-yl)-6-(lH-l,2,4-triazol-l-ylmethyl)-l,4-dihydroindeno[l,2-clpyrazole Example 332E (250 mg, 1.17 mmol), Example 324A (0.55 g, 2.35 mmol), 95% NaH (0.120 g, 4.69 mmol) and THF (50 mL) were mixed, and stirred under N_ for 1 hour. The mixture was concentrated. To the residue was added ethanol (100 mL), acetic acid (5 mL) and hydrazine monohydrate (5 mL). The reaction mixture was heated to reflux for 2 hours, and then cooled to room temperature. All the solvents were removed. To the residue was added water (100 mL). The precipitate was filtered, washed with water (30 mLx3) and CC14 (30 mLx3), and dried in vacuo to give the above intermediate (200.5 mg, 49%). MS (ESI) m/z 349 (M+H)+; h NMR (400 MHz, DMSO-Dg) δ ppm 3.89 (s, 2 H) 5.47 (s, 2 H) 7.31 (d, 3=7.67 Hz, 1 H) 7.42 (m, 1 H) 7.50 (s, 1 H) 7.64 (d, 3=7.98 Hz, 2 H) 7.97 (d, J=7.98 Hz, 1 H) 8.22 (dd, 3=8.44, 2.61 Hz, 1 H) 8.68 (s, 1 H) 8.83 (d, 3=2.15 Hz, 1 H) Example 332G 5-[6-( IH- 1 ,2,4-triazol- 1 -ylmethyl)- 1 ,4-dihydroindeno[ 1 ,2-c]pyrazol-3-yl]pyridine-2-carbomtrile Example 332F (50 mg, 0.143 mmol), Pd(PPh3)4 (16.5 mg, 0.0143 mmol), Zn(CN)2(0.200 g, 1.71 mmol) and DMF (2 mL) were mixed, pumped with _, stirred, and heated to 18CC for 5 minutes in a Smith Synthesizer. The reaction mixture was filtered. The solution was concentrated. To the residue was added DMSO (2.5 mL). The suspension was filtered. The precipitate was washed with ethyl acetate (2 mLχ3), and dried to give the title compound (33 mg, 68%). MS (ESI) m/z 340 (M+H)+; Η NMR (500 MHz, DMSODg) δ ppm 3.91 (s, 2 H) 5.45 (s, 2 H) 7.28 (s, 1 H) 7.45-7.65 (m, 3 H) 7.95 (s, 1 H) 8.33 (s, 1 H) 8.65 (m, 1 H) 9.11 (s, 1 H) 13.60 (m, 1 H)
Example 333 4-{ 5-f6-( 1 H- 1 ,2,4-triazol- 1 -ylmethyl)- 1 ,4-dihydroindenoF 1 ,2-c1pyrazol-3-yll pyridin-2-yl } phenol
Example 332F (50 mg, 0.143 mmol), (4-hydroxyphenyl)boronic acid (24 mg, 0.172 mmol), Pd(PPh3)2Cl2 (10 mg, 0.0143 mmol), DME/EtOH/H20 (7/2/3, 2 mL) and IMN-1CO3 (1 mL) were mixed, and heated to 160°C for 10 minutes in a Smith Synthesizer. All the solvents were removed. The residue was purified by HPLC to give the title compound (29 mg, 50%). MS (ESI) m/z 407 (M+H)+; !H NMR (500 MHz, DMSO-Dg) δ ppm 3.93 (s, 2 H) 5.48 (s, 2 H) 6.87- 6.90 (m, 2 H) 7.31 (d, 3=7.49 Hz, 1 H) 7.51 (s, 1 H) 7.65 (d, J=7.80 Hz, 1 H) 7.968.01 (m, 4 H) 8.20 (dd, J=8.42, 2.18 Hz, 1 H) 8.69 (s, 1 H) 9.01 (d, 3=2.18 Hz, 1 H)
Example 334 4- \6-( IH- 1 ,2,4-triazol- 1 -ylmethyl)- 1 ,4-dihydroindeno \ 1 ,2-clpyrazol-3-yllbenzonitrile
Example 334A 3-(4-bromophenyl)-6-(lH- 1 ,2,4-triazol- 1 -ylmethyl)- 1 ,4-dihydroindeno Fl ,2-clpyrazole Example 332E (250 mg, 1.17 mmol), phenyl 4-bromobenzoate (0.65g, 2.35 mmol), 95% NaH (0.120 g, 4.69 mmol) and THF (50 mL) were mixed, and stirred for 3 hours. The mixture was then concentrated. To the residue was added ethanol (100 mL), acetic acid (5 mL) and hydrazine monohydrate (5 mL). The reaction mixture was heated to reflux for 2 hours. All the solvents were removed. To the residue was added water (100 mL). The precipitate was filtered, washed with water (30 mLx3) and CC1 (30 mLx3), and dried in vacuo to give the above intermediate (307 g, 67%). MS (ESI) m/z 393 (M+H)+; 1H NMR (500 MHz, DMSODg) δ ppm 3.85 (s, 2 H) 5.48 (s, 2 H) 7.30 (d, J=7.80 Hz, 1 H) 7.50 (s, 1 H) 7.64 (d, J=7.80 Hz, 1 H) 7.69 (d, J=8.11 Hz, 2 H) 7.76 (d, J=8.11 Hz, 2 H) 7.99 (s, 1 H) 8.68 (s, 1 H) 13.30 (s, 1 H)
Example 334B 4-F6-(lH-l,2,4-triazol-l-ylmethyl)-l,4-dihydroindenori,2-clpyrazol-3-yl1benzonitrile Example 334A (50 mg, 0.127 mmol), Pd(PPh3)4 (14.7 mg, 0.0127 mmol), Zn(CN)2 (0.179 g, 1.524 mmol) and DMF (2 mL) were mixed, purged withN2, stirred, and heated to 180°C for 5 minutes in a Smith Synthesizer. The reaction mixture was filtered. The solution was concentrated. To the residue was added DMSO (2.5 mL). The suspension was filtered. The precipitate was washed with ethyl acetate (2 mLx3), and dried to give the title compound (40 mg, 93%). MS (ESI) m/z 339 (M+H)+; 1H NMR (500 MHz, DMSODg) δ ppm 3.92 (s, 2 H) 5.49 (s, 2 H) 7.31 (m, 1 H) 7.51 (m, 1 H) 7.66 (m, 1 H) 7.86-8.03 (m, 5 H) 8.70 (s, 1 H) 13.49 (s, 1 H)
Example 335 835613 4'- F6-( 1 H- 1 ,2,4-triazol- 1 -ylmethyl)- 1 ,4-dihydroindeno \ 1 ,2-cl pyrazol-3-yll -1,1 '-biphenyl-4-ol Example 334A (50 mg, 0.127 mmol), (4-hydroxyphenyl)boronic acid (21 mg, 0.152 mmol), Pd(PPh3)2Cl2 (9 mg, 0.0127 mmol), DME/EtOH/H2O (7/2/3, 2 mL) and lMNa2CO3 (1 mL) were mixed, and heated to 160°C for 10 minutes in a Smith Synthesizer. All the solvents were removed. The residue was purified by HPLC to give the title compound (18 mg, 35%). MS (ESI) m/z 406 (M+H)+; JH NMR (500 MHz, DMSO-Dg) δ ppm 3.88 (s, 2 H) 5.47 (s, 2 H) 6.84- 6.88 (m, 2 H) 7.30 (d, J=8.11 Hz, 1 H) 7.50 (s, 1 H) 7.547.57 (m, 2 H) 7.64 (d, J=7.17 Hz, 1 H) 7.70 (d, J=8.42 Hz, 2 H) 7.83 (d, 3=8.42 Hz, 2 H) 7.99 (s, 1 H) 8.68 (s, 1 H) Example 336 4-{5-F6-(diethylamino)-l,4-dihydroindenoFl,2-clpyrazol-3-yllpyridin-2-yl}phenol
Example 336 A 5-(diethylamino)indan- 1 -one 5-Amino-indan-l-one (408 mg, 2.77 mmol), iodoethane (0.89 mL, 11.1 mmol), Na2CO3 (0.88g, 8.31 mmol) and water (10 mL) were mixed, and stirred at 100°C in a high pressure tube overnight. The reaction was concentrated. The residue was purified by flash chromatography to give the above intermediate (0.40 g, 47%). MS (DCI/NH3) m z 204 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 1.21 (t, J=7.12 Hz, 6 H) 2.56-2.62 (m, 2 H) 2.99-3.06 (m, 2 H) 3.50 (q, 3=7.12 Hz, 4 H) 6.67 (s, 1 H) 6.73 (dd, 3=8.82, 2.37 Hz, 1 H) 7.52 (d, J=8.82 Hz, 1 H)
Example 336B 3-(6-chloiOpyridin-3-yl)-N,N-diethyl-l,4-dihydroindenoFl,2-clpyrazol-6-amine Example 336A (0.40 g, 1.97 mmol), Example 324A (0.92 g, 3.94 mmol), 95% NaH (0.20 g, 7.88 mmol) and benzene (30 mL) were mixed, stirred, and heated to reflux overnight. The mixture was concentrated. To the residue was added ethanol (100 mL), acetic acid (5 mL) and hydrazine monohydrate (5 L). The reaction mixture was heated to reflux for 2 hours. All the solvents were removed. To the residue was added water (100 mL). The precipitate was filtered, washed with water (30 mLx3) and ethyl acetate (30 mLχ3), and dried in vacuo to give the above intermediate (0.50 g, 75%). MS (ESI) m/z 339 (M+H)+; !H NMR (300 MHz, DMSO-Dg) δ ppm 1.12 (t, 3=6.95 Hz, 6 H) 3.34-3.43 (m, 4 H) 3.80 (s, 2 H) 6.67 (dd, 3=8.65, 2.20 Hz, 1 H) 6.90 (s, 1 H) 7.43 (s, 1 H) 7.65 (s, 1 H) 8.22 (s, 1 H) 8.80 (d, J=2.37 Hz, 1 H) 13.05 (s, 1 H)
Example 336C 5-F6-(diethylamino)-l,4-dihydroindenoFl,2-clpyrazol-3-yllpyridine-2-carbonitrile Example 336B (100 mg, 0.294 mmol), Pd(PPh3)4 (34 mg, 0.0294 mmol), Zn(CN)2(0.416 g, 3.54 mmol) and DMF (5 mL) were mixed, pumped with N2, stirred, and heated to 180°C for 5 minutes in a Smith Synthesizer. The reaction mixture was filtered. The solution was concentrated. To the residue was added DMSO (2.5 mL). The suspension was filtered. The precipitate was washed with ethyl acetate (2 mLx3), and dried to give the title compound (71 mg, 73%). MS (ESI) m z 330 (M+H)+; Η NMR (400 MHz, DMSODg) δ ppm 1.07 (t, 3=6.90 Hz, 6 H) 3.33-3.37 (m, 4 H) 3.75-3.84 (m, 2 H) 6.63 (d, 3=8.59 Hz, 1 H) 6.86 (d, J=1.23 Hz, 1 H) 7.34 (m, 1 H) 8.07 (m, 1 H) 8.27 (s, 1 H) 9.09 (s, 1 H) 13.22 (s, 1 H)
Example 336D 4-{5-F6-(diethylamino)-l,4-dihydroindenoFl,2-clpyrazol-3-yllpyridin-2-yl}phenol Example 336B (100 mg, 0.294 mmol), (4-hydroxyphenyl)boronic acid (49 mg, 0.0.353 mmol), Pd(PPh3)2Cl2 (21 mg, 0.0294 mmol), DME EtOH/H2O (7/2/3, 3.5 mL) and lM NijCOs (1.5 mL) were mixed, and heated to 160°C for 10 minutes in a Smith Synthesizer. All the solvents were removed. The residue was purified by HPLC to give the title compound (29 mg, 25%). MS (ESI) m/z 397 (M+H)+; 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.07 (t, J=6.87 Hz, 6 H) 3.61 (s, 2 H) 4.02 (s, 4 H) 6.90 (d, J=8.85 Hz, 2 H) 7.99-8.03 (m, 3 H) 8.23 (dd, J=8.54, 2.14 Hz, 1 H) 9.03 (s, 1 H)
Example 337 4- { 5 - r6-(diethy lamino)- 1 ,4-dih droindeno F 1 ,2-cl py razol-3 -yl] pyridin-2-yl } -2-meτhoxyphenol Example 337 was synthesized in a similar fashion as Example 336D, substituting (4- hydroxyphenyl)boronic acid with 2-methoxy~4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- phenol (45 mg, 36%). MS (ESI) m/z 427 (M+H)+; 1H NMR (500 MHz, DMSO-Dg) δ ppm 1.03- 1.12 (m, 6 H) 3.60 (s, 2 H) 3.89 (s, 3 H) 3.93-4.06 (m, 4 H) 6.90 (d, J=8.24 Hz, 1 H) 7.408.00 (m, 4 H) 8.06 (d, J=8.54 Hz, 1 H) 8.23 (dd, 3=8.39, 1.98 Hz, 1 H) 9.03 (s, 1 H) 9.41 (s, 1 H)
Example 338 5-F6-(tetrahydrofuran-3-ylmethoxy)-l,4-dihydroindenoFl,2-clpyrazol-3-yllpyridine-2- carbonitrile Example 338A 1 - Fchloro(4-methoxyphenyl)methyll -4-methoxybenzene Bis-(4-methoxy-phenyl)-methanol (25 g, 102 mmol) and SOCl2 (60 mL, 823 mmol) were mixed, and heated to reflux for 4 hours. The reaction mixture was concentrated under vacuum pump, and dried completely to give the above intermediate (26.5 g, 99%). MS (DCI/NH3) m/z 263 (M+H)+; Η NMR (300 MHz, CDC13) δ ppm 3.80 (s, 6 H) 6.12 (s, 1 H) 6.82-6.91 (m, 4 H) 7.29 7.36 (m, 4 H)
Example 338B 5-(cyclohex-2-en- 1 -yloxy)indan- 1 -one 5-Hydroxy-indan-l-one (6.60 g, 46.4 mmol), cyclohex-2-enol (7.68 mL, 77.00 mmol), PPh3-polymer supported (18.93 g, 56.79 mmol), DBAD (13.08 g, 56.80 mmol) and THF (300 mL) were mixed, and shaken overnight. The reaction mixture was filtered. The solution was concentrated. The residue was purified by flash chromatography to give the above intermediate (6.75 g, 64%). MS (DCI/NH3) m/z 229 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 1.70 (m, 1 H) 1.77-1.91 (m, 2 H) 1.99 (m, 1 H) 2.04-2.15 (m, 2 H) 2.62-2.68 (m, 2 H) 3.07-3.14 (m, 2 H) 4.99 (m, 1 H) 5.85 (m, 1 H) 6.00 (m, 1 H) 6.93 (dd, 3=8.48, 2.37 Hz, 1 H) 7.05 (d, 3=2.37 Hz, 1 H) 7.61 (d, J=8.81 Hz, 1 H)
Example 338C 3-(6-chloropyridin-3-yl)-6-(cyclohex-2-en- 1 -yloxy)- 1 ,4-dihydroindeno Fl ,2-clpyrazole Example 338B (6.70 g, 29.3 mmol), Example 324A (13.7 g, 58.7 mmol), 95% NaH (3.71 g, 146.7 mmol) and benzene (200 mL) were mixed, stirred, and bsated to reflux overnight. The mixture was concentrated. To the residue was added ethanol (150 mL), acetic acid (25 mL) and hydrazine monohydrate (25 mL). The reaction mixture was heated to reflux for 3 hours. All the solvents were removed. To the residue was added water (300 mL). The precipitate was filtered, washed with water (100 mLx3) and ethyl acetate (50 mLx3), and dried in vacuo to give the above intermediate (8.54 g, 80%). MS (ESI) m/z 364 (M+H)+; !H NMR (300 MHz, DMSODg) δ ppm 1.64 (m, 1 H) 1.69-1.81 (m, 2 H) 1.95 (m, 1 H) 2.00-2.10 (m, 2 H) 3.86 (s, 2 H) 4.93 (s, 1 H) 5.85 (m, 1 H) 5.95 (m, 1 H) 6.96 (m, 1 H) 7.20 (s, 1 H) 7.54 (s, 1 H) 7.67 (s, 1 H) 8.22 (dd, J=8.48, 2.03 Hz, 1 H) 8.82 (d, J=2.37 Hz, 1 H) 13.26 (s, 1 H)
Example 338D l-Fbis(4-methoxyphenyl)methyl1-3-(6-chloropyridin-3-yl)-6-(cyclohex-2-en-l-yloxy)-l,4- dihydroindenori ,2-clpyrazole Example 338C (8.54 g, 23.47 mmol), Example 338A (8.02 g, 30.51 mmol), triethylamine (6.54 mL, 46.94 mmol) and THF (200 mL) were mixed, stirred, and heated to 60°C for 2 hours. The reaction mixture was cooled, filtered, and concentrated. The residue was purified by flash chromatography to give the above intermediate (12.96 g, 94%). MS (ESI) m/z 591 (M+H)+; 1H NMR (300 MHz, CDC13) δ ppm 1.65 (m, 1 H) 1.76-2.15 (m, 5 H) 3.75 (s, 2 H) 3.79 (s, 6 H) 4.79 (m, 1 H) 5.85 (m, 1 H) 5.97 (m, 1 H) 6.66 (d, J=8.48 Hz, 1 H) 6.72 (m, 1 H) 6.83-6.89 (m, 4 H) 6.93 (s, 1 H) 7.11 (s, 1 H) 7.197.25 (m, 4 H) 7.34 (d, 3=8.14 Hz, 1 H) 8.16 (dd, J=8.31, 2.20 Hz, 1 H) 8.80 (d, J=2.03 Hz, 1 H)
Example 338E 5-{ 1 -Fbis(4-methoxyphenyl)methyll-6-hydroxy- 1 ,4-dihydroindenoF 1 ,2-c1pyrazol-3-yl}ρyridine-
2-carbonitrile Example 338D (3.18 g, 5.39 mmol), Pd(PPh3) (1.62 g, 0.147 mmd), Zn(CN)2(7.59 g, 64.67 mmol) and DMF (200 mL) were mixed, pumped with N2, stirred, and heated to reflux for 6 hours. The reaction mixture was filtered. The filtrate was concentrated. The residue was purfied by flash chromatography to give the above intermediate (2.06 g, 76%). MS (ESI) m/z 501 (M+H)+; 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.73 (s, 6 H) 3.87 (s, 2 H) 6.68 (dd, J=8.11, 2.18 Hz, 1 H) 6.90-6.95 (m, J=8.73 Hz, 4 H) 7.00 (d, 3=1.87 Hz, 1 H) 7.12 (s, 1 H) 7.267.30 (m, 4 H) 8.07 (d, J=8.11 Hz, 1 H) 8.28 (dd, 3=8.11, 2.18 Hz, 1 H) 9.09 (d, 3=1.25 Hz, 1 H) 9.66 (s, 1 H)
Example 338F 5-F6-(tetrahydroftιran-3-ylmethoxy)-l,4-dihydroindenoFl,2-clpyrazol-3-yllpyridine-2- carbonitrile Example 338E (100 mg, 0.20 mmol), (tetrahydro-furan-3-yl)-methanol (82 mg, 0.80 mmol), DBAD (92 mg, 0.40 mmol), PPhj-polymer supported (133 mg, 0.40 mmol) and THF (5 mL) were mixed, and shaken overnight. The mixture was filtered. The filtrate was concentrated. To the residue was added methanol (8.0 mL) and 4N HCl in dioxane (0.50 mL). The mixture was stirred at room temperature for 8 hours. All the solvents were removed. The residue was washed with ethyl acetate (10 mLx2), and dried to give the desired product (48 mg, 67%).
Examples 339 to 343 represented by Figure (XVIII) and shown in Table 18 were synthesized in a similar fashion as described in Example 338F using the appropriate alcohol instead of (tetrahydro-furan-3-yl)-methanol.
FIGURE (XVIII) TABLE 18
Example 344 5- { 6- F(4-hydroxycyclohexyl)oxyl - 1 ,4-dihydroindeno F 1 ,2-cl pyrazol-3 -y 1 } pyridine-2-carbonitrile
Example 344A 4-{F2-(trimethylsilyl)ethoxylmethoxy)cyclohexanol Cyclohexane- 1,4-diol (4 g, 34.8 mmol) was dissolved in THF (200 mL). To this solution was added 95% NaH (0.922 g, 36.6 mmol). The mixture was heated to reflux for 1 hour. Then the reaction was cooled down. SEMCl (6.44 mL, 36.6 mmol) was added dropwise. The reaction mixture was heated to reflux again overnight. THF was removed.
The residue was purified by flash chromatography to give the desired product (2.10 g, 16%). MS (DCI/NH3) m/z 247 (M+H)+; !H NMR (400 MHz, CDC13) δ ppm 0.02 (s, 9 H) 0.87-0.95 (m, 2 H) 1.30-1.38 (m, 2 H) 1.57 (m, 1 H) 1.641.70 (m, 2 H) 1.80 (m, 1 H) 1.91-2.01 (m, 2 H) 3.50- 3.70 (m, 4 H) 4.69 (s, 2 H) Example 344B 5-{6-F(4-hydroxycyclohexyl)oxyl-l,4-dihydroindenoFl,2-clpyrazol-3-yl pyridine-2-carbonitrile Example 338E (20 mg, 0.040 mmol), Example 344A (20 mg, 0.080 mmol), DBAD (13.8 mg, 0.060 mmol), PPh3-polymer supported (20 mg, 0.060 mmol) and THF (2 mL) were mixed and shaken overnight. The reaction mixture was filtered. The filtrate was concentrated. To the residue was added methanol (5 mL) and 4N HCl in dioxane (0.5 mL). After 4 hours, the reaction was completed. The solution was concentrated. The residue was purified by HPLC to give the title compound (4.0 mg, 27%). MS (ESI) m/z 373 (M+H)+; 1H NMR (400 MHz, DMSODg) δ ppm 1.57-1.76 (m, 2 H) 1.77-1.95 (m, 4 H) 1.98-2.10 (m, 2 H) 3.92 (s, 2 H) 4.56 (s, 1 H) 5.15 (s, 1 H) 7.01 (m, 1 H) 7.25 (m, 1 H) 7.56 (d, 3=8.29 Hz, 1 H) 8.14 (d, 3=8.29 Hz, 1 H) 8.36 (dd, 3=8.29, 2.15 Hz, 1 H) 9.16 (s, 1 H)
Example 345 5-{6-F2-(4-methyl-l,3-thiazol-5-yl)ethoxyl-l,4-dihydroindenoFl,2-clpyrazol-3-yl}pyridine-2- carboxamide Example 338E (100 mg, 0.192 mmol), 2-(4-methyl-thiazol-5-yl)-ethanol (55 mg, 0.384 mmol), DBAD (66 mg, 0.288 mmol), PPh3-polymer supported (96 mg, 0.288 mmol) and THF (5 mL) were mixed, and shaken overnight. The mixture was filtered. The filtrate was concentrated. To the residue was added 4N HCl in dioxane (4 mL). The mixture was stirred at room temperature overnight. All the solvents were removed. The residue was purified by HPLC to give the title compound (18 mg, 22%). MS (ESI) m/z 418 (M+H)+;1H NMR (400 MHz, DMSODg) δ ppm 2.38 (s, 3 H) 3.25 (t, 3=6.29 Hz, 2 H) 3.91 (s, 2 H) 4.22 (t, 3=5.98 Hz, 2 H) 6.96 (dd, 3=8.44, 1.99 Hz, 1 H) 7.20 (d, J=1.53 Hz, 1 H) 7.56 (d, 3=8.29 Hz, 1 H) 7.65 (s, 1 H) 8.13 (s, 1 H) 8.15 (s, 1 H) 8.33 (dd, J=7.98, 2.15 Hz, 1 H) 8.89 (s, 1 H) 9.04 (d, J=1.53 Hz, 1 H)
Example 346 5-F6-(2-hydroxyethyl)-l,4-dihydroindenoFl,2-clpyrazol-3-yllpyridine-2-carbonitrile
Example 346A 5'-bromo-2',3'-dihydrospiroF 1 ,3-dioxolane-2, 1 '-indenel 5-Bromo-indan-l-one (15 g, 71.1 mmol), ethylene glycol (19.8 mL, 355.2 mmol), p- toluene-sulfonic acid monohydrate (15 mg, 0.079 mmol) and benzene (400 mL) were mixed, stirred, and heated to reflux in a Dean-Stark apparatus overnight. The mixture was poured into saturated NaHCO3 solution (200 mL) in a separatory funnel, and shaken. The organic layer was separated and dried over K2CO3 powder. The solution was concentrated, and purified by flash chromatography to give the above intermediate (10.50 g, 60%). MS (DCI/NH3) m z 256 (M+H)+; 1H NMR (300 MHz, CDC13) δ ppm 2.24-2.34 (m, 2 H) 2.93 (t, J=6.95 Hz, 2 H) 4.04 4.20 (m, 4 H) 7.22 (d, 3=8.48 Hz, 1 H) 7.35-7.40 (m, 2 H)
Example 346B 5'-vinyl-2',3'-dihydrospiro \ 1 ,3-dioxolane-2, 1 '-indenel Example 346A (7.80 g, 30.58 mmol), tributyl(vinyl)tin (10.71 mL, 36.69 mmol), Pd(PPh3) (3.52 g, 3.06 mmol) and DMF (100 mL) were mixed, pumped with N2 and heated to 80°C overnight. All the solvent was removed. The residue was purified by flash chromatography to give the above intermediate (4.53 g, 66%). MS (DCI/NH3) m z 203 (M+H)+; 1H NMR (300 MHz, CDCI3) δ ppm 2.25-2.34 (m, 2 H) 2.89-2.94 (m, 2 H) 4.04-4.23 (m, 4 H) 5.24 (d, J=10.85 Hz, 1 H) 5.74 (d, J=17.63 Hz, 1 H) 6.72 (dd, J=17.63, 10.85 Hz, 1 H) 7.297.31 (m, 2 H) 7.39 (s, I H)
Example 346C 2-(2',3'-dihydrospiroFl,3-dioxolane-2,r-indenl-5'-yl)ethanol To a solution of Example 346B (4.53 g, 22.39 mmol) in anhydrous THF (100 mL) was added 0.5M 9-BBN in THF (54 mL, 26.88 mmol). The reaction was run at room temperature overnight. A solution of NaOH (1.08 g, 26.88 mmol) in water (5 mL) was added, followed by dropwise addition of 30% H202 solution (3.05 mL, 26.88 mmol). The mixture was stirred for 4 hours at room temperature. The reaction mixture was concentrated. Ethyl acetate (100 mL) and water (100 mL) was added to the residue. The organic layer was separated. To the water phase was added ethyl acetate (100 mLx5). The organic layers were combined, dried over K2CO3 powder, and concentrated. The residue was purified by flash chromatography to give the above intermediate (2.96 g, 60%). MS (DCI/NH3) m/z 221 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 2.21-2.29 (m, 2 H) 2.78-2.92 (m, 4 H) 3.73 (t, 3=7.12 Hz, 2 H) 4.01-4.19 (m, 4 H) 7.08-7.13 (m, 2 H) 7.25 (d, 3=8.14 Hz, 1 H)
Example 346D 5-(2-hydroxyethyl)indan- 1 -one Example 346C (2.96 g, 13.43 mmol) was dissolved in THF (30 mL). To this solution was added 2N HCl solution (40 mL). The reaction mixture was stirred at room temperature overnight, concentrated, and extracted with ethyl acetate (50 mLx5). The organic solution was dried with MgS0 , concentrated, and purified by flash chromatography to give above intermediate (1.63 g, 69%). MS (DCI/NH3) m/z 177 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 2.64-2.70 (m, 2 H) 2.92 (t, J=6.78 Hz, 2 H) 3.11-3.17 (m, 2 H) 3.80 (t, J=6.78 Hz, 2 H) 7.29 (d, J=7.80 Hz, 1 H) 7.43 (s, 1 H) 7.63 (d, J=7.80 Hz, 1 H)
Example 346E 5-F2-(pyridin-4-yloxy)ethyllindan- 1 -one Example 346D (0.2933 g, 1.646 mmol), pyridin-4-ol (0.156 g, 1.646 mmol), PPhr polymer supported (1.097 g, 3.292 mmol), DBAD (0.758 g, 3.292 mmol) and THF (15 mL) were mixed, and shaken at room temperature overnight. The solution was filtered, concentrated, and purified by flash chromatography to give the above intermediate (213 mg, 51%). MS (DCI NH3) m/z 254 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 2.65-2.77 (m, 2 H) 3.12-3.18 (m, 2 H) 3.22 (t, J=6.44 Hz, 2 H) 4.37 (t, J=6.44 Hz, 2 H) 6.97 (dd, 3=4.92, 1.53 Hz, 2 H) 7.38 (d, 3=7.46 Hz, 1 H) 7.51 (s, 1 H) 7.65 (d, 3=7.80 Hz, 1 H) 8.31 (dd, J=5.09, 1.70 Hz, 2 H)
Example 346F 2-F3-(6-chloropyridin-3-yl)- 1 ,4-dihydroindenoF 1 ,2-c|pyrazol-6-yllethanol Example 346E (115.2 mg, 0.61 mmol), 324A (360.0 mg, 1.53 mmol), 95% NaH (77 mg, 3.05 mmol) and benzene (20 mL) were mixed, stirred, and heated to reflux 3 hours. The mixture was then concentrated. To the residue was added ethanol (20 mL), acetic acid (2 mL) and hydrazine monohydrate (2 L). The reaction mixture was heated to reflux for 2 hours. All the solvents were removed. To the residue was added water (20 mL). The precipitate was filtered, washed with water (10 mLx3) and ethyl acetate (10 mLχ3), and dried in vacuo to give the above intermediate (64 mg, 34%). MS (ESI) m/z 312 (M+H)+; 1H NMR (400 MHz, DMSO-Dg) δ ppm 2.80 (t, 3=7.06 Hz, 2 H) 3.64-3.66 (m, 2 H) 3.85-3.88 (m, 2 H) 4.64 (t, J=5.22 Hz, 1 H) 7.23 (s, 1 H) 7.43 (s, 1 H) 7.59 (d, J=5.52 Hz, 1 H) 7.68 (m, 1 H) 8.24 (m, 1 H) 8.84 (s, 1 H) 13.35 (s, 1 H)
Example 346G 5-F6-(2-hydroxyethyl)-l,4-dihydroindenoFl,2-clpyrazol-3-yllpyridine-2-carbonitrile Example 346F (64 mg, 0.205 mmol), Pd(PPh3) (24 mg, 0.0205 mmol), Zn(CN)2(0.29 g, 22.463 mmol) and DMF (4 mL) were mixed, pumped with N , stirred, and heated to lδO'C for 5 minutes in a Smith Synthesizer. The reaction mixture was filtered. The filtrate was concentrated. The residue was purified by HPLC to give the title product (30.5 mg, 49%). MS (ESI) m/z 303 (M+H)+; 1H NMR (400 MHz, DMSO-D6) δ ppm 2.80 (t, J=7.06 Hz, 2 H) 3.66 (t, J=7.06 Hz, 2 H) 3.92 (s, 2 H) 4.65 (br. s, 1 H) 7.24 (d, J=7.36 Hz, 1 H) 7.45 (s, 1 H) 7.57 (s, 1 H) 8.16 (s, 1 H) 8.38 (dd, 3=7.98, 2.15 Hz, 1 H) 9.17 (s, 1 H) 13.56 (s, 1 H)
Example 347 5-F6-(difluoromethoxy)-7-methoxy- 1 ,4-dihydroindeno Fl ,2-clpyrazol-3-yl1pyridine-2-carbonitrile
Example 347A 5-(difluoromethoxy)-6-methoxyindan- 1 -one 5-Hydroxy-6-methoxy-indan-l-one (0.78 g, 4.38 mmol), C1CHF2 (7.0 g, 80.95 mmol), K2CO3 (3.6 g, 26.04 mmol) and DMF (40 mL) were stirred, and heated to 100°C for 2 hours. The reaction mixture was filtered. The filtrate was concentrated. The residue was purified by flash chromatography to give the above intermediate (0.59 g, 59%). MS (DCI/NH3) m z 229 (M+H)+; 1H NMR (300 MHz, CD3OD) δ ppm 2.67-2.73 (m, 2 H) 3.06-3.13 (m, 2 H) 3.91 (s, 3 H) 6.90 (t, 3=74.43 Hz, 1 H) 7.31 (s, 1 H) 7.32 (s, 1 H)
Example 347B 3-(6-chloropyridin-3-yl)-6-(difluoromethoxy)-7-methoxy-l,4-dihydroindenori,2-clpyrazole Example 347A (0.59 g, 2.59 mmol), Example 324A (1.21 g, 5.17 mmol), 95% NaH (0.26 g, 10.34 mmol) and anhydrous THF (30 mL) were mixed, and stirred at room temperature for 1 hour. All the solvent was removed. To the residue was added ethanol (50 mL), acetic acid (2 mL) and hydrazine monohydrate (2 mL). The mixture was heated to reflux for 2 hours, and cooled. All the solvents were removed. To the residue was added water (50 mL). The precipitate was filtered, washed with water (5 mLx3) and ethyl acetate (5 mLx3), and dried to give the above intermediate (0.64 g, 68%). MS (ESI) m/z 364 (M+H)+; 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.83 (s, 2 H) 3.91 (s, 3 H) 7.06 (t, 3=74.87 Hz, 1 H) 7.40 (d, J=7.49 Hz, 2 H) 7.64 (d, J=8.42 Hz, 1 H) 8.20 (dd, J=8.42, 1.87 Hz, 1 H) 8.81 (d, J=1.56 Hz, 1 H) 13.41 (s, 1 H)
Example 347C 5-F6-(difluoromethoxy)-7-methoxy-l,4-dihydroindenoFl,2-c1pyrazol-3-yl1pyridine-2-carbonitrile Example 347B (100 mg, 0.282 mmol), Pd(PPh3)4 (33 mg, 0.0282 mmol), Zn(CN)2(0.331 g, 2.82 mmol) and DMF (5 mL) were mixed, pumped withN2, stirred, and heated to 18CC for 5 minutes in a Smith Synthesizer. The reaction mixture was filtered. The filtrate was concentrated. To the residue was added DMSO (2.5 mL). The suspension was stirred for 0.5 hour. The precipitate was then filtered, washed by water (5 mLx3) and ethyl acetate (5 mLχ3), and dried in vacuo to give the title compound (32 mg, 32%). MS (ESI) m/z 355 (M+H)+; !H NMR (500 MHz, DMSO-D6) δ ppm 3.84-3.92 (m, 5 H) 7.08 (t, 3=74.71 Hz, 1 H) 7.347.52 (m, 2 H) 8.13 (m, 1 H) 8.35 (s, 1 H) 9.15 (d, 3=1.87 Hz, 1 H)
Example 348 4-{5-F6-(difluoromethoxy)-7-methoxy-l,4-dihydroindenoFl,2-c1pyrazol-3-yllpyridin-2- yljphenol Example 347B (100 mg, 0.275 mmol), (4-hydroxyphenyl)boronic acid (49 mg, 0.356 mmol), Pd(PPh3)2Cl2 (17 mg, 0.0237 mmol), DME/EtOH/H2O (7/2/3, 3.5 mL) and IM NϋCO3 (1.5 mL) were mixed, and heated to 160°C for 10 minutes in a Smith Synthesizer. All the solvents were removed. The residue was purified by HPLC to give the title compound (42 mg, 36%). MS (ESI) m/z 422 (M+H)+; 1H NMR (500 MHz, DMSO-Dg) δ ppm 3.89 (s, 2 H) 3.93 (s, 3 H) 6.89 (d, 3=8.73 Hz, 2 H) 7.08 (t, J=74.87 Hz, 1 H) 7.43 (d, J=12.17 Hz, 2 H) 7.988.02 (m, 3 H) 8.20 (dd, J=8.42, 2.18 Hz, 1 H) 9.02 (d, J=2.18 Hz, 1 H).
It will be evident to one skilled in the art that the present invention is not limited to the foregoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

Claims

What is claimed is:
1. A compound of formula (I)
(I), or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein
R] and R2 are independently selected from the group consisting of hydrogen, alkenyl, alkenyloxy, alkoxy, alkoxyalkoxy, alkoxyalkoxyalkynyl, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, cycloalkenylalkoxy, cycloalkylalkoxy, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkyloxy, formyl, haloalkoxy, haloalkoxyalkynyl, haloalkyl, halogen, heteroarylalkoxy, heteroarylalkoxyalkoxy, heteroarylalkyl, heteroarylalkynyl, heteroaryloxyalkyl, heterocycle, heterocyclealkoxy, heterocyclealkyl, heterocyclecarbonyl, heterocycleoxy, hydroxy, hydroxyalkoxy, hydroxyalkyl, hydroxyalkynyl, hydroxysulfonyl, hydroxysulfonylalkyl, mercapto, mercaptoalkyl, nitro, -NRARB. (NRARB)alkoxy, (NRARB)alkyl, (NRARB)alkynyl, (NR RB)carbonyl, (NRARB)carbonylalkoxy, (NRARB)carbonylalkyl, and or
Ri and R2 together with the carbon atoms to which they are attached form a 5, 6, 7, or 8- membered nonaromatic ring wherein the ring contains 0, 1, or 2 heteroatoms selected from the group consisting of O, N(Rc), and N(RD), wherein the nonaromatic ring is substituted with 0, 1 , or 2 substituents selected from the group consisting of alkyl and hydroxy;
R3 is selected from the group consisting of hydrogen, alkenyl, alkenyloxy, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NRERF, (NRE p)al oxy ( ^R^ -kyl, (NRERF)carbonyl, and (NRERp)carbonylalkyl;
I ( is selected from the group consisting of hydrogen, alkoxycarbonyl, alkylcarbonylalkoxy, aryl, arylalkoxy, arylalkyl, aryloxy, carboxy, cyano, halogen, heteroaryl, heteroarylalkoxy, heteroarylalkyl, heteroaryloxy, heterocycle, heterocyclealkoxy, heterocyclealkyl, heterocycleoxy, hydroxy, -NRERF, and (NRERp)c rbonyl;
R5 is absent or selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, halogen, heteroaryl, hydroxy, nitro, -NRERF, and (NRERF)carbonyl; provided that when R5 is hydrogen, R4 is other than hydrogen; or
R-t and R5, together with the atoms to which they are attached, form a phenyl ring optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkylthioalkyl, alkynyl, carboxy, carboxyalkyl, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, -NRGRH, and (NRoRi sulfonyl; or
Rt and R5, together with the atoms to which they are attached, form a heterocycle optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro, oxo, -NRGRH, and (NRoR^carbonyl;
Rg is selected from the group consisting of hydrogen, lower alkoxy, lower alkyl, halogen, hydroxy, and -NRERF;
R and Rβ are independently selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkoxyalkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkylcarbonyl, alkoxysulfonyl, alkoxysulfonylalkyl, alkoxysulfonylalkylcarbonyl, alkyl, alkylcarbonyl, alkynyl, aryl, carboxyalkyl, carboxyalkylcarbonyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkylcarbonyl, cycloalkylcarbonyl, cycloalkylcarbonylalkyl, cycloalkylcarbonylalkylcarbonyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, heterocyclealkylcarbonyl, heterocyclecarbonyl, heterocyclecarbonylalkyl, heterocyclecarbonylalkylcarbonyl, hydroxyalkyl, hydroxyalkylcarbonyl, hydroxysulfonyl, hydroxysulfonylalkyl, hydroxysulfonylalkylcarbonyl, (NRERF) lkyl, (NRERF)alkylcarbonyl, (NRERF)carbonyl, (NRERF)carbonylalkyl, (NRERF)carbonylalkylcarbonyl, (NRERF)sulfonyl, (NRERF)sulfonylalkyl, and (NRERF)sulfonylalkylcarbonyl;
Re and RD are independently selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, and alkylcarbonyl;
RE and RF are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, cycloalkyl, heteroarylalkyl, and hydroxyalkyl;
X,, X3, and X are independently selected from the group consisting of CH and N;
X2 is selected from the group consisting of CH(R7), C(R7)(R8), C=O, N(R8);
X5 is selected from the group consisting of C and N;
R7 is selected from the group consisting of hydrogen, alkoxy, alkyl, hydroxy, lower alkoxy, lower alkyl, and hydroxyalkyl; and
R8 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, alkylcarbonyl, and hydroxyalkyl.
2. The compound according to claim 1 wherein
X2 is CH(R7);
X5 is C;
Ri and R2 are independently selected from the group consisting of hydrogen, alkenyloxy, alkoxy, alkoxyalkyl, heterocyclealkyl, hydroxy, hydroxyalkyl, (NR RB)alkyl, and (NRARB)carbonyl;
R3 is hydrogen;
R4 is selected from the group consisting of hydrogen, alkoxycarbonyl, aryl, carboxy, cyano, heteroaryl, hydroxy, -NRERF, and (NRERF)carbonyl;
R5 is selected from the group consisting of hydrogen and-NRεRF;
Rg is hydrogen;
R7 is hydrogen;
RA is selected from the group consisting of hydrogen and alkyl;
RB is selected from the group consisting of hydrogen, alkyl, cycloalkyl, heteroarylalkyl, heterocycle, and hydroxyalkyl; RE is selected from the group consisting of hydrogen and alkyl; and
RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
3. The compound according to claim 1 wherein X], X3, and X4 are CH;
X2 is CH(R7);
X5 is C;
Ri and R2 are independently selected from the group consisting of hydrogen, alkenyloxy, alkoxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARβ)alkyl, (NRARβ)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l-piperidinyl;
R3 is hydrogen;
R4 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, cyano, heteroaryl, hydroxy, -NRERF, (NRERF)carbonyl, and aryl, wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NRQRH;
R5 is selected from the group consisting of hydrogen and -NRERF;
Rg is hydrogen;
R7 is hydrogen;
R is selected from the group consisting of hydrogen and alkyl;
RB is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy;
RE is selected from the group consisting of hydrogen and alkyl; and
RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
4. The compound according to claim 1 wherein X], X3, and X are CH
X2 is CH(R7); X5 is C; Ri, R3, R5, and Rg are hydrogen;
R2 is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARβ)alkyl, (NRARβ)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; ,
R is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, and (N ERF)carbonyl;
R7 is hydrogen;
RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; and
RB, RE and RF are hydrogen.
5. The compound according to claim 4 selected from the group consisting of
4-(6-{[(trans-4-methylcyclohexyl)amino]methyl}-l,4-dihydroindeno[l,2-c]ρyrazol-3- yl)benzoic acid;
4-(6-{[(cis-4-methylcyclohexyl)amino]methyl}-l,4-dihydroindeno[l,2-c]pyrazol-3- yPbenzoic acid; ethyl 4-(6- { [(trans-4-methylcyclohexyl)amino]methyl} - 1 ,4-dihydroindeno[ 1 ,2-c]pyrazol- 3-yl)benzoate;
4-(6- { [(trans-4-hydroxycyclohexyl)amino]methyl} - 1 ,4-dihydroindeno[ 1 ,2-c]pyrazol-3- yl)benzoic acid;
4-(6- { [(trans-4-hydroxycyclohexyl)amino]methyl} - 1 ,4-dihydroindeno[ 1 ,2-c]pyrazol-3- yl)benzamide;
4-[6-(4-morpholinylmethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]benzoic acid; methyl 4-[6-(4-morpholinylmethyl)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]benzoate;
4-[6-(4-morpholinylmethyl)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]benzamide;
4- { 6- [(4-hydroxy- 1 -piperidinyl)methyl] - 1 ,4-dihydroindeno [ 1 ,2-c] pyrazol-3-yl } benzoic acid; and 4- { 6- [(4-hydroxy- 1 -piperidinyl)methyl] - 1 ,4-dihydroindeno [ 1 ,2-c] pyrazol-3- yl}benzamide;
4- { 6-[(neopentylamino)methyl]- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yljbenzoic acid;
4-{6-[(neopentylamino)methyl]-l,4-dihydroindeno[l,2-c]pyrazol-3-yl}benzamide;
4-(6-{[(3-hydroxy-2,2-dimethylpropyl)amino]methyl}-l,4-dihydroindeno[l,2-c]pyrazol- 3-yl)benzoic acid;
4-(6-{ [(3-hydroxy-2,2-dimethylpropyl)amino]methyl} - 1 ,4-dihydroindeno[l ,2-c]pyrazol- 3-yl)benzamide;
4- [6-(hy droxymethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl] benzoic acid;
4-[6-(hydroxymethyl)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]benzamide;
4- [6-(methoxymethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl] benzoic acid;
4-[6-(allyloxy)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]benzoic acid; methyl 4- [6-(allyloxy)- 1 ,4-dihydroindeno [ 1 ,2-c ]pyrazol-3 -yl]benzoate ;
4-[6-(allyloxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]benzamide; methyl 4-(6-hydroxy-l ,4-dihydroindeno[l ,2-c]pyrazol-3-yl)benzoate;
4-(6-hydroxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)benzoic acid;
4-(6- { [(trans-4-hydroxycyclohexyl)amino]carbonyl} - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl)benzoic acid;
4-{6-[(neopentylamino)carbonyl]-l,4-dihydroindeno[l,2-c]pyrazol-3-yl}benzoic acid;
3-[4-(aminocarbonyl)phenyl]-N-neopentyl-l,4-dihydroindeno[l,2-c]pyrazole-6- carboxamide; and
4-(6- { [(trans-4-methylcyclohexyl)amino]methyl}- 1 ,4-dihydroindeno[ 1 ,2-c]pyrazol-3- yl)phenol.
6. The compound according to claim 1 wherein Xi, X3, and X4 are CH X2 is CH(R7); X5 is C; Ri, R3, R5, and Rg are hydrogen; R2 is selected from the group consisting of hydrogen, alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARβ)alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl; is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NRGRH;
R7 is hydrogen;
RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; and
RB, RE, and Rp are hydrogen.
7. The compound according to claim 6 selected from the group consisting of
4'-(6- { [(cis-4-methylcyclohexyl)amino] methyl } - 1 ,4-dihydroindeno [ 1 ,2-c ]pyrazol-3 -yl)- 1 , 1 '-biphenyl-4-ol;
4'-(6-{ F(trans-4-hydroxycyclohexyl)amino]methyl}- 1 ,4-dihydroindeno [ 1 ,2-c] pyrazol-3 - yl)-3-methoxy- 1 , 1 '-biphenyl-4-ol;
4'-(6- { [(trans-4-hydroxycyclohexyl)amino]methyl} - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl)-3-(hydroxymethyl)- 1 , 1 '-biphenyl-4-ol;
3-methoxy-4'- {6- [(neopentylamino)methyl]- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl} - 1,1'- biphenyl-4-ol;
4'-(6-{[(3-hydroxy-2,2-dimethylpropyl)amino]methyl}-l,4-dihydroindeno[l,2-c]pyrazol- 3-yl)-3-methoxy- 1 , 1 '-biphenyl-4-ol;
3-(4'-hydroxy- 1 , 1 -biphenyl-4-yl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6-ol;
3-(4'-hydroxy-3'-methoxy-l , 1 '-biphenyl-4-yl)- 1 ,4-dihydroindeno [1 ,2-c]pyrazol-6-ol;
4'-[6-(hydroxymethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]- 1 , 1 '-biphenyl-4-ol;
4'-(l,4-dihydroindeno[l,2-c]pyrazol-3-yl)-l,r-biphenyl-4-ol;
4'-[6-(hydroxymethyl)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]-3-methoxy-l,l'-biphenyl- 4-ol;
3 -(3 '-fluoro-4'-hydroxy- 1 , 1 '-biphenyl-4-y 1)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6-ol; 3 -(3 -amino-4'-hydroxy- 1 , 1 -biphenyl-4-yl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6-ol;
4-hydroxy-4'-[6-(hydroxymethyl)-l ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]-5-methoxy- 1,1 - biphenyl-2-carbaldehyde;
3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-N-(trans-4-hydroxy cyclohexyl)- 1 ,4-dihydroindeno [ 1 ,2- c]pyrazole-6-carboxamide; and
3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-N-neopentyl- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazole-6- carboxamide.
8. The compound according to claim 1 wherein
X2 is CH(R7);
X5 is C;
Ri, R3, R5, and Rg are hydrogen;
R2 is selected from the group consisting of hydrogen, alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARβ)alkyl, (NRARβ)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl;
Rt is heteroaryl;
R7 is hydrogen;
RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy; and
RB is selected from the group consisting of hydrogen and alkyl.
9. The compound according to claim 8 that is 6-(allyloxy)-3-[4-(lH-tetraazol-5-yl)phenyl]- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazole.
10. The compound according to claim 1 wherein X2 is CH(R7); X5 is C;
Rl5 R3, and Rg are hydrogen;
R2 is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARB)alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl;
R4 is selected from the group consisting of hydrogen, carboxy, and cyano;
R5 is selected from the group consisting of alkoxycarbonyl, carboxy, hydroxy, hydroxyalkyl, -NRERF, and (NRERF)carbonyl;
R7 is hydrogen;
RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy;
RB is selected from the group consisting of hydrogen and alkyl;
RE is selected from the group consisting of hydrogen and alkyl; and
RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
11. The compound according to claim 10 selected from the group consisting of N-[3-(6-{[(trans-4-hydroxycyclohexyl)amino]methyl}-l,4-dihydroindeno[l,2-c]pyrazol-
3 -y l)phenyl]acetamide ;
N-{3-[6-(4-morpholinylmethyl)-l,4-dihydiOindeno[l,2-c]p3'razol-3- yl]phenyl} acetamide;
2-(acetylamino)-4- [6-(4-morpholinylmethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 - yl]benzoic acid; and
N-(3 - { 6- [(4-hydroxy- 1 -piperidinyl)methyl] - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl}phenyl)acetamide.
12. The compound according to claim 1 wherein Xι, X3, and X4 are CH;
X2 is CH(R7); X5 is C;
R2, R3, R5, and Rg are hydrogen;
R} is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARB)alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl;
Is4 is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NRERF, and (NRERF)carbonyl;
R7 is hydrogen;
R is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy;
RB is selected from the group consisting of hydrogen and alkyl;
RE is selected from the group consisting of hydrogen and alkyl; and
RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
13. The compound according to claim 12 selected from the group consisting of
4-[7-(hydroxymethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]benzoic acid;
4-[7-(hydroxymethyl)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]benzamide;
4-[7-(4-morpholinylmethyl)-l,4-dihydiOindeno[l,2-c]pyrazol-3-yl]benzoic acid;
4-[7-(4-mo holinylmethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]benzamide;
4-(7- { [(2-hydroxyethyl)amino]methyl} - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)benzoic acid;
4- { 7- [(neopentylamino)methyl] - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl } benzamide;
4-{7-[(methylamino)carbonyl]- 1 ,4-dihydroindeno [1 ,2-c]pyrazol-3-yl}benzoic acid;
3-[4-(aminocarbonyl)phenyl]-N-methyl-l,4-dihydroindeno[l,2-c]pyrazole-7- carboxamide;
4- { 7- [(neopentylamino)carbonyl] - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl } benzoic acid; and 4-(7-{[(trans-4-hydroxycyclohexyl)amino]carbonyl}-l,4-dihydroindeno[l,2-c]pyrazol-3- yl)benzoic acid.
14. The compound according to claim 1 wherein
Xi, X3, and X4 are CH;
X2 is CH(R7);
X5 is C;
R2, R3, R5, and Rg are hydrogen;
Ri is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARB)alkyl, (NR RB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl;
Rt is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, and -NRGRH;
R7 is hydrogen;
R is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy;
RB s selected from the group consisting of hydrogen and alkyl; RE s selected from the group consisting of hydrogen and alkyl; and s selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
15. The compound according to claim 14 selected from the group consisting of
4'-[7-(hydroxymethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl] -3 -methoxy- 1 , 1 '-biphenyl- 4-ol;
4'-[7-(hydroxymethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]- 1 , 1 -biphenyl-4-ol;
4'-{7-[(neopentylamino)methyl]-l,4-dihydroindeno[l,2-c]pyrazol-3-yl}-l, -biphenyl-4- ol;
3 -(4-hydroxy- 1 , 1 '-biphenyl-4-yl)-N-methyl- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazole-7- carboxamide; and 3 -(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-N-neopentyl- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazole-7- carboxamide.
16. The compound according to claim 1 wherein
Xi, X3, and X4 are CH;
X2 is CH(R7);
X5 is C;
R2, R3, and Rg are hydrogen;
Ri is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARβ)alkyl, (NRARB)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl;
R is selected from the group consisting of hydrogen, carboxy, and cyano;
R5 is selected from the group consisting of alkoxycarbonyl, carboxy, hydroxy, hydroxyalkyl, -NRERF, and (MRERF)carbonyl;
R7 is hydrogen;
RA is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy;
RB s selected from the group consisting of hydrogen and alkyl; RE s selected from the group consisting of hydrogen and alkyl; and F s selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
17. The compound according to claim 16 that is N-{3-[7-(hydroxymethyl)-l,4- dihydroindeno[l,2-c]pyrazol-3-yl]phenyl}acetamide.
18. The compound according to claim 1 wherein
X2 is CH(R7); X5 is C; Ri and R2 are alkoxy; R3 and Rg are hydrogen;
R is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, -NRERF, and (NRERF)carbonyl;
Rs is selected from the group consisting of hydrogen and carboxy;
R7 is hydrogen;
RE is selected from the group consisting of hydrogen and alkyl; and
RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
19. The compound according to claim 18 that is 4-{6,7-dimethoxy-l,4-dihydroindeno[l,2- c]pyrazol-3-yl)benzoic acid.
20. The compound according to claim 1 wherein Xi, X3, and X are CH;
X2 is CH(R7); X5 is C; and R2 are alkoxy; R3, R5, and Rg are hydrogen;
Rt is aryl wherein the aryl is phenyl substituted with 1, 2, or 3 substituents selected from the group consisting of alkoxy, formyl, halogen, hydroxy, hydroxyalkyl, a d-NRoR-H R7 is hydrogen;
RE is selected from the group consisting of hydrogen and alkyl; and RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
21. The compound according to claim 20 that is 4'-(6,7-dimethoxy- 1 ,4-dihydroindeno [ 1 ,2- c]pyrazol-3-yl)- 1 , 1 '-biphenyl-4-ol.
22. The compound according to claim 1 wherein X1} X3, and X4 are CH;
X2 is CH(R7); X5 is C;
Ri and R2 are alkoxy;
R3, R5, and Rg are hydrogen;
R4 is heteroaryl; and
R7 is hydrogen.
23. The compound according to claim 22 that is 6,7-dimethoxy-3-[4-(lH-tetraazol-5- yl)phenyl]-l,4-dihydroindeno[l,2-c]pyrazole.
24. The compound according to claim 1 wherein Xl5 X3, and X are CH;
X2 is CH(R7); X5 is C;
Ri, R2, R3, R5, and Rg are hydrogen;
R is selected from the group consisting of alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NRERF, and (NRE F)carbonyl; and
R7 is selected from the group consisting of alkoxy and hydroxy.
25. The compound according to claim 24 that is 4-{4-hydroxy-l,4-dihydroindeno[l,2- c]pyrazol-3-yl)benzoic acid.
26. The compound according to claim 1 wherein
X2 is CH(R7); X3 is N; X4 is CH; X5 is C;
Ri, R3, R5, and Rg are hydrogen;
R2 is selected from the group consisting of alkenyloxy, alkoxyalkyl, hydroxy, hydroxyalkyl, (NRARB)alkyl, (NRARβ)carbonyl, and heterocyclealkyl, wherein the heterocycle of heterocyclealkyl is selected from the group consisting of 4-morpholinyl and 4-hydroxy-l- piperidinyl;
R4 is selected from the group consisting of hydrogen, alkoxycarbonyl, carboxy, cyano, hydroxy, hydroxyalkyl, -NRERF, and (NRERF)carbonyl;
R7 is hydrogen;
R is selected from the group consisting of alkyl, hydroxyalkyl, and cycloalkyl, wherein the cycloalkyl is cyclohexyl substituted with 1 substituent selected from the group consisting of alkyl and hydroxy;
RB is selected from the group consisting of hydrogen and alkyl;
RE is selected from the group consisting of hydrogen and alkyl; and
RF is selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl.
27. The compound according to claim 26 selected from the group consisting of 6-[6-(allyloxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]nicotinic acid; and 6-(6-hydroxy- 1 ,4-dihydroindeno[ 1 ,2-c]pyrazol-3-yl)nicotinic acid.
28. The compound according to claim 1 selected from the group consisting of 4'-[6-(morpholin-4-ylmethyl)- 1 ,4-dihydroindeno [1 ,2-c]pyrazol-3-yl]- 1 , 1 '-biphenyl-4-ol; 4 - { 5- [(neopenty lamino)mefhyl] - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl } - 1 , 1 '-biphenyl-4- ol;
4'- { 6- [(neopentylamino)methyl]- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl } - 1 , 1 '-biphenyl-4- ol;
4'-(5-{ [(2-hydroxyethyl)amino]methyl}- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)- 1,1'- biphenyl-4-ol;
4'-(6- { [(2-hydroxyethyl)amino]methyl} - 1 ,4-dihydroindeno [1 ,2-c]pyrazol-3-yl)- 1,1'- biphenyl-4-ol;
4'-(7- { [(2-hydroxy ethyl)amino]methyl} - 1 ,4-dihydroindeno [ 1 ,2-c] pyrazol-3 -yl)- 1,1'- biphenyl-4-ol;
4'- { 6- [(butylamino)methyl] - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl } - 1 , 1 '-biphenyl-4-ol; 1 - { [3-(4'-hydroxy- 1 , 1 -biphenyl-4-yl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6- yl]methyl}piperidin-4-ol;
4'-{6-[(4-methylpiperazin-l-yl)methyl]-l ,4-dihydroindeno[ 1 ,2-c]pyrazol-3-yl}- 1 , 1 '- biphenyl-4-ol;
4'- { 6- [(pyridin-4-y lamino)methyl] - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl} - 1 , 1 '-biphenyl- 4-ol;
4'-(6-{[(3-hydroxy-2,2-dimethylpropyl)amino]methyl}-l,4-dihydroindeno[l,2-c]pyrazol- 3-yl)-l,l*-biphenyl-4-ol;
1 -{ [3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)- 1 ,4-dihydroindeno [1 ,2-c]pyrazol-6- yl]methyl}piperidine-4-carboxamide;
4'-[6-({ [(5-methylpyrazin-2-yl)methyl]amino}methyl)- 1 ,4-dihydroindeno [1 ,2-c]pyrazol- 3-yl]-l,l'-biphenyl-4-ol;
4'-(6-{ [(pyridin-2-ylmethyl)amino]methyl} - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)- 1,1'- biphenyl-4-ol;
4' -(7- { [(2-pyrrolidin- 1 -ylethyl)amino]methy 1} - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)- l,l'-biphenyl-4-ol;
4'-[6-(thiomorpholin-4-ylmethyl)- l,4-dihydroindeno[ 1 ,2-c]pyrazol-3-yl]- 1 , 1 '-biphenyl-4- ol;
[3-(4'-Hydroxy-biphenyl-4-yl)-l,4-dihydro-indeno[l,2-g]pyrazol-6-yl]- morpholin-4-yl-methanone 4'-[6-(morpholin-4-ylcarbonyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]- 1 , 1 '-biphenyl-4-ol;
N-cyclohexyl-3-(4'-hydroxy-l,l'-biphenyl-4-yl)-l,4-dihydroindeno[l,2-c]pyrazole-6- carboxamide;
4'- [7-(morpholin-4-ylcarbonyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl] -1,1 -biphenyl-4-ol;
3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-N-(2-hydroxy ethyl)- 1 ,4-dihydroindeno[ 1 ,2-c]pyrazole- 7-carboxamide;
1 - { [3-(4'-hydroxy- 1 , 1 '-bipheny 1-4-yl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6- yl]carbonyl}piperidin-4-ol;
4'- [6-(piperazin- 1 -y lcarbonyl)- 1 ,4-dihy droindeno[ 1 ,2-c]pyrazol-3-yl] -1,1 '-biphenyl-4-ol; 4'- { 6- [(4-methylpiperazin- 1 -yl)carbony 1]- 1 ,4-dihydroindeno [ 1 ,2-c]ρyrazol-3 -yl} - 1 , 1'- biphenyl-4-ol;
3-(4'-hydroxy- 1 , 1 '-biphenyl-4-y l)-N-(pyridin-4-ytoaethyl)- 1 ,4-dih droindeno [ 1 ,2- c]pyrazole-6-carboxamide;
1 - { [3-(4'-hydroxy- 1 , 1 '-bipheny 1-4-yl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6- yl]carbonyl}piperidine-4-carboxamide;
3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-N-[(5-methylpyrazin-2-yl)methyl]- 1 ,4- dihydroindeno[l,2-c]pyrazole-6-carboxamide;
3 -(4'-hydroxy- 1 , 1 '-bipheny l-4-yl)-N-(pyridin-2-ylmethyl)- 1 ,4-dihydroindeno [1,2- c]pyrazole-6-carboxamide;
3 -(4'-hydroxy- 1 , 1 -bipheny 1-4-y 1)-N- { [6-(trifluoromethyl)pyridin-3 -yl]methyl } - 1 ,4- dihydroindeno[l,2-c]pyrazole-6-carboxamide;
N-[2-(dimethylamino)ethyl]-3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)- 1 ,4-dihydroindeno [1 ,2- c]pyrazole-6-carboxamide;
3-(4' -hydroxy- 1 , 1 '-biphenyl-4-yl)-N-(pyridin-3-ylmethyl)- 1 ,4-dihydroindeno[ 1 ,2- c]pyrazole-6-carboxamide;
N- [3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6-yl] -2- morpholin-4-ylacetamide;
N-[3-(4'-hydroxy-l,l'-biphenyl-4-yl)-l,4-dihydroindeno[l,2-c]pyrazol-5-yl]acetamide;
N-[3-(4'-hydroxy- 1 , l'-bipheny 1-4-yl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6-yl]-2- [(pyridin- 4-ylmethyl)amino] acetamide;
N-[3-(4'-hydroxy-l,r-biphenyl-4-yl)-l,4-dihydroindeno[l,2-c]pyrazol-6-yl]-2-[trans-(4- hydroxycyclohexyl)amino]acetamide;
2-(butylamino)-N- [3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6- yl]acetamide;
N-[3-(4'-hydroxy-l,l'-biphenyl-4-yl)-l,4-dihydroindeno[l,2-c]pyrazol-6-yl]-2-[(2- hydroxy ethy l)amino] acetamide;
3-(4 -hydroxy- 1 , 1 '-biphenyl-4-yl)-7-methoxy-N-(pyridin-4-ylmethyl)- 1 ,4- dihydroindeno [ 1 ,2-c]pyrazole-6-carboxamide; 4'-(6-{ [(2-hydroxyethyl)amino]methyl} -7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl)- 1 , 1 '-biphenyl-4-ol;
4'-{7-methoxy-6-[(4-methylpiperazin-l-yl)carbonyl]-l,4-dihydroindeno[l,2-c]pyrazol-3- yl} - 1 , 1 '-biphenyl-4-ol;
3-(4'-hydroxy- 1 , 1 '-bipheny l-4-yl)-N-(trans-4-hydroxycyclohexyl)-7-methoxy- 1 ,4- dihydroindeno [ 1 ,2-c]pyrazole-6-carboxamide;
4'-[7-methoxy-6-(morpholin-4-ylcarbonyl)~ 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl] -1,1'- biphenyl-4-ol;
1 -{ [3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6- yl]carbonyl}piperidine-4-carboxamide;
1 - { [3-(4'-hydroxy- 1 , 1 '-bipheny l-4-yl)-7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6- yl] carbonyl }piperidin-4-ol;
4'-{7-methoxy-6-[(4-methylpiperazin-l-yl)methyl]-l,4-dihydroindeno[l,2-c]pyrazol-3- yl}-l,l'-biphenyl-4-ol;
4'-(7-methoxy-6- { [(2-ρyrrolidin- 1 -ylethyl)amino]methyl } - 1 ,4-dihydroindeno [ 1 ,2- c]pyrazol-3 -yl)- 1 , 1 '-bipheny l-4-ol;
4'-(6- { [(trans-4-hydroxycyclohexyl)amino]methyl} -7-methoxy- 1 ,4-dihydroindeno [ 1 ,2- c]pyrazol-3-yl)- 1 , 1 '-biρhenyl-4-ol;
4'-{7-methoxy-6-[(pyridin-4-ylamino)methyl]- 1 ,4-dihydroindeno [1 ,2-c]pyrazol-3-yl}- 1 , r-biphenyl-4-ol;
1 -{ [3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6- yl]methyl}piperidine-4-carboxamide;
1 - { [3-(4'-hydroxy- 1 , 1 '-bipheny l-4-yl)-7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6- yl]methyl}piperidine-4-carboxamide;
3 -fluoro-4'- [6-(hydroxymethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]- 1 , 1 '-biphenyl-4- ol;
3-fluoro-4'-(7-methoxy-6-{[(2-pyrrolidin-l-ylethyl)amino]methyl}-l,4- dihydroindeno[ 1 ,2-c]pyrazol-3-yl)- 1 , 1 '-biphenyl-4-ol;
3 -fluoro-4'- {6- [(4-methylpiperazin- 1 -yl)methyl] - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl } - l,l'-biphenyl-4-ol; 3-(3'-fluoro-4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-N-(pyridin-2-ylmethyl)- 1 ,4- dihydroindeno [ 1 ,2-c]pyrazole~6-carboxamide;
3-fluoro-4'-(7- { [(2-pyrrolidin- 1 -ylethyl)amino]methyl} - 1 ,4-dihydroindeno [ 1 ,2-c]pyr azol- 3-yl)-l,l'-biphenyl-4-ol;
3 -fluoro-4'- [7-methoxy-6-(morpholin-4-ylcarbonyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl]-l,l'-biphenyl-4-ol;
5- { 6- [(4-methylpiperazin- 1 -yPmefhyl] - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl }pyridine-2- carbonitrile;
3-(6-cyanopyridin-3-yl)-N-(pyridin-2-ylmethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazole-6- carboxamide;
5- { 6-[(4-hydroxypiperidin- 1 -yl)methyl]- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl}pyridine- 2-carbonitrile;
5 -(6- { [(pyridin-2-ylmethyl)amino]methyl } - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 - yl)pyridine-2-carbonirrile;
5 -(6- { [(trans-4-hydroxycyclohexyl)amino]methyl} - 1 ,4-dihy droindeno[ 1 ,2-c]pyrazol-3- yl)pyridine-2-carbonitrile;
3-(6-cyanopyridin-3-yl)-N-(tι-ans-4-hydroxycyclohexyl)-l,4-dihydroindeno[l,2- c]pyrazole-6-carboxamide;
3-(6-cyanopyridin-3-yl)-N- { [6-(trifluoromethyl)pyridin-3-yl]methyl} - 1 ,4- dihydroindeno[ 1 ,2-c]pyrazole-6-carboxamide;
5 - [6-(hydroxymethyl)- 1 ,4-dihydroindeno [ 1 ,2-c] pyrazol-3 -yl]pyridine-2-carbonitrile;
5-{6-[(pyridin-3-yloxy)methyl]-l,4-dihydroindeno[l,2-c]pyrazol-3-yl}pyridine-2- carbonitrile;
5-{6-[(pyridin-4-yloxy)methyl]-l,4-dihydroindeno[l,2-c]pyrazol-3-yl}pyridine-2- carbonitrile;
3-(6-fluoropyridin-3-yl)-7-methoxy-4,4-dimethyl-l,4-dihydroindeno[l,2-c]pyrazol-6-ol;
5-(6-hydroxy-7-methoxy-4,4-dimethyl-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)pyridine-2- carbonitrile;
5-[7-methoxy-4,4-dimethyl-6-(pyridin-3-ylmethoxy)-l,4-dihydroindeno[l,2-c]pyrazol-3- yl]pyridine-2-carbonitrile; 5-[7-methoxy-4,4-dimethyl-6-(3-morpholin-4-ylpropoxy)-l,4-dihydroindeno[l,2- c]pyrazol-3-yl]pyridine-2-carbonitrile;
5-[7-methoxy-4,4-dimethyl-6-(tetrahydrofuran-3-yloxy)-l,4-dihydroindeno[l,2- c]pyrazol-3-yl]pyridine-2-carbonitrile;
5-(6-{[(2R)-2,3-dihydroxypropyl]oxy}-7-methoxy-4,4-dimethyl-l,4-dihydroindeno[l,2- c]pyrazol-3-yl)pyridine-2-carbonitrile;
5-[7-methoxy-4,4-dimethyl-6-(pyridin-2-ylmethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- y l]pyridine-2-carbonitrile ;
5-[7-methoxy-4,4-dimethyl-6-(3-piperidin- 1 -ylpropoxy)- 1 ,4-dihydroindeno [1 ,2- c]pyrazol-3-yl]pyridine-2-carbonitrile;
5-(6,7-dimethoxy-4,4-dimethyl-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)pyridine-2- carbonitrile;
5-[7-methoxy-6-(pyridin-2-ylmethoxy)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]pyridine-2- carbonitrile;
5-{7-[(6-chloropyridin-3-yl)methoxy]-6-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-3- yl } pyridine-2-carbonitrile;
5-[6-methoxy-7-(pyridin-2-ylmethoxy)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]pyridine-2- carbonitrile;
5-[6-methoxy-7-(2-piperidin-l-ylethoxy)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]pyridine- 2-carbonitrile;
5-[6-methoxy-7-(pyridin-3-ylmethoxy)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]pyridine-2- carbonitrile;
5-[6-methoxy-7-(2-morpholin-4-ylethoxy)- 1 ,4-dihydroindeno[ 1 ,2-c]pyrazol-3- yl]pyridine-2-carbonitrile;
5-{6-methoxy-7-[2-(4-methyl- 1 ,3-thiazol-5-yl)ethoxy]- 1 ,4-dihydroindeno [1 ,2-c]pyrazol- 3-yl}pyridine-2-carbonitrile;
5-[6-methoxy-7-(2-pyrrolidin-l-ylethoxy)-l,4-dihydroindeno[l,2-c]pyrazol-3- yl]pyridine-2-carbonitrile;
5- {6-methoxy-7-[2-(2-oxopyrrolidin- 1 -yl)ethoxy]- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl}pyridine-2-carbonitrile; 5-[7-(2-hydroxyethoxy)-6-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]pyridine-2- carbonitrile;
5-{7-[(6-bromopyridin-2-yl)methoxy]-6-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-3- yl}pyridine-2-carbonitrile;
5-[7-methoxy-6-(pyridin-3-ylmethoxy)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]pyridine-2- carbonitrile;
5- [7-methoxy-6-(3 -morpholin-4-ylpropoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 - yl]pyridine-2-carbonitrile;
5-[7-methoxy-6-(tetrahydrofuran-3-yloxy)- 1 ,4-dihydroindeno[ 1 ,2-c]pyrazol-3- yl]pyridine-2-carbonitrile;
5-{6-[3-(dimethylamino)propoxy]-7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl }pyridine-2-carbonitrile;
5-{7-methoxy-6-[2-(4-methyl-l,3-thiazol-5-yl)ethoxy]-l,4-dihydroindeno[l,2-c]pyrazol- 3-yl}pyridine-2-carbonitrile;
5-[6-(2-hydroxyethoxy)-7-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]pyridine-2- carbonitrile;
5-{6-[(6-bromopyridin-2-yl)methoxy]-7-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-3- yl}pyridine-2-carbonitrile;
5-{6-[(6-chloropyridin-3-yl)methoxy]-7-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-3- yl] pyridine-2-carbonitrile;
5-[7-methoxy-6-(2-moφholin-4-ylethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl]pyridine-2-carbonitrile;
5 - { 6- [2-(5-ethylpyridin-2-yl)ethoxy] -7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl}pyridine-2-carbonitrile;
4'-(6,7-dimethoxy- 1 ,4-dihydroindeno [1 ,2-c]pyrazol-3-yl)-3-methoxy- 1 , 1 '-biphenyl-4-ol;
4-(6,7-dimethoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)phenol;
3-(4'-hydroxy-l ,l'-biphenyl-4-yl)-l ,4-dihydroindeno [1 ,2-c]pyrazole-6,7-diol;
4-(6,7-dimethoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)benzonitrile;
3-(6-hydroxy-2-naphthyl)- 1 ,4-dihydroindeno[ 1 ,2-c]pyrazol-6-ol;
6,7-dimethoxy-3-[4-(lH-pyrrol-2-yl)phenyl]-l,4-dihydroindeno[l,2-c]pyrazole; 6,7-dimethoxy-3-[4-(lH-pyrazol-4-yl)phenyl]-l,4-dihydroindeno[l,2-c]pyrazole;
3 -(4-bromophenyl)-7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6-ol;
3-(4'-hydroxy-l,l'-biphenyl-4-yl)-7-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-6-ol;
3 -(4'-hy droxy-3 '-methoxy- 1 , 1 '-bipheny l-4-yl)-7-methoxy- 1 ,4-dihydroindeno [ 1 ,2- c]pyrazol-6-ol;
4'- [7-methoxy-6-(pyridin-2-ylmethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl] -1,1'- biphenyl-4-ol;
4'-[7-methoxy-6-(pyridin-4-ylmethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]- 1,1'- biphenyl-4-ol;
4'-(7-methoxy-6-{3-[4-(2-methoxyphenyl)piperazin-l-yl]propoxy}-l,4- dihydroindeno[ 1 ,2-c]pyrazol-3-yl)- 1 , 1 '-biphenyl-4-ol;
4'-(6- { 3- [4-(3-chlorophenyl)piperazin- 1 -yl]propoxy } -7-methoxy- 1 ,4-dihydroindeno [1,2- c]pyrazol-3-yl)- 1 , 1 '-bipheny l-4-ol;
4'- { 6- [2-(dimethylamino)ethoxy] -7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl } - 1 , 1 '- biphenyl-4-ol;
4'-[7-methoxy-6-(2-piperidin- 1 -ylethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl] -1,1'- biphenyl-4-ol;
4'-[7-methoxy-6-(3-piperidin- 1 -ylpropoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]- 1 , 1 '- biphenyl-4-ol;
4'-{6-[2-(dimethylamino)-l-methylethoxy]-7-methoxy-l,4-dihydroindeno[l,2-c]pyrazol- 3 -yl } - 1 , 1 '-bipheny l-4-ol;
4'- { 7-methoxy-6- [2-( 1 -methylpyrrolidin-2-yl)ethoxy] - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol- 3-yl}- 1 , 1 '-biphenyl-4-ol;
4'-{6-[2-(l H-imidazol- 1 -yl)ethoxy] -7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl } - l,l'-biphenyl-4-ol;
4'- [7-methoxy-6-(2-morpholin-4-ylethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]- 1 , 1 '- biphenyl-4-ol;
4'- { 6-[3-(dimethy lamino)propoxy] -7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl } - l,l'-biphenyl-4-ol; 4'-[7-methoxy-6-(2-pyrrolidin- 1 -ylethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]- 1 , 1 '- biphenyl-4-ol;
4'-{6-[2-(diethylamino)ethoxy]-7-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl}-l,r- biphenyl-4-ol;
4'- [7-methoxy-6-(pyridin-3 -ylmethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl] -1,1'- biphenyl-4-ol;
4'-[7-methoxy-6-(2-pyridin-2-ylethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]- 1 , 1 '- biphenyl-4-ol;
4'-{6-[2-(5-ethylpyridin-2-yl)ethoxy]-7-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl}- 1 , l'-biphenyl-4-ol;
4'- [7-methoxy-6-(2-pyridin-4-ylethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl] -1,1'- biphenyl-4-ol;
2- { [3 -(4'-hydroxy- 1 , 1 '-bipheny l-4-yl)-7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6- yl]oxy }propane- 1 ,3-diol;
(2S)-3- { [3-(4' -hydroxy- 1 , l'-biphenyl-4-yl)-7-methoxy- 1 ,4-dihy droindeno[l ,2-c]pyrazol- 6-yl] oxy }propane- 1 ,2-diol ;
(2R)-3 - { [3 -(4'-hydroxy- 1 , 1 '-bipheny l-4-yl)-7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol- 6-yl]oxy}propane-l ,2-diol;
4'-(7-methoxy-6-{2-[3-(6-methylpyridin-2-yl)propoxy]ethoxy}-l,4-dihydroindeno[l,2- c]pyrazol-3-yl)-l,r-biphenyl-4-ol;
4'- { 6- [3-chloiO-2-(hydroxy methy l)-2-methylpropoxy] -7-methoxy- 1 ,4-dihydroindeno [ 1 ,2- c]pyrazol-3-yl}- 1 , 1 '-biphenyl-4-ol;
N,N-diethyl-2- { [3 -(4'-hydroxy- 1 , 1 '-bipheny l-4-yl)-7-methoxy- 1 ,4-dihydroindeno [ 1 ,2- c]pyrazol-6-yl]oxy}acetamide;
4'-[7-methoxy-6-(tefrahydrofuran-3-ylmethoxy)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]- l,l'-biphenyl-4-ol;
4'-[7-methoxy-6-(tetrahydro-2H-pyran-4-yloxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl] - l,l'-biphenyl-4-ol;
4'- [7-methoxy-6-(2-pyridin-3-ylethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl] -1,1'- biphenyl-4-ol; 4'- [7-methoxy-6-(tefrahydrofuran-3 -yloxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]- 1 , 1'- biphenyl-4-ol;
4'-[6-(cyclohex-3-en-l-ylmethoxy)-7-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]- l,l'-biphenyl-4-ol;
4'-[7-methoxy-6-(3-morpholin-4-ylpropoxy)- 1 ,4-dihydroindeno [1 ,2-c]pyrazol-3-yl]- 1,1'- biphenyl-4-ol;
4-(6-hydroxy-7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)benzonitrile;
4-[7-methoxy-6-(pyridin-2-ylmethoxy)-l,4-dihydroindeno[l,2-c]pyrazol-3- yl]benzonitrile;
4-[7-methoxy-6-(pyridin-3-ylmethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl]benzonitrile;
4-[7-methoxy-6-(pyridin-4-ylmethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl]benzonitrile;
4-[7-methoxy-6-(tetrahydro-2H-pyran-4-yloxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl]benzonitrile;
4-[7-methoxy-6-(3-morpholin-4-ylpropoxy)-l,4-dihydroindeno[l,2-c]pyrazol-3- yl]benzonitrile;
4-(6-{[(2R)-2,3-dihydroxypropyl]oxy}-7-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-3- yl)benzonitrile;
4- { 6- [2-hydroxy- 1 -(hydroxymethy l)ethoxy] -7-methoxy- 1 ,4-dihydroindeno [1,2- c]pyrazol-3-yl}benzonitrile;
4-{6-[2-(5-ethylpyridin-2-yl)ethoxy]-7-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-3- yl}benzonitrile;
4-{7-methoxy-6-[2-(5-methyl- 1 ,3-thiazol-4-yl)ethoxy]-l ,4-dihydroindeno [1 ,2-c]pyrazol- 3-yl}benzonitrile;
4- { 6- [3 -(dimethylamino)propoxy]-7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 - yl}benzonitrile;
4-[7-methoxy-6-(tetrahydrofuran-3-ylmethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl]benzonitrile; 4- [7-methoxy-6-(tetrahydrofuran-3 -yloxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 - yl]benzonitrile;
4-{6-[2-(2,5-dioxopyrrolidin-l-yl)ethoxy]-7-methoxy-l,4-dihydroindeno[l,2-c]pyrazol- 3-yl}benzonitrile;
4- { 6- [2-(3 ,5-dimethyl- 1 H-pyrazol- 1 -yl)efhoxy] -7-methoxy- 1 ,4-dihydroindeno [ 1 ,2- c]pyrazol-3-yl}benzonitrile;
3 -(4-cyanophenyl)-N-(4-hydroxycyclohexyl)-7-methoxy- 1 ,4-dihydroindeno [1,2- c]pyrazole-6-carboxamide;
3-(4-cyanophenyl)-7-methoxy-l,4-dihydroindeno[l,2-c]pyrazole-6-carboxylic acid;
3-(4-cyanophenyl)-7-methoxy-N-(pyridin-2-ylmethyl)-l,4-dihydroindeno[l,2-c]pyrazole- 6-carboxamide;
3-(4-cyanophenyl)-7-methoxy-N-(pyridin-3-ylmethyl)-l,4-dihydroindeno[l,2-c]pyrazole- 6-carboxamide;
3-(4-cyanophenyl)-7-methoxy-N-(pyridin-4-ylmethyl)- 1 ,4-dihydroindeno[ 1 ,2-c]pyrazole- 6-carboxamide;
3-(4-cyanophenyl)-7-methoxy-N-(4-morpholin-4-ylphenyl)-l,4-dihydroindeno[l,2- c]pyrazole-6-carboxamide;
3 -(4-cy anophenyl)-7-methoxy-N-(2-pyrrolidin- 1 -ylethyl)- 1 ,4-dihydroindeno [1,2- c]pyrazole-6-carboxamide;
3-(4-cyanopheny l)-7-methoxy-N-(2-piperidin- 1 -ylethyl)- 1 ,4-dihydroindeno [ 1 ,2- c]pyrazole-6-carboxamide;
3-(4-cyanophenyl)-7-methoxy-N-(2-morpholin-4-ylethyl)-l,4-dihydroindeno[l,2- c]pyrazole-6-carboxamide;
4-(6-{[(4-hydroxycyclohexyl)amino]methyl}-7-methoxy-l,4-dihydroindeno[l,2- c]pyrazol-3-yl)benzonitrile;
4- [6-( 1 H-imidazol- 1 -ylmethyl)-7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl]benzonitrile;
3 -(6-chloropyridin-3 -yl)-6,7-dimethoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazole;
4-[5-(6,7-dimethoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)pyridin-2-yl]phenol; 4- [5-(6,7-dimethoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)pyridin-2-yl]-2- methoxyphenol;
4-[5-(6,7-dimethoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)pyridin-2-yl]-2-fluorophenol;
5-(6,7-dimethoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)pyridine-2-carbonitrile;
6-(6,7-dimethoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)nicotinonitrile;
3-(5-bromopyridin-2-yl)-6,7-dimethoxy-l,4-dihydroindeno[l,2-c]pyrazole;
4'- [6-( 1 -hydroxy- 1 -methylethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl] -1,1 '-biphenyl-4- ol;
4- [6-( 1 -hydroxy- 1 -methylethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]benzonitrile;
2-[3-(6-chloropyridin-3-yl)-l,4-dihydroindeno[l,2-c]pyrazol-6-yl]propan-2-ol;
4-{ 5-[6-( 1 -hydroxy- 1 -methylethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]pyridin-2- yl}phenol;
3-(5,6-dichloropyridin-3-yl)-6,7-dimethoxy-l,4-dihydroindeno[l,2-c]pyrazole;
2-[3-(6-fluoropyridin-3-yl)-l,4-dihydroindeno[l,2-c]pyrazol-6-yl]propan-2-ol;
6,7-dimethoxy-3 -py razin-2-yl- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazole;
6,7-dimethoxy-3-pyridin-3-yl- 1 ,4-dihydroindeno [1 ,2-c] pyrazole;
6,7-dimethoxy-3-pyrimidin-5-yl-l,4-dihydroindeno[l,2-c]pyrazole;
3 -(6-chloropyridin-3-yl)-7-ethyl-6-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazole;
5-(7-ethyl-6-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)pyridine-2-carbonitrile;
3-(6-chloropyridin-3-yl)-7-ethyl-6-(tetrahydro-2H-pyran-4-yloxy)-l,4- dihydroindeno[l ,2-c]pyrazole;
4-{5-[7-ethyl-6-(tetrahydro-2H-pyran-4-yloxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl]pyridin-2-yl}phenol;
5-[7-ethyl-6-(3-morpholin-4-ylpropoxy)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]pyridine- 2-carbonitrile;
5 - [7-ethyl-6-(tetrahydrofuran-3 -ylmethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c] pyrazol-3 - yl]pyridine-2-carbonitrile;
5-[7-ethyl-6-(tetrahydrofuran-3-yloxy)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]pyridine-2- carbonitrile; 5-{7-ethyl-6-[(4-hydroxycyclohexyl)oxy]-l,4-dihydroindeno[l,2-c]pyrazol-3- yl }pyridine-2-carbonitrile;
5-[7-ethyl-6-(tetrahydro-2H-pyran-4-yloxy)-l,4-dihydroindeno[l,2-c]pyrazol-3- yl]pyridine-2-carbonitrile;
5- [7-ethyl-6-(pyridin-2-ylmethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl]pyridine-2- carbonitrile;
5-(6,7-diethyl- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)pyridine-2-carbonitrile;
3-(6-chloropyridin-3-yl)-6,7-bis(2-methoxyethoxy)- 1 ,4-dihydroindeno [1 ,2-c]pyrazole;
5-[6,7-bis(2-methoxyethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]pyridine-2- carbonitrile;
6-hydroxy-3-(4'-hydroxy- 1 , 1 '-bipheny l-4-yl)-7-methoxyindeno[ 1 ,2-c]pyrazol-4( 1 H)-one;
3 -(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-7-methoxy-6-(2-piperidin- 1 -ylethoxy)indeno [1,2- c]pyrazol-4(lH)-one;
3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-7-methoxy-6-[(l -methy lpiperidin-3- yl)methoxy] indeno [ 1 ,2-c]pyrazol-4( 1 H)-one;
6-{3-[4-(3-chlorophenyl)piperazin-l-yl]propoxy}-3-(4'-hydroxy-l,l'-biphenyl-4-yl)-7- methoxy indeno [ 1 ,2-c]pyrazol-4( 1 H)-one;
4-{6-[3-(dimethylamino)propoxy]-7-methoxy-4-oxo-l,4-dihydroindeno[l,2-c]pyrazol-3- yl}benzonitrile;
4-(6-hydroxy-7-methoxy-4-oxo-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)benzonitrile;
4-[7-methoxy-4-oxo-6-(tetrahydrofuran-3-yloxy)-l,4-dihydroindeno[l,2-c]pyrazol-3- yl]benzonitrile;
4-[7-methoxy-6-(3-moφholin-4-ylpropoxy)-4-oxo- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl]benzonitrile;
3-(6-chloropyridin-3-yl)-6,7-dimethoxy-4-methyl- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-4-ol;
4'- [6-methoxy-7-(2-pyrrolidin- 1 -ylethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl] -1,1'- biphenyl-4-ol;
4'-[6-methoxy-7-(2-moφholin-4-ylethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]- 1 , 1 '- biphenyl-4-ol; 4'- {7- [2-(diethylamino)ethoxy] -6-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl} - 1,1'- biphenyl-4-ol;
4'-[6-methoxy-7-(pyridin-3-ylmethoxy)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]-l,l'- biphenyl-4-ol;
4'- [6-methoxy-7-(pyridin-2-ylmethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl] -1,1'- biphenyl-4-ol;
4'-(7-{3-[4-(3-chlorophenyl)piperazin-l-yl]propoxy}-6-methoxy-l,4-dihydroindeno[l,2- c]pyrazol-3-yl)- 1 , 1 '-biphenyl-4-ol;
4'- [6-methoxy-7-(pyridin-4-ylmethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl] -1,1 - biphenyl-4-ol;
4'- { 7- [2-(dimethylamino)ethoxy] -6-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl } - 1 , 1 '- biphenyl-4-ol;
4'- [6-methoxy-7-(2-piperidin- 1 -ylethoxy)- 1 ,4-dihydroindeno [1 ,2-c]pyrazol-3-yl]- 1,1'- biphenyl-4-ol;
4'- {7-[3 -(dimethy lamino)propoxy] -6-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl } - l,l'-biphenyl-4-ol;
4'-[6-methoxy-7-(3-piperidin- 1 -ylpropoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]- 1 , 1 '- biphenyl-4-ol;
4'-{7-[2-(dimethylamino)-l-methylethoxy]-6-methoxy-l,4-dihydroindeno[l,2-c]pyrazol- 3-yl] - 1 , 1 '-biphenyl-4-ol;
4'-(7- {2-(dimethylamino)- 1 -[(dimethylamino)methyl] ethoxy } -6-methoxy- 1 ,4- dihydroindeno[ 1 ,2-c]pyrazol-3-yl)- 1 , 1 '-biphenyl-4-ol;
4'-{7-[(l-ethylpiperidin-3-yl)oxy]-6-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl}- l,l'-biphenyl-4-ol;
4'- { 7- [3 -(dimethylamino)-2-methylpropoxy]-6-methoxy- 1 ,4-dihydroindeno [1,2- c]pyrazol-3 -yl ] - 1 , 1 '-bipheny l-4-ol;
4'-{6-methoxy-7-[2-(l-methylpyrrolidin-2-yl)ethoxy]-l,4-dihydroindeno[l,2-c]pyrazol- 3-yl}-l,l'-biphenyl-4-ol;
4'- { 7-[2-( 1 H-imidazol- 1 -y l)ethoxy] -6-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl } - l,r-biphenyl-4-ol; 4'-{6-methoxy-7-[3-(4-methylpiperazin- 1 -yPpropoxy]- 1 ,4-dihydroindeno [1 ,2-c]pyrazol- 3-yl}-l,l'-biphenyl-4-ol;
3-(4'-hydroxy-l,r-biphenyl-4-yl)-6-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-7-ol;
3-(4'-hydroxy- 1 , 1 '-bipheny l-4-yl)-6-methoxy-N-[2-(4-methylpiperazin- 1 -yl)ethyl]- 1 ,4- dihydroindeno[l,2-c]pyrazole-7-carboxamide;
3 -(4'-hy droxy- 1 , 1 '-bipheny l-4-yl)-6-methoxy-N-(pyridin-2-ylmethyl)- 1 ,4- dihydroindeno[l,2-c]pyrazole-7-carboxamide;
3-(4'-hy droxy- 1 , 1 '-bipheny l-4-yl)-6-methoxy-N-(pyridin-4-ylmethyl)- 1 ,4- dihydroindeno [ 1 ,2-c]pyrazole-7-carboxamide;
N-[2-(diethylamino)ethyl]-3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-6-methoxy- 1 ,4- dihydroindeno [ 1 ,2-c]pyrazole-7-carboxamide;
N-[3-(diethylamino)propyl]-3-(4'-hydroxy-l,l'-biphenyl-4-yl)-6-methoxy-l,4- dihydroindeno[l,2-c]pyrazole-7-carboxamide;
N-[4-(diethylamino)butyl]-3-(4'-hydroxy- 1 , 1 '-bipheny l-4-yl)-6-methoxy- 1 ,4- dihydroindeno[l,2-c]ρyrazole-7-carboxamide;
N-[2-(dimethylamino)ethyl]-3-(4'-hydroxy-l,r-biphenyl-4-yl)-6-methoxy-l,4- dihydroindeno[ 1 ,2-c]pyrazole-7-carboxamide;
3 -(4'-hy droxy- 1 , 1 '-bipheny 1-4-y l)-6-methoxy-N-(2-pyrrolidin- 1 -ylethyl)- 1 ,4- dihydroindeno [ 1 ,2-c]pyrazole-7-carboxamide;
3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-6-methoxy-N-(3-pyιτolidin- 1 -ylpropyl)- 1 ,4- dihydroindeno[l,2-c]pyrazole-7-carboxamide;
3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-6-methoxy-N-(2-piperidin- 1 -ylethyl)- 1 ,4- dihydroindeno [ 1 ,2-c]pyrazole-7-carboxamide;
3 -(4'-hy droxy- 1 , 1 '-biphenyl-4-y l)-6-methoxy-N-(3 -piperidin- 1 -ylpropyl)- 1 ,4- dihydroindeno[l,2-c]pyrazole-7-carboxamide;
3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-6-methoxy-N-(2-morpholin-4-ylethyl)- 1 ,4- dihydroindeno[ 1 ,2-c]pyrazole-7-carboxamide;
N-[2-(dimethylamino)ethyl]-3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-6-methoxy-N-methyl- 1 ,4- dihydroindeno [ 1 ,2-c]pyrazole-7-carboxamide; N-[3-(dimethylamino)propyl]-3-(4'-hydroxy- 1 , 1 '-biphenyl-4-yl)-6-methoxy-N-methyl- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazole-7-carboxamide;
4'- { 6-methoxy-7- [(4-methyl- 1 ,4-diazepan- 1 -y l)carbonyl] - 1 ,4-dihy droindeno[ 1 ,2- c]pyrazol-3-yl } - 1 , 1 '-biphenyl-4-ol;
6-methoxy-3-{4-[3-(l-methylpyrrolidin-2-yl)propoxy]phenyl}-7-(2-piperidin-l- ylethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazole;
1 - { 4- [6-methoxy-7-(2-piperidin- 1 -ylethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 - y l]phenoxy } acetone;
[4-(6,7-dimethoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)phenyl]methanol;
3-(4-cyanophenyl)-6-methoxy-N-(pyridin-4-ylmethyl)-l,4-dihydroindeno[l,2-c]pyrazole- 7-carboxamide; methyl 3-(4-cyanophenyl)-6-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazole-7-carboxylate;
3-(4-cyanophenyl)-N-(tans-4-hydroxycyclohexyl)-6-methoxy- 1 ,4-dihydroindeno [1 ,2- c]pyrazole-7-carboxamide;
4-[6-methoxy-7-(pyridin-3-ylmethoxy)- 1 ,4-dihydroindeno [1 ,2-c]pyrazol-3- yl]benzonitrile;
4- { 7- [2-(dimethylamino)ethoxy] -6-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c] pyrazol-3 - yl}benzonitrile;
4-[6-methoxy-7-(pyridin-4-ylmethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3- yl]benzonitrile;
4'-[6-methoxy-7-(trifluoromethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]- 1 , 1 '-bipheny 1- 4-ol;
4-[(6,7-dimethoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)ethynyl]phenol;
4-[(6,7-dimethoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)ethynyl]-2-methoxyphenol;
4'-(6-morpholin-4-yl- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)- 1 , 1 '-bipheny l-4-ol;
3-methoxy-4'-(6-morpholin-4-yl- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)- 1 , 1 '-biphenyl-4- ol;
4-(6-morpholin-4-yl-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)benzonitrile;
4-[5-(6-morpholin-4-yl- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)pyridin-2-yl]phenol;
3-(6-chloropyridin-3-yl)-6-morpholin-4-yl-l,4-dihydroindeno[l,2-c]pyrazole; 2-methoxy-4-[5-(6-morpholin-4-yl-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)pyridin-2- yl]phenol;
5-(6-morpholin-4-yl-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)pyridine-2-carbonitrile;
5-(6,7-diisopropoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)pyridine-2-carbonitrile;
3 -(6-chloropyridin-3 -yl)-6,7-diisopropoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazole;
4-[5-(6,7-diisopropoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)pyridin-2-yl]phenol;
4-[5-(6,7-diisopropoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)pyridin-2-yl]-2- methoxyphenol;
5- [6-(tetrahydro-2H-pyran-4-yloxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]pyridine-2- carbonitrile;
3 -(6-chloropyridin-3 -yl)-6-(tetrahydiO-2H-pyran-4-yloxy)- 1 ,4-dihydroindeno [ 1 ,2- c]pyrazole;
4-{5-[6-(tetrahydro-2H-pyran-4-yloxy)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]pyridin-2- yl}phenol;
2-methoxy-4-{5-[6-(tetrahydro-2H-pyran-4-yloxy)-l,4-dihydroindeno[l,2-c]pyrazol-3- yl]pyridin-2-yl}phenol;
5 -(6-isopropoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -y l)pyridine-2-carbonirrile;
5-(6-isopropoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl)pyridine-2-carbonitrile;
4-[5-(6-isopropoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)pyridin-2-yl]phenol;
4- [5-(6-isopropoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -y l)pyridin-2-y 1] -2- methoxyphenol;
5-(6,7-diethoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)pyridine-2-carbonitrile;
3-(6-chloropyridin-3-yl)-6,7-diethoxy-l,4-dihydroindeno[l,2-c]pyrazole;
4-[5-(6,7-diethoxy-l,4-dilιydroindeno[l,2-c]pyrazol-3-yl)pyridin-2-yl]phenol;
4-[5-(6,7-diethoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)pyridin-2-yl]-2-methoxyphenol;
5-[6,7-bis(difluoromethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]pyridine-2- carbonitrile;
3-(6-chloropyridin-3-yl)-6,7-bis(difluoromethoxy)-l,4-dihydroindeno[l,2-c]pyrazole;
4-{ 5-[6,7-bis(difluoromethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]pyridin-2- yl}phenol; 5- [6-( 1 H- 1 ,2,4-triazol- 1 -ylmethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 -yl]pyridine-2- carbonitrile;
3 -(6-chloropyridin-3 -yl)-6-( 1 H- 1 ,2,4-triazol- 1 -ylmethyl)- 1 ,4-dihy droindeno[ 1 ,2- c]pyrazole;
4-{5-[6-(lH-l ,2,4-triazol- 1 -ylmethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]pyridin-2- yl}phenol;
4-[6-( IH- 1 ,2,4-triazol- 1 -ylmethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]benzonitrile;
3-(4-bromophenyl)-6-(lH- 1 ,2,4-triazol- 1 -ylmethyl)- 1 ,4-dihydroindeno [1 ,2-c]pyrazole;
4'- [6-( 1 H- 1 ,2,4-triazol- 1 -ylmethyl)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl] -1,1 '-biphenyl- 4-ol;
4-{5-[6-(diethylamino)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]pyridin-2-yl}phenol;
3-(6-chloropyridin-3-yl)-N,N-diethyl- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-6-amine;
5-[6-(diethylamino)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]pyridine-2-carbonitrile;
4- { 5-[6-(diethylamino)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]pyridin-2-yl}-2- methoxyphenol;
5 -[6-(tetrahydrofuran-3-y Imethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]pyridine-2- carbonitrile;
5-{6-[(3-methylcyclohexyl)oxy]-l,4-dihydroindeno[l,2-c]pyrazol-3-yl}pyridine-2- carbonitrile;
5 - [6-(cyclohexy Imethoxy)- 1 ,4-dihydroindeno [ 1 ,2-c] pyrazol-3 -yl] pyridine-2-carbonitτile ;
5-[6-(pyridin-2-ylmethoxy)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]pyridine-2- carbonitrile;
5-[6-(2-pyridin-2-ylethoxy)-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]pyridine-2- carbonitrile;
5 -(6- {2- [4-(dimethy lamino)pheny 1] ethoxy } - 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3 - yl)pyridine-2-carbonitrile;
5-{6-[(4-hydroxycyclohexyl)oxy]-l,4-dihydroindeno[l,2-c]pyrazol-3-yl}pyridine-2- carbonitrile;
5-{6-[2-(4-methyl-l,3-thiazol-5-yl)ethoxy]-l,4-dihydroindeno[l,2-c]pyrazol-3- yl}pyridine-2-carboxamide; 5-[6-(2-hydroxyethyl)- 1 ,4-dihydroindeno [1 ,2-c]pyrazol-3-yl]pyridine-2-carbonitrile;
5-[6-(difluoromethoxy)-7-methoxy- 1 ,4-dihydroindeno [ 1 ,2-c]pyrazol-3-yl]pyridine-2- carbonitrile;
3-(6-chloropyridin-3-yl)-6-(difluoromethoxy)-7-methoxy-l,4-dihydroindeno[l,2- c]pyrazole; and
4-{5-[6-(difluoromethoxy)-7-methoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl]pyridin-2- yl}phenol.
29. A compound that is 4'-(6,7-dimethoxy-l,4-dihydroindeno[l,2-c]pyrazol-3-yl)-l,l'- biphenyl-4-yl 1 ,4'-bipiperidine- 1 '-carboxylate.
30. A pharmaceutical composition comprising a compound of formula (I) or a therapeutically acceptable salt thereof in combination with a therapeutically acceptable carrier.
31. A method for inhibiting protein kinases in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I) or a therapeutically acceptable salt thereof.
32. A method for treating cancer in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of formula (I) or a therapeutically acceptable salt thereof.
EP04717503A 2003-03-07 2004-03-04 Fused tri and tetra-cyclic pyrazole kinase inhibitors Withdrawn EP1603885A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38432503A 2003-03-07 2003-03-07
US384325 2003-03-07
US10/792,564 US7320986B2 (en) 2003-03-07 2004-03-03 Fused tri and tetra-cyclic pyrazole kinase inhibitors
US792564 2004-03-03
PCT/US2004/006921 WO2004080973A1 (en) 2003-03-07 2004-03-04 Fused tri and tetra-cyclic pyrazole kinase inhibitors

Publications (1)

Publication Number Publication Date
EP1603885A1 true EP1603885A1 (en) 2005-12-14

Family

ID=32993814

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04717503A Withdrawn EP1603885A1 (en) 2003-03-07 2004-03-04 Fused tri and tetra-cyclic pyrazole kinase inhibitors

Country Status (5)

Country Link
EP (1) EP1603885A1 (en)
JP (1) JP2006520400A (en)
CA (1) CA2517885A1 (en)
MX (1) MXPA05009576A (en)
WO (1) WO2004080973A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118543A1 (en) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. Kinase inhibitor and use thereof
CN102584830A (en) * 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 Dihydroindene amide compounds, and medicinal composition and application thereof
US8853207B2 (en) 2012-04-12 2014-10-07 Development Center For Biotechnology Heterocyclic pyrazole compounds, method for preparing the same and use thereof
US9475816B2 (en) 2012-09-07 2016-10-25 Takeda Pharmaceutical Company Limited Substituted-1,4-dihydropyrazolo[4,3-b]indoles
ES2651367T3 (en) * 2013-07-15 2018-01-25 Basf Se Pesticide compounds
WO2016113261A1 (en) * 2015-01-13 2016-07-21 Basf Se Fused tricyclic compounds, compositions comprising these compounds and their use for con-trolling invertebrate pests
TW202409023A (en) 2022-07-14 2024-03-01 美商富曼西公司 Herbicidal benzoxazines
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2969371A (en) * 1959-02-03 1961-01-24 Robert A Braun Substituted indeno [1, 2-c] pyrazole derivatives
US2969373A (en) * 1959-10-27 1961-01-24 Smith Kline French Lab Trifluoromethylpyrazoloindenone derivatives
US3004983A (en) * 1960-05-16 1961-10-17 Smith Kline French Lab 4-aminopyrazolo [3, 4-a] indene derivatives
DD100256A5 (en) * 1971-10-13 1973-09-12
BE789948A (en) * 1971-10-13 1973-04-11 Sandoz Sa NEW DERIVATIVES OF PYRAZOLE, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS
US3843665A (en) * 1973-04-11 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US3843666A (en) * 1973-05-29 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
JPS60130521A (en) * 1983-12-19 1985-07-12 Morishita Seiyaku Kk Anticancer agent
CN1278724A (en) * 1997-10-06 2001-01-03 巴斯福股份公司 Indeno [1,2-c] pyrazole derivatives for inhibiting tyrosine kinase activty
JP2001518501A (en) * 1997-10-06 2001-10-16 ビーエーエスエフ アクチェンゲゼルシャフト Indeno [1,2-c]-, naphtho [1,2-c]-and benzo [6,7] cyclohepta [1,2-c] pyrazole derivatives
AU762992B2 (en) * 1998-11-06 2003-07-10 Abbott Gmbh & Co. Kg Tricyclic pyrazole derivatives
US6462036B1 (en) * 1998-11-06 2002-10-08 Basf Aktiengesellschaft Tricyclic pyrazole derivatives
PL350891A1 (en) * 1999-04-06 2003-02-10 Knoll Gmbh Substituted 1,4-dichlorindene[1,2-c]pyrazoles as inhibitors of tyrosine kinase
US6297238B1 (en) * 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6670358B2 (en) * 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004080973A1 *

Also Published As

Publication number Publication date
WO2004080973A1 (en) 2004-09-23
CA2517885A1 (en) 2004-09-23
JP2006520400A (en) 2006-09-07
MXPA05009576A (en) 2005-12-12

Similar Documents

Publication Publication Date Title
JP7446316B2 (en) Substituted pyrrolidine amide III
CA2464333C (en) Heteroindanes: a new class of potent cannabimimetic ligands
CN1934091B (en) imidazole compounds for the treatment of neurodegenerative disorders
CN107406457A (en) Piperidine derivatives, its preparation method and its application in medicine
TW200918054A (en) New heterocyclic H3 antagonists
IE903379A1 (en) Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
CA2498966A1 (en) Novel pyrazole analogs acting on cannabinoid receptors
CA2515790C (en) Heterocyclic kinase inhibitors
JP2010539180A (en) Isoquinolinyl and isoindolinyl derivatives as histamine 3 antagonists
CN101641346A (en) Pyridine and pyrimidine derivatives as MGLUR2 antagonists
JP2013521250A (en) Derivatives of aminoindane, their preparation and their application in therapy
JP2017502010A (en) Piperidine derivatives with multimodal activity against pain
JP6877771B2 (en) Pyrrolidine derivative
US7320986B2 (en) Fused tri and tetra-cyclic pyrazole kinase inhibitors
EP1603885A1 (en) Fused tri and tetra-cyclic pyrazole kinase inhibitors
EP3986886A2 (en) Substituted pyrrolidine amides v
Habib et al. Catalyst-free 1, 3-dipolar cycloaddition of 3-nitrochromen with sodium azide: a facile method for the synthesis of 4-aryl-1, 4-dihydrochromeno [4, 3-d][1, 2, 3] triazole derivatives
WO2006065646A1 (en) Benzisothiazole-1, 1-dioxide acting as antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof
AU2016378154B2 (en) Phenylimidazole compound
WO2016014913A1 (en) Indazole retinoic acid receptor-related orphan receptor modulators and uses thereof
EP3986885A1 (en) Substituted pyrrolidine amides iv
JP5929812B2 (en) Medicament containing 1,2,4-triazolone derivative
CN121263410A (en) Benzofuran derivatives as SIK inhibitors and uses thereof
EP3212638A1 (en) New dihydroquinoline pyrazolyl compounds as aldosterone synthase inhibitors
AU2002353895A1 (en) Heteroindanes: a new class of potent cannabimimetic ligands

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080511